

10

**New Bicyclic Compounds and Their Use as Antibacterial Agents and
 β -Lactamase Inhibitors**

15 Field of the invention

The present invention relates to new bicyclic compounds, their preparation and their use as antibacterial agents either alone or in combination with an antibiotic (or plural antibiotics) for the treatment of infections caused by β -lactamase-producing pathogenic bacteria. The compounds of the present invention are β -lactamase inhibiting or non- β -lactamase inhibiting (i.e., some of the compounds of the present invention by themselves would directly inhibit β -lactamase enzymatic function, and others of the compounds of the present invention by themselves would not inhibit some β -lactamase's enzymatic function though they provide synergy and increased potency of activity in combination with antibiotics, e.g., β -lactam antibiotics or non- β -lactam antibiotics). More particularly, the invention is concerned with

20

methods for overcoming antibiotic resistance caused by β -lactamase producing bacteria, the method of preparation of the new compounds, pharmaceutical compositions containing the new compounds, methods of treatment, uses of the compounds, and other subject matter.

Background of the invention

5 Microbial drug resistance is an unavoidable consequence resulting from abuse and overuse of antimicrobial agents. The rate at which resistance arises among microbial population is often dictated by the extent of use of particular agents in a given environment. Given the degree of popularity of β -lactam (also known as β -lactam) antibiotics, it is not surprising that the prevalence of β -lactamase (also known as β -lactamase) producing strains is increasing
10 worldwide. The most significant known mechanism related to the development of bacterial resistance to the β -lactam antibiotics is the production of class-A, class-B, class-C and class-D β -lactamases that are able to hydrolyze the β -lactam antibiotics resulting in the loss of antibacterial activity. Class-A enzymes preferentially hydrolyze penicillins, class-B enzymes hydrolyze all β -lactams including carbapenems, class-C β -lactamases have a
15 substrate profile favoring cephalosporin hydrolysis, whereas substrate preference for class D β -lactamases include oxacillin and cloxacillin.

The possibility of rescuing individual β -lactam antibiotics by combination with a β -lactamase inhibitor that inactivates the β -lactamase before it can hydrolyze the β -lactam antibiotic has been demonstrated with clinically useful combination between penicillins such as amoxicillin,
20 ampicillin, piperacillin and ticarcillin and β -lactamase inhibitors such as clavulanic acid, sulbactam and tazobactam. Further potential combinations have been described involving various β -lactam antibiotics and newly reported β -lactamase inhibitors including bicyclic monobactams, exomethylene penems and 7-oxo-6-diazabicyclo[3.2.1]octane-2-carboxamide derivatives.


25 As a result of point mutations and plasmid transfer, the diversity of β -lactamases is increasing constantly. The currently commercial β -lactamase inhibitors are insufficient to

counter these new β -lactamases – particularly ineffective against class C producing organisms, newly emerged extended-spectrum β -lactamases (ESBLs) and carbapenemases like IMP, VIM, OXA, KPC, and NDM. Thus there is a need for broad-spectrum β -lactamase inhibitor to combat over 900 β -lactamases including the newly emerged β -lactamases.

- 5 Recently, certain diazabicyclic compounds have been disclosed in WO 2009/091856 which is hereby incorporated by reference in its entirety. In addition, a number of diazabicyclic heterocycles have been disclosed in the following patents as β -lactamase inhibitors: US 2003/0199541 A1, US 2004/0157826 A1, US 2004/0097490 A1, US 2005/0020572 A1, US 2006/7112592 B2, US 2006/0189652 A1, US 2008/7439253 B2, US 2009/0018329 A1, EP
10 1307457 B1, EP 1537117 B1, WO 2002/100860 A2, WO 2002/10172 A1, WO 2003/063864 A2, WO 2004/052891 A1, WO 2004/022563 A1, WO 2008/142285 A1, WO 2009/090320 A1, US 2010/0092443 A1, WO 2010/126820 A2, US 2012/0165533 A1.

The compounds of the present invention are new and the structural features are significantly distinct from the compounds described in the patent references cited above.

- 15 In one aspect, the present invention provides a compound of formula (I):



wherein:

M is hydrogen or a pharmaceutically acceptable salt-forming cation;

Y is OR¹;

- 20 R¹ is a radical selected from the group consisting of:

- (1) C₁₋₆ straight or branched chain alkyl which is optionally substituted;
- (2) C₃₋₇ cycloalkyl which is optionally substituted;

(3) C₄₋₇ saturated heterocycles containing at least one heteroatom selected from O, N and S wherein the said heterocycle is optionally substituted, the ring S is optionally oxidized to S(O) or S(O)₂ and the free ring N atom may optionally take a substituent;

5 (4) Heterocyclyl (C₁₋₆) alkyl wherein the said heterocycle has the same definition as defined in (3), and the said heterocycle is optionally substituted;

10 (5) C₅₋₇ membered saturated heterocycles optionally fused with a C₃₋₇ membered cycloalkyl group to form a bicyclic ring system where the bicyclic ring system so formed is fused either through two adjacent carbon atoms or through a N atom shared by both the rings and the other end of the cycloalkyl chain is attached to the adjacent carbon atom of the molecule, each ring of the said bicyclic ring system independently optionally substituted;

15 (6) C₅₋₇ membered saturated heterocycles optionally fused with another C₅₋₇ saturated heterocycle to form a bicyclic ring system where the bicyclic ring system so formed is fused either through two adjacent carbon atoms or through a N atom shared by both the rings, each ring of the said bi-cyclic ring system independently optionally substituted;

20 (7) C₃₋₇ cycloalkyl which is optionally fused with a C₅₋₇ membered saturated heterocycle containing at least one heteroatom selected from O, N and S, the said bicyclic ring optionally substituted;


(8) Bridged bicyclic ring system having optionally one or two heteroatoms selected from O, N and S, the bicyclic ring system optionally substituted either at the carbon atom or at the free N atom present in the ring;

25 (9) C₅₋₇ membered saturated heterocycles optionally fused with C₅₋₇ membered heteroaryl ring where the bicyclic ring system so formed is fused either through two adjacent carbon atoms or through N atom shared by both the rings;

(10) C₅₋₇ membered saturated heterocycles optionally fused to a C₃₋₆ membered ring system through a common carbon atom to form a spiro system optionally containing one heteroatom selected from O, N and S that is present in the spiro ring where the ring S is optionally oxidized to S(O) or S(O)₂ and the free N atom present in either ring may optionally take a substituent; and

(11) C₅₋₇ membered heteroaryl (C₁₋₆) alkyl which is optionally substituted, or a deuterated compound of any such compound.

In another aspect, the present invention provides a compound of formula (I):



wherein:

M is hydrogen or a pharmaceutically acceptable salt-forming cation;

Y is NR²R³;

R² is hydrogen or optionally substituted C₁₋₆ lower alkyl;

R³ is a radical selected from any of following groups consisting of:

(1) C₁₋₆ straight or branched chain alkyl which is optionally substituted;

(2) C₃₋₇ cycloalkyl which is optionally substituted;

(3) C₄₋₇ saturated heterocycles containing at least one heteroatom selected from O, N and S wherein the said heterocycle is optionally substituted, the ring S is optionally oxidized to S(O) or S(O)₂ and the free ring N atom may optionally take a substituent;

(4) C₁₋₆ straight or branched chain alkyl carbonyl which is optionally substituted;

(5) C₃₋₇ cycloalkyl carbonyl which is optionally substituted;

(6) C₄₋₇ membered saturated heterocyclyl carbonyl containing at least one heteroatom selected from O, N and S wherein the said heterocycle is optionally substituted, the ring S is optionally oxidized to S(O) or S(O)₂ and the free ring N atom may optionally take a substituent;

(7) C₃₋₇ membered saturated heterocyclyl (C₁₋₆) alkyl carbonyl wherein the said heterocycle has the same definition as defined in (6), and the free ring N atom may optionally take a substituent;

(8) C₆₋₁₀ aryl carbonyl which is optionally substituted;

(9) C₆₋₁₀ aryl (C₁₋₆) alkyl carbonyl which is optionally substituted;

(10) C₅₋₆ membered heteroaryl carbonyl containing at least one heteroatom selected from O, S and N wherein the heteroaryl is optionally substituted;

(11) C₅₋₆ heteroaryl (C₁₋₆) alkyl carbonyl wherein the said heteroaryl has the same definition as defined in (10);

(12) CF₃CO-, CH₃SO₂-, NH₂CO-, and NH₂SO₂- ;

(13) C₆₋₁₀ aryl which is optionally substituted;

(14) C₅₋₆ membered heteroaryl which is optionally substituted;

(15) or R² and R³ together may form an optionally substituted ring system and the said ring may contain another heteroatom selected from O, N, and S,

or a deuterated compound of any such compound.

In yet another aspect, the present invention provides use of an antibacterially effective amount of a compound as described herein in the manufacture of a medicament for treating a bacterial infection in a mammal in need thereof.

In yet another aspect, the present invention provides a pharmaceutical composition containing as an active ingredient, at least one compound as described herein.


In yet another aspect, the present invention provides use of an effective amount of a compound as described herein in manufacture of a medicament for treating bacterial infection in a mammal in need thereof, wherein said medicament is to be administered into the mammal in combination with an effective amount of at least one β -lactam antibiotic, at least one salt of a β -lactam antibiotic, at least one hydrate of a β -lactam antibiotic or at least one prodrug of a β -lactam antibiotic.

In yet another aspect, the present invention provides use of an effective amount of a compound as described herein in the manufacture of a medicament for treating bacterial infection in a mammal in need thereof, wherein said medicament is to be administered into the mammal in combination with an effective amount of at least one antibiotic, at least one salt of an antibiotic, at least one hydrate of an antibiotic or at least one prodrug of an antibiotic.


In yet another aspect, the present invention provides a molecular complex comprising a compound as described herein and at least one solvent.

In yet another aspect, the present invention provides a process for preparing a compound as described herein, wherein $M = H$, and wherein the process comprises:


[A] Reacting substituted hydroxylamine (V) with an acid (VI) in presence of a coupling agent selected from the group consisting of EDCI, HOBT-DCC and PyBop to provide an intermediate of formula (VII);



[B] Removing the benzyl protecting group of the intermediate (VII) with a source of hydrogen in presence of Pd catalyst to provide debenzylated product (VIII);



[C] Contacting compound (VIII) with a sulfating agent in the presence of solvent to obtain compound of formula (Ia)




Detailed description of the invention

In one aspect, the present invention relates to new, low molecular weight diazabicyclic compounds (some of which have potent broad-spectrum β -lactamase inhibitory activity and others do not have such activity) that when used in combination with a β -lactam antibiotic or with other non β -lactam antibiotics enhance the activity of the antibiotic against class A, Class B, class C, and class D enzyme producing organisms and thereby enhance the antibacterial properties. The compounds are therefore useful in the treatment of bacterial infections in humans or animals either alone or in combination with β -lactam antibiotics and/or with other non β -lactam antibiotics.

In accordance with the present invention, there are provided (A) new compounds of general formula (I), (B) pharmaceutically acceptable salts of the compounds of formula (I), (C) pharmaceutically acceptable solvates of the compounds of formula (I) and of their salts, and

- (D) deuterated compounds of compounds of (A), (B) and (C), (namely, (i) compounds of formula (I) modified in that they have been deuterated, (ii) pharmaceutically acceptable salts of compounds of formula (I) modified in that they have been deuterated, and (iii) pharmaceutically solvates of compounds of formula (I) and of their salts modified in that they have been deuterated):



Wherein;

M is hydrogen or a pharmaceutically acceptable salt forming cation,




- 10 a "pharmaceutically acceptable salt" refers to a salt of a compound, which salt possesses the desired pharmacological activity of the parent compound,




reference to specified compounds "modified in that they have been deuterated" refers to compounds obtained by modifying the specified compounds so that one or more hydrogen atoms in the compound have been replaced with or converted to deuterium,

- 15 Y = OR¹ or NR²R³,




In the formula (I), when Y = OR¹, R¹ is a radical selected from any of the following groups:

- (1) C₁₋₆ straight or branched chain alkyl which is optionally substituted. Non-limiting examples of such compounds are:







5




10





- (2) C₃₋₇ cycloalkyl which is optionally substituted. Non-limiting examples of such compounds are:




- (3) C₄₋₇ saturated heterocycles containing at least one heteroatom selected from O, N and S wherein the said heterocycle is optionally substituted. Furthermore the ring S is optionally oxidized to S(O) or S(O)₂ and the free ring N atom may optionally take a substituent. Non-limiting examples of such compounds are:









- (4) Heterocyclyl (C_{1-6}) alkyl wherein the said heterocycle has the same definition as defined in (3). Furthermore, the said heterocycle is optionally substituted. Non-limiting examples of such compounds are:







- (5) C₅₋₇ membered saturated heterocycles which is optionally fused with a C₃₋₇ membered cycloalkyl group to form a bicyclic ring system where the bicyclic ring system so formed is fused either through two adjacent carbon atoms or through a N atom shared by both the rings and the other end of the cycloalkyl chain is attached to the adjacent carbon atom of the molecule. Furthermore, each ring of the said bicyclic ring system is optionally substituted. Non-limiting examples of such compounds are:




- (6) C₅₋₇ membered saturated heterocycles which is optionally fused with another C₅₋₇ saturated heterocycle to form a bicyclic ring system where the bicyclic ring system so formed is fused either through two adjacent carbon atoms or through a N atom shared by both the rings. Furthermore, each ring of the said bi-cyclic ring system is optionally substituted. Non-limiting examples of such compounds are:



- (7) C₃₋₇ cycloalkyl which is optionally fused with a C₅₋₇ membered saturated heterocycle containing at least one heteroatom selected from O, N and S. Furthermore, the said bicyclic ring is optionally substituted. Non-limiting examples of such compounds are:




- (8) Bridged bicyclic ring system having optionally one or two heteroatoms selected from O, N and S. Furthermore, the bicyclic ring system is optionally substituted either at the carbon atom or at the free N atom present in the ring. Non-limiting examples of such compounds are:




- (9) C₅₋₇ membered saturated heterocycles which is optionally fused with C₅₋₇ membered heteroaryl ring where the bicyclic ring system so formed is fused either

through two adjacent carbon atoms or through N atom shared by both the rings.


Non-limiting examples of such compounds are:





- 5 (10) C₅₋₇ membered saturated heterocycles which is optionally fused to a C₃₋₆ membered ring system through a common carbon atom to form a spiro system optionally containing one heteroatom selected from O, N and S that is present in the spiro ring where the ring S is optionally oxidized to S(O) or S(O)₂ and the free N atom present in either ring may optionally take a substituent. Non-limiting examples of such
- 10 compounds are:




- (11) C₅₋₇ membered heteroarylalkyl which is optionally substituted. Non-limiting examples of such compounds are:









In the above formula (I), when $Y = OR^1$, several non-limiting examples of the compounds of the present invention are mentioned below:






5


10





5





10












5 In another embodiment, in the formula (I), Y is NR^2R^3 .

Wherein, R^2 is hydrogen, optionally substituted C_{1-6} lower alkyl, even more preferably R^2 is hydrogen;


In the formula (I), when $\text{Y} = \text{NR}^2\text{R}^3$; R^3 is a radical selected from any of the following groups:

(1) C_{1-6} straight or branched chain alkyl which is optionally substituted. Non-limiting


10 examples of such compounds are:




(2) C_{3-7} cycloalkyl which is optionally substituted. Non-limiting examples of such compounds are:




- (3) C_{4-7} saturated heterocycles containing at least one heteroatom selected from O, N and S wherein the said heterocycle is optionally substituted. Furthermore the ring S is optionally oxidized to S(O) or S(O)_2 and the free ring N atom may optionally take a substituent. Non-limiting examples of such compounds are:





- (4) C_{1-6} straight or branched chain alkyl carbonyl which is optionally substituted. Non-limiting examples of such compounds are:





(5) C₃₋₇ cycloalkyl carbonyl which is optionally substituted. Non-limiting examples of such compounds are:







5


- (6) C₄₋₇ membered saturated heterocyclyl carbonyl containing at least one heteroatom selected from O, N and S wherein the said heterocycle is optionally substituted. Furthermore the ring S is optionally oxidized to S(O) or S(O)₂ and the free ring N atom may optionally take a substituent. Non-limiting examples of such compounds


are:






- (7) C₃₋₇ membered saturated heterocyclyl (C₁₋₆) alkyl carbonyl wherein the said
 5 heterocycle has the same definition as defined in (6). The free ring N atom may optionally take a substituent. Non-limiting examples of such compounds are:







- (8) C₆₋₁₀ aryl carbonyl which is optionally substituted. Non-limiting examples of such compounds are:




- (9) C₆₋₁₀ aryl (C₁₋₆) alkyl carbonyl which is optionally substituted. Non-limiting examples of such compounds are:




- (10) C₅₋₆ membered heteroaryl carbonyl containing at least one heteroatom selected from O, S and N wherein the heteroaryl is optionally substituted. Non-limiting examples of such compounds are:



(11) C_{5-6} heteroaryl (C_{1-6}) alkyl carbonyl wherein the said heteroaryl has the same definition as defined in (10). Non-limiting examples of such compounds are:




- (12) In the formula (I), when $Y = NR^2R^3$; R^3 may also be selected from the following groups like CF_3CO- , CH_3SO_2- , NH_2CO- , NH_2SO_2- . Non-limiting examples of such compounds are:




5

- (13) C_{6-10} aryl which is optionally substituted. Non-limiting examples of such compounds are:




- (14) C_{5-6} membered heteroaryl which is optionally substituted. Non-limiting examples of such compounds are:




10






- (15) In the formula (I), when $Y = NR^2R^3$; R^2 and R^3 together may form an optionally substituted ring system and the said ring may contain another heteroatom selected from O, N, and S. Furthermore, the ring may be optionally substituted. Non-limiting examples of such compounds are:

15












- 5 In the above formula (I), when $Y = NR^2R^3$, several non-limiting examples of such compounds of the present invention are mentioned below:




















5














5

Examples of the groups for forming a pharmaceutically acceptable salt represented by M in the formula (I) include: inorganic base salts, ammonium salts, organic base salts, basic amino acid salts, inorganic acid addition salts, and organic acid addition salts. Inorganic bases that can form the inorganic base salts include alkali metals (e.g., sodium, potassium, and lithium) and alkaline earth metals (e.g., calcium and magnesium). Organic bases that can form the organic base salts include n-propylamine, n-butylamine, cyclohexylamine, benzylamine, octylamine, ethanolamine, diethanolamine, diethylamine, triethylamine, dicyclohexylamine, procaine, choline, N-methylglucamine, morpholine, pyrrolidine, piperidine, N-ethylpiperidine and N-methylmorpholine. Basic amino acids that can form the basic amino acid salts include lysine, arginine, ornithine and histidine. As will be appreciated by one

skilled in the art, the compounds of formula (I) containing a basic nitrogen atom are capable of forming acid addition salts. Such salts with pharmaceutically acceptable acids are included in the invention. Examples of such acids are hydrochloric, hydrobromic, phosphoric, sulphuric, citric, oxalic, maleic, fumaric, glycolic, mandelic, tartaric, aspartic, succinic, malic, formic, acetic, trifluoroacetic, methanesulfonic, ethanesulfonic, trifluoromethanesulfonic, benzenesulfonic, p-toluenesulfonic and the like.

Moreover, some compounds of formula (I) when they contain a basic group such as NH, NH₂ or pyridine and the like may form an inner, zwitterionic salt with OSO₃H; such inner salts are also included in this invention.

Another aspect of the present invention is to include all possible isomers of formula (I). As used herein, the term 'isomers' refers to different compounds that have the same molecular formula but differ in arrangement and configuration of the atoms, such as geometrical isomers and optical isomers. For a given compound of the present invention, it is understood that a substituent may be attached at a chiral center of a carbon atom. Therefore the invention includes enantiomers, diastereoisomers or racemates of the compound. By definition 'enantiomers' are a pair of stereoisomers that are non-superimposable mirror images of each other, and 1:1 mixture of a pair of enantiomers is a racemic mixture. By definition, 'diastereoisomers' are stereoisomers that have at least two asymmetric carbon atoms but which are not mirror-images of each other. When a compound of formula (I) is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S.

Compounds may also exist in several tautomeric forms including the enol form, the keto form, and mixtures of any of the foregoing. Accordingly, the chemical structures depicted herein encompass all possible tautomeric forms of the illustrated compounds.

A variety of protecting groups conventionally used in the β -lactam field to protect a reactive functional group present in the molecule of formula (I) can be used. 'Protecting group' refers to a group of atoms that when attached to a reactive functional group in a molecule masks, reduces or prevents reactivity of the functional group. Examples of protecting groups can be

found in Green et al., "Protective Groups in Organic Chemistry", (Wiley, 2nd, 1991) and Harrison et al., "Compendium of Synthetic Organic Methods," Vols. 1-8 (John Wiley and Sons, 1971-1996). Representative amino protecting groups include, but are not limited to formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (CBZ), *tert*-butoxycarbonyl (Boc),


5 trimethylsilyl (TMS), 2-trimethylsilyl-ethanesulfonyl (SES), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (Fmoc), nitro-veratryloxycarbonyl (NVOC), and the like. Examples of hydroxy protecting groups include, but are not limited to, those where the hydroxyl group is either acylated or alkylated such as benzyl, and trityl ethers as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers, and allyl ethers.

- 10 The term 'optionally substituted' refers to unsubstituted or substituted with one or two of the following substituents each of which is independently selected from:

-Lower alkyl including from one to six carbon atoms in any arrangement, e.g., methyl, ethyl, i-propyl or t-butyl

-Amino

- 15 -Substituted amino such as $-\text{NHCH}_3$, $-\text{N}(\text{CH}_3)_2$, $-\text{NHCH}_2\text{CH}_3$, $-\text{NHPr}^i$, $-\text{NHBu}^t$,



-Alkoxy such as $-\text{OCH}_3$, $-\text{OC}_2\text{H}_5$, $-\text{OPr}^i$ (i.e., isopropoxy), $-\text{OBu}^t$ (i.e., isobutyloxy)

-Hydroxyalkyl such as $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CH}_2\text{OH}$

-Halogen such as F, Cl, Br

-Hydroxy

- 20 -Carboxy

-Alkoxycarbonyl such as $-\text{COOCH}_3$, $-\text{COOC}_2\text{H}_5$, $-\text{COOPr}^i$, and $-\text{COOBu}^t$

-Haloalkyl such as $-\text{CH}_2\text{Cl}$, $-\text{CH}_2\text{F}$


-Trifluoromethyl

-Trifluoromethoxy

- 25 -Alkylamine such as $-\text{CH}_2\text{NH}_2$, $-\text{CH}_2\text{CH}_2\text{NH}_2$

-Substituted alkylamine such as $-\text{CH}_2\text{NHCH}_3$, $-\text{CH}_2\text{N}(\text{CH}_3)_2$, $-\text{CH}_2\text{CH}_2\text{NHCH}_3$,

$-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$,



-Carboxamide

-Thiocarboxamide

5 -Sulfonic acid




-Sulfate

-Acylamino

-Sulfonylamino

-Sulfonamide

10 -Substituted sulfonamide such as $-\text{SO}_2\text{NHCH}_3$, $-\text{SO}_2\text{NHCH}_2\text{CH}_3$, $-\text{SO}_2\text{NHPr}^t$, $-\text{SO}_2\text{NHBu}^t$,



-Urea ($-\text{NHCONH}_2$) which may be optionally substituted

-Thiourea ($-\text{NHCSNH}_2$) which may be optionally substituted

-Sulfonylurea ($-\text{NHSO}_2\text{NH}_2$) which may be optionally substituted

15 -Oxo ($=\text{O}$) when oxygen is bonded through double bond to a carbon atom

-Oxyimino ($=\text{N}-\text{O}-\text{A}$) where the nitrogen is bonded through double bond to a carbon atom which is attached to the rest of the molecule and A can be hydrogen, or optionally substituted straight or branched lower alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl

-Hydroxamic acid ($-\text{CONHOH}$)

20 -Acyl ($-\text{COCH}_3$)

-Trifluoromethyl carbonyl ($-\text{COCF}_3$)

-Cyano ($-\text{CN}$)

-Amidino $-\text{C}(=\text{NH})\text{NH}_2$ which may be optionally substituted

-Guanidino -NHC(=NH)NH₂ which may be optionally substituted

-Aryloxy

-Heterocyclyl

-Heteroaryl

5 -Heterocyclyloxy

-Heteroaryloxy


-Heterocyclalkyloxy

-Trialkylammonium

The substituent mentioned above could be substituted at the carbon atom or at the free N-
10 atom of the molecule as appropriate.

Among the compounds of formula (I), a particular subject of the invention are those in which M is hydrogen or a pharmaceutically acceptable salt forming cation.

A group of preferred examples of compounds of the formula (I), when Y = OR¹, are from the following Table 1.
























Y = OR¹










* = point of attachment with O











Table 1: List of compounds










Compound No.	M	R ¹
1	H	











Compound No.	M	R ¹
2	H	
3	H	
4	H	
5	Na	
6	H	
7	Na	
8	H	
9	H	
10	H	
11	H	
12	H	
13	Na	












Compound No.	M	R ¹
14	H	
15	H	
16	H	
17	H	
18	H	
19	H	
20	H	
21	H	
22	H	
23	H	
24	H	













Compound No.	M	R ¹
25	H	
26	H	
27	H	
28	H	CH ₃
29	H	
30	H	
31	H	
32	H	
33	H	
34	H	
35	H	
36	Na	












Compound No.	M	R ¹
37	H	
38	H	
39	H	
40	H	
41	H	
42	H	
43	H	
44	H	
45	H	
46	H	










Compound No.	M	R ¹
47	H	
48	H	
49	H	
50	H	
51	H	
52	H	
53	H	
54	H	
55	H	
56	H	












Compound No.	M	R ¹
57	H	
58	H	
59	H	
60	H	
61	H	
62	H	
63	H	
64	H	
65	H	
66	H	
67	H	











Compound No.	M	R ¹
68	H	
69	H	
70	Na	
71	H	
72	H	
73	H	
74	H	
75	H	
76	H	
77	H	
78	H	










Compound No.	M	R ¹
79	H	
80	H	
81	H	
82	Na	
83	Na	
84	H	
85	H	
86	H	
87	H	
88	H	
89	H	
90	H	











Compound No.	M	R ¹
91	H	
92	H	
93	H	
94	H	
95	Na	
96	H	
97	H	
98	H	
99	H	
100	Na	
101	H	




Compound No.	M	R ¹
102	H	
103	H	
104	Na	
105	H	
106	H	
107	H	
108	H	
109	H	
110	H	

Compound No.	M	R ¹
111	H	
112	H	
113	H	
114	H	
115	H	
116	H	
117	H	
118	H	
119	H	
120	H	
121	H	


Compound No.	M	R ¹
122	H	
123	H	
124	H	
125	H	
126	H	
127	H	
128	H	
129	H	
130	H	
131	Na	

Compound No.	M	R ¹
132	H	
133	H	
134	H	
135	H	
136	H	
137	H	
138	H	
139	H	
140	H	

Compound No.	M	R ¹
141	H	
142	Na	
143	H	
144	H	
145	H	
146	H	
147	H	
148	H	
149	Na	
150	Na	
151	H	
152	Na	

Compound No.	M	R ¹
153	H	
154	H	
155	H	

A group of preferred examples of compounds of the formula (I), when $Y = NR^2R^3$, are from the following Table 2.














$$Y = NR^2R^3$$














5












* = point of attachment with N













Table 2: List of compounds












Compound No.	M	R ²	R ³
1	H	H	H ₃ C-*
2	H	H	
3	H	H	
4	H	CH ₃	H ₃ C-*
5	H	CH ₂ CH ₃	
6	H	CH(CH ₃) ₂	











Compound No.	M	R ²	R ³
7	H	H	
8	H	H	
9	H	H	
10	H	H	
11	H	H	
12	H	H	
13	H	H	
14	H	H	
15	H	H	
16	H	H	
17	H	H	
18	H	H	
19	H	CH ₃	
20	H	CH ₃	














Compound No.	M	R ²	R ³
21	H	CH ₃	
22	H	CH ₂ CH ₃	
23	H	CH ₂ CH ₃	
24	H	H	
25	H	H	
26	H	H	
27	H	H	
28	H	H	
29	H	H	
30	H	H	
31	H	H	
32	H	H	
33	H	H	

Compound No.	M	R ²	R ³
34	H	H	
35	H	H	
36	H	H	
37	H	H	
38	H	H	
39	H	H	
40	H	H	
41	H	H	
42	H	H	
43	H	H	
44	H	CH ₃	











Compound No.	M	R ²	R ³
45	H	H	
46	H	H	
47	H	H	
48	H	H	
49	H	H	
50	H	H	
51	H	H	
52	H	H	
53	H	H	
54	H	H	
55	H	H	
56	H	H	





Compound No.	M	R ²	R ³
57	H	H	
58	H	H	
59	H	H	
60	H	H	
61	H	H	
62	H	H	
63	H	H	
64	H	H	
65	H	H	
66	H	CH ₃	
67	H	CH ₂ CH ₃	

Compound No.	M	R ²	R ³
68	H	H	
69	H	H	
70	H	CH ₃	
71	H	CH ₂ CH ₃	
72	H	H	
73	H	H	
74	H	H	
75	H	H	
76	H	H	
77	H	H	

Compound No.	M	R ²	R ³
78	H	H	
79	H	CH ₃	
80	H	H	
81	H	H	
82	H	H	
83	H	H	
84	H	H	
85	H	H	
86	H	H	
87	H	CH ₃	
88	H	CH ₃	
89	H	H	
90	H	H	

Compound No.	M	R ²	R ³
91	H	H	
92	H	H	
93	H	H	
94	H	CH ₃	
95	H	H	
96	H	CH ₃	
97	H		
98	H		
99	H		
100	H		
101	H		
102	H		
103	H		
104	H		

Compound No.	M	R ²	R ³
105	H		
106	H		
107	H		
108	H		
109	H	H	
110	H	CH ₃	
111	H	H	
112	H	H	
113	H	H	
114	H	CH ₃	
115	H	H	

Compound No.	M	R ²	R ³
116	H	H	
117	H	H	
118	H	H	
119	H	H	

It is also an object of this invention to provide a combination of a compound of general formula (I) having antibacterial activity with another existing antibacterial agent, thus causing synergistic effect and the use of the same as drugs for the treatment of bacterial infections.

- 5 It is another object of the invention to provide methods for preparing the compounds of the invention of formula (I).

It is a further object of the invention to provide pharmaceutical compositions comprising a compound of formula (I) of this invention (some of which directly inhibit β -lactamase enzymatic function and others of which do not directly inhibit β -lactamase's enzymatic

- 10 function (at pharmaceutically accessible concentrations) as an active ingredient in combination with an antibiotic (e.g., a β -lactam antibiotic or some other non β -lactam antibiotic) and a suitable amount of pharmaceutically acceptable carrier or diluent, so as to provide a form for proper administration to a patient. These compositions can be administered by parenteral, in particular intramuscular route, oral, sublingual, rectal, aerosol
- 15 or by local route in a topical application on the skin and the mucous membranes. Suitable

pharmaceutical vehicles include excipients such as starch, glucose, lactose, sucrose, gelatin, gum arabic, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like.

Other examples of suitable pharmaceutical vehicles have been described in the art

5 (Remington's Science and Practice of Pharmacy, 21st Edition, 2006). Compositions of the present disclosure, if desired, can also contain minor amounts of wetting, dispersing or emulsifying agents, or pH buffering agents, and preservatives. In addition, auxiliary, stabilizing, thickening, lubricating, and coloring agents can be included. Pharmaceutical compositions can be formulated in a conventional manner. Proper formulation is dependent
10 upon the route of administration chosen. The present pharmaceutical compositions can take the form of injectable preparations, suspensions, emulsions, sugar-coated tablets, pellets, gelatin-capsules, capsules containing liquids, powders, granules, sustained-release formulations, suppositories, aerosols, sprays, ointments, creams or any other form suitable for use.

15 In another aspect, the present invention also provides for the use, in the manufacture of a medicament, of a compound within formula (I) above as an active ingredient in an antibacterial composition in admixture with a carrier.

In another aspect, the present invention also provides for the use, in the manufacture of a medicament, of a compound within formula (I) above as an active ingredient.

20 In another aspect, the present invention also provides for the use, in the manufacture of a medicament, of a compound within formula (I) above as an active ingredient, along with one or more antibiotics (e.g., a β -lactam antibiotic or some other non β -lactam antibiotic), in an antibacterial composition in admixture with a carrier.

In another aspect, the present invention also provides for the use, in the manufacture of a
25 medicament, of a compound within formula (I) above as an active ingredient, along with one or more antibiotics (e.g., a β -lactam antibiotic or some other non β -lactam antibiotic).

The parenteral administration which includes intramuscular, intraperitoneal, subcutaneous and intravenous use, sterile solutions of the active ingredient are usually prepared and the pH of the solutions are suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled to render the preparation isotonic. Suitable solvents include saline solution (e.g., 0.9% NaCl solution) and apyrogenic sterile water. Pharmaceutical compositions for oral delivery can be, for example, in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs. Orally administered compositions can contain one or more optional agents, for example, sweetening agents such as fructose, aspartame, or saccharin, flavoring agents such as peppermint, oil of wintergreen, cherry, coloring agents, and preserving agents to provide a pharmaceutically palatable preparation. Moreover, when in tablet form, the compositions can be coated to delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained action over an extended period of time. Oral compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. For oral liquid preparations, for example, suspensions, elixirs, and solutions, suitable carriers, excipients, or diluents include water, saline, alkylene glycols (e.g. propylene glycol), polyalkylene glycols (e.g., polyethylene glycol), oils, alcohols, slightly acidic buffers ranging from about pH 4 to about pH 6 (e.g., acetate, citrate, ascorbate ranging from about 5 mM to about 50 mM), and the like. Additionally, flavoring agents, preservatives, coloring agents, bile salts, acylcarnitines, and the like can be added.

For topical formulations of compounds of the present invention, creams, gels, ointments or viscous lotions can be used as appropriate delivery forms. Topical delivery systems also include transdermal patches containing at least one compound of formula (I) to be administered. Delivery through the skin can be achieved by diffusion or by more active energy sources such as iontophoresis or electrotransport. Formulations of a compound of the present invention, for topical use, such as in creams, ointments, and gels, can include an oleaginous or water soluble ointment base, for example, topical compositions can include

vegetable oils, animal fats, and in certain embodiments, semisolid hydrocarbons obtained from petroleum. Topical compositions can further include white ointment, yellow ointment, cetyl esters wax, oleic acid, olive oil, paraffin, petrolatum, white petrolatum, spermaceti, starch glycerite, white wax, yellow wax, lanolin, and glyceryl monostearate. Various water-
5 soluble ointment bases can also be used, including glycol ethers and derivatives, polyethylene glycols, polyoxyl 40 stearate, and polysorbates.

In a pharmaceutical composition containing a compound of this invention, the weight ratio of active ingredient to carrier will normally be in the range of 1:20 to 20:1. The administered daily dose varies according to the illness treated, and the administration route. However in
10 most instances, an effective dose (e.g., in some instances, a β -lactamase inhibiting dose) of a compound of formula (I) or a pharmaceutically acceptable salt thereof will be a daily dose in the range from about 1 to about 500 mg per kilogram of body weight orally, and from about 1 to about 500 mg per kilogram of body weight parenterally. The weight ratio of the compound of present invention and an antibiotic (if it is being administered with an antibiotic,
15 e.g., a β -lactam antibiotic or some other non β -lactam antibiotic) will normally be in the range from 1:20 to 20:1.

In some aspects of the present invention, an additional object is to provide an improved method for the treatment of bacterial infections caused by β -lactamase producing bacteria in a patient in need of such treatment comprising administering to the patient a therapeutically
20 effective amount of at least one compound chosen from formula (I) or a pharmaceutically acceptable salt thereof in combination with a known β -lactam antibiotic. In such an aspect of the present invention, the compounds increase the antibacterial effectiveness of β -lactamase susceptible β -lactam antibiotics, that is, they increase the effectiveness of the antibiotic against infections caused by β -lactamase producing microorganisms in
25 mammalian subjects, particularly in human. In these aspects of the present invention, this makes the compounds of formula (I) and pharmaceutically acceptable salts thereof, valuable for co-administration with β -lactam antibiotics. In the treatment of a bacterial infection in such

aspects of the present invention, said compounds of formula (I) or a pharmaceutically salt thereof can be mixed with the β -lactam antibiotic, and the two agents thereby administered simultaneously. When co-administered with a β -lactam antibiotic in such aspects of the present invention, the combination of the compound of the invention and the antibiotic can provide a synergistic effect. The term 'synergistic effect' refers to the effect produced when two or more agents are co-administered is greater than the effect produced when the agents are administered individually. Alternatively, the compound of formula (I) or a salt thereof can be administered as a separate agent during a course of treatment with the antibiotic.

'Therapeutically effective amount' refers to the amount of a compound that, when administered to a subject for treating a disease, or at least one of the clinical symptoms of a disease, is sufficient to affect such treatment of the disease, disorder, or symptom. The therapeutically effective amount can vary depending, for example, on the compound, the disease, disorder, and/or symptoms of the disease, severity of the disease, disorder, and/or symptoms of the disease, the age, weight, and/or health of the patient to be treated, and the judgement of the prescribing physician.

The term ' β -lactam antibiotic' refers to a compound with antibiotic property that contains a β -lactam functionality. Examples of β -lactam antibiotics which can be used in combination with the compounds of the present invention represented by formula (I) are commonly marketed penicillins, cephalosporins, penems, carbapenems and monobactams.

Examples of β -lactam antibiotics which can be used in combination with the compounds of the present invention represented by formula (I) are commonly used penicillins, such as amoxicillin, ampicillin, azlocillin, mezlocillin, apalcillin, hetacillin, bacampicillin, carbenicillin, sulbenicillin, ticarcillin, piperacillin, methicillin, ciclacillin, talampicillin, oxacillin, cloxacillin, dicloxacillin and commonly used cephalosporins such as cephalothin, cephaloridine, cefaclor, cefadroxil, cefamandole, cefazolin, cephalixin, cephradine, cepipirin, cefuroxime, cefoxitin, cephacetrile, cefotiam, cefotaxime, ceftriaxone, cefsulodin, cefoperazone, ceftizoxime, cefmenoxime, cefmetazole, cephaloglycin, cefonicid, cefodizime, cefpirome, cefepime,

ceftazidime, cefpiramide, ceftriaxone, cefbuperazone, cefprozil, cefixime, ceftobiprole, ceftaroline, cefalonium, cefminox, ceforanide, cefuzonam, cefoxitin, cefotetan, loracarbef, cefdinir, cefditoren, cefetamet, cefcapene, cefdaloxime, ceftibuten, cefroxadine, latamoxef (moxalactam), and CXA-101. From the carbapenem class of β -lactam antibiotics such as
5 imipenem, meropenem, panipenem, biapenem, doripenem, ertapenem and the like could be used. From monobactam class of β -lactam antibiotics such as aztreonam, carumonam, tigemonam, and the like could be used as the combination partner of antibiotic.

Examples of antibiotics (which are not β -lactam antibiotics) which can be used in combination with the compounds of the present invention (i.e., compounds of formula (I)
10 above, salts thereof, solvates of such compounds and salts, and deuterated compounds of any such compounds) include aminoglycosides, quinolones, tetracyclines, glycylicyclines, glycopeptides, lipopeptides, macrolides, ketolides, lincosamides, streptogramin, oxazolidinones, polymyxins, and other compounds known to have antibacterial properties.

'Pharmaceutically acceptable solvate' refers to a molecular complex of a compound with one
15 or more solvent molecules in a stoichiometric or non-stoichiometric amount. Such solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to recipient, e.g., water, ethanol, and the like. A molecular complex of a compound or moiety of a compound and a solvent can be stabilized by non-covalent intramolecular forces such as, for example, electrostatic forces, Van der Waals forces or
20 hydrogen bonds. The term hydrate refers to a complex where the one or more solvent molecules are water.

Among the compounds of formula (I), a particular subject of the invention is the compounds with the following names. The following examples illustrate the invention, and are not intended to be limiting of its scope. To the contrary, the claims are intended to cover
25 alternatives, modifications, and equivalents.

The non-limiting examples of the compounds of the present invention are:

- (2*S*,5*R*)-*N*-(2-hydroxyethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-methoxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-propoxy-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-*N*-(2-aminoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(2-aminopropoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(2-amino-2-oxoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-*N*-[2-(carbamoylamino)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-[2-(sulfamoylamino)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 [([[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)amino)oxy]acetic acid
- 2-methyl-2-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)amino)oxy]propanoic acid
- (2*S*,5*R*)-7-oxo-*N*-[2-(piperidin-4-yloxy)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-7-oxo-*N*-(propan-2-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-*tert*-butoxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(cyclobutyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2*S*,5*R*)-*N*-(cyclopentyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(cyclohexyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 30 (2*S*,5*R*)-*N*-(cycloheptyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

- (2*S*,5*R*)-*N*-[(3-aminocyclopentyl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(2-aminocyclopentyl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-*N*-[[3-(methylamino)cyclopentyl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[[4-(dimethylamino)cyclohexyl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-*N*-[(3-aminocyclohexyl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[[3-(methylamino)cyclohexyl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-3-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-7-oxo-*N*-[(5-oxopyrrolidin-3-yl)oxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-acetylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-methylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-7-oxo-*N*-(piperidin-3-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-(piperidin-4-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2*S*,5*R*)-*N*-(azetidin-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydro-2*H*-pyran-4-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydro-2*H*-thiopyran-4-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 30 (2*S*,5*R*)-*N*-[(1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

- (2*S*,5*R*)-*N*-(azepan-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(1,4-oxazepan-6-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-*N*-[(1-methylpiperidin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-carbamimidoylpiperidin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-2-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-(piperidin-2-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-(piperidin-3-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-7-oxo-*N*-(piperidin-4-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(morpholin-3-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-(piperazin-2-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(thiomorpholin-3-ylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(decahydroquinolin-4-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2*S*,5*R*)-*N*-(hexahydro-1*H*-pyrrolizin-2-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(octahydroindolizin-1-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(octahydropyrrolo[1,2-*a*]pyrazin-8-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 30 (2*S*,5*R*)-*N*-(octahydropyrrolo[1,2-*a*]pyrazin-7-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

- (2*S*,5*R*)-*N*-(octahydrofuro[2,3-*c*]pyridin-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(3-azabicyclo[3.1.0]hex-6-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-*N*-(decahydroquinolin-5-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(hexahydro-4*aH*-cyclopenta[*b*][1,4]dioxin-6-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(octahydrocyclopenta[*c*]pyrrol-5-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-*N*-(hexahydro-1*H*-cyclopenta[*c*]furan-5-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(hexahydro-1*H*-cyclopenta[*c*]thiophen-5-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-*N*-(bicyclo[2.2.1]hept-2-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(7,7-dimethylbicyclo[2.2.1]hept-2-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-*N*-(8-azabicyclo[3.2.1]oct-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(4,5,6,7-tetrahydrothieno[3,2-*c*]pyridin-7-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(6,7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazol-7-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(7-azaspiro[4.5]dec-10-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 30 (2*S*,5*R*)-*N*-(7-oxaspiro[4.5]dec-10-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-(1H-imidazol-2-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-7-oxo-6-(sulfooxy)-N-(4,5,6,7-tetrahydro-1H-4,7-methanoindazol-3-ylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

5 (2S,5R)-7-oxo-N-(1H-pyrazol-3-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-7-oxo-N-[2-(pyridin-2-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

10 (2S,5R)-7-oxo-N-[2-(piperidin-4-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-7-oxo-N-[2-(piperazin-1-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-7-oxo-N-[(1-sulfamoylpyrrolidin-3-yl)oxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

15 (2S,5R)-N-{[1-(methylsulfamoyl)pyrrolidin-3-yl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(1-carbamoylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

20 (2S,5R)-N-[(5-carbamoylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(1-carbamimidoylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(1-ethanimidoylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

25 (2S,5R)-N-{[1-(iminomethyl)pyrrolidin-3-yl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-7-oxo-6-(sulfooxy)-N-(tetrahydrofuran-3-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

30 (2S,5R)-7-oxo-6-(sulfooxy)-N-(tetrahydro-2H-thiopyran-3-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(4-methylpiperidin-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

- (2*S*,5*R*)-*N*-(1,4-oxazepan-2-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydrofuran-2-ylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(4,5,6,7-tetrahydrofuro[3,2-*c*]pyridin-7-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-methyl-4,5,6,7-tetrahydro-1*H*-pyrazolo[3,4-*c*]pyridin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(4,5,6,7-tetrahydro-1*H*-pyrazolo[3,4-*c*]pyridin-4-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-*N*-[2-(1*H*-imidazol-1-yl)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(4-fluoropyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(1,2-oxazolidin-4-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-7-oxo-*N*-(pyrazolidin-4-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(4-aminopyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-7-oxo-*N*-[(4-oxopyrrolidin-3-yl)oxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(4-hydroxypyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-{[(4*E*)-4-(hydroxyimino)pyrrolidin-3-yl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2*S*,5*R*)-*N*-{[(4*E*)-4-(methoxyimino)pyrrolidin-3-yl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-{[(4*E*)-4-[(1,5-dihydroxy-4-oxo-1,4-dihydropyridin-2-yl)methoxy]imino]pyrrolidin-3-yl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 30

- (2*S*,5*R*)-*N*-[(4,4-dimethylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(4-fluoropiperidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-*N*-[(3-fluoropiperidin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-[(5-oxopiperidin-3-yl)oxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(5,5-dimethylpiperidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-*N*-(2-methoxyethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[2-(morpholin-4-yl)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-7-oxo-*N*-[2-(pyrrolidin-1-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-[2-(piperidin-1-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[2-(1,1-dioxidothiomorpholin-4-yl)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-*N*-[(1-methylazetidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[[5-(dimethylcarbamoyl)pyrrolidin-3-yl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 methyl 4-[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]prolinate
- (2*S*,5*R*)-*N*-[[6-(dimethylcarbamoyl)piperidin-3-yl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-methylpyrrolidin-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 30 (2*S*,5*R*)-*N*-[(1-acetylpyrrolidin-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

- (2*S*,5*R*)-*N*-[(1-carbamoylpyrrolidin-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-[(1-sulfamoylpyrrolidin-2-yl)methoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-*N*-[(1-carbamimidoylpyrrolidin-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-methyl-1*H*-pyrazol-3-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-methyl-1*H*-imidazol-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-*N*-[(1-methyl-4,5,6,7-tetrahydro-1*H*-4,7-methanoindazol-3-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1,8-dimethyl-4,5,6,7-tetrahydro-1*H*-4,7-epiminindazol-3-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-*N*-(1*H*-benzimidazol-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(2,3-dihydro-1*H*-indol-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(2-methyl-1*H*-imidazol-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-*N*-[(1-methyl-1*H*-imidazol-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-methyl-1*H*-imidazol-5-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2*S*,5*R*)-*N*-[(2-amino-1,3-thiazol-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(1,3-oxazol-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(1,3-thiazol-4-yl)methoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 30 (2*S*,5*R*)-*N*-[(1-methyl-1*H*-1,2,3-triazol-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-(1*H*-imidazol-4-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[2-(1*H*-imidazol-5-yl)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

5 (2*S*,5*R*)-*N*-[1-(1*H*-imidazol-5-yl)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[(1-methyl-1*H*-pyrrol-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

10 (2*S*,5*R*)-*N*-(1,2-oxazol-3-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(1*H*-1,2,4-triazol-3-ylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[(5-methylpyrazin-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

15 (2*S*,5*R*)-*N*-[(2-aminocyclopropyl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-(morpholin-2-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

20 (2*S*,5*R*)-*N*-[2-(azetidin-3-yloxy)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-7-oxo-*N*-[2-(pyrrolidin-3-yloxy)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-7-oxo-*N*-[2-(piperidin-3-yloxy)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

25 (2*S*,5*R*)-*N*-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-*N*-ethyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-7-oxo-*N*-(propan-2-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

30 (2*S*,5*R*)-*N,N*-dimethyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-*N,N*-diethyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

- (2*S*,5*R*)-7-oxo-*N,N*-di(propan-2-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-cyclopropyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-*N*-cyclobutyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-cyclopentyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(piperidin-4-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydro-2*H*-pyran-4-yl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydro-2*H*-thiopyran-4-yl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(piperidin-3-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-3-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-*N*-acetyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-propanoyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(2-methylpropanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-acetyl-*N*-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-*N*-methyl-7-oxo-*N*-propanoyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-methyl-*N*-(2-methylpropanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 30 (2*S*,5*R*)-*N*-acetyl-*N*-ethyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

- (2*S*,5*R*)-*N*-ethyl-7-oxo-*N*'-propanoyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(2,2-dimethylpropanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-*N*-butanoyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(2-methylbutanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(dimethylamino)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*'-(4,4,4-trifluoropropanoyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(methoxyacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-[(2*R*)-2-aminopropanoyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (non-preferred name)
- 15 (2*S*,5*R*)-*N*'-[amino(phenyl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-(cyclopropylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-*N*'-(cyclobutylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-[(2,2-dimethylcyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-[(2-methylcyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-*N*'-[(2,2-difluorocyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-[(2-fluorocyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 30 (2*S*,5*R*)-*N*'-(cyclopentylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

- (2*S*,5*R*)-*N*'-(cyclohexylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-[(2*R*)-2-aminocyclopentyl]carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-7-oxo-*N*'-(pyrrolidin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*'-(pyrrolidin-3-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-7-oxo-*N*'-(piperidin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-methyl-7-oxo-*N*'-(pyrrolidin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*'-(piperidin-3-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-7-oxo-*N*'-(piperidin-4-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*'-(tetrahydro-2*H*-pyran-4-ylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-[(1-methylpyrrolidin-2-yl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-*N*'-[(1-methylpiperidin-4-yl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*'-(tetrahydro-2*H*-thiopyran-4-ylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-*N*'-[(1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*'-(pyrrolidin-2-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*'-(pyrrolidin-3-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 30 (2*S*,5*R*)-*N*'-[(1-methylpyrrolidin-2-yl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

- (2*S*,5*R*)-*N'*-(cyclopropylacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N'*-(piperidin-2-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-*N'*-[(1-methylpiperidin-2-yl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N'*-(piperidin-3-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-7-oxo-*N'*-(piperidin-4-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N'*-[(1-methylpiperidin-4-yl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N'*-(pyrrolidin-1-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-7-oxo-*N'*-(piperazin-1-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N'*-(morpholin-4-ylacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N'*-(phenylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-*N'*-(naphthalen-2-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N'*-methyl-7-oxo-*N'*-(phenylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-*N'*-ethyl-7-oxo-*N'*-(phenylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N'*-(phenylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N'*-(naphthalen-2-ylacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 30 (2*S*,5*R*)-*N'*-methyl-7-oxo-*N'*-(phenylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

- (2*S*,5*R*)-*N*'-ethyl-7-oxo-*N*'-(phenylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*'-(pyridin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-7-oxo-*N*'-(pyridin-3-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*'-(pyridin-4-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*'-(thiophen-3-ylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-(furan-3-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*'-(thiophen-2-ylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-*N*'-(furan-2-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-methyl-7-oxo-*N*'-(pyridin-3-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*'-(1*H*-pyrrol-2-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*'-(thiophen-2-ylacetyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-[(2-amino-1,3-thiazol-4-yl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-*N*'-(furan-2-ylacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*'-(pyridin-2-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*'-(pyridin-3-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 30 (2*S*,5*R*)-7-oxo-*N*'-(pyridin-4-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-*N*'-[(2-amino-1,3-thiazol-4-yl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-*N*'-[(2-amino-1,3-thiazol-4-yl)acetyl]-*N*'-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

5 (2*S*,5*R*)-*N*'-methyl-7-oxo-*N*'-(pyridin-3-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*'-(trifluoroacetyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

10 (2*S*,5*R*)-*N*'-(methylsulfonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

2-[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}hydrazinecarboxamide

2-[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}hydrazinesulfonamide

15 (2*S*,5*R*)-7-oxo-*N*'-phenyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-*N*'-methyl-7-oxo-*N*'-phenyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-7-oxo-*N*'-(pyridin-3-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

20 (2*S*,5*R*)-*N*'-methyl-7-oxo-*N*'-(pyridin-3-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-7-oxo-*N*'-(piperidin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

25 (2*S*,5*R*)-7-oxo-*N*'-(pyrrolidin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*'-(morpholin-4-yl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-7-oxo-*N*'-(piperazin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

30 (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*'-(thiomorpholin-4-yl)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

- (2S,5R)-N-(1,1-dioxidothiomorpholin-4-yl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-7-oxo-N-(2-oxopiperidin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2S,5R)-7-oxo-N-(3-oxomorpholin-4-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-7-oxo-N-(2-oxopiperazin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2S,5R)-7-oxo-6-(sulfooxy)-N-(tetrahydropyrimidin-1(2H)-yl)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-7-oxo-N-(2-oxotetrahydropyrimidin-1(2H)-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-N-(3-aminopiperidin-1-yl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2S,5R)-N-[(2-aminocyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2S,5R)-N-[(2-aminocyclopropyl)carbonyl]-N'-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2S,5R)-N-(azetidin-2-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2S,5R)-N-(azetidin-3-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2S,5R)-N-[(2S)-2-aminopropanoyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2S,5R)-N-[(2S)-2-aminopropanoyl]-N'-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2S,5R)-N-[3-(dimethylamino)propanoyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2S,5R)-N-[(3,3-difluorocyclobutyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 30 (2S,5R)-N-[(3-aminocyclobutyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-*N*-[3-(methylamino)cyclobutyl]carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-*N*-[3-(dimethylamino)cyclobutyl]carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

5

The compounds of the present invention of formula (I, when Y = OR¹) can be readily prepared by the following reaction Scheme 2 and examples using readily available starting materials, reagents and conventional synthesis procedures known to those of ordinary skill in this art. The methods differ according to the kind of substituted hydroxylamines of general formula (V) used to prepare the bicyclic diazaoctane derivatives. The bicyclic intermediate acid (VI) may be prepared following the patent literature WO 2009/091856.

Compounds of general formula (I, Y = OR¹, M = H) can be prepared by coupling an appropriately substituted hydroxylamine (V) with the bicyclic acid (VI) in presence of a suitable coupling reagent to give the desired intermediate (VII). The coupling reagents useful for carrying out this step include, but are not limited to, EDCI, HOBT-DCC, HATU, HOBT, PyBop and the like. The organic solvents useful in the reaction are not particularly limited and include any of those which do not adversely affect the coupling reaction. Typical solvents include DCM, chloroform, dimethylformamide, dimethylacetamide, tetrahydrofuran, acetonitrile, dimethylsulfoxide, acetonitrile, and the like. The reaction is normally carried out at a temperature of from about 0 °C to about 30 °C and preferably at room temperature under nitrogen. After completion of the reaction the desired product can be easily separated by conventional methods such as column chromatography, crystallization or similar methods.

In the following step, the intermediate (VII) could be converted to compound (VIII) under an atmosphere of hydrogen or hydrogen mixed with an inert diluent such as nitrogen or argon in the presence of a hydrogenation catalyst. The catalysts used in this hydrogenation reaction are the type of agents known in the art for this kind of deprotection and typical examples are the noble metals, such as nickel, palladium, platinum and rhodium. Examples of the catalysts are platinum, platinum oxide, palladium, palladium oxide and the like. The catalyst is usually present in the amount from about 1 to about 50 weight percent and preferably from about 5 to about 10 weight percent based on the compound of formula (I). It is often convenient to suspend the catalyst on an inert support. A particularly convenient catalyst is palladium suspended on an inert support such as carbon, e.g 10 % by weight palladium on carbon. This reaction may be conveniently effected at ambient temperature at 40 psi until reaction is complete (2 to 12 hours). Suitable solvents for this reaction are those which substantially dissolve the starting material of the formula (VII), are sufficiently volatile to be removed by evaporation and do not themselves suffer hydrogenation. Examples of such solvents include


methanol, ethanol, dioxane, ethyl acetate, tetrahydrofuran or a mixture of these solvents. Upon completion, the hydroxy intermediate (VIII) can be purified by silica gel column chromatography or in many cases can be directly carried out to the next step without further purification.

- 5 Sulfation of the intermediate (VIII) can be achieved using a sulfating reagent (e.g., pyridine-SO₃ complex, ClSO₃H and DMF-SO₃ complex) in an appropriate solvent (e.g., pyridine or 2-picoline), e.g., as described in the literature (US 4337197 A1, *J. Am. Chem. Soc.*, 1982, 104, 6053-6060). Thus, SO₃-Py complex can be added to a solution of the intermediate (VIII) in a solvent in excess amount, if desired, to force the reaction to completion. The organic
10 solvents useful for this transformation are not particularly limited and include those which do not adversely affect the reaction. Typical solvents include, but not limited to, pyridine, dimethyl formamide, dimethylacetamide, acetonitrile, DCM, and the like. The transformation can be carried out at from 10 °C to 40 °C, and more preferably at room temperature. The product (IX) can be isolated by standard procedure that is by filtering the reaction mixture,
15 concentrating the filtrate, suspending the concentrate in a saturated aqueous potassium dihydrogenphosphate solution, washing the aqueous layer with ethyl acetate, adding excess amount of tetrabutylammonium hydrogen sulfate to the aqueous layer, extracting the mixture with organic solvent, such as ethyl acetate, combining the organic layers, drying and concentrating to provide the tetrabutylammonium salt intermediate. Treating the intermediate
20 (IX) with an acid to obtain a compound of formula (Ia, M = H), wherein R¹ has the same definition as in formula (I). Suitable organic acids include trifluoroacetic acid, methanesulfonic acid, trifluoromethane sulfonic acid, and formic acid. The treatment is suitably conducted at a temperature in a range from about -10 °C to about 30 °C and is typically conducted at a temperature in a range of from about 0 °C to about 10 °C.
- 25 The substituted hydroxylamines (V) used in the invention can be prepared by a two steps procedure using the methods well known in the art. Thus, the alcohol (II) is reacted with *N*-hydroxyphthalimide (III) in presence of PPh₃ under Mitsunobu conditions to provide the intermediate (IV). Treating (IV) with hydrazine hydrate in presence of a solvent provides the desired substituted hydroxylamine (V) which can be used without further purification
30 (Scheme 1).

Similarly, compounds of general formula (I, Y = NR²R³, M = H) can be prepared by coupling an appropriately substituted hydrazine (Va) with the bicyclic acid (VI) in presence of a suitable coupling reagent to give the desired intermediate (VIIa). Utilizing the intermediate (VIIa) and carrying out similar sets of experiments as described for (Ia), the desired
35 compounds (Ib, M = H) of the present invention can be obtained as shown in Scheme 3. The


substituted hydrazines (Va) used in the present invention can be obtained from the commercial source or can be prepared by the known literature procedure.

Scheme 1




5

Scheme 2



Scheme 3



Examples

5 In the examples, the following abbreviations have been used:

Bn: benzyl

Boc: *N*-*tert*-butoxycarbonyl

br s: broad singlet

CDCl_3 : deuterated chloroform

10 CD_3OD : deuterated methanol

d: doublet

D_2O : deuterium oxide

DCC: *N,N'*-dicyclohexylcarbodiimide

DCM: dichloromethane

15 DIAD: diisopropyl azodicarboxylate

DMAP: 4-dimethylaminopyridine

EDCI: 1-(3-dimethylamino-propyl)-3-ethylcarbodiimide hydrochloride

El: electron impact

ES: electron spray

FAB: fast atom bombardment

5 g: gram(s)

h: hour(s)

HOBT: *N*-hydroxybenzotriazole

HATU: 2-(7-aza-1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate

10 HPLC: high-performance liquid chromatography

Hz: Hertz

J: coupling constant

m: multiplet

mL: milliliter(s)

15 mmol: millimole(s)

MHz: megahertz

MS: mass spectrometry

m/z: mass-to-charge ratio

NMR: nuclear magnetic resonance

20 Pd/C: palladium on carbon

PyBop: (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate

s: singlet

t: triplet

TFA: trifluoroacetic acid


THF: tetrahydrofuran

δ : chemical shift in parts per million (ppm) by frequency

5


Example 1

(2S,5R)-7-Oxo-N-[(3R)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 1, Table 1)



Step 1. *tert*-Butyl (3R)-3-[[[[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]pyrrolidine-1-carboxylate (3)

10




To a solution of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.15 g, 0.54 mmol) in dry DCM (20 mL) were added *tert*-butyl (3R)-3-(aminooxy)pyrrolidine-1-carboxylate **2** (0.17 g, 0.81 mmol, *J. Med. Chem.* 2008, 51, 4601-4608), 1-hydroxybenzotriazole (0.11 g, 0.81 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.16 g, 0.81 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight, and then concentrated under vacuum. The residue was purified by column chromatography to give compound *tert*-butyl (3R)-3-[[[[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]pyrrolidine-1-carboxylate **3** (0.23 g, 93%) as a clear thick oil.

15

20

^1H NMR (400 MHz, CDCl_3): δ 1.26 (9H, s), 1.62 (1H, m), 1.96 (3H, m), 2.17 (1H, m), 2.28 (1H, m), 2.75 (1H, d, $J = 11.6$ Hz), 3.01 (1H, d, $J = 12.0$ Hz), 3.31-3.66 (5H, m), 3.96 (1H, m), 4.64 (1H, m), 4.89 (1H, d, $J = 11.2$ Hz), 5.04 (1H, d, $J = 11.6$ Hz), 7.41 (5H, m), 9.16 (1H, br s).


Step 2. *tert*-Butyl (3*R*)-3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]pyrrolidine-1-carboxylate (4)



To a solution of *tert*-butyl (3*R*)-3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]pyrrolidine-1-carboxylate **3** (0.23 g, 0.50 mmol) in methanol (15 mL) was added 5% Pd/C (0.3 g). The mixture was hydrogenated at 35 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give *tert*-butyl (3*R*)-3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]pyrrolidine-1-carboxylate **4** (0.18 g, 93%) as a colorless foam.


¹H NMR (400 MHz, CD₃OD): δ 1.43 (9H, s), 1.68-2.09 (4H, m), 2.20 (2H, m), 3.03 (1H, d, J = 12.0 Hz), 3.20 (3H, m), 3.60 (1H, d, J = 12.0 Hz), 3.70 (1H, s), 3.86 (1H, d, J = 7.2 Hz), 4.60 (1H, m), 2 protons were not observed in CD₃OD.

Step 3. *tert*-Butyl (3*R*)-3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]pyrrolidine-1-carboxylate pyridine salt (5)



To a solution of *tert*-butyl (3*R*)-3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]pyrrolidine-1-carboxylate **4** (0.18 g, 0.486 mmol) in dry pyridine (7 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.31 g, 1.94 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated to give *tert*-butyl (3*R*)-3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]pyrrolidine-1-carboxylate pyridine salt **5** (0.22 g crude) which was used in the next step without purification.


Step 4. *N,N,N*-Tributylbutan-1-aminium ([[(2*S*,5*R*)-2-([[(3*R*)-1-(*tert*-butoxycarbonyl)pyrrolidin-3-yl]oxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide (**6**)



tert-Butyl (3*R*)-3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]-amino]oxy]pyrrolidine-1-carboxylate pyridine salt **5** (0.22 g, 0.48 mmol) was introduced into a concentrated aqueous solution of monosodium dihydrogen phosphate solution (7 mL) so as to obtain a pH of 4. The mixture was washed with ethyl acetate, then added tetrabutyl ammonium hydrogen sulfate (0.10 g, 0.30 mmol) and stirred at room temperature for 10 min. The mixture was extracted with ethyl acetate (3 x 10 mL), and the extracts were combined, dried over sodium sulfate and evaporated to give *N,N,N*-tributylbutan-1-aminium ([[(2*S*,5*R*)-2-([[(3*R*)-1-(*tert*-butoxycarbonyl)pyrrolidin-3-yl]oxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide **6** (0.245 g, 80%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.00 (12H, t, J = 7.2 Hz), 1.43 (17H, m), 1.65 (8H, m), 1.90 (3H, m), 2.18 (2H, m), 2.34 (1H, m), 2.82 (1H, d, J = 12 Hz), 3.28 (8H, m), 3.30-3.66 (5H, m), 3.94 (1H, d, J = 7.6 Hz), 4.35 (1H, m), 4.66 (1H, s), 9.17 (1H, br s).

Step 5. (2*S*,5*R*)-7-Oxo-*N*-[(3*R*)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 1, Table 1)



To a solution of *N,N,N*-tributylbutan-1-aminium ([[(2*S*,5*R*)-2-([[(3*R*)-1-(*tert*-butoxycarbonyl)pyrrolidin-3-yl]oxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide **6** (0.245 g, 0.35 mmol) in DCM (14 mL) was added trifluoroacetic acid (0.70 mL, 9.08 mmol) dropwise at 0 °C. The reaction mixture was stirred for 1 h, then evaporated. Ether was added to the residue and the resulting white precipitate was collected by centrifugation. The solid was triturated with acetonitrile (2 x) and the white solid was

collected by centrifugation. The white solid was purified by HPLC on a prep-X Bridge-19 x 250 mm column and freeze-dried to give (2*S*,5*R*)-7-oxo-*N*-[(3*R*)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **Compound 1** (Table 1) (0.03 g, 25%) as a white solid.

- 5 ¹H NMR (400 MHz, D₂O): δ 1.73 (1H, m), 1.87 (1H, m), 1.95-2.13 (3H, m), 2.16-2.40 (2H, m), 2.99 (1H, d, J = 12.4 Hz), 3.19 (1H, d, J = 11.6 Hz), 3.26-3.90 (3H, m), 3.46 (1H, d, J = 13.2 Hz), 3.96 (1H, d, J = 7.2 Hz), 4.08 (1H, s), 3 protons were not observed in D₂O.


HPLC: 97.24 %

MS (ES⁺): m/z: [M]⁺ = 348.89

10


Example 2

(2*S*,5*R*)-7-Oxo-*N*-[(3*S*)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (**Compound 2**, Table 1)



Step 1. *tert*-Butyl (3*S*)-3-[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]pyrrolidine-1-carboxylate (**8**)

15




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.150 g, 0.543 mmol, US 2005/20572 A1) in DCM (4.0 mL) were added *tert*-butyl (3*S*)-3-(aminooxy)pyrrolidine-1-carboxylate **7** (0.164 g, 0.814 mmol, WO 2008/67481 A1), 1-hydroxybenzotriazole (0.110 g, 0.814 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.156 g, 0.814 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **8** (0.22 g, 88 %) as a white foam.

20

^1H NMR (400 MHz, CDCl_3): δ 1.46 (9H, s), 1.61 (1H, m), 1.93 (3H, m), 2.17 (1H, m), 2.30 (1H, m), 2.72 (1H, d, $J = 11.6$ Hz), 2.99 (1H, m), 3.45 (5H, m), 3.99 (1H, m), 4.60 (1H, m), 4.92 (1H, d, $J = 11.6$ Hz), 5.04 (1H, d, $J = 11.6$ Hz), 7.42 (5H, m), 9.00 (1H, br s).

MS (ES $^-$) m/z : $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{23}\text{H}_{31}\text{N}_4\text{O}_6$: 459.22. Found: 459.08.

5 **Step 2.** *tert*-Butyl (3*S*)-3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo [3.2.1]oct-2-yl]carbonyl]amino)oxy]pyrrolidine-1-carboxylate (**9**)




A mixture of *tert*-butyl (3*S*)-3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1] oct-2-yl]carbonyl]amino)oxy]pyrrolidine-1-carboxylate **8** (0.22 g, 0.48 mmol) and Pd/C (0.070 g) in methanol (10 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to provide **9** (0.19 g, quant. yield) as a light yellow foam.

^1H NMR (400 MHz, CD_3OD): δ 1.46 (9H, m), 1.75-2.20 (6H, m), 3.03 (1H, d, $J = 11.6$ Hz), 3.17 (1H, m), 3.44 (3H, m), 3.63 (1H, d, $J = 13.2$ Hz), 3.69 (1H, m), 3.86 (1H, d, $J = 7.2$ Hz), 4.58 (1H, t, $J = 3.6$ Hz). 2 protons were not observed in CD_3OD .

MS (ES $^-$): m/z $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{16}\text{H}_{25}\text{N}_4\text{O}_6$: 369.18. Found: 369.06.

Step 3. *tert*-Butyl (3*S*)-3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1] oct-2-yl]carbonyl]amino)oxy]pyrrolidine-1-carboxylate (**10**)



To a mixture of *tert*-butyl (3*S*)-3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]pyrrolidine-1-carboxylate **9** (0.19 g, 0.51 mmol) in pyridine (7.0 mL) was added sulfur trioxide pyridine complex (0.326 g, 2.05 mmol). The mixture was stirred at room temperature for 23 h and concentrated to provide a residue which was subjected to chromatography to give **10** (0.11 g, 48 %) as a white solid.

^1H NMR (400 MHz, CD_3OD): δ 1.47 (9H, s), 1.80-2.20 (6H, m), 3.07 (1H, d, $J = 12$ Hz), 3.27 (1H, m), 3.44 (3H, m), 3.60 (1H, m), 3.92 (1H, d, $J = 11.6$ Hz), 4.14 (1H, m), 4.59 (1H, m). 2 protons were not observed in CD_3OD .

MS (ES^-): m/z $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{16}\text{H}_{25}\text{N}_4\text{O}_9\text{S}$: 449.13. Found: 448.99.

5 **Step 4. (2S,5R)-7-Oxo-N-[(3S)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 2, Table 1)**



10 To a mixture of *tert*-butyl (3S)-3-[[[(2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]pyrrolidine-1-carboxylate **10** (0.11 g, 0.24 mmol) in DCM (4.0 mL) was added trifluoroacetic acid (0.20 mL) at 0°C . The mixture was stirred at 0°C for 1 h, concentrated and washed with ether. The white solid was collected by centrifugation. The crude product was purified by preparative HPLC to provide **Compound 2 (Table 1)** (30.4 mg, 36 %) as a white solid.


15 ^1H NMR (400 MHz, D_2O): δ 1.74-1.83 (2H, m), 1.91-2.11 (3H, m), 2.18-2.22 (1H, m), 2.98 (1H, d, $J = 12$ Hz), 3.17 (1H, m), 3.27-3.34 (3H, m), 3.45 (1H, dd, $J = 0.8$ Hz, 13.6 Hz), 3.94 (1H, m), 4.06 (1H, m), 4.71 (1H, m). 3 protons were not observed in D_2O .

HPLC: 96.77 %


MS (ES^-): m/z $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{11}\text{H}_{17}\text{N}_4\text{O}_7\text{S}$: 349.08. Found: 348.95.

Example 3

20 **(2S,5R)-7-Oxo-N-[(3R)-piperidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 3, Table 1)**




Step 1. *tert*-Butyl (3*R*)-3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate (12)



To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.20 g, 0.72 mmol) in dry DCM (20 mL) were added *tert*-butyl (3*R*)-3-(aminooxy)piperidine-1-carboxylate **11** (0.19 g, 0.86 mmol, *J. Med. Chem.* 2008, 51, 4601-4608), 1-hydroxybenzotriazole (0.14 g, 1.03 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.20 g, 1.03 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight, and then concentrated under vacuum. The residue was purified by column chromatography to give *tert*-butyl (3*R*)-3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate **12** (0.28 g, 82 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.46 (9H, s), 1.61 (1H, m), 1.83 (2H, m), 2.01 (4H, m), 2.31 (1H, m), 2.79 (1H, d, *J* = 11.2 Hz), 2.99 (3H, m), 3.30 (1H, s), 3.60-4.11 (4H, m), 4.88 (1H, d, *J* = 11.6 Hz), 5.05 (1H, d, *J* = 11.6 Hz), 7.39 (5H, m), 9.96 (1H, br s).


Step 2. *tert*-Butyl (3*R*)-3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate (13)



To a solution of *tert*-butyl (3*R*)-3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate **12** (0.28 g, 0.59 mmol) in methanol (20 mL) was added 5% Pd/C (0.25 g). The mixture was hydrogenated at 35 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give *tert*-butyl (3*R*)-3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate **13** (0.21 g, 91%) as a white solid.


^1H NMR (400 MHz, CD_3OD): δ 1.45 (9H, s), 1.68-1.98 (6H, m), 2.05 (1H, m), 2.22 (1H, m), 3.03 (1H, d, $J = 12.0$ Hz), 3.13 (1H, d, $J = 11.6$ Hz), 3.28-3.59 (4H, m), 3.71 (1H, s), 3.87 (2H, m), 2 protons were not observed in CD_3OD .

Step 3. *tert*-Butyl (3*R*)-3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate pyridine salt (14)



To a solution of *tert*-butyl (3*R*)-3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate **13** (0.21 g, 0.55 mmol) in dry pyridine (8 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.35 g, 2.20 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated to give *tert*-butyl (3*R*)-3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate pyridine salt **14** (0.30 g crude) which was used in the next step without purification.

Step 4. *N,N,N*-Tributylbutan-1-aminium ([[(2*S*,5*R*)-2-([[(3*R*)-1-(*tert*-butoxycarbonyl)piperidin-3-yl]oxy]carbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide (15)




tert-Butyl (3*R*)-3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate pyridine salt **14** (0.30 g, 0.55 mmol) was introduced into a concentrated aqueous solution of monosodium dihydrogen phosphate solution (8 mL) so as to obtain a pH of 4. The mixture was washed with ethyl acetate, then added tetrabutyl ammonium hydrogen sulfate (0.117 g, 0.34 mmol) and stirred at room temperature for 10 min. The mixture was extracted with ethyl acetate (3 x 20 mL), and the extracts were combined, dried over sodium sulfate and evaporated to give *N,N,N*-tributylbutan-1-aminium ([[(2*S*,5*R*)-2-([[(3*R*)-1-(*tert*-butoxycarbonyl)piperidin-3-

yl]oxy}carbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide **15** (0.3 g, 77%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 0.98 (12H, t, J = 7.2 Hz), 1.42 (17H, m), 1.65 (8H, m), 1.77 (4H, m), 2.05 (3H, m), 2.33 (1H, m), 2.85 (1H, d, J = 11.6 Hz), 2.96 (2H, m), 3.24 (9H, m), 3.65 (1H, m), 3.95 (2H, m), 4.10 (1H, m), 4.13 (1H, s), 10.00 (1H, br s).

Step 5. (2S,5R)-7-Oxo-N-[(3R)-piperidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 3, Table 1)



To a solution of *N,N,N*-tributylbutan-1-aminium ([[(2*S*,5*R*)-2-([(3*R*)-1-(*tert*-butoxycarbonyl)piperidin-3-yl]oxy}carbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide **15** (0.30 g, 0.42 mmol) in DCM (17 mL) was added trifluoroacetic acid (0.84 mL, 10.9 mmol) dropwise at 0 °C. The reaction mixture was stirred for 1 h, then evaporated. Ether was added to the residue and the resulting white precipitate was collected by centrifugation. The solid was triturated with acetonitrile (2 x) and the white solid was collected by centrifugation. The white solid was purified by HPLC and freeze-dried to give (2*S*,5*R*)-7-oxo-*N*-[(3*R*)-piperidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **Compound 3 (Table 1)** (0.045 g, 29.41 %) as a white solid.


¹H NMR (400 MHz, CD₃OD): δ 1.60-1.78 (3H, m), 1.80-2.08 (5H, m), 2.92-3.04 (2H, m), 3.14-3.26 (2H, m), 3.30 (1H, d, J = 13.2 Hz), 3.94-4.02 (2H, m), 4.08 (1H, d, s), 4.18 (1H, s), 3 protons were not observed in CD₃OD.

HPLC: 95.81 %


MS (ES⁺): m/z: [M]⁺ = 363.02

Example 4

(2*S*,5*R*)-7-Oxo-*N*-[(3*S*)-piperidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 4, Table 1)




- 5 Step 1. *tert*-Butyl (3*S*)-3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate (17)



To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.20 g, 0.72 mmol) in dry DCM (20 mL) were added *tert*-butyl (3*S*)-3-(aminooxy)piperidine-1-carboxylate **16** (0.19 g, 0.86 mmol, *J. Med. Chem.* 2008, 51, 4601-4608), 1-hydroxybenzotriazole (0.14 g, 1.03 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.20 g, 1.03 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give *tert*-butyl (3*S*)-3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate **17** (0.28 g, 82 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.46 (9H, s), 1.61 (1H, m), 1.83 (2H, m), 2.01 (4H, m), 2.31 (1H, m), 2.79 (1H, d, *J* = 11.2 Hz), 2.99 (3H, m), 3.30 (1H, s), 3.60-4.11 (4H, m), 4.88 (1H, d, *J* = 11.6 Hz), 5.05 (1H, d, *J* = 11.6 Hz), 7.39 (5H, m), 9.96 (1H, br s).


Step 2. *tert*-Butyl (3*S*)-3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate (18)



To a solution of *tert*-butyl (3*S*)-3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate **17** (0.28 g, 0.59 mmol) in methanol (20 mL) was added 5 % Pd/C (0.25 g). The mixture was hydrogenated at 35 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give *tert*-butyl (3*S*)-3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate **18** (0.22 g, 97 %) as a white solid.


¹H NMR (400 MHz, CDCl₃): δ 1.45 (9H, s), 1.68-1.98 (6H, m), 2.05 (1H, m), 2.22 (1H, m), 3.03 (1H, d, J = 12.0 Hz), 3.13 (1H, d, J = 11.6 Hz), 3.28-3.59 (4H, m), 3.71 (1H, s), 3.87 (2H, m), 2 protons were not observed in CD₃OD.

Step 3. *tert*-Butyl (3*S*)-3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate pyridine salt (19)




To a solution of *tert*-butyl (3*S*)-3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate **18** (0.22 g, 0.57 mmol) in dry pyridine (8 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.40 g, 2.51 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated to give *tert*-butyl (3*S*)-3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate pyridine salt **19** (0.23 g crude) which was used in the next step without purification.

Step 4. *N,N,N*-Tributylbutan-1-aminium (((2*S*,5*R*)-2-(((3*S*)-1-(*tert*-butoxycarbonyl)piperidin-3-yl]oxy)carbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide (20)



- 5 *tert*-Butyl (3*S*)-3-((((2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)amino)oxy)piperidine-1-carboxylate pyridine salt **19** (0.23 g, 0.42 mmol) was introduced into a concentrated aqueous solution of monosodium dihydrogen phosphate solution (8 mL) so as to obtain a pH of 4. The mixture was washed with ethyl acetate, then added tetrabutyl ammonium hydrogen sulfate (0.088 g, 0.26 mmol) and stirred at room
- 10 temperature for 10 min. The mixture was extracted with ethyl acetate (3 x 20 mL), and the extracts were combined, dried over sodium sulfate and evaporated to give *N,N,N*-tributylbutan-1-aminium (((2*S*,5*R*)-2-(((3*S*)-1-(*tert*-butoxycarbonyl)piperidin-3-yl]oxy)carbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide **20** (0.23 g, 52.5 %) as a white solid.
- 15 ^1H NMR (400 MHz, CDCl_3): δ 0.98 (12H, t, $J = 7.2$ Hz), 1.42 (17H, m), 1.65 (8H, m), 1.77 (4H, m), 2.05 (3H, m), 2.33 (1H, m), 2.85 (1H, d, $J = 11.6$ Hz), 2.96 (2H, m), 3.24 (9H, m), 3.65 (1H, m), 3.95 (2H, m), 4.10 (1H, m), 4.13 (1H, s), 10.00 (1H, br s).

Step 5. (2*S*,5*R*)-7-Oxo-*N*-[(3*S*)-piperidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 4, Table 1)



20

20

compound 4, Table 1

- To a solution of *N,N,N*-tributylbutan-1-aminium (((2*S*,5*R*)-2-(((3*S*)-1-(*tert*-butoxycarbonyl)piperidin-3-yl]oxy)carbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide **20** (0.23 g, 0.32 mmol) in DCM (15 mL) was added trifluoroacetic acid (0.64 mL, 8.32 mmol) dropwise at 0 °C. The reaction mixture was stirred for 1 h, then
- 25 evaporated. Ether was added to the residue and the resulting white precipitate was collected by centrifugation. The solid was triturated with acetonitrile (2 x) and the white solid was

collected by centrifugation. The white solid was purified by HPLC and freeze-dried to give (2*S*,5*R*)-7-oxo-*N*-[(3*S*)-piperidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **Compound 4** (Table 1) (0.008 g, 6.8 %) as a white solid.


¹H NMR (400 MHz, CD₃OD): δ 1.60-1.78 (3H, m), 1.80-2.08 (5H, m), 2.92-3.04 (2H, m),
 5 3.14-3.26 (2H, m), 3.30 (1H, d, *J* = 13.2 Hz), 3.94-4.02 (2H, m), 4.08 (1H, d, *s*), 4.18 (1H, *s*),
 3 protons were not observed in CD₃OD.

HPLC: 97.05 %


MS (ES⁻): *m/z* [*M*]⁻ = 363.02

Example 5

10 **Sodium [(((2*S*,5*R*)-2-[(cyclohexyloxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide (Compound 5, Table 1)**



Step 1. (2*S*,5*R*)-6-(Benzyloxy)-*N*-(cyclohexyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (22)




15

To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.2 g, 0.72 mmol) in dry DCM (20 mL) were added (aminooxy)cyclohexane **21** (0.1 g, 0.86 mmol, US 2008/146625 A1), 1-hydroxybenzotriazole (0.14 g, 1.1 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.2 g, 1.1 mmol) at room temperature. The
 20 reaction mixture was stirred at room temperature overnight, and then concentrated under vacuum. The residue was purified by column chromatography to give (2*S*,5*R*)-6-(benzyloxy)-*N*-(cyclohexyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **22** (0.24 g, 89.5 %) as a clear thick oil.

^1H NMR (400 MHz, CDCl_3): δ 1.23 (3H, m), 1.42 (2H, m), 1.54 (1H, m), 1.68 (1H, m), 1.76 (2H, m), 2.02 (4H, m), 2.36 (1H, m), 2.80 (1H, d, $J = 11.6$ Hz), 2.99 (1H, d, $J = 12.0$ Hz), 3.30 (1H, s), 3.86 (1H, m), 3.96 (1H, d, $J = 7.2$ Hz), 4.89 (1H, d, $J = 11.2$ Hz), 5.04 (1H, d, $J = 12.0$ Hz), 7.39 (5H, m), 8.92 (1H, br s).


5 **Step 2. (2S,5R)-N-(Cyclohexyloxy)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (23)**



To a solution of (2S,5R)-6-(benzyloxy)-N-(cyclohexyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **22** (0.24 g, 0.64 mmol) in methanol (20 mL) was added 5 % Pd/C (0.30 g). The mixture was hydrogenated at 35 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give (2S,5R)-N-(cyclohexyloxy)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **23** (0.155 g, 85 %) as a colorless foam.

^1H NMR (400 MHz, CD_3OD): δ 1.32 (3H, m), 1.44 (2H, m), 1.55 (1H, m), 1.79 (3H, m), 1.87 (3H, m), 2.06 (1H, m), 2.16 (1H, m), 3.10 (2H, m), 3.70 (1H, s), 3.80 (2H, m), 2 protons were not observed in CD_3OD .


Step 3. (2S,5R)-N-(Cyclohexyloxy)-7-oxo-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide pyridine salt (24)



To a solution of (2S,5R)-N-(cyclohexyloxy)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **23** (0.155 g, 0.55 mmol) in dry pyridine (7 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.40 g, 2.51 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated to give (2S,5R)-N-(cyclohexyloxy)-7-oxo-6-

(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide pyridine salt **24** (0.21 g crude) which was used in the next step without purification.


Step 4. *N,N,N*-Tributylbutan-1-aminium [(((2*S*,5*R*)-2-[(cyclohexyloxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide (25**)**



(2*S*,5*R*)-*N*-(Cyclohexyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide pyridine salt **24** (0.21 g, 0.47 mmol) was introduced into a concentrated aqueous solution of monosodium dihydrogen phosphate solution (8 mL) so as to obtain a pH of 4. The mixture was washed with ethyl acetate, then added tetrabutyl ammonium hydrogen sulfate (0.11 g, 0.32 mmol) and stirred at room temperature for 10 min. The mixture was extracted with ethyl acetate (3 x 20 mL), and the extracts were combined, dried over sodium sulfate and evaporated to give *N,N,N*-tributylbutan-1-aminium [(((2*S*,5*R*)-2-[(cyclohexyloxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide **25** (0.16 g, 56 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.00 (12H, t, *J* = 7.2 Hz), 1.18 (3H, m), 1.46 (12H, m), 1.66 (12H, m), 1.94 (2H, m), 2.15 (1H, m), 2.38 (1H, m), 2.84 (1H, d, *J* = 11.2 Hz), 3.29 (8H, m), 3.87 (1H, m), 3.93 (1H, d, *J* = 8.0 Hz), 4.35 (1H, s), 8.98 (1H, br s).

Step 5. Sodium [(((2*S*,5*R*)-2-[(cyclohexyloxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide (Compound 5, Table 1)



To a suspension of *N,N,N*-tributylbutan-1-aminium [(((2*S*,5*R*)-2-[(cyclohexyloxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide **25** (0.16 g, 0.26 mmol) in water (20 mL) was added DOWEX 50WX4 (2 g). The mixture was stirred at room temperature for 2 h, and then filtered. The filtrate was freeze-dried to give a yellow solid which was purified by HPLC and freeze-dried to give sodium [(((2*S*,5*R*)-2-[(cyclohexyloxy)carbamoyl]-7-oxo-1,6-

diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide **Compound 5** (Table 1) (0.05 g, 50 %) as a white solid.


¹H NMR (400 MHz, CD₃OD): δ 1.22-1.35 (3H, m), 1.38-1.45 (2H, m), 1.55 (1H, m), 1.78-1.89 (4H, m), 1.91-1.97 (3H, m), 2.07 (1H, m), 2.10 (1H, m), 3.10 (1H, d, J = 11.6 Hz), 3.80 (1H, m), 3.90 (1H, d, J = 6.8 Hz), 4.15 (1H, m), 1 proton was not observed in CD₃OD.

HPLC: 96.82 %


MS (ES⁻): m/z [M-Na]⁺ = 362.08

Example 6

(2S,5R)-7-Oxo-N-(piperidin-4-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 6, Table 1)



Step 1. tert-Butyl 4-[[{[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}amino]oxy]piperidine-1-carboxylate (27)




To a solution of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.3 g, 1.085 mmol) in dry DCM (20 mL) were added *tert*-butyl 4-(aminooxy)piperidine-1-carboxylate **26** (0.29 g, 1.302 mmol, *J. Med. Chem.* 2008, 51, 4601-4608), 1-hydroxybenzotriazole (0.22 g, 1.63 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.31 g, 1.63 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give *tert*-butyl 4-[[{[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-

diazabicyclo[3.2.1]oct-2-yl]carbonyl)amino)oxy]piperidine-1-carboxylate **27** (0.5 g, 98 %) as a clear thick oil.

¹H NMR (400 MHz, CDCl₃): δ 1.45 (9H, s), 1.64 (4H, m), 1.93 (3H, m), 2.34 (1H, m), 2.75 (1H, d, J = 11.6 Hz), 3.00 (1H, d, J = 11.6 Hz), 3.13 (2H, m), 3.31 (1H, s), 3.77 (2H, m), 3.96 (1H, d, J = 7.2 Hz), 4.04 (1H, m), 4.92 (1H, d, J = 11.6 Hz), 5.05 (1H, d, J = 11.6 Hz), 7.41 (5H, m), 8.99 (1H, br s).


Step 2. *tert*-Butyl 4-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)amino)oxy]piperidine-1-carboxylate (28**)**



To a solution of *tert*-butyl 4-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)amino)oxy]piperidine-1-carboxylate **27** (0.5 g, 1.05 mmol) in methanol (30 mL) was added 5 % Pd/C (0.5 g). The mixture was hydrogenated under 35 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give *tert*-butyl 4-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)amino)oxy]piperidine-1-carboxylate **28** (0.395 g, 98 %) as a colorless foam.

¹H NMR (400 MHz, CD₃OD): δ 1.45 (9H, s), 1.60 (2H, m), 1.85 (4H, m), 2.06 (1H, m), 2.18 (1H, m), 3.25 (4H, m), 3.73 (3H, m), 3.84 (1H, d, J = 7.2 Hz), 4.00 (1H, m), 2 protons were not observed in CD₃OD.

Step 3. *tert*-Butyl 4-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)amino)oxy]piperidine-1-carboxylate pyridine salt (29**)**




To a solution of *tert*-butyl 4-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)amino)oxy]piperidine-1-carboxylate **28** (0.395 g, 1.03 mmol) in dry pyridine (15

mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.8 g, 4.86 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated to give *tert*-butyl

4-[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate pyridine salt **29** (0.49 g crude) which was

5 used in the next step without purification.

Step 4. *N,N,N*-Tributylbutan-1-aminium ([[(2*S*,5*R*)-2-([1-(*tert*-butoxycarbonyl)piperidin-4-yl]oxy)carbonyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl]oxidanide (**30**)




10 *tert*-Butyl 4-[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidine-1-carboxylate pyridine salt **29** (0.49 g, 1.02 mmol) was introduced into a concentrated aqueous solution of monosodium dihydrogen phosphate solution (11 mL) so as to obtain a pH of 4. The mixture was washed with ethyl acetate, then added tetrabutyl ammonium hydrogen sulfate (0.31 g, 0.91 mmol) and stirred at room

15 temperature for 10 min. The mixture was extracted with ethyl acetate (3 x 40 mL), and the extracts were combined, dried over sodium sulfate and evaporated to give *N,N,N*-tributylbutan-1-aminium ([[(2*S*,5*R*)-2-([1-(*tert*-butoxycarbonyl)piperidin-4-yl]oxy)carbonyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl]oxidanide **30** (0.64 g, 87 %) as a white solid.

20 ¹H NMR (400 MHz, CDCl₃): δ 1.00 (12H, t, J = 7.2 Hz), 1.43 (17H, m), 1.67 (11H, m), 1.88 (3H, m), 2.19 (1H, m), 2.36 (1H, m), 2.82 (1H, d, J = 11.6), 3.17 (2H, m), 3.29 (9H, m), 3.78 (2H, m), 3.94 (1H, d, J = 8.0 Hz), 4.06 (1H, m), 4.35 (1H, s), 9.06 (1H, br s).

Step 5. (2*S*,5*R*)-7-Oxo-*N*-(piperidin-4-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 6, Table 1)



To a solution of *N,N,N*-tributylbutan-1-aminium ([[(2*S*,5*R*)-2-([1-(*tert*-butoxycarbonyl)piperidin-4-yl]oxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl]oxidanide **30** (0.64 g, 0.89 mmol) in DCM (36 mL) was added trifluoroacetic acid (1.78 mL, 23.1 mmol) dropwise at 0 °C. The reaction mixture was stirred for 1 h, then evaporated. Ether was added to the residue and the resulting white precipitate was collected by centrifugation. The solid was triturated with acetonitrile (2 x) and the white solid was collected by centrifugation. The white solid was purified by HPLC and freeze-dried to give (2*S*,5*R*)-7-oxo-*N*-(piperidin-4-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **Compound 6 (Table 1)** (0.08 g, 25 %) as a white solid.


¹H NMR (400 MHz, CD₃OD): δ 1.68 (1H, m), 1.70-1.87 (3H, m), 1.90 - 2.01 (4H, m), 2.94-3.04 (3H, m), 3.16 (1H, m), 3.25 (2H, m), 3.92 (1H, d, *J* = 6.4 Hz), 4.07 (2H, m), 3 protons were not observed in CD₃OD.

HPLC: 98.21 %


MS (ES⁻): *m/z* [M]⁻ = 362.92

Example 7

Sodium [[[(2*S*,5*R*)-7-oxo-2-[(tetrahydro-2*H*-pyran-4-yloxy)carbamoyl]-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl]oxidanide (Compound 7, Table 1)




Step 1. (2S,5R)-6-(Benzyloxy)-7-oxo-N-(tetrahydro-2H-pyran-4-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (32)



To a solution of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid
 5 1 (0.204 g, 0.74 mmol) in dry DCM (20 mL) were added 4-(aminooxy)tetrahydro-2H-pyran 31
 (0.131 g, 1.11 mmol, *J. Med. Chem.* 2008, 51, 4601-4608), 1-hydroxybenzotriazole (0.142 g,
 1.11 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.201 g, 1.11
 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight
 and concentrated under vacuum. The residue was purified by column chromatography to
 10 give (2S,5R)-6-(benzyloxy)-7-oxo-N-(tetrahydro-2H-pyran-4-yloxy)-1,6-
 diazabicyclo[3.2.1]octane-2-carboxamide 32 (0.26 g, 93 %) as a clear thick oil.

¹H NMR (400 MHz, CDCl₃): δ 1.69 (4H, m), 1.97 (3H, m), 2.32 (1H, m), 2.75 (1H, d, J = 11.2
 Hz), 3.00 (1H, d, J = 11.6 Hz), 3.31 (1H, s), 3.99 (3H, m), 4.06 (1H, m), 4.89 (1H, d, J = 11.2
 Hz), 5.04 (1H, d, J = 11.6 Hz), 7.41 (5H, m), 8.94 (1H, br s).


Step 2. (2S,5R)-6-Hydroxy-7-oxo-N-(tetrahydro-2H-pyran-4-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (33)



To a solution of (2S,5R)-6-(benzyloxy)-7-oxo-N-(tetrahydro-2H-pyran-4-yloxy)-1,6-
 diazabicyclo[3.2.1]octane-2-carboxamide 32 (0.26 g, 0.69 mmol) in methanol (20 mL) was
 20 added 5 % Pd/C (0.30 g). The mixture was hydrogenated under 35 psi hydrogen atmosphere
 at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was
 evaporated to give (2S,5R)-6-hydroxy-7-oxo-N-(tetrahydro-2H-pyran-4-yloxy)-1,6-
 diazabicyclo[3.2.1]octane-2-carboxamide 33 (0.19 g, 99 %) as a colorless foam.


¹H NMR (400 MHz, CD₃OD): δ 1.65 (2H, m), 1.81 (1H, m), 1.95 (3H, m), 2.08 (1H, m), 2.15 (1H, m), 3.05 (2H, m), 3.45 (2H, m), 3.70 (1H, s), 3.84 (1H, d, J = 7.2 Hz), 3.91 (2H, m), 4.04 (1H, m), 2 protons were not observed in CD₃OD.

Step 3. (2S,5R)-7-Oxo-6-(sulfooxy)-N-(tetrahydro-2H-pyran-4-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide pyridine salt (34)



To a solution of (2S,5R)-6-hydroxy-7-oxo-N-(tetrahydro-2H-pyran-4-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **33** (0.197 g, 0.69 mmol) in dry pyridine (7 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.44 g, 2.76 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated to give (2S,5R)-7-oxo-6-(sulfooxy)-N-(tetrahydro-2H-pyran-4-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide pyridine salt **34** (0.28 g crude) which was used in the next step without purification.

Step 4. N,N,N-Tributylbutan-1-aminium [(((2S,5R)-7-oxo-2-[(tetrahydro-2H-pyran-4-yloxy)carbamoyl]-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide (35)




(2S,5R)-7-Oxo-6-(sulfooxy)-N-(tetrahydro-2H-pyran-4-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide pyridine salt **34** (0.28 g, 0.63 mmol) was introduced into a concentrated aqueous solution of monosodium dihydrogen phosphate solution (9 mL) so as to obtain a pH of 4. The mixture was washed with ethyl acetate, then added tetrabutyl ammonium hydrogen sulfate (0.13 g, 0.38 mmol) and stirred at room temperature for 10 min. The mixture was extracted with ethyl acetate (3 x 20 mL), and the extracts were combined, dried over sodium sulfate and evaporated to give N,N,N-tributylbutan-1-aminium [(((2S,5R)-7-oxo-2-[(tetrahydro-2H-pyran-4-yloxy)carbamoyl]-1,6-diazabicyclo[3.2.1]oct-6

yl)oxy)sulfonyl]oxidanide **35** (0.21 g, 55 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.00 (12H, t, J = 7.2 Hz), 1.47 (8H, m), 1.69 (11H, m), 1.88 (3H, m), 2.17 (1H, m), 2.35 (1H, m), 2.86 (1H, d, J = 11.2 Hz), 3.31 (8H, m), 3.46 (1H, m), 3.99 (2H, m), 4.12 (1H, m), 4.32 (1H, s), 9.17 (1H, br s).

5 Step 5. Sodium [(((2S,5R)-7-oxo-2-[(tetrahydro-2H-pyran-4-yloxy)carbamoyl]-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide (Compound 7, Table 1)



To a suspension of *N,N,N*-tributylbutan-1-aminium [(((2S,5R)-7-oxo-2-[(tetrahydro-2H-pyran-4-yloxy)carbamoyl]-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide **35** (0.21 g, 0.34 mmol) in water (20 mL) was added DOWEX 50WX4 (2g). The mixture was stirred at room temperature for 2 h and filtered. The filtrate was freeze-dried to give a yellow solid which was purified by HPLC and freeze-dried again to give sodium [(((2S,5R)-7-oxo-2-[(tetrahydro-2H-pyran-4-yloxy)carbamoyl]-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide **Compound 7 (Table 1)** (0.07 g, 46 %) as a white solid.


¹H NMR (400 MHz, CD₃OD): δ 1.65 (2H, m), 1.81-1.98 (4H, m), 2.09 (1H, m), 2.19 (1 H, m), 3.10 (1H, d, J = 11.6 Hz), 3.24 (1H, d, J = 12.0 Hz), 3.47 (2H, m), 3.95 (3H, m), 4.15 (1H, m), 1 proton was not observed in CD₃OD.

HPLC: 98.88 %


MS (ES⁺): m/z [M]⁺ = 364.02

Example 8

(2S,5R)-N-(Azetidin-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 8, Table 1)




Step 1. *tert*-Butyl 3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]azetidine-1-carboxylate (37)



To a solution of compound (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.193 g, 0.70 mmol) in dry DCM (20 mL) were added *tert*-butyl 3-
 5 (aminooxy)azetidine-1-carboxylate **36** (0.198 g, 1.05 mmol, *J. Med. Chem.* 2008, 51, 4601-4608), 1-hydroxybenzotriazole (0.142 g, 1.05 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.201 g, 1.05 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight, and then concentrated
 10 under vacuum. The residue was purified by column chromatography to give *tert*-butyl 3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]azetidine-1-carboxylate **37** (0.15 g, 48 %) as a clear thick oil.

¹H NMR (400 MHz, CDCl₃): δ 1.42 (9H, s), 1.65 (1H, m), 1.99 (2H, m), 2.32 (1H, m), 2.37 (1H, d, J = 11.6 Hz), 2.99 (1H, d, J = 12.0 Hz), 3.32 (1H, s), 3.99 (3H, m), 4.09 (2H, m), 4.72 (1H, m), 4.88 (1H, d, J = 11.6 Hz), 5.05 (1H, d, J = 11.6 Hz), 7.37 (5H, m), 9.03 (1H, br s).


Step 2. *tert*-Butyl 3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]azetidine-1-carboxylate (38)



To a solution of *tert*-butyl 3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]azetidine-1-carboxylate **37** (0.15 g, 0.34 mmol) in methanol (15 mL) was added 5% Pd/C (0.3 g). The mixture was hydrogenated under 35 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give *tert*-butyl 3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]azetidine-1-carboxylate **38** (0.11 g, 91 %) as
 25 a colorless foam.


^1H NMR (400 MHz, CD_3OD): δ 1.44 (9H, s), 1.78 (1H, m), 1.91 (1H, m), 2.08 (1H, m), 2.21 (1H, m), 2.98 (1H, d, $J = 12$ Hz), 3.11 (1H, d, $J = 12$ Hz), 3.70 (1H, s), 3.85 (1H, d, $J = 7.6$ Hz), 3.95 (2H, m), 4.10 (2H, m), 4.74 (1H, m), 2 protons were not observed in CD_3OD .

Step 3. *tert*-Butyl 3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]azetidine-1-carboxylate pyridine salt (**39**)



To a solution of *tert*-butyl 3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]azetidine-1-carboxylate **38** (0.11 g, 0.31 mmol) in dry pyridine (6 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.197 g, 1.24 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated to give *tert*-butyl 3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]azetidine-1-carboxylate pyridine salt **39** (0.10 g crude) which was used in the next step without purification.

Step 4. *N,N,N*-Tributylbutan-1-aminium ([[(2*S*,5*R*)-2-[[[1-(*tert*-butoxycarbonyl)azetidin-3-yl]oxy]carbonyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy]sulfonyl)oxidanide (**40**)




tert-Butyl 3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]azetidine-1-carboxylate pyridine salt **39** (0.13 g, 0.31 mmol) was introduced into a concentrated aqueous solution of monosodium dihydrogen phosphate solution (6 mL) so as to obtain a pH of 4. The mixture was washed with ethyl acetate, then added tetrabutyl ammonium hydrogen sulfate (0.1 g, 0.29 mmol) and stirred at room temperature for 10 min. The mixture was extracted with ethyl acetate (3 x 10 mL), and the extracts were combined, dried over sodium sulfate and evaporated to give *N,N,N*-

tributylbutan-1-aminium ([[(2*S*,5*R*)-2-([1-(*tert*-butoxycarbonyl)azetidin-3-yl]oxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide **40** (0.1 g, 51 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 0.98 (12H, t, J = 7.2 Hz), 1.39 (17H, m), 1.70 (8H, m), 1.90 (1H, m), 2.05 (1H, m), 2.20 (1H, m), 2.35 (1H, m), 2.78 (1H, d, J = 12 Hz), 3.00 (8H, m), 3.33 (1H, m), 4.00 (5H, m), 4.36 (1H, m), 5.01 (1H, m), 9.20 (1H, br s).

Step 5. (2*S*,5*R*)-*N*-(Azetidin-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 8, Table 1)





To a solution of *N,N,N*-tributylbutan-1-aminium ([[(2*S*,5*R*)-2-([1-(*tert*-butoxycarbonyl)azetidin-3-yl]oxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide **40** (0.1 g, 0.15 mmol) in DCM (8.8 mL) was added trifluoroacetic acid (0.44 mL, 5.7 mmol) dropwise at 0 °C. The reaction mixture was stirred for 1 h, then evaporated. Ether was added to the residue and the resulting white precipitate was collected by centrifugation. The solid was triturated with acetonitrile (2 x) and the white solid was collected by centrifugation. The white solid was purified by HPLC and freeze-dried to give (2*S*,5*R*)-*N*-(azetidin-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **Compound 8 (Table 1)** (0.01 g, 20 %) as a white solid.

¹H NMR (400 MHz, D₂O): δ 1.65-2.08 (4H, m), 2.98 (1H, d, J = 12.4 Hz), 3.18 (1H, d, J = 11.6 Hz), 3.96 (1H, d, J = 6.8 Hz), 4.09 (3H, m), 4.28 (2H, m), 4.80 (1H, m), 3 protons were not observed in D₂O.

HPLC: 92.34 %

MS (ES⁺): m/z [M]⁺ = 334.92

Example 9


(2S,5R)-N-(2-Aminoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide (Compound 9, Table 1)**5 Step 1. *tert*-Butyl {2-[[[[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1] oct-2-yl]carbonyl]amino)oxy]ethyl}carbamate (42)**

To a mixture of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.150 g, 0.543 mmol, US 2005/20572 A1) in DCM (4.0 mL) was added *tert*-butyl [2-(aminooxy)ethyl]carbamate **41** (0.143 g, 0.814 mmol, US 2005/54701 A1), 1-hydroxybenzotriazole (0.110 g, 0.814 mmol), 1-ethyl-(3-dimethylamino propyl) carbodiimide hydrochloride (0.156 g, 0.814 mmol) and DMAP (0.100 g, 0.814 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **42** (0.21 g, 89 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.44 (9H, s), 1.65 (1H, m), 1.93 (2H, m), 2.31 (1H, m), 2.76 (1H, d, *J* = 12 Hz), 3.04 (1H, d, *J* = 11.2 Hz), 3.26 (2H, m), 3.38 (1H, m), 3.91 (2H, m), 3.98 (1H, d, *J* = 12 Hz), 4.89 (1H, d, *J* = 11.2 Hz), 5.07 (1H, d, *J* = 11.2 Hz), 5.41 (1H, br s), 7.41 (5H, m), 9.30 (1H, br s).

20 MS (ES⁺): *m/z* [M+H]⁺ calcd for C₂₁H₃₁N₄O₆: 435.22. Found: 435.02.

Step 2. *tert*-Butyl {2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]ethyl}carbamate (43**)**




A mixture of *tert*-butyl {2-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]ethyl}carbamate **42** (0.21 g, 0.48 mmol) and Pd/C (0.063 g) in methanol (10 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through celite pad and concentrated to provide **43** (0.17 g, quant. yield) as a light yellow foam.

¹H NMR (400 MHz, CD₃OD): δ 1.44 (9H, s), 1.75 (1H, m), 1.92 (1H, m), 2.05 (1H, m), 2.23 (1H, m), 3.04 (1H, d, *J* = 12 Hz), 3.12 (2H, m), 3.69 (1H, s), 3.89 (3H, m), 6.74 (1H, br s). 3 protons were not observed in CD₃OD.

MS (ES⁺): *m/z* [M-H]⁺ calcd for C₁₄H₂₃N₄O₆: 343.16. Found: 343.00.

Step 3. *tert*-Butyl {2-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]ethyl}carbamate (44**)**




To a mixture of *tert*-butyl {2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]ethyl}carbamate **43** (0.17 g, 0.49 mmol) in pyridine (7.0 mL) was added sulfur trioxide pyridine complex (0.314 g, 1.98 mmol). The mixture was stirred at room temperature for 23 h and concentrated to provide a residue which was subjected to chromatography to give **44** (0.19 g, 92 %) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.44 (9H, s), 1.80 (1H, m), 1.92 (1H, m), 2.07 (1H, m), 2.20 (1H, m), 3.06 (1H, d, *J* = 12 Hz), 3.28 (2H, m), 3.88 (4H, m), 4.15 (1H, m). 3 protons were not observed in CD₃OD.

MS (ES⁺): *m/z* [M-H]⁺ calcd for C₁₄H₂₃N₄O₉S: 423.12. Found: 422.93.

Step 4. (2S,5R)-N-(2-aminoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 9, Table 1)



To a mixture of *tert*-butyl {2-[[[(2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]ethyl}carbamate **44** (0.19 g, 0.45 mmol) in DCM (6.0 mL) was added trifluoroacetic acid (0.30 mL) at 0°C. The mixture was stirred at 0°C for 1 h, concentrated and washed with ether. The white solid was collected by centrifugation. The crude product was purified by preparative HPLC to provide **Compound 9 (Table 1)** (44 mg) as a white solid.


¹H NMR (400 MHz, D₂O): δ 1.75 (1H, m), 1.86 (1H, m), 1.95 (1H, m), 2.04 (1H, m), 3.03 (1H, d, *J* = 12 Hz), 3.19 (3H, m), 3.98 (1H, d, *J* = 6.8 Hz), 4.08 (3H, m). 4 protons were not observed in D₂O.

HPLC: 90.18 %.


MS (ES⁺): *m/z* [M-H]⁺ calcd for C₉H₁₅N₄O₇S: 323.07. Found: 322.95.

Example 10

(2S,5R)-N-(8-Azabicyclo[3.2.1]oct-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 27, Table 1)




Step 1. *tert*-Butyl 3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]-8-azabicyclo[3.2.1]octane-8-carboxylate (**46**)



To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid
 5 **1** (0.15 g, 0.54 mmol) in dry DCM (20 mL) were added *tert*-butyl 3-(aminooxy)-8-azabicyclo[3.2.1]octane-8-carboxylate **45** (0.15 g, 0.62 mmol, *J. Med. Chem.* 2008, 51, 4601-4608), 1-hydroxybenzotriazole (0.11 g, 0.81 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.16 g, 0.81 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give *tert*-butyl 3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]-8-azabicyclo[3.2.1]octane-8-carboxylate **46** (0.26 g, 96 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.46 (9H, s), 1.50-1.80 (7H, m), 1.83-2.04 (5H, m), 2.32 (1H, m), 2.72 (1H, d, *J* = 11.6 Hz), 2.99 (1H, d, *J* = 11.2 Hz), 3.29 (1H, m), 3.95 (1H, d, *J* = 7.2 Hz),
 15 4.20-4.38 (2H, m), 4.89 (1H, d, *J* = 11.2 Hz), 5.05 (1H, d, *J* = 11.6 Hz), 7.39 (5H, m), 8.90 (1H, br s).

Step 2. *tert*-Butyl 3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]-8-azabicyclo[3.2.1]octane-8-carboxylate (47)




To a solution of *tert*-butyl 3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]-8-azabicyclo[3.2.1]octane-8-carboxylate **46** (0.26 g, 0.52 mmol) in methanol (20 mL) was added 5% Pd/C (0.3 g). The mixture was hydrogenated under 35 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give *tert*-butyl 3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]-8-azabicyclo[3.2.1]octane-8-carboxylate

47 (0.14 g, 66 %) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.48 (9H, s), 1.62-1.76 (4H, m), 1.79-1.85 (1H, m), 1.89-2.00 (3H, m), 2.02-2.11 (3H, m), 2.15-2.20 (1H, m), 3.04-3.17 (2H, m), 3.69 (1H, s), 3.83 (1H, d, *J* = 7.2 Hz), 4.24 (2H, m), 4.35 (1H, m), 2 protons were not observed in CD₃OD.


Step 3. *tert*-Butyl 3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]-8-azabicyclo[3.2.1]octane-8-carboxylate (48)



To a solution of *tert*-butyl 3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]-8-azabicyclo[3.2.1]octane-8-carboxylate **47** (0.14 g, 0.34 mmol) in dry pyridine (6 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.22

g, 1.36 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated. The crude compound was suspended in aqueous acid (a mixture of NaH_2PO_4 and H_3PO_4 to pH 3) and extracted with ethyl acetate (30 mL x 2). The organic extracts were combined, washed with brine, dried over sodium sulfate and evaporated to give *tert*-butyl 3-[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]-8-azabicyclo[3.2.1]octane-8-carboxylate **48** (0.077 g) which was used in the next step without purification.

Step 4. (2*S*,5*R*)-*N*-(8-Azabicyclo[3.2.1]oct-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 27, Table 1)



To a solution of *tert*-butyl 3-[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]-8-azabicyclo[3.2.1]octane-8-carboxylate **48** (0.077 g, 0.17 mmol) in DCM (7 mL) was added trifluoroacetic acid (0.34 mL, 4.42 mmol) dropwise at 0 °C. The reaction mixture was stirred for 1 h, then evaporated. Ether was added to the residue and the resulting white precipitate was collected by centrifugation. The solid was triturated with acetonitrile (2 x) and the white solid was collected by centrifugation. The white solid was purified by HPLC and freeze-dried to give (2*S*,5*R*)-*N*-(8-azabicyclo[3.2.1]oct-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **Compound 27 (Table 1)** (0.003 g, 7 %) as a white solid.


^1H NMR (400 MHz, CD_3OD): δ 1.70-2.14 (9H, m), 2.16 - 2.58 (3H, m), 3.07 (1H, d, J = 11.2 Hz), 3.25 (1H, d, J = 11.6 Hz), 3.91 (1H, d, J = 7.2 Hz), 4.00 (2H, m), 4.16 (1H, m), 4.26 (1H, m), 3 protons were not observed in CD_3OD .

HPLC: 81.82 %


MS (ES^-): m/z $[\text{M}-\text{H}]^-$ = 388.96

Example 11

(2*S*,5*R*)-*N*-[(1-Methylpiperidin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 67 Table 1)




5 Step 1. 4-(Aminooxy)-1-methylpiperidine (**50**)



To a solution of 2-[(1-methylpiperidin-4-yl)oxy]-1*H*-isindole-1,3(2*H*)-dione **49** (1.18 g, 4.53 mmol) in a mixture of ethanol (3 mL) and DCM (18 mL) was added hydrazine hydrate (0.268 g, 4.53 mmol). The reaction mixture was stirred at room temperature for 4.5 h. Precipitate was filtered off. The filtrate was evaporated and sonicated in ethyl acetate (20 mL). Solid was filtered off and filtrate was evaporated to give the residue which was subjected to chromatography to give **50** (0.15 g, 25 %) as a colorless oil.

¹H NMR (400 MHz, CD₃OD): δ 1.60 - 1.70 (2H, m), 1.88 - 1.97 (2H, m), 2.23 - 2.33 (5H, m), 2.64 - 2.74 (2H, m), 3.51-3.59 (1H, m), 2 protons were not observed in CD₃OD.

15 Step 2. (2*S*,5*R*)-6-(Benzyloxy)-*N*-[(1-methylpiperidin-4-yl)oxy]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (**51**)




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.150 g, 0.543 mmol, US 2005/20572 A1) in DCM (10 mL) were added 4-(aminooxy)-1-methylpiperidine **50** (0.129 g, 0.99 mmol), 1-hydroxybenzotriazole (0.110 g, 0.814 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.156 g, 0.814 mmol)

sequentially at room temperature. The mixture was stirred at room temperature for 16 h, diluted with DCM, washed with water, brine, dried over sodium sulfate and concentrated to provide a residue which was subjected to chromatography to give **51** (0.065 g, 31 %) as a yellow oil.

- ¹H NMR (400 MHz, CD₃OD): δ 1.64-2.02 (7H, m), 2.11-2.19 (1H, m), 2.20-2.38 (5H, m), 2.62-2.80 (2H, m), 3.00 (2H, s), 3.58 (1H, s), 3.80-3.90 (2H, m), 4.91 (2H, q, *J* = 11.2 Hz), 7.30-7.50 (5H, m), one proton was not observed in CD₃OD.

MS (ES⁺): *m/z* [M+H]⁺ calcd for C₂₀H₂₈N₄O₄: 389.47. Found: 389.02.

Step 3. (2*S*,5*R*)-6-Hydroxy-*N*-[(1-methylpiperidin-4-yl)oxy]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (52**)**




- A mixture of (2*S*,5*R*)-6-(benzyloxy)-*N*-[(1-methylpiperidin-4-yl)oxy]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **51** (0.065 g, 0.167 mmol) and Pd/C (0.060 g) in methanol (30 mL) was hydrogenated at 35 psi at room temperature for 2 h. The mixture was filtered through a Celite pad and concentrated to provide **52** (0.050 g, quantitative) as a light yellow solid.

¹H NMR (400 MHz, CD₃OD): δ 1.76-2.21 (8H, m), 2.37 (3H, s), 2.39-2.48 (2H, m), 2.80-2.90 (2H, m), 3.00-3.17 (2H, m), 3.68-3.72 (1H, m), 3.85 (1H, d, *J* = 7.6 Hz), 3.91-3.98 (1H, m), 2 protons were not observed in CD₃OD.

- MS (ES⁺): *m/z* [M+H]⁺ calcd for C₁₃H₂₂N₄O₄: 299.34. Found 299.0.

Step 4. (2*S*,5*R*)-*N*-[(1-Methylpiperidin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 67, Table 1)



- To a mixture of (2*S*,5*R*)-6-hydroxy-*N*-[(1-methylpiperidin-4-yl)oxy]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **52** (0.047 g, 0.517 mmol) in pyridine (1.5 mL) was

added sulfur trioxide pyridine complex (0.070 g, 1.438 mmol). The mixture was stirred at room temperature for 16 h, evaporated to dryness. The residue was sonicated in ethyl acetate (5 mL), solid was obtained and subjected to chromatography to give **Compound 67** (Table 1) (0.024 g, 40 %) as a white solid.

- 5 ¹H NMR (400 MHz, CD₃OD): δ 1.78-2.37 (8H, m), 2.90 (3H, s), 3.07-3.16 (2H, m), 3.20-3.41 (3H, m), 3.55-3.65 (1H, m), 3.92-3.98 (1H, m), 4.12-4.22 (2H, m), 2 protons were not observed in CD₃OD.


HPLC: 96.05 %

MS (ES⁺): *m/z* [M+H]⁺ calcd for C₁₃H₂₂N₄O₇S: 379.41. Found: 378.93.

10


Example 12

(2S,5R)-N-(2-Amino-2-oxoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 73, Table 1)



Step 1. **(2S,5R)-N-(2-Amino-2-oxoethoxy)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (54)**

15




20

To a mixture of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.200 g, 0.723 mmol, US 2005/20572 A1) in DCM (6.0 mL) were added 2-(aminooxy)acetamide **53** (0.098 g, 1.086 mmol), 1-hydroxybenzotriazole (0.147 g, 1.086 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.208 g, 1.086 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **54** (0.203 g, 81 %) as a white solid.

^1H NMR (400 MHz, CD_3OD): δ 1.70 (1H, m), 1.90 (1H, m), 2.00 (1H, m), 2.15 (1H, m), 2.96 (2H, m), 3.56 (1H, m), 3.89 (1H, d), 4.33 (2H, s), 4.98 (2H, ABq), 7.36 (3H, m), 7.46 (2H, m). 3 protons were not observed in CD_3OD .

MS (ES^+): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{21}\text{N}_4\text{O}_5$: 349.15. Found: 349.39.

5 **Step 2. (2S,5R)-N-(2-Amino-2-oxoethoxy)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (55)**




A mixture of (2S,5R)-N-(2-amino-2-oxoethoxy)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **54** (0.11 g, 0.40 mmol) and Pd/C (0.040 g) in methanol (10 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to provide **55** (0.10 g, 98 %) as a white solid.

^1H NMR (400 MHz, CD_3OD): δ 1.76 (1H, m), 1.92 (1H, m), 2.07 (1H, m), 2.19 (1H, m), 2.98 (1H, d, $J = 11.6$ Hz), 3.11 (1H, m), 3.69 (1H, m), 3.88 (1H, d, $J = 7.6$ Hz), 4.35 (2H, s). 4 protons were not observed in CD_3OD .

15 MS (ES^-): m/z $[\text{M}-\text{H}]^-$ calcd for $\text{C}_9\text{H}_{13}\text{N}_4\text{O}_5$: 257.09. Found: 257.44.

Step 3. (2S,5R)-N-(2-Amino-2-oxoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 73, Table 1)



To a mixture of (2S,5R)-N-(2-amino-2-oxoethoxy)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **55** (0.11 g, 0.43 mmol) in pyridine (4.0 mL) was added sulfur trioxide pyridine complex (0.27 g, 1.70 mmol). The mixture was stirred at room temperature overnight and concentrated to provide a residue which was dissolved in KH_2PO_4 (7 mL), extracted with ethyl acetate and freeze-dried to give a white solid which was purified by HPLC to provide **Compound 73 (Table 1)** (3.6 mg) as a white solid.


^1H NMR (400 MHz, D_2O): δ 1.73 (1H, m), 1.82 (1H, m), 1.95 (1H, m), 2.03 (1H, m), 3.02 (1H, d, $J = 12.0$ Hz), 3.18 (1H, m), 3.95 (1H, d, $J = 6.4$ Hz), 4.08 (1H, m), 4.38 (2H, s). 4 protons were not observed in D_2O .

HPLC: 88.53 %


5 MS (ES^+): m/z $[\text{M}-\text{H}]^-$ calcd for $\text{C}_9\text{H}_{13}\text{N}_4\text{O}_8\text{S}$: 337.05. Found: 336.90.

Example 13

(2*S*,5*R*)-*N*-{[(2*S*)-2-Aminopropyl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 74, Table 1)



10 Step 1. *tert*-Butyl [(1*S*)-2-hydroxy-1-methylethyl]carbamate (**57**)




To a mixture of (*S*)-(+)-2 amino-1-propanol **56** (3.76 g, 50 mmol) and triethylamine (6.97 mL, 50 mmol) in THF (70 mL) at 0 °C under nitrogen was added dropwise di-*tert*-butyl dicarbonate (10.91 g, 50 mmol) in THF (30 mL). The mixture was stirred at room temperature for 2 h. Solvent was evaporated off. Residue was dissolved in ethyl acetate, washed with water, brine, dried over sodium sulfate, filtered and evaporated to provide **57** (crude, 8.29 g, 95 %) as a white solid which was used in the next step without purification.

^1H NMR (400 MHz, CDCl_3): δ 1.15 (3H, d, $J = 6.8$ Hz), 1.46 (9H, s), 3.42-3.61 (3H, m), 3.75 (1H, br s), 4.94 (1H, br s).

20 MS (ES^+): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_8\text{H}_{17}\text{NO}_3$: 176.23. Found: 175.96.

Step 2. *tert*-Butyl {(1*S*)-2-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]-1-methylethyl}carbamate (58**)**




To a mixture of *tert*-butyl [(1*S*)-2-hydroxy-1-methylethyl]carbamate **57** (4.03 g, 23.0 mmol),
 5 *N*-hydroxyphthalimide (5.63 g, 34.5 mmol) and triphenylphosphine (9.05 g, 34.5 mmol) in anhydrous THF (172 mL) at 0 °C under nitrogen was added DIAD (6.69 mL, 34.5 mmol) in anhydrous THF (40 mL) over 15 minutes. The mixture was stirred at 0 °C for 30 min and at room temperature for 2.5 h. Solvent was evaporated off and the residue was subjected to chromatography to give a white solid **58** (7.38 g).

10 ¹H NMR (400 MHz, CDCl₃): δ 1.26 (3H, d, *J* = 6.8 Hz), 1.43 (9H, s), 3.90–4.03 (1H, m), 4.12–4.30 (2H, m), 5.20 (1H, br s), 7.71–7.88 (4H, m).

MS (ES⁺): *m/z* [M+H]⁺ calcd for C₁₆H₂₀N₂O₅: 321.35. Found: 320.89.


Step 3. *tert*-Butyl [(1*S*)-2-(aminooxy)-1-methylethyl]carbamate (59**)**



15 To a solution of *tert*-butyl {(1*S*)-2-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]-1-methylethyl}carbamate **58** (1.2 g, 3.74 mmol) in a mixture of ethanol (3 mL) and DCM (20 mL) was added hydrazine hydrate (0.215 mL, 3.74 mmol). The reaction mixture was stirred at room temperature for 6 h. Precipitate was filtered off, the filtrate was evaporated and the residue was subjected to chromatography to give **59** (0.55 g, 77 %) as a white solid.

20 ¹H NMR (400 MHz, CD₃OD): δ 1.03 (3H, d, *J* = 6.8 Hz), 1.36 (9H, s), 3.38–3.42 (1H, m), 3.53–3.56 (1H, m), 3.89 (1H, br s), 4.79 (1H, br s), 5.54 (2H, br s).

Step 4. *tert*-Butyl {(2*S*)-1-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]propan-2-yl}carbamate (60)




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid
 5 **1** (0.150 g, 0.543 mmol) in DCM (15 mL) were added *tert*-butyl [(1*S*)-2-(aminooxy)-1-methylethyl]carbamate **59** (0.176 g, 0.923 mmol), 1-hydroxybenzotriazole (0.110 g, 0.814 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.156 g, 0.814 mmol) sequentially at room temperature. The mixture was stirred at room temperature for 18 h, diluted with DCM, washed with water and brine, dried over sodium sulfate and
 10 concentrated to provide a residue which was subjected to chromatography to give **60** (0.237 g, 97 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.67 (3H, d, *J* = 6.8 Hz), 1.42 (9H, s), 1.63-1.69 (1H, m), 1.91-2.05 (2H, m), 2.28-2.33 (1H, m), 2.81 (1H, d, *J* = 12.0 Hz), 3.04-3.07 (1H, m), 3.29 (1H, s), 3.66-3.70 (1H, m), 3.87-3.96 (3H, m), 4.83-5.07 (3H, m), 7.32-7.42 (5H, m), 9.72 (1H, br s).


15 MS (ES⁺): *m/z* [M-H]⁺ calcd for C₂₂H₃₂N₄O₆: 447.52. Found: 447.47.

Step 5. *tert*-Butyl {(2*S*)-1-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]propan-2-yl}carbamate (61)



A mixture of *tert*-butyl {(2*S*)-1-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]propan-2-yl}carbamate **60** (0.237 g, 0.528 mmol) and Pd/C (0.200 g) in methanol (20 mL) was hydrogenated at 35 psi at room temperature for 2 h. The mixture was filtered through a Celite pad and concentrated to provide **61** (crude, 0.189 g, quant.) as a colorless foam which was used in the next step without purification.

Step 6. *tert*-Butyl {(2*S*)-1-[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]propan-2-yl}carbamate (62)




To a mixture of *tert*-butyl {(2*S*)-1-[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]propan-2-yl}carbamate **61** (0.189 g, 0.527 mmol) in pyridine (5.0 mL) was added sulfur trioxide pyridine complex (0.233 g, 1.466 mmol). The mixture was stirred at room temperature for 20 h. Solid was filtered off. The filtrate was evaporated to provide a residue which was subjected to chromatography to give **62** (0.214 g, 93 %) as a light yellow foam.

¹H NMR (400 MHz, CDCl₃): δ 1.20 (3H, d, *J* = 6.0 Hz), 1.42 (9H, m), 1.80-2.27 (4H, m), 3.03 (1H, d, *J* = 12.0 Hz), 3.27-3.35 (1H, m), 3.90-3.97 (3H, m), 4.26 (1H, s), 5.13 (1H, br s), 3 protons were not observed in moisture-containing CDCl₃.

MS (ES⁺): *m/z* [M-H]⁺ calcd for C₁₅H₂₆N₄O₉S: 437.46. Found: 437.38.

Step 7. (2*S*,5*R*)-*N*-{[(2*S*)-2-Aminopropyl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 74, Table 1)



To a mixture of *tert*-butyl {(2*S*)-1-[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]propan-2-yl}carbamate **62** (0.214 g, 0.488 mmol) in DCM (9.0 mL) was added trifluoroacetic acid (0.44 mL) at 0 °C. The mixture was stirred at 0 °C for 1 h, concentrated and washed with ether. The white solid was collected by centrifugation. The crude product was purified by preparative HPLC to provide **Compound 74 (Table 1)** (27 mg) as a light yellow solid.


¹H NMR (400 MHz, CD₃OD): δ 1.27 (3H, d, *J* = 6.8 Hz), 1.78-2.25 (4H, m), 3.03 (1H, d, *J* = 12.0 Hz), 3.22-3.30 (1H, m), 3.51-3.60 (1H, m), 3.82-3.90 (1H, m), 3.96-4.07 (2H, m), 4.12-4.18 (1H, m), 4 protons were not observed in CD₃OD.

HPLC: 83.80 %


MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₀H₁₈N₄O₇S: 337.34. Found: 336.96.

Example 14

(2*S*,5*R*)-*N*-[(1-Carbamimidoylpiperidin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 75, Table 1)



Step 1. Di-*tert*-butyl [(4-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]piperidin-1-yl)methylidene]biscarbamate (**64**)




- 10 To a mixture of *N*-hydroxyphthalimide (1.89 g, 11.62 mmol), di-*tert*-butyl [(4-hydroxypiperidin-1-yl)methylidene]biscarbamate **63** (2.00 g, 5.81 mmol, US 2004/209921 A1) and triphenylphosphine (3.05 g, 11.62 mmol) in THF (100 mL) was added diisopropyl azodicarboxylate (2.47 mL, 12.78 mmol) slowly at room temperature. The resulting mixture was stirred at room temperature overnight and concentrated to provide a residue which was
- 15 subjected to chromatography to give **64** (0.9 g) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.49 (18H, s), 2.04 (4H, m), 3.57 (2H, br s), 3.89 (2H, br s), 4.50 (1H, m), 7.76 (2H, m), 7.85 (2H, m), 10.20 (1H, br s).

MS (ES⁺): *m/z* [M+H]⁺ calcd for C₂₄H₃₃N₄O₇: 489.23. Found: 489.07.

Step 2. Di-*tert*-butyl {[4-(aminooxy)piperidin-1-yl]methylidene} biscarbamate (65)




To a mixture di-*tert*-butyl {[4-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]piperidin-1-yl]methylidene}biscarbamate **64** (2.30 g, 4.71 mmol) in a solution of DCM (40 mL) and ethanol (6 mL) was added hydrazine hydrate (0.270 mL, 4.71 mmol) at room temperature. The mixture was stirred at room temperature overnight, filtered and concentrated to provide a residue which was subjected to chromatography to give **65** (0.72 g, 43 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.47 (9H, s), 1.50 (9H, s), 1.72 (2H, m), 1.95 (2H, m), 3.38 (2H, m), 3.77 (3H, m), 5.30 (2H, s), 10.15 (1H, s).

MS (ES⁺): *m/z* [M+H]⁺ calcd for C₁₆H₃₁N₄O₅: 359.23. Found: 359.07.

Step 3. Di-*tert*-butyl {[4-[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidin-1-yl]methylidene} biscarbamate (66)




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.200 g, 0.723 mmol, US 2005/20572 A1) in DCM (6.0 mL) was added di-*tert*-butyl {[4-(aminooxy)piperidin-1-yl]methylidene}biscarbamate **65** (0.389 g, 1.086 mmol), 1-hydroxybenzotriazole (0.147 g, 1.086 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.208 g, 1.086 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **66** (0.33 g, 74 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.48 (18H, m), 1.62 (2H, m), 1.82 (2H, m), 2.01 (4H, m), 2.32 (1H, m), 2.77 (1H, d, *J* = 11.6 Hz), 3.03 (1H, d, *J* = 11.2 Hz), 3.32 (1H, s), 3.43 (2H, br s),

3.78 (2H, br s), 3.95 (1H, d, $J = 7.6$ Hz), 4.09 (1H, m), 4.92 (2H, ABq), 7.41 (5H, m), 8.95 (1H, s).

MS (ES⁺): m/z [M+H]⁺ calcd for C₃₀H₄₅N₆O₈: 617.33. Found: 617.18.

Step 4. Di-tert-butyl [{4-[[[(2S,5R)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidin-1-yl)methylidene]biscarbamate (67)




A mixture of di-tert-butyl [{4-[[[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidin-1-yl)methylidene]biscarbamate **66** (0.26 g, 0.42 mmol) and Pd/C (0.080 g) in methanol (10 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to provide **67** (0.21 g, 98 %) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.51 (18H, s), 1.60 (1H, m), 1.96 (3H, m), 2.06 (3H, m), 2.17 (1H, m), 3.04 (1H, d, $J = 11.6$ Hz), 3.12 (1H, m), 3.64 (2H, m), 3.71 (1H, m), 3.84 (3H, m), 4.18 (1H, m). 3 protons were not observed in CD₃OD.

MS (ES⁺): m/z [M+H]⁺ calcd for C₂₃H₃₉N₆O₈: 527.28. Found: 527.09.

Step 5. Di-tert-butyl [{4-[[[(2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidin-1-yl)methylidene]biscarbamate (68)




To a mixture of di-tert-butyl [{4-[[[(2S,5R)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]piperidin-1-yl)methylidene]biscarbamate **67** (0.26 g, 0.50 mmol) in pyridine (8.0 mL) was added sulfur trioxide pyridine complex (0.23 g, 1.49 mmol). The mixture was stirred at room temperature overnight and concentrated to provide a residue which was subjected to chromatography to give **68** (0.20 g, 67 %) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.47 (18H, s), 1.80 (3H, m), 1.94 (3H, m), 2.10 (1H, m), 2.20 (1H, m), 3.10 (1H, d, $J = 11.6$ Hz), 3.25 (1H, m), 3.43 (2H, m), 3.75 (2H, m), 3.92 (1H, d, $J = 6.0$ Hz), 4.14 (2H, m), 3 protons were not observed in CD₃OD.

MS (ES⁻) m/z : [M-H]⁻ calcd for C₂₃H₃₇N₆O₁₁S: 605.22. Found: 605.03.

Step 6. (2S,5R)-N-[(1-Carbamimidoylpiperidin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 75, Table 1)



To a mixture of di-*tert*-butyl [(4-[[[(2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]piperidin-1-yl)methylidene]biscarbamate **68** (0.15 g, 0.25 mmol) in DCM (5.0 mL) was added trifluoroacetic acid (1.0 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 h and at room temperature for 2 h, concentrated and washed with ether. The white solid was collected by centrifugation. The crude product was purified by preparative HPLC to provide **Compound 75 (Table 1)** (40 mg) as a white solid.


¹H NMR (400 MHz, D₂O): δ 1.60-2.10 (8H, m), 3.01 (1H, d, *J* = 12 Hz), 3.22 (3H, m), 3.56 (2H, m), 3.96 (1H, d, *J* = 6.8 Hz), 4.09 (2H, m). 5 protons were not observed in D₂O.

HPLC: 95.56 %


MS (ES⁺): *m/z* [M-H]⁺ calcd for C₁₃H₂₁N₅O₇S: 405.12. Found: 404.93.

Example 15

15. (2S,5R)-7-Oxo-N-[2-(piperidin-4-yloxy)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 76, Table 1)



Step 1. *tert*-Butyl 4-{2-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]ethoxy}piperidine-1-carboxylate (70**)**




To a solution of *tert*-butyl 4-(2-hydroxyethoxy)piperidine-1-carboxylate **69** (0.9 g, 3.67 mmol, WO 2009/87649 A1) in THF (28 mL) were added *N*-hydroxyphthalimide (0.9 g, 5.51 mmol), triphenylphosphine (1.44 g, 5.51 mmol) and DIAD (1.07 mL, 5.51 mmol) sequentially at 0 °C under nitrogen. The mixture was stirred at 0 °C for 30 min and at room temperature for 16 h. Solvent was evaporated off and the residue was subjected to chromatography to give **70** (0.69 g, 48 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.27-1.40 (11H, m), 1.67-1.75 (2H, m), 2.95-3.00 (2H, m), 3.42-3.46 (1H, m), 3.56-3.59 (2H, m), 3.76-3.80 (2H, m), 4.29-4.31 (2H, m), 7.67-7.78 (4H, m).

MS (ES⁺): *m/z* [M+H]⁺ calcd for C₂₀H₂₆N₂O₆: 391.44. Found: 391.02.

Step 2. *tert*-Butyl 4-[2-(aminooxy)ethoxy]piperidine-1-carboxylate (71**)**




To a solution of *tert*-butyl 4-{2-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]ethoxy}piperidine-1-carboxylate **70** (0.57 g, 1.46 mmol) in a mixture of ethanol (1 mL) and DCM (6 mL) was added hydrazine hydrate (0.086 g, 1.46 mmol). The reaction mixture was stirred at room temperature for 16 h. Precipitate was filtered off. The filtrate was evaporated and the residue was subjected to chromatography to give **71** (0.327 g, 86 %) as a colorless oil.

¹H NMR (400 MHz, CD₃OD): δ 1.45-1.57 (11H, m), 1.80-1.90 (2H, m), 3.00-3.19 (2H, m), 3.45-3.51 (2H, m), 3.62-3.68 (1H, m), 3.75-3.85 (4H, m), 5.50 (2H, br s).

MS (ES⁺): *m/z* [M+H]⁺ calcd for C₁₂H₂₄N₂O₄: 261.34. Found: 261.04.

Step 3. *tert*-Butyl 4-{2-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]ethoxy}piperidine-1-carboxylate (72)




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid
 5 **1** (0.150 g, 0.543 mmol, US 2005/20572 A1) in DCM (4.0 mL) were added *tert*-butyl 4-[2-(aminooxy)ethoxy]piperidine-1-carboxylate **71** (0.240 g, 0.543 mmol), 1-hydroxybenzotriazole (0.110 g, 0.814 mmol) and 1-ethyl-(3-dimethylamino-propyl) carbodiimide hydrochloride (0.156 g, 0.814 mmol) sequentially at room temperature. The mixture was stirred at room temperature for 16 h, diluted with DCM, washed with water, brine,
 10 dried over sodium sulfate and concentrated to provide a residue which was subjected to chromatography to give **72** (0.276 g, 98 %) as a colorless foam.

¹H NMR (400 MHz, CDCl₃): δ 1.46-1.67 (12H, m), 1.84-2.04 (4H, m), 2.30-2.35 (1H, m), 2.77 (1H, d, *J* = 11.6 Hz), 2.98-3.09 (3H, m), 3.31 (1H, s), 3.45-3.53 (1H, m), 3.64-3.85 (4H, m), 3.94 (1H, d, *J* = 7.6 Hz), 4.05-4.11 (2H, m), 4.90 (1H, d, *J* = 11.2 Hz), 5.05 (1H, d, *J* = 12.0 Hz), 7.35-7.46 (5H, m), 1 proton was not observed in moisture-containing CDCl₃.
 15

MS (ES⁺): *m/z* [M-H]⁺ calcd for C₂₆H₃₈N₄O₇: 517.62. Found: 517.13.

Step 4. *tert*-Butyl 4-{2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]ethoxy}piperidine-1-carboxylate (73)




A mixture of *tert*-butyl 4-{2-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]ethoxy}piperidine-1-carboxylate **72** (0.270 g, 0.521 mmol) and Pd/C (0.270 g) in methanol (25 mL) was hydrogenated at 35 psi at room temperature for 2 h. The mixture was filtered through a Celite pad and concentrated to provide **73** (0.221 g, 99 %) as a light grey solid.

¹H NMR (400 MHz, CDCl₃): δ 1.45-1.58 (11H, m), 1.70-2.05 (4H, m), 2.11-2.20 (1H, m), 2.33-2.42 (1H, m), 2.90-3.20 (4H, m), 3.46-3.60 (2H, m), 3.68-3.85 (6H, m), 3.90-3.96 (1H, m), 4.05-4.18 (1H, m), 9.61 (1H, br s).

MS (ES⁺): m/z [M-H]⁺ calcd for C₁₉H₃₂N₄O₇: 427.49. Found: 426.98.

Step 5. *tert*-Butyl 4-{2-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]ethoxy}piperidine-1-carboxylate (74**)**




- 5 To a mixture of *tert*-butyl 4-{2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]ethoxy}piperidine-1-carboxylate **73** (0.221 g, 0.516 mmol) in pyridine (5.0 mL) was added sulfur trioxide pyridine complex (0.228 g, 1.434 mmol). The mixture was stirred at room temperature for 20 h. Solid was filtered off. The filtrate was evaporated to provide a residue which was subjected to chromatography to give **74** (0.197 g, 75 %) as a light yellow solid.

¹H NMR (400 MHz, CD₃OD): δ 1.40-1.53 (11H, m), 1.79-1.97 (4H, m), 2.05-2.09 (1H, m), 2.19-2.24 (1H, m), 3.05-3.18 (3H, m), 3.21-3.28 (1H, m), 3.53-3.61 (1H, m), 3.68-3.78 (4H, m), 3.92 (1H, d, J = 6.8 Hz), 4.00-4.06 (2H, m), 4.12-4.18 (1H, m).

MS (ES⁺): m/z [M-H]⁺ calcd for C₁₉H₃₂N₄O₁₀S: 507.55. Found: 506.92.

Step 6. (2*S*,5*R*)-7-Oxo-*N*-[2-(piperidin-4-yloxy)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound **76, Table 1)**



- To a mixture of *tert*-butyl 4-{2-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]ethoxy}piperidine-1-carboxylate **74** (0.195 g, 0.386 mmol) in DCM (9.0 mL) was added trifluoroacetic acid (0.44 mL) at 0 °C. The mixture was stirred at 0 °C for 1 h, concentrated and washed with ether. The white solid was collected by centrifugation. The crude product was purified by preparative HPLC to provide **Compound 76** (Table 1) (25 mg) as a white solid.


¹H NMR (400 MHz, CD₃OD): δ 1.80-2.01 (6H, m), 2.06-2.15 (1H, m), 2.18-2.22 (1H, m), 3.04-3.12 (4H, m), 3.24-3.27 (1H, m), 3.72-3.78 (4H, m), 3.90 (1H, d, J = 6.0 Hz), 4.02-4.06 (2H, m), 4.15 (1H, d, J = 3.2 Hz), 3 protons were not observed in CD₃OD.

HPLC: 92.51 %


MS (ES⁺): m/z [M-H]⁺ calcd for C₁₄H₂₄N₄O₈S: 407.45. Found: 406.93.

Example 16

(2*S*,5*R*)-7-Oxo-*N*-[2-(sulfamoylamino)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 77, Table 1)




Step 1. *tert*-Butyl ({2-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]ethyl} sulfamoyl)carbamate (77)



To a mixture of 2-(2-aminoethoxy)-1*H*-isoindole-1,3(2*H*)-dione hydrochloride **75** (0.53 g, 2.19 mmol, EP 16744522 A1, 2006), *tert*-butyl (chlorosulfonyl)carbamate **76** (0.71 g, 3.28 mmol, WO 2006/84281 A1) in DCM (10 mL) was added triethylamine (0.92 mL, 6.57 mmol) slowly at 0 °C. The resulting mixture was stirred at room temperature for 7 h and concentrated to provide a residue which was subjected to chromatography to give **77** (0.63 g, 74 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.50 (9H, s), 3.49 (2H, m), 4.36 (2H, t, $J = 4.8$ Hz), 6.28 (1H, t, $J = 4.8$ Hz), 7.11 (1H, s), 7.79 (2H, m), 7.86 (2H, m).


MS (ES⁺): m/z [M-H]⁺ calcd for C₁₅H₁₈N₃O₇S: 384.09. Found: 383.94.

Step 2. *tert*-Butyl {[2-(aminooxy)ethyl]sulfamoyl}carbamate (78)

To a mixture of *tert*-butyl {[2-[(1,3-dioxo-1,3-dihydro-2*H*-isindol-2-yl)oxy]ethyl]sulfamoyl}carbamate **77** (0.62 g, 1.61 mmol) in a solution of DCM (10 mL) and ethanol (2 mL) was added hydrazine hydrate (0.092 mL, 1.61 mmol) at room temperature. The mixture was stirred at room temperature overnight, filtered and concentrated to provide a residue which was subjected to chromatography to give **78** (0.18 g, 44 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.49 (9H, s), 3.33 (2H, m), 3.81 (2H, m), 5.28 (2H, br s), 5.93 (1H, br s), 7.24 (1H, br s).

MS (ES⁺): *m/z* [M+H]⁺ calcd for C₇H₁₆N₃O₅S: 256.10. Found: 255.91.


Step 3. *tert*-Butyl {[2-[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]ethyl]sulfamoyl}carbamate (79)

To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.200 g, 0.723 mmol) in DCM (6.0 mL) was added *tert*-butyl {[2-(aminooxy)ethyl]sulfamoyl}carbamate **78** (0.276 g, 1.085 mmol), 1-hydroxybenzotriazole (0.147 g, 1.086 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.208 g, 1.086 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **79** (0.35 g, 93 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.48 (9H, m), 1.64 (1H, m), 1.95 (2H, m), 2.33 (1H, m), 2.76 (1H, d, *J* = 11.2 Hz), 3.01 (1H, d, *J* = 12.0 Hz), 3.32 (1H, s), 3.38 (2H, br s), 3.95 (1H, d, *J* = 7.2 Hz), 4.03 (2H, m), 4.92 (2H, ABq), 6.38 (1H, br s), 7.26 (1H, m), 7.41 (5H, m), 9.20 (1H, s).

MS (ES⁺): *m/z* [M+H]⁺ calcd for C₂₁H₃₂N₅O₈S: 514.20. Found: 514.00.

Step 4. *tert*-Butyl ({2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]ethyl}sulfamoyl)carbamate (80)




A mixture of *tert*-butyl ({2-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]ethyl}sulfamoyl)carbamate **79** (0.35 g, 0.67 mmol) and Pd/C (10 %, 0.12 g) in methanol (10 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to provide **80** (0.25 g, 88 %) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.48 (9H, s), 1.80 (1H, m), 1.96 (1H, m), 2.06 (1H, m), 2.20 (1H, m), 3.03 (1H, d, *J* = 11.6 Hz), 3.12 (1H, m), 3.28 (2H, m), 3.70 (1H, m), 3.84 (1H, d, *J* = 8.0 Hz), 3.98 (2H, t, *J* = 5.6 Hz). 4 protons were not observed in CD₃OD.

MS (ES⁺): *m/z* [M+H]⁺ calcd for C₁₄H₂₆N₅O₈S: 424.15. Found: 423.97.

Step 5. *tert*-Butyl ({2-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]ethyl}sulfamoyl)carbamate (81)




To a mixture of *tert*-butyl ({2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]ethyl}sulfamoyl)carbamate **80** (0.25 g, 0.59 mmol) in pyridine (10.0 mL) was added sulfur trioxide pyridine complex (0.28 g, 1.77 mmol). The mixture was stirred at room temperature overnight and concentrated to provide a residue which was subjected to chromatography to give **81** (0.20 g, 67 %) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.48 (9H, s), 1.83 (1H, m), 1.91 (1H, m), 2.06 (1H, m), 2.21 (1H, m), 3.08 (1H, d, *J* = 11.6 Hz), 3.24 (1H, m), 3.28 (2H, m), 3.91 (1H, d, *J* = 7.2 Hz), 3.98 (2H, t, *J* = 5.6 Hz), 4.15 (1H, m). 4 protons were not observed in CD₃OD.

MS (ES⁻): *m/z* [M-H]⁻ calcd for C₁₄H₂₄N₅O₁₁S₂: 502.09. Found: 501.97.

Step 6. (2S,5R)-7-Oxo-N-[2-(sulfamoylamino)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 77, Table 1)



To a mixture of *tert*-butyl ({2-[[[(2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy}ethyl)sulfamoyl)carbamate **81** (0.20 g, 0.40 mmol) in DCM (5.0 mL) was added trifluoroacetic acid (1.0 mL) at 0°C. The mixture was stirred at 0°C for 0.5 h and at room temperature for 2 h, concentrated and washed with ether. The white solid was collected by centrifugation. The crude product was purified by preparative HPLC to provide **Compound 77 (Table 1)** (37 mg, 23 %) as a white solid.


¹H NMR (400 MHz, D₂O): δ 1.68-2.06 (4H, m), 3.00 (1H, d, *J* = 12.0 Hz), 3.17-3.22 (3H, m), 3.94 (3H, m), 4.07 (1H, d, *J* = 2.8 Hz). 5 protons were not observed in D₂O.

HPLC: 95.56 %


MS (ES⁺) *m/z*: [M-H]⁺ calcd for C₉H₁₆N₅O₉S₂: 402.04. Found: 401.99.

Example 17

(2S,5R)-N-[2-(Carbamoylamino)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 78, Table 1)




Step 1. *tert*-Butyl ({2-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]ethyl} carbamoyl)carbamate (83**)**



To a mixture of 2-(2-aminoethoxy)-1*H*-isoindole-1,3-dione hydrochloride **75** (0.40 g, 1.65 mmol, EP 1674452 A1, 2006), *tert*-butyl (chlorocarbonyl)carbamate **82** (1.70 g crude, US 2005/187277 A1) in DCM (10 mL) was added triethylamine (0.69 mL, 4.95 mmol) slowly at 0 °C. The resulting mixture was stirred at room temperature overnight and concentrated to provide a residue which was subjected to chromatography to give **83** (0.56 g, 96 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.50 (9H, s), 3.64 (2H, m), 4.30 (2H, t, *J* = 5.2 Hz), 6.91 (1H, br s), 7.75 (2H, m), 7.87 (2H, m), 8.45 (1H, m).


Step 2. *tert*-Butyl {[2-(aminooxy)ethyl]carbamoyl}carbamate (84**)**



To a mixture of *tert*-butyl ({2-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]ethyl} carbamoyl)carbamate **83** (0.56 g, 1.59 mmol) in a solution of DCM (10 mL) and ethanol (2 mL) was added hydrazine hydrate (0.091 mL, 1.59 mmol) at room temperature. The mixture was stirred at room temperature overnight, filtered and concentrated to provide a residue which was subjected to chromatography to give **84** (0.25 g, 72 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.49 (9H, s), 3.53 (2H, q, *J* = 5.2 Hz), 3.76 (2H, t, *J* = 5.2 Hz), 5.51 (2H, br s), 6.83 (1H, br s), 7.80 (1H, br s).

Step 3. *tert*-Butyl ((2-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]ethyl]carbamoyl)carbamate (85)




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.210 g, 0.760 mmol, US 2005/20572 A1) in DCM (6.0 mL) were added *tert*-butyl ((2-aminooxy)ethyl)carbamoyl)carbamate **84** (0.250 g, 1.140 mmol), 1-hydroxybenzotriazole (0.154 g, 1.140 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.218 g, 1.140 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **85** (0.31 g, 85 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.48 (9H, m), 1.64 (2H, m), 1.98 (2H, m), 2.34 (1H, m), 2.77 (1H, d, *J* = 11.2 Hz), 3.02 (1H, m), 3.28 (1H, m), 3.47 (1H, m), 3.63 (1H, m), 3.97 (2H, m), 4.90 (2H, ABq), 6.79 (1H, br s), 7.39 (5H, m), 8.11 (1H, m), 9.77 (1H, s).

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₂₂H₃₂N₅O₇: 478.23. Found: 478.10.

Step 4. *tert*-Butyl ((2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]ethyl]carbamoyl)carbamate (86)




A mixture of *tert*-butyl ((2-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]ethyl]carbamoyl)carbamate **85** (0.31 g, 0.64 mmol) and Pd/C (10 %, 0.11 g) in methanol (10 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to provide **86** (0.25 g, quantitative) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.48 (9H, s), 1.80 (1H, m), 1.92 (1H, m), 2.05 (1H, m), 2.20 (1H, m), 3.02 (1H, d, *J* = 11.6 Hz), 3.15 (1H, m), 3.51 (2H, t, *J* = 5.6 Hz), 3.70 (1H, m), 3.85 (1H, d, *J* = 7.2 Hz), 3.94 (2H, t, *J* = 5.6 Hz). 4 protons were not observed in CD₃OD.

MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₅H₂₄N₅O₇: 386.17. Found: 386.07.

Step 5. *tert*-Butyl ({2-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]ethyl}carbamoyl)carbamate (**87**)




To a mixture of *tert*-butyl ({2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]ethyl}carbamoyl)carbamate **86** (0.25 g, 0.65 mmol) in pyridine (10.0 mL) was added sulfur trioxide pyridine complex (0.30 g, 1.94 mmol). The mixture was stirred at room temperature overnight and concentrated to provide a residue which was subjected to chromatography to give **87** (0.25 g, 83 %) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.49 (9H, s), 1.83 (1H, m), 1.93 (1H, m), 2.07 (1H, m), 2.21 (1H, m), 3.07 (1H, d, *J* = 21.0 Hz), 3.27 (1H, m), 3.51 (2H, t, *J* = 5.2 Hz), 3.92 (1H, m), 3.95 (2H, t, *J* = 5.2 Hz), 4.15 (1H, m). 4 protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M-H]⁺ calcd for C₁₅H₂₄N₅O₁₀S: 466.12. Found: 466.01.

Step 6. (2*S*,5*R*)-*N*-[2-(Carbamoylamino)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound **78**, Table 1)





To a mixture of *tert*-butyl ({2-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]ethyl}carbamoyl)carbamate **87** (0.25 g, 0.54 mmol) in DCM (5.0 mL) was added trifluoroacetic acid (1.0 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 h and at room temperature for 2 h, concentrated and washed with ether. The white solid was collected by centrifugation. The crude product was purified by preparative HPLC to provide **Compound 78 (Table 1)** (11 mg, 5.6 %) as a white solid.

¹H NMR (400 MHz, D₂O): δ 1.69-1.88 (2H, m), 1.90-2.09 (2H, m), 2.98 (1H, d, *J* = 12.0 Hz), 3.17-3.21 (1H, m), 3.24 (2H, t, *J* = 5.2 Hz), 3.84 (2H, t, *J* = 5.2 Hz), 3.93 (1H, d, *J* = 7.6 Hz), 4.07 (1H, s). 5 protons were not observed in D₂O.

HPLC: 85.17 %


MS (ES⁺) *m/z*: [M-H]⁺ calcd for C₁₀H₁₆N₅O₈S: 366.07. Found: 365.96.

Example 18

Disodium [(((2*S*,5*R*)-7-oxo-6-(sulfonatooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]acetate (Compound 82, Table 1)5 Step 1. *tert*-Butyl [(((2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]acetate (**89**)

To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.20 g, 0.72 mmol) in dry DCM (20 mL) were added *tert*-butyl (aminooxy)acetate **88** (0.13 g, 0.86 mmol, *Organic Letters*, 2002, 4(6) 869-872), 1-hydroxybenzotriazole (0.15 g, 1.11 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.21 g, 1.10 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give *tert*-butyl [(((2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]acetate **89** (0.23 g, 79 %) as a white solid.


¹H NMR (400 MHz, CDCl₃): δ 1.49 (9H, s), 1.65 (1H, m), 1.98 (2H, m), 2.33 (1H, m), 2.72 (1H, d, J = 11.6 Hz), 2.99 (1H, d, J = 11.2 Hz), 3.30 (1H, s), 3.95 (1H, d, J = 7.2 Hz), 4.34 (2H, m), 4.89 (1H, d, J = 11.2 Hz), 5.04 (1H, d, J = 12.0 Hz), 7.39 (5H, m), 9.68 (1H, br s).

20 Step 2. *tert*-Butyl [(((2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]acetate (**90**)

To a solution of *tert*-butyl [((((2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]acetate **89** (0.23 g, 0.57 mmol) in methanol (20 mL) was added 5 % Pd/C (0.30 g). The mixture was hydrogenated under 35 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give *tert*-butyl [((((2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]acetate **90** (0.16 g, 89 %) as a clear thick oil.


¹H NMR (400 MHz, CD₃OD): δ 1.48 (9H, s), 1.77 (1H, m), 1.90 (1H, m), 2.06 (1H, m), 2.20 (1H, m), 3.10 (2H, m), 3.70 (1H, m), 3.84 (1H, d, J = 7.2 Hz), 4.35 (2H, m), 2 protons were not observed in CD₃OD.

Step 3. *tert*-Butyl [((((2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]acetate pyridine salt (91**)**



To a solution of *tert*-butyl [((((2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]acetate **90** (0.16 g, 0.51 mmol) in dry pyridine (7 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.325 g, 2.04 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated to give *tert*-butyl [((((2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]acetate pyridine salt **91** (0.20 g crude) which was used in the next step without purification.

Step 4. *N,N,N*-Tributylbutan-1-aminium [((((2*S*,5*R*)-2-((2-*tert*-butoxy-2-oxoethoxy)carbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide (92**)**




tert-Butyl [((((2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]acetate pyridine salt **91** (0.20 g, 0.51 mmol) was introduced into a concentrated aqueous solution of monosodium dihydrogen phosphate solution (8 mL) so as to obtain a pH of 4. The mixture was washed with ethyl acetate, then added tetrabutyl ammonium hydrogen sulfate

(0.10 g, 0.29 mmol) and stirred at room temperature for 10 min. The mixture was extracted with ethyl acetate (3 x 10 mL), and the extracts were combined, dried over sodium sulfate and evaporated to give *N,N,N*-tributylbutan-1-aminium [(((2*S*,5*R*)-2-[(2-*tert*-butoxy-2-oxoethoxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide **92** (0.15 g, 46 % in 2 steps) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.01 (12H, t, J = 7.2 Hz), 1.42 (17H, m), 1.65 (9H, m), 1.90 (1H, m), 2.18 (1H, m), 2.34 (1H, m), 2.76 (1H, d, J = 11.6), 3.29 (9H, m), 3.91 (1H, d, J = 7.2 Hz), 4.34 (3H, m), 9.78 (1H, br s).

Step 5. Disodium [(((2*S*,5*R*)-7-oxo-6-(sulfonatooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]acetate (Compound **82**, Table 1)



To a solution of *N,N,N*-tributylbutan-1-aminium [(((2*S*,5*R*)-2-[(2-*tert*-butoxy-2-oxoethoxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide **92** (0.15 g, 0.24 mmol) in DCM (2 mL) was added trifluoroacetic acid (0.50 mL, 6.49 mmol) dropwise at 0 °C. The reaction mixture was stirred for 1 h, then evaporated. The residue after washing with ether (3 x) was suspended in water (5 mL) and DOWEX 50WX4 (1 g) was added. The mixture was stirred at room temperature for 1 h, and then filtered. The filtrate was freeze-dried, purified by HPLC and freeze-dried again to give disodium [(((2*S*,5*R*)-7-oxo-6-(sulfonatooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]acetate **Compound 82** (Table 1) (0.012 g, 15%) as a white solid.


¹H NMR (400 MHz, CD₃OD): δ 1.82 (1H, m), 1.91 (1H, m), 2.06 (1H, m), 2.22 (1H, m), 3.09 (1H, d, J = 12.0 Hz), 3.24 (1H, d, J = 10.8 Hz), 3.92 (1H, d, J = 7.6 Hz), 4.14 (1H, m), 4.25 (2H, m), 1 proton was not observed in CD₃OD.

HPLC 95.36%


MS (ES⁻): m/z [M-2Na+H]⁻ = 337.86.

Example 19

(2S,5R)-7-Oxo-N-[(2S)-pyrrolidin-2-ylmethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 16, Table 1)



- 5 Step 1. *tert*-Butyl (2S)-2-[[[[(2S,5R)-6-(Benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]pyrrolidine-1-carboxylate (94)




- To a mixture of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid 1 (0.200 g, 0.720 mmol, US 2005/20572 A1) in DCM (6.0 mL) were added *tert*-butyl (2S)-2-[[[amino]oxy]methyl]pyrrolidine-1-carboxylate 93 (0.234 g, 1.085 mmol, US 2007/118830 A1), 1-hydroxybenzotriazole (0.147 g, 1.085 mmol) and 1-ethyl-(3-dimethylamino propyl) carbodiimide hydrochloride (0.208 g, 1.085 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give 94 (0.30 g, 88 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.47 (9H, s), 1.70 (1H, m), 1.94 (5H, m), 2.29 (1H, m), 2.89 (1H, d, *J* = 12 Hz), 3.03 (1H, m), 3.27 (1H, m), 3.36 (2H, m), 3.73 (1H, m), 3.83 (1H, m), 3.93 (1H, m), 4.12 (1H, m), 4.89 (1H, d, *J* = 11.2 Hz), 5.07 (1H, d, *J* = 11.2 Hz), 7.41 (5H, m), 10.12 (1H, br s). One proton was not observed in moisture-containing CDCl₃.

- 20 MS (ES⁺): *m/z* [M+H]⁺ calcd for C₂₄H₃₅N₄O₆: 475.26. Found: 475.38.

Step 2. *tert*-Butyl (2*S*)-2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]pyrrolidine-1-carboxylate (95)




A mixture of *tert*-butyl (2*S*)-2-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo [3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]pyrrolidine-1-carboxylate **94** (0.30 g, 0.63 mmol) and Pd/C (0.10 g) in methanol (10 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to provide **95** (0.26 g, quant. yield) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.46 (9H, s), 1.72-2.22 (7H, m), 3.06 (1H, m), 3.12 (1H, m), 3.30 (3H, m), 3.69 (1H, m), 3.37-4.05 (4H, m). 2 protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₇H₂₉N₄O₆: 385.21. Found: 385.33.

Step 3. *tert*-Butyl (2*S*)-2-[[[[(2*S*,5*R*)-7-Oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]pyrrolidine-1-carboxylate (96)




To a mixture of *tert*-butyl (2*S*)-2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1] oct-2-yl]carbonyl]amino]oxy]methyl]pyrrolidine-1-carboxylate **95** (0.26 g, 0.67 mmol) in pyridine (10.0 mL) was added sulfur trioxide pyridine complex (0.32 g, 2.03 mmol). The mixture was stirred at room temperature for 23 h and concentrated to provide a residue which was subjected to chromatography to give **96** (0.20 g, 64 %) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.46 (9H, s), 1.83-2.18 (7H, m), 3.10 (2H, m), 3.27 (2H, m), 3.72-4.10 (5H, m), 4.15 (1H, m). 2 protons were not observed in CD₃OD.

MS (ES⁻): *m/z* [M-H]⁻ calcd for C₁₇H₂₇N₄O₉S: 463.15. Found: 463.22.

Step 4. (2S,5R)-7-Oxo-N-[(2S)-pyrrolidin-2-ylmethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 16, Table 1)



To a mixture of *tert*-butyl (2S)-2-[[[[(2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]pyrrolidine-1-carboxylate **96** (0.20 g, 0.43 mmol) in DCM (4.0 mL) was added trifluoroacetic acid (0.20 mL) at 0°C. The mixture was stirred at 0°C for 1 h and at room temperature for 2 h, concentrated and washed with ether. The white solid was collected by centrifugation. Half of the crude product was purified by preparative HPLC (3 % MeOH in water) to provide **Compound 16 (Table 1)** (12 mg) as a white solid.


¹H NMR (400 MHz, D₂O): δ 1.60-2.05 (8H, m), 3.03-3.15 (2H, m), 3.20 (2H, m), 3.78-3.90 (3H, m), 4.00-4.05 (2H, m). 3 protons were not observed in D₂O.

HPLC: 96.10 %


MS (ES⁺): *m/z* [M-H]⁺ calcd for C₁₂H₁₉N₄O₇S: 363.10. Found: 363.16.

Example 20

(2S,5R)-N-Methoxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 28, Table 1)




Step 1. (2S,5R)-6-(Benzyloxy)-N-methoxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (98):



To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.334 g, 1.21 mmol) in DCM (25.0 mL) were added *O*-methylhydroxylamine **97** (0.193 g, 2.31 mmol), 1-hydroxybenzotriazole (0.25 g, 1.85 mmol), 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.35 g, 1.82 mmol) and 4-di(methylamino)pyridine (0.34 g, 2.78 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue, which was subjected to chromatography to give (2*S*,5*R*)-6-(benzyloxy)-*N*-methoxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **98** (0.17 g, 46 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.67 (1H, m), 1.99 (2H, m), 2.30 (1H, m), 2.80 (1H, d, *J* = 11.6 Hz), 3.01 (1H, m), 3.33 (1H, m), 3.77 (3H, s), 3.92 (1H, d, *J* = 7.6 Hz), 4.87 (1H, d, *J* = 11.6 Hz), 4.98 (1H, d, *J* = 11.6 Hz), 7.36 (5H, m), 9.34 (1H, br s).


Step 2. (2*S*,5*R*)-6-hydroxy-*N*-methoxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (99**):**



A mixture of (2*S*,5*R*)-6-(benzyloxy)-*N*-methoxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **98** (0.17 g, 0.56 mmol) and 5 % Pd/C (0.2 g) in methanol (15 mL) was hydrogenated at 10 psi for 1 h. The mixture was filtered through Celite pad and concentrated to provide (2*S*,5*R*)-6-hydroxy-*N*-methoxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **99** (0.12 g, quant. yield) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.78-2.23 (4H, m), 3.03 (1H, d, *J* = 12.0 Hz), 3.11 (1H, m), 3.50 (4H, m), 3.81 (1H, d, *J* = 7.6 Hz). 2 protons were not observed in CD₃OD.

Step 3. (2*S*,5*R*)-*N*-methoxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 28, Table 1)



To a mixture of (2*S*,5*R*)-6-hydroxy-*N*-methoxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **99** (0.12 g, 0.55 mmol) in pyridine (7.0 mL) was added sulfur trioxide pyridine complex (0.35 g, 2.20 mmol). The mixture was stirred at room temperature for 23 h and concentrated to provide a residue, which was purified by chromatography and again purified by HPLC and freeze-dried to give (2*S*,5*R*)-*N*-methoxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **compound 28** (Table 1) (0.02 g, 12 %) as a white solid.


¹H NMR (400 MHz, CD₃OD): δ 1.81-1.96 (2H, m), 2.09 (1H, m), 2.21 (1H, m), 3.09 (1H, d, *J* = 11.6 Hz), 3.24 (1H, m), 3.71 (3H, s), 3.90 (1H, d, *J* = 6.8 Hz), 4.14 (1H, m). 2 protons were not observed in CD₃OD.

HPLC 96.87 %


MS (ES⁺): *m/z* [M-H]⁺ = 293.89

Example 21

(2*S*,5*R*)-*N*-[(1-methyl-1*H*-imidazol-5-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 137, Table 1)



Step 1. (2*S*,5*R*)-6-(benzyloxy)-*N*-[(1-methyl-1*H*-imidazol-5-yl)methoxy]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (**101**)




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (10.0 mL) was added 5-[(aminooxy)methyl]-1-methyl-1*H*-imidazole **100** (0.172 g, 1.358 mmol), 1-hydroxybenzotriazole (0.183 g, 1.358 mmol) and 1-

ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **101** (0.40 g, quantitative yield) as a white foam.

- 5 ^1H NMR (400 MHz, CDCl_3): δ 1.56 (1H, m), 1.91 (2H, m), 2.21 (1H, m), 2.65 (1H, d, $J = 12.0$ Hz), 2.95 (1H, d, $J = 11.6$ Hz), 3.30 (1H, s), 3.82 (3H, s), 3.91 (1H, d, $J = 11.2$ Hz), 4.84 (3H, m), 5.04 (1H, d, $J = 11.6$ Hz), 7.05 (1H, s), 7.33 (5H, m), 7.62 (1H, s).

MS (ES^+) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{24}\text{N}_5\text{O}_4$: 386.2. Found: 386.1.

Step 2. (2*S*,5*R*)-6-hydroxy-*N*-[(1-methyl-1*H*-imidazol-5-yl)methoxy]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (**102**)




- A mixture of (2*S*,5*R*)-6-(benzyloxy)-*N*-[(1-methyl-1*H*-imidazol-5-yl)methoxy]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **101** (0.40 g, 0.90 mmol) and Pd/C (0.13 g) in methanol (20 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to give a residue which was subjected to chromatography to give **102** (0.21 g, 75 %) as a white foam.

^1H NMR (400 MHz, CD_3OD): δ 1.74 (1H, m), 1.89 (1H, m), 2.04 (1H, m), 2.15 (1H, m), 2.91 (1H, d, $J = 12.0$ Hz), 3.09 (1H, m), 3.67 (1H, s), 3.79 (1H, d, $J = 6.8$ Hz), 3.85 (3H, s), 4.92 (2H, m), 7.07 (1H, s), 7.73 (1H, s). 2 protons were not observed in CD_3OD .

- MS (ES^+) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{12}\text{H}_{18}\text{N}_5\text{O}_4$: 296.13. Found: 296.10.

Step 3. (2*S*,5*R*)-*N*-[(1-methyl-1*H*-imidazol-5-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 137, Table 1).



To a mixture of (2*S*,5*R*)-6-hydroxy-*N*-[(1-methyl-1*H*-imidazol-5-yl)methoxy]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **102** (0.21 g, 0.71 mmol) in pyridine (6 mL) was added sulfur trioxide pyridine complex (0.33 g, 2.13 mmol). The mixture was stirred at room temperature for 23 h and concentrated to provide a residue which was subjected to flash chromatography to give **Compound 137** (Table 1) (64 mg) as a white solid.


¹H NMR (400 MHz, D₂O): δ 1.62 (1H, m), 1.75 (1H, m), 1.91 (2H, m), 2.82 (1H, d, *J* = 11.6 Hz), 3.13 (1H, d, *J* = 11.2 Hz), 3.86 (3H, s), 3.89 (1H, s), 4.05 (1H, s), 4.93 (2H, s), 7.49 (1H, s), 8.61 (1H, s). Two protons were not observed in D₂O.

HPLC: 98.14 %


MS (ES⁺) *m/z*: [M-H]⁺ calcd for C₁₂H₁₆N₅O₇S: 374.1. Found: 373.9.

Example 22

1-(Acetyloxy)ethyl (3*S*)-3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]pyrrolidine-1-carboxylate (Compound 101, Table 1)



Step 1. 1-(Acetyloxy)ethyl (3*S*)-3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]pyrrolidine-1-carboxylate (Compound 101, Table 1)



To a mixture of (2*S*,5*R*)-7-oxo-*N*-[(3*S*)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **Compound 2** (Table 1) (0.030 g, 0.086 mmol,

Example 2) in DMF (dimethyl formamide) (1.5 mL) was added 1-[(4-nitrophenoxy)carbonyl]oxyethyl acetate **103** (0.027 g, 0.102 mmol, *J. Med. Chem.*, 1988, vol 31, 2, p318-322) and triethylamine (0.023 mL, 0.171 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue, which was subjected to chromatography and preparative HPLC to give **Compound 101** (Table 1) (0.011g) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.47 (3H, m), 1.82-2.00 (2H, m), 2.04-2.06 (3H, m), 2.10 (1H, m), 2.27 (2H, m), 3.08 (1H, dd, *J* = 4.2, 12.0 Hz), 3.24-3.30 (2H, m), 3.41-3.53 (3H, m), 3.65 (1H, m), 3.94 (1H, d, *J* = 7.6 Hz), 4.15 (1H, s), 4.62 (1H, s), 6.76 (1H, m).


2 protons were not observed in CD₃OD.

HPLC: 86.89 %


MS (ES⁺): *m/z* [M-H]⁺ calcd for C₁₆H₂₃N₄O₁₁S: 479.11. Found: 479.04.

Example 23

(2S,5R)-7-oxo-N-(piperidin-2-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide trifluoroacetate (Compound 50, Table 1)




Step 1. *tert*-butyl 2-[(aminooxy)methyl]piperidine-1-carboxylate (105**)**



To a mixture of *tert*-butyl 2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)oxy]methylpiperidine-1-carboxylate **104** (1.50 g, 4.16 mmol) in a solution of methanol (20 mL) was added methylhydrazine hydrate (4.16 mmol) at room temperature. The mixture was stirred at room temperature overnight, filtered and concentrated to provide a residue which was subjected to chromatography to give **105** (0.50 g, 53 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.36-1.60 (15H, m), 2.75 (1H, m), 3.53 (1H, m), 3.91 (2H, m), 4.57 (1H, br s), 5.70 (2H, br s).

Step 2. *tert*-butyl 2-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate (**106**)




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (15.0 mL) were added *tert*-butyl 2-[(aminooxy)methyl]piperidine-1-carboxylate **105** (0.312 g, 1.358 mmol), 1-hydroxybenzotriazole (0.183 g, 1.358 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **106** (0.40 g, 91 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.41 (9H, m), 1.61 (6H, m), 1.97 (2H, m), 2.29 (1H, m), 2.78 (3H, m), 2.97 (1H, m), 3.26 (1H, m), 3.70 (1H, m), 3.99 (2H, m), 4.15 (1H, m), 4.51 (1H, m), 4.88 (1H, d, *J* = 11.6 Hz), 5.06 (1H, m), 7.42 (5H, m). One proton was not observed in moisture containing CDCl₃.

MS (ES⁺) *m/z*: [M-H]⁺ calcd for C₂₅H₃₅N₄O₈: 487.2. Found: 487.1.

Step 3. *tert*-butyl 2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate (**107**)




A mixture of *tert*-butyl 2-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate **106** (0.40 g, 0.82 mmol) and Pd/C (0.13 g) in methanol (20 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to give **107** (0.33 g, quantitative yield) as a white foam.

^1H NMR (400 MHz, CD_3OD): δ 1.45 (9H, s), 1.60 (5H, m), 1.80 (2H, m), 1.93 (1H, m), 2.04 (1H, m), 2.21 (1H, m), 2.84 (1H, m), 2.99 (1H, m), 3.31 (1H, m), 3.68 (1H, s), 3.89 (1H, s), 4.02 (3H, m), 4.47 (1H, m). Two protons were not observed in CD_3OD .

MS (ES^+) m/z : $[\text{M}+\text{H}]^+$ calcd. For $\text{C}_{18}\text{H}_{31}\text{N}_4\text{O}_6$: 399.2. Found: 399.1.


5 **Step 4.** *tert*-butyl 2-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate (**108**)



To a mixture of *tert*-butyl 2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate **107** (0.33 g, 0.83 mmol) in pyridine
10 (4.0 mL) was added sulfur trioxide pyridine complex (0.38 g, 2.48 mmol). The mixture was stirred at room temperature for 23 h and concentrated to provide a residue which was subjected to chromatography to give **108** (0.27 g, 69 %) as a white foam.

^1H NMR (400 MHz, CD_3OD): δ 1.45 (10H, m), 1.63 (4H, m), 1.84 (2H, m), 1.92 (1H, m), 2.06 (1H, m), 2.21 (1H, m), 2.87 (1H, m), 3.09 (1H, m), 3.24 (2H, m), 3.91 (2H, m), 4.03 (1H, m),
15 4.11 (1H, m), 4.46 (1H, m). Two protons were not observed in CD_3OD .

Step 5. (2*S*,5*R*)-7-oxo-*N*-(piperidin-2-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide trifluoroacetate (Compound **50**, Table 1)



To a mixture of *tert*-butyl 2-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate **108** (0.27 g, 0.58 mmol) in DCM (8.0
20 mL) was added trifluoroacetic acid (0.40 mL) at 0°C. The mixture was stirred at 0°C for 3 h, concentrated and washed with ether, EtOAc and DCM to give TFA salt of **Compound 50** (Table 1) (61 mg) as a white solid as a pair of diastereomers.


^1H NMR (400 MHz, D_2O): δ 1.38 (2H, m), 1.54 (1H, m), 1.75 (5H, m), 2.01 (2H, m), 2.85 (1H, m), 3.00 (1H, m), 3.21 (1H, m), 3.36 (2H, m), 3.91 (3H, m), 4.08 (1H, s). Three protons were not observed in D_2O .

HPLC: 95.23 %


5 MS (ES^-) m/z : $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{13}\text{H}_{21}\text{N}_4\text{O}_7\text{S}$: 377.1. Found: 377.0.

Example 24

Sodium (((((2S,5R)-2-((((3S)-1-methylpyrrolidin-3-yl)oxy)carbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl)oxidanide (Compound 149, Table 1)



10 **Step 1. ((2S,5R)-6-(benzyloxy)-N-((((3S)-1-methylpyrrolidin-3-yl)oxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (110)**




To a mixture of ((2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.25 g, 0.90 mmol, US2005/20572 A1, 2005) in DCM (20 mL) was added (3S)-3-(aminooxy)-1-methylpyrrolidine **109** (0.32 g, 1.39 mmol, J. Med. Chem., 2008, **51**, 4601-4608), 1-hydroxybenzotriazole (0.18 g, 1.33 mmol), and 1-ethyl-(3-dimethylamino propyl) carbodiimide hydrochloride (0.26 g, 1.36 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, then concentrated in vacuo to provide a residue, which was subjected to chromatography to give **110** (0.26 g, 77 %) as a yellow foam.

20 ^1H NMR (400 MHz, CDCl_3): δ 1.60 (1H, m), 2.00 (4H, m), 2.26 (4H, m), 2.71 (1H, d, $J = 11.7$ Hz), 2.84 (1H, m), 2.93 (4H, m), 3.12 (1H, m), 3.30 (1H, m), 3.97 (1H, d, $J = 6.3$ Hz), 4.74 (1H, br s), 4.90 (1H, d, $J = 11.3$ Hz), 5.04 (1H, d, $J = 11.3$ Hz), 7.39 (5H, m).

MS (ES^+) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{27}\text{N}_4\text{O}_4$: 375.20. Found: 375.21

Step 2. (2S,5R)-6-hydroxy-N-[[[(3S)-1-methylpyrrolidin-3-yl]oxy]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (111)




A mixture of (2S,5R)-6-(benzyloxy)-N-[[[(3S)-1-methylpyrrolidin-3-yl]oxy]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **110** (0.26 g, 0.69 mmol) and Pd/C (0.50 g) in methanol (25 mL) was hydrogenated at 20 psi at room temperature for 2 hours. The mixture was filtered through a Celite pad and concentrated to provide **111** (0.20 g) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.99 (3H, m), 2.29 (3H, m), 2.99 (3H, s), 3.03 (1H, d, *J* = 11.7 Hz), 3.15 (1H, m), 3.41 (2H, m), 3.66 (2H, d, *J* = 13.3 Hz), 3.71 (1H, br s), 3.89 (1H, d, *J* = 7.8 Hz), 4.74 (1H, m). 2 protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₂H₂₁N₄O₄: 285.16. Found: 285.19.

Step 3. Sodium ([[(2S,5R)-2-([[(3S)-1-methylpyrrolidin-3-yl]oxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl]oxidanide (Compound 149, Table 1)



To a mixture of (2S,5R)-6-hydroxy-N-[[[(3S)-1-methylpyrrolidin-3-yl]oxy]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **111** (0.21 g, 0.74 mmol) in pyridine (5 mL) was added sulfur trioxide pyridine complex (0.24 g, 1.51 mmol). The mixture was stirred at room temperature overnight. The mixture was concentrated in vacuo, then diluted with toluene and concentrated in vacuo (repeated twice). The residue was washed with DCM, then the organics were decanted off to give a sticky residue (repeat twice). The residue was dried to give an off white solid. The crude product was passed through a resin column (DOWEX 50W X4) eluting with water, then lyophilized to afford **Compound 149 (Table 1)** (0.017 g, 8 %, over 2 steps) as sodium salt as a white solid.


^1H NMR (400 MHz, D_2O): δ 1.76 (2H, m), 1.97 (2H, m), 2.15 (1H, m), 2.28 (1H, m), 2.84 (3H, s), 2.99 (1H, d, $J = 12.1$ Hz), 3.16 (1H, d, $J = 12.5$ Hz), 3.30 (2H, br m), 3.54 (2H, br s), 3.92 (1H, d, $J = 5.5$ Hz), 4.05 (1H, d, $J = 3.1$ Hz), 4.65 (1H, m), 2 protons were not observed in D_2O .

5 HPLC: 93.67 %.

MS (ES^+) m/z : $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{12}\text{H}_{19}\text{N}_4\text{O}_7\text{S}$: 363.10. Found: 363.05.

Example 25

(2*S*,5*R*)-*N*-{[trans-3-(methylamino)cyclopentyl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 45, Table 1)



10

Step 1. cis-3-(methylamino)cyclopentanol (113)



To an ice-cold mixture of *tert*-butyl [cis (1*R*,3*R*)-3-hydroxycyclopentyl]carbamate **112** (0.32 g, 1.59 mmol, US2005/54658 A1, 2005) in tetrahydrofuran (10 mL) was added lithium aluminum hydride (1 M solution in tetrahydrofuran, 3.2 mL, 3.2 mmol). The mixture was refluxed for 4 hours, cooled to room temperature then quenched with a minimum amount of saturated sodium sulfate solution. Solid sodium sulfate was added to the mixture to give a suspension. The mixture was filtered through a pad of Celite, and the filtrate was concentrated in vacuo to afford **113** as colorless oil. The oil was used in the next step without further purification.

^1H NMR (400 MHz, CDCl_3): δ 1.54 (1H, m), 1.66 (1H, m), 1.83 (4H, m), 2.38 (3H, s), 3.21 (1H, m), 4.24 (1H, m).


MS (ES^+) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_6\text{H}_{14}\text{NO}$: 116.11. Found: 116.05.

Step 2. *tert*-butyl (cis-3-hydroxycyclopentyl)methylcarbamate (114)

To a mixture of cis-3-(methylamino)cyclopentanol **113** (1.59 mmol) in DCM (20 mL) was added di-*tert*-butyldicarbonate (0.35 g, 1.59 mmol) followed by triethylamine (0.45 mL, 3.23 mmol). The mixture was stirred at room temperature overnight, then concentrated in vacuo to give a yellow oil which was purified by chromatography to give **114** (0.18 g, 52 %, over 2 steps) as a white foam.

^1H NMR (400 MHz, CDCl_3): δ 1.46 (9H, s), 1.64 (2H, m), 1.79 (2H, m), 1.94 (1H, m), 2.18 (1H, ddd, $J = 15.1, 9.2, 5.9$ Hz), 2.83 (3H, s), 4.23 (2H, m). 1 proton was not observed in CDCl_3 .


MS (ES^+) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{11}\text{H}_{21}\text{NO}_3$: 216.16. Found: 216.15.

Step 3. *tert*-butyl {trans-3-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]cyclopentyl)methylcarbamate (115)

An ice-cold mixture of *tert*-butyl (cis-3-hydroxycyclopentyl)methylcarbamate **114** (0.19 g, 0.88 mmol), *N*-hydroxyphthalimide (0.29 g, 1.78 mmol), and triphenylphosphine (0.46 g, 1.75 mmol) in tetrahydrofuran (10 mL) was treated with diisopropylazodicarboxylate (0.40 g, 1.98 mmol). The mixture was stirred at room temperature overnight, then concentrated in vacuo to a yellow foam which was purified by chromatography to give **115** (0.19 g, containing DIAD byproduct) as a yellow oil. The mixture was used in the next step without further purification.

^1H NMR (400 MHz, CDCl_3): δ 1.69 (2H, m), 2.04 (2H, m), 2.20 (2H, m), 2.77 (3H, s), 4.95 (2H, m), 7.76 (2H, m), 7.85 (2H, m).

MS (ES^+) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{25}\text{N}_2\text{O}_5$: 361.18. Found: 361.15.


Step 4. *tert*-butyl [trans-3-(aminooxy)cyclopentyl)methylcarbamate (116)

A mixture of *tert*-butyl {trans-3-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]cyclopentyl}methylcarbamate **115** (0.19 g, 0.53 mmol) was treated with hydrazine hydrate (0.03 g, 0.60 mmol). The mixture was stirred at room temperature for 2 hours. The solid was filtered off and the filtrate was concentrated in vacuo. The residue was diluted with DCM, and the insoluble solid was filtered off. The filtrate was concentrated in vacuo to give an oil which was purified by chromatography to give **116** (0.09 g, 44 % over 2 steps) as a light yellow oil.

¹H NMR (400 MHz, CDCl₃): δ 1.46 (9H, s), 1.53 (1H, m), 1.68 (2H, m), 1.95 (3H, m), 2.72 (3H, s), 4.20 (1H, m), 4.60 (1H, br s), 5.28 (2H, br s).

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₁H₂₂N₂O₃: 231.17. Found: 231.15.

Step 5. *tert*-butyl {trans-3-[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]cyclopentyl}methylcarbamate (**117**)




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.25 g, 0.90 mmol, US2005/20572 A1, 2005) in DCM (20 mL) was added *tert*-butyl [trans-3-(aminooxy)cyclopentyl]methylcarbamate **116** (0.32 g, 1.39 mmol), 1-hydroxybenzotriazole (0.18 g, 1.33 mmol), and 1-ethyl-(3-dimethylamino propyl) carbodiimide hydrochloride (0.26 g, 1.36 mmol) sequentially at room temperature. The mixture was stirred at room temperature for 6 hours, then concentrated in vacuo to provide a residue which was subjected to chromatography to give **117** (0.45 g, contains some byproduct) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.45 (9H, s), 1.77 (10H, m), 2.31 (1H, m), 2.72 (3H, s), 2.78 (1H, dd, *J* = 11.3, 3.1 Hz), 3.15 (1H, br d, *J* = 14.1 Hz), 3.30 (1H, br s), 3.96 (1H, br d, *J* = 7.4 Hz), 4.60 (2H, m), 4.90 (1H, d, *J* = 11.3 Hz), 5.05 (1H, d, *J* = 11.3 Hz), 7.40 (5H, m).

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₂₅H₃₇N₄O₆: 489.27. Found: 489.20.

Step 6. *tert*-butyl {trans-3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]cyclopentyl)methylcarbamate (118)




A mixture of *tert*-butyl {trans-3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]cyclopentyl)methylcarbamate **117** (0.90 mmol) and Pd/C (0.50 g) in methanol (20 mL) was hydrogenated at 30 psi at room temperature for 1 hour. The mixture was filtered through a Celite pad and concentrated to provide **118** (0.40 g) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.46 (9H, s), 1.80 (9H, m), 2.20 (1H, m), 2.74 (3H, s), 3.11 (2H, m), 3.70 (1H, br s), 3.83 (1H, d, *J* = 7.4 Hz), 4.50 (1H, br s), 4.67 (1H, m). 2 protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₈H₃₀N₄O₆: 399.22. Found: 399.15.

Step 7. *tert*-butyl methyl{trans-3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]cyclopentyl}carbamate (119)




To a mixture of *tert*-butyl {trans-3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]cyclopentyl)methylcarbamate **118** (0.40 g, 1.00 mmol) in pyridine (10 mL) was added sulfur trioxide pyridine complex (0.24 g, 1.50 mmol). The mixture was stirred at room temperature for 3 days. The reaction showed little conversion to the product by ¹H NMR. Additional sulfur trioxide pyridine complex (0.46 g, 2.90 mmol) and pyridine (5 mL) were added to the mixture, and stirring was continued for 1 day. Conversion was 50 % by ¹H NMR, so more sulfur trioxide pyridine complex (0.62 g, 3.90 mmol) and pyridine (10 mL) were added, and stirring was continued for 1 day. The solid was filtered off and the filtrate was concentrated in vacuo. The residue was diluted with DCM and the solid was filtered off again. The filtrate was concentrated in vacuo, then subjected to chromatography to give **119** (0.20 g, 47 %, over 3 steps) as a pale yellow solid.

^1H NMR (400 MHz, CD_3OD): δ 1.46 (9H, s), 1.87 (9H, m), 2.19 (1H, m), 2.74 (3H, s), 3.10 (1H, d, $J = 11.7$ Hz), 3.27 (1H, m), 3.91 (1H, d, $J = 7.0$ Hz), 4.15 (1H, br s), 4.51 (1H, br s), 4.79 (1H, m). 2 protons were not observed in CD_3OD .

MS (ES $^-$) m/z : $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{18}\text{H}_{29}\text{N}_4\text{O}_9\text{S}$: 477.17. Found: 477.04.

5 **Step 8. (2S,5R)-N-[[trans-3-(methylamino)cyclopentyl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 45, Table 1)**



To a mixture of *tert*-butyl methyl{trans-3-[[[(2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]cyclopentyl}carbamate **119** (0.20 g, 0.42 mmol) in DCM (4.0 mL) was added trifluoroacetic acid (0.20 mL) at 0 °C. The mixture was stirred at 0 °C for 30 minutes, then at room temperature for 2 hours. The mixture was concentrated in vacuo to give a yellow oil, then diluted with diethyl ether and sonicated. The suspension was filtered to give an off-white solid. The solid was purified by triturating with methanol and diethyl ether to give a white suspension. The white solid was collected by vacuum filtration (hygroscopic) to give a residue on the filter paper. The residue was washed with methanol and diethyl ether, and the washings were discarded. The residue was dissolved in water and the aqueous solution was lyophilized to a white solid to afford **Compound 45 (Table 1)** (45 mg, 22 %, as a mixture of diastereoisomers, trifluoroacetate salt) as a white solid.

20 ^1H NMR (400 MHz, D_2O): δ 1.72 (6H, m), 1.98 (3H, m), 2.17 (1H, m), 2.28 (1H, m), 2.57 (3H, s), 2.98 (1H, dd, $J = 12.1, 4.7$ Hz), 3.19 (1H, d, $J = 11.7$ Hz), 3.63 (1H, m), 3.94 (1H, d, $J = 7.4$ Hz), 4.07 (1H, d, $J = 3.1$), 4.50 (1H, d, $J = 2.0$ Hz). 2 protons were not observed in D_2O .


^{19}F NMR (376 MHz, D_2O): δ -76.05.

HPLC: 90.9 %


25 MS (ES $^-$) m/z : $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{13}\text{H}_{22}\text{N}_4\text{O}_7\text{S}$: 377.11. Found: 377.05.

Example 26

Sodium [({(2*S*,5*R*)-2-[(1*H*-imidazol-4-ylmethoxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide (Compound 142, Table 1)



5 **Step 1.** *tert*-butyl 4-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]methyl)-1*H*-imidazole-1-carboxylate (**121**)




To a mixture of 2-hydroxy-1*H*-isoindole-1,3(2*H*)-dione (2.70 g, 16.6 mmol), *tert*-butyl 4-(hydroxymethyl)-1*H*-imidazole-1-carboxylate **120** (*Bull.Chem.Soc., Japan, 2002, Vol 75, No*
 10 *11, 2517-2526*, 1.64 g, 8.27 mmol) and triphenylphosphine (4.34 g, 16.6 mmol) in THF (100 mL) was added DIAD (3.52 mL, 18.2 mmol) slowly at room temperature. The resulting mixture was stirred at room temperature overnight and concentrated to provide a residue which was subjected to chromatography to give **121** (1.7 g, 61 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.61 (9H, s), 5.17 (2H, m), 7.56 (1H, s), 7.64 (2H, m), 7.82 (2H,
 15 m), 8.01 (1H, s).

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₇H₁₈N₃O₅: 344.13. Found: 344.08.

Step 2. *tert*-butyl 4-[(aminooxy)methyl]-1*H*-imidazole-1-carboxylate (**122**)




To a mixture of *tert*-butyl 4-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]methyl)-1*H*-
 20 imidazole-1-carboxylate **121** (1.72 g, 5.00 mmol) in a solution of DCM (20 mL) and ethanol (4 mL) was added hydrazine hydrate (0.287 mL, 5.00 mmol) at room temperature. The mixture

was stirred at room temperature overnight, filtered and concentrated to provide a residue which was washed with ether and methanol to give **122** (0.54 g, 51 %) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.62 (9H, m), 4.64 (2H, s), 5.51 (2H, br s), 7.38 (1H, s), 8.06 (1H, s).

5 MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₉H₁₆N₃O₃: 214.12. Found: 214.09.

Step 3. *tert*-butyl 4-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo [3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]-1*H*-imidazole-1-carboxylate (**123**)




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (10.0 mL) was added *tert*-butyl 4-[(aminooxy)methyl]-1*H*-imidazole-1-carboxylate **122** (0.289 g, 1.358 mmol), 1-hydroxybenzotriazole (0.183 g, 1.358 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **123** (0.40 g, 94 %) as a colorless oil.

¹H NMR (400 MHz, CDCl₃): δ 1.62 (9H, s), 1.95 (3H, m), 2.34 (1H, dd, *J* = 6.0, 14.4 Hz), 2.76 (1H, d, *J* = 11.6 Hz), 3.00 (1H, m), 3.29 (1H, s), 3.93 (1H, d, *J* = 6.8 Hz), 4.86 (3H, m), 5.06 (1H, d, *J* = 11.6 Hz), 7.40 (6H, m), 8.10 (1H, s). One proton was not observed in moisture-containing CDCl₃.

20 MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₂₃H₃₀N₅O₆: 472.22. Found: 472.11.

Step 4. *tert*-butyl 4-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]-1*H*-imidazole-1-carboxylate (**124**).




A mixture of *tert*-butyl 4-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]-1*H*-imidazole-1-carboxylate **123** (0.40 g, 0.85 mmol) and Pd/C (0.10 g) in methanol (15 mL) was hydrogenated at 1 atm at room temperature for 13 h. The mixture was filtered through Celite pad and concentrated to provide **124** (0.33 g, quantitative) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.63 (9H, s), 1.80-2.20 (4H, m), 3.08 (2H, m), 3.69 (1H, s), 3.82 (1H, d, *J* = 7.6 Hz), 4.80 (2H, s), 7.64 (1H, s), 8.19 (1H, s). 2 protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₆H₂₄N₅O₆: 382.17. Found: 382.10.

Step 5. sodium [(((2*S*,5*R*)-2-[(1*H*-imidazol-4-ylmethoxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide (Compound 142, Table 1)



To a mixture of *tert*-butyl 4-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]-1*H*-imidazole-1-carboxylate **124** (0.33 g, 0.86 mmol) in pyridine (10.0 mL) was added sulfur trioxide pyridine complex (0.40 g, 2.60 mmol). The mixture was stirred at room temperature for 3 days and concentrated to provide a residue, which was subjected to chromatography to give a yellow solid which was purified by ion-exchange resin (Dowex50 Na⁺ form, water) to give **Compound 142 (Table 1)** (10.7 mg) as a white solid.


¹H NMR (400 MHz, D₂O): δ 1.57-1.76 (2H, m), 1.86-1.99 (2H, m), 2.79 (1H, d, *J* = 12.4 Hz), 2.06 (1H, d, *J* = 12.4 Hz), 3.83 (1H, d, *J* = 7.2 Hz), 3.99 (1H, m), 4.72 (2H, s), 7.14 (1H, s), 7.69 (1H, s). 3 protons were not observed in D₂O.

HPLC: 87 %.


MS (ES⁻) *m/z*: [M-Na]⁻ calcd for C₁₁H₁₄N₅O₇SNa: 360.06. Found: 359.97.

Example 27

(2*S*,5*R*)-7-oxo-*N*-[2-(pyridin-2-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 69, Table 1)




5 **Step 1.** (2*S*,5*R*)-6-(benzyloxy)-7-oxo-*N*-[2-(pyridin-2-yl)ethoxy]-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (**126**)



To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.20 g, 0.72 mmol) in dry DCM (20 mL) were added 2-[2-(aminooxy)ethyl]pyridine **125** (0.12 g, 0.86 mmol, *J. Med. Chem.* 1997, 40(15), 2363-2373), 1-hydroxybenzotriazole (0.14 g, 1.10 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.20 g, 1.10 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight, and then concentrated under vacuum. The residue was purified by column chromatography to give (2*S*,5*R*)-6-(benzyloxy)-7-oxo-*N*-[2-(pyridin-2-yl)ethoxy]-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **126** (0.26 g, 91%) as a clear thick oil.

¹H NMR (400 MHz, CDCl₃): δ 1.62 (1H, m), 1.95 (2H, m), 2.30 (1H, m), 2.75 (1H, d, J= 11.6 Hz), 2.92 (1H, d, J= 11.2 Hz), 3.24 (3H, m), 3.95 (1H, d, J= 7.6 Hz), 4.27 (2H, m), 4.87 (1H, d, J= 11.2 Hz), 5.02 (1H, d, J= 11.2 Hz), 7.34 (6H, m), 7.70 (1H, d, J= 8.0 Hz), 7.79 (2H, m), 8.53 (1H, br s).


Step 2. (2S,5R)-6-hydroxy-7-oxo-N-[2-(pyridin-2-yl)ethoxy]-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (127)



To a solution of (2S,5R)-6-(benzyloxy)-7-oxo-N-[2-(pyridin-2-yl)ethoxy]-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **126** (0.26 g, 0.65 mmol) in methanol (20 mL) was added 5% Pd/C (0.25 g). The mixture was hydrogenated at 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give (2S,5R)-6-hydroxy-7-oxo-N-[2-(pyridin-2-yl)ethoxy]-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **127** (0.10 g, 50%) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.78 (1H, m), 1.97 (1H, m), 2.11 (1H, m), 2.28 (1H, m), 2.91 (1H, d, J = 12.0 Hz), 3.20 (2H, m), 3.70 (1H, s), 3.97 (1H, d, J = 7.6 Hz), 4.26 (2H, m), 7.30 (2H, m), 7.72 (2H, m), 8.47 (1H, s), 1 proton was not observed.

Step 3. (2S,5R)-7-oxo-N-[2-(pyridin-2-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 69, Table 1)



To a solution of (2S,5R)-6-hydroxy-7-oxo-N-[2-(pyridin-2-yl)ethoxy]-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **127** (0.10 g, 0.33 mmol) in dry pyridine (7 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.30 g, 1.88 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated. The residue was purified by HPLC and freeze dried to give (2S,5R)-7-oxo-N-[2-(pyridin-2-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **Compound 69 (Table 1)** (0.0025g, 2%) as a white solid.


¹H NMR (400 MHz, CD₃OD): δ 1.83 (1H, m), 1.91 (1H, m), 2.08 (1H, m), 2.21 (1H, m), 3.06 (1H, d, J = 12.0 Hz), 3.13 (2H, t, J = 6.4 Hz), 3.25 (1H, m), 3.86 (1H, d, J = 7.2 Hz), 4.14 (1H, s), 4.23 (2H, t, J = 6.4 Hz), 7.27 (1H, m), 7.46 (1H, d, J = 8.0 Hz), 7.76 (1H, m), 8.45 (1H, d, J = 2.4 Hz), 2 protons were not observed in CD₃OD.

HPLC: 76.3%


MS (ES⁻): m/z: [M]⁻ = 385.06

Example 28

sodium ({{{(2*S*,5*R*)-7-oxo-2-[[[(5-oxopyrrolidin-3-yl)oxy]carbonyl]-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy}sulfonyl)oxidanide (Compound 150, Table 1)




Step 1. (2*S*,5*R*)-6-(benzyloxy)-7-oxo-*N*-[[[(3*R*)-5-oxopyrrolidin-3-yl]oxy]-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (129)



To solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.20 g, 0.72 mmol) in dry DCM (25 mL) were added (4*R*)-4-(aminooxy)pyrrolidin-2-one **128** (0.12 g, 0.86 mmol, *J. Med. Chem.* 1997, 40(15), 2363-2373), 1-hydroxybenzotriazole (0.14 g, 1.10 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.20 g, 1.10 mmol) and 4-dimethylaminopyridine (0.13 g, 1.08 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight, and then concentrated under vacuum. The residue was purified by column chromatography to give (2*S*,5*R*)-6-(benzyloxy)-7-oxo-*N*-[[[(3*R*)-5-oxopyrrolidin-3-yl]oxy]-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **129** (0.22 g, 82%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.66 (1H, m), 1.96 (2H, m), 2.29 (1H, m), 3.56 (2H, m), 2.78 (1H, d, *J* = 12.0 Hz), 3.00 (1H, d, *J* = 12.0 Hz), 3.33 (1H, s), 3.58 (2H, m), 3.93 (1H, d, *J* = 7.6 Hz), 3.93 (1H, m), 4.84 (1H, m), 4.88 (1H, d, *J* = 12.0 Hz), 5.03 (1H, d, *J* = 11.2 Hz), 6.15 (1H, br s), 7.41 (5H, m), 9.63 (1H, br s).


Step 2. (2S,5R)-6-hydroxy-7-oxo-N-[(3R)-5-oxopyrrolidin-3-yl]oxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (130)



To a solution of (2S,5R)-6-(benzyloxy)-7-oxo-N-[(3R)-5-oxopyrrolidin-3-yl]oxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **129** (0.22 g, 0.59 mmol) in methanol (20 mL) was added 5% Pd/C (0.30 g). The mixture was hydrogenated at 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give (2S,5R)-6-hydroxy-7-oxo-N-[(3R)-5-oxopyrrolidin-3-yl]oxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **130** (0.156 g, 93 %) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.79 (1H, m), 1.97 (1H, m), 2.09 (1H, m), 2.22 (1H, m), 2.46 (1H, d, J = 16.4 Hz), 2.64 (1H, dd, 6.8 Hz, 18.0 Hz), 3.01 (1H, d, J = 11.6 Hz), 3.12 (1H, m), 3.59 (3H, m), 3.85 (1H, d, J = 7.2 Hz), 4.74 (1H, m), 3 protons were not observed in CD₃OD.

Step 3. sodium ([[(2S,5R)-7-oxo-2-[(5-oxopyrrolidin-3-yl)oxy]carbamoyl]-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl]oxidanide (Compound 150, Table 1)



To a solution of (2S,5R)-6-hydroxy-7-oxo-N-[(3R)-5-oxopyrrolidin-3-yl]oxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **130** (0.156 g, 0.55 mmol) in dry pyridine (9 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.40 g, 2.51 mmol). The mixture was stirred at room temperature for 20 h, then filtered and evaporated. Ether was added to the residue and the resulting white precipitate was collected by centrifugation. The white solid was purified by resin DOWEX 50WX4 column using water as eluent and freeze dried to give sodium ([[(2S,5R)-7-oxo-2-[(5-oxopyrrolidin-3-yl)oxy]carbamoyl]-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl]oxidanide **Compound 150 (Table 1)** (0.025 g, 12%) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.84 (1H, m), 1.93 (1H, m), 2.07 (1H, m), 2.20 (1H, m), 2.47 (1H, d, J = 18.0 Hz), 2.65 (1H, dd, J = 6.4 Hz and 18.0 Hz), 3.05 (1H, d, J = 11.6 Hz), 3.24

(1H, m), 3.59 (2H, m), 3.92 (1H, d, J = 6.8 Hz), 4.14 (1H, m), 4.75 (1H, m), 2 protons were not observed in CD₃OD.


HPLC: 97.3%

MS (ES⁻): m/z: [M]⁻ = 362.97

5


Example 29

Sodium [(((2S,5R)-2-[[1,4-oxazepan-2-ylmethoxy]carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide (Compound 13, Table 1)



Step 1. *tert*-butyl 2-[[[(((2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]methyl]-1,4-oxazepane-4-carboxylate (132)

10




To a solution of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.22 g, 0.80 mmol) in dry DCM (20 mL) were added *tert*-butyl 2-[[[amino]oxy]methyl]-1,4-oxazepane-4-carboxylate **131** (0.23 g, 0.93 mmol, US 2010/0168080 and J. Med. Chem. 2008, 51, 4601-4608), 1-hydroxybenzotriazole (0.15 g, 1.12 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.21 g, 1.12 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give *tert*-butyl 2-[[[(((2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]methyl]-1,4-oxazepane-4-carboxylate **132** (0.32 g, 80%) as a clear thick oil.

15

20

¹H NMR (400 MHz, CDCl₃): δ 1.46 (9H, s), 1.62 (2H, m), 2.01 (4H, m), 2.34 (1H, m), 2.77 (1H, m), 3.03 (2H, m), 3.30 (2H, m), 3.49 (1H, m), 3.57-4.00 (5H, m), 4.11 (1H, m), 4.89 (1H, d, J = 11.6 Hz), 5.04 (1H, d, J = 11.6 Hz), 7.39 (5H, m), 9.39 (1H, m).


Step 2. *tert*-butyl 2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]-1,4-oxazepane-4-carboxylate (133)



To a solution of *tert*-butyl 2-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]-1,4-oxazepane-4-carboxylate **132** (0.32 g, 0.63 mmol) in methanol (20 mL) was added 5% Pd/C (0.30 g). The mixture was hydrogenated at 15 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give *tert*-butyl 2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]-1,4-oxazepane-4-carboxylate **133** (0.205 g, 78%) as a colorless foam.

¹H NMR (400 MHz, CD₃OD): δ 1.47 (9H, s), 1.70-1.98 (4H, m), 2.05 (1H, m), 2.18 (1H, m), 3.08 (2H, m), 3.41-4.00 (10H, m), 4.06 (1H, m), 2 protons were not observed in CD₃OD.


Step 3. *tert*-butyl 2-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]-1,4-oxazepane-4-carboxylate pyridine salt (134)



15

To a solution of *tert*-butyl 2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]-1,4-oxazepane-4-carboxylate **133** (0.20 g, 0.48 mmol) in dry pyridine (6 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.34 g, 2.14 mmol). The mixture was stirred at room temperature for 20 h, then filtered and evaporated. The residue was washed 4 times with ether to give *tert*-butyl 2-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]-1,4-oxazepane-4-carboxylate pyridine salt **134** (0.16 g) which was used in the next step without purification.

Step 4. sodium [(((2*S*,5*R*)-2-[(1,4-oxazepan-2-ylmethoxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide (Compound 13, Table 1)



To a solution of *tert*-butyl 2-[[[(((2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy)methyl]-1,4-oxazepane-4-carboxylate pyridine salt **134** (0.16 g, 0.28 mmol) in DCM (5 mL) was added trifluoroacetic acid (0.30 mL, 3.89 mmol) dropwise at 0 °C. The reaction mixture was stirred for 1 h then evaporated. Ether was added to the residue and the resulting white precipitate was collected by centrifugation. The white solid was purified by resin DOWEX 50WX4 column using water as eluent and freeze dried to give sodium [(((2*S*,5*R*)-2-[(1,4-oxazepan-2-ylmethoxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide **Compound 13 (Table 1)** (0.04 g, 34%) as a white solid.


¹H NMR (400 MHz, D₂O): δ 1.68 (1H, m), 1.79 (1H, m), 1.93 (4H, m), 2.97 (1H, d, J = 11.2 Hz), 3.13 (2H, m), 3.24 (2H, m), 3.32 (1H, m), 3.61 (1H, m), 3.78-3.99 (4H, m), 4.04 (2H, m), 2 protons were not observed in D₂O.

HPLC: 97.4%

MS (ES⁻) m/z: [M]⁻ = 393.04

Example 30

Sodium [(((2*S*,5*R*)-2-[(1,4-oxazepan-6-yloxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide (Compound 35, Table 1)



Using the similar procedures as described earlier but using *tert*-butyl 6-(aminooxy)-1,4-oxazepane-4-carboxylate, **Compound 35 (Table 1)** was prepared as a diastereoisomeric mixture as a white solid in 20 % yield.


¹H NMR (400 MHz, CD₃OD): δ 1.82 (1H, m), 1.94 (1H, m), 2.07 (1H, m), 2.23 (1H, m), 3.00 (1H, d, *J* = 12.0 Hz), 3.09 (1H, d, *J* = 12.0 Hz), 3.21 (1H, m), 3.44 (2H, m), 3.63 (1H, m), 3.85-4.04 (5H, m), 4.15 (1H, s), 4.36 (1H, m), 2 protons were not observed in CD₃OD.

HPLC: 95.5%

5 MS (ES⁻): *m/z*: [M]⁻ = 379.01

Example 31

Sodium ((([(2*S*,5*R*)-2-[[2-(1*H*-imidazol-1-yl)ethoxy]carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide (Compound 100, Table 1)



10 Using the similar procedures as describe earlier but using O-(2-(1*H*-imidazol-1-yl)ethyl)hydroxylamine, **Compound 100 (Table 1)** was prepared as a white solid.


¹H NMR (400 MHz, D₂O): δ 1.64-1.90 (4H, m), 2.90 (1H, d, *J* = 12.0 Hz), 3.06 (1H, d, *J* = 12.0 Hz), 3.78 (1H, d, *J* = 6.8 Hz), 4.00 (1H, m), 4.06 (2H, m), 4.15 (2H, m), 6.89 (1H, s), 7.09 (1H, s), 7.67 (1H, s). 2 protons were not observed in D₂O.

15 HPLC: 87.4 %,

MS (ES⁻) *m/z*: [M-Na]⁻ calcd for C₁₂H₁₆N₅O₇S: 374.08. Found: 374.01.

Example 32

Sodium ((([(2*S*,5*R*)-7-oxo-2-[[[(3*R*)-tetrahydrofuran-3-yloxy] carbamoyl]-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide (Compound 95, Table 1)



20

Using the similar procedures as describe earlier but using O-[(3*R*)-tetrahydrofuran-3-yl]hydroxylamine, **Compound 95 (Table 1)** was prepared as a white solid.

¹H NMR (400 MHz, D₂O): δ 1.62-1.83 (2H, m), 1.90-2.03 (4H, m), 2.94 (1H, d, *J* = 12.8 Hz), 3.14 (1H, d, *J* = 12.8 Hz), 3.60-3.73 (2H, m), 3.75-3.93 (3H, m), 4.04 (1H, m), 4.60 (1H, m). 2


25 protons were not observed in D₂O.

HPLC: 95.2 %,


MS (ES⁺) *m/z*: [M-Na]⁺ calcd for C₁₁H₁₆N₃O₈S: 350.07. Found: 349.99.

Example 33

Sodium (((((2*S*,5*R*)-2-(((1-methyl-4,5,6,7-tetrahydro-1*H*-pyrazolo[3,4-*c*]pyridin-4-yl)oxy)carbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl) oxidanide
(Compound 70, Table 1)



Step 1. *tert*-butyl 4-(((1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy)-1-methyl-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridine-6-carboxylate (136)




To a mixture of 2-hydroxy-1*H*-isoindole-1,3(2*H*)-dione (2.95 g, 18.1 mmol), *tert*-butyl 4-hydroxy-1-methyl-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridine-6-carboxylate **135** (US2005/245505 A1, 2.29 g, 9.04 mmol) and triphenylphosphine (4.74 g, 18.1 mmol) in THF (100 mL) was added DIAD (3.85 mL, 19.9 mmol) slowly at room temperature. The resulting mixture was stirred at room temperature overnight and concentrated to provide a residue which was subjected to chromatography to give **136** (2.5 g, 35 %) as a yellow solid.

¹H NMR (400 MHz, CDCl₃): δ 1.52 (9H, s), 3.29 (2H, m), 3.76 (3H, s), 4.25-5.16 (2H, m), 5.44 (1H, m), 7.80 (5H, m).

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₂₀H₂₃N₄O₅: 399.17. Found: 399.11.

Step 2. *tert*-butyl 4-(aminooxy)-1-methyl-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridine-6-carboxylate (137**)**




To a mixture of *tert*-butyl 4-[(1,3-dioxo-1,3-dihydro-2*H*-isindol-2-yl)oxy]-1-methyl-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridine-6-carboxylate **136** (2.50 g, 6.27 mmol) in a solution of DCM (20 mL) and ethanol (4 mL) was added hydrazine hydrate (0.360 mL, 6.27 mmol) at room temperature. The mixture was stirred at room temperature overnight, filtered and concentrated to provide a residue which was washed with ether and methanol to give **137** (1.06 g, 62 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.50 (9H, s), 2.88 (1H, m), 3.76 (3H, s), 4.05 (1H, m), 4.57 (1H, m), 4.78-5.10 (2H, m), 5.47 (2H, m), 7.51 (1H, s).

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₂H₂₁N₄O₃: 269.16. Found: 269.10.

Step 3. *tert*-butyl 4-((((2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy)-1-methyl-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridine-6-carboxylate (138**)**




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (10.0 mL) were added *tert*-butyl 4-(aminooxy)-1-methyl-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridine-6-carboxylate **137** (0.360 g, 1.358 mmol), 1-hydroxybenzotriazole (0.183 g, 1.358 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to

provide a residue which was subjected to chromatography to give **138** (0.42 g, 89 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.50 (9H, s), 1.62 (1H, m), 2.00 (2H, m), 2.32 (1H, m), 2.70-3.10 (3H, m), 3.29 (1H, s), 3.76 (3H, s), 4.06 (2H, m), 4.58 (1H, m), 4.88 (1H, d, *J* = 11.6 Hz), 4.99 (2H, m), 5.04 (1H, d, *J* = 11.6 Hz), 7.42 (5H, m), 7.60 (1H, s). One proton was not observed.

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₂₆H₃₅N₆O₆: 527.26. Found: 527.17.

Step 4. *tert*-butyl 4-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]-1-methyl-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridine-6-carboxylate (**139**).




A mixture of *tert*-butyl 4-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]-1-methyl-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridine-6-carboxylate **138** (0.42 g, 0.80 mmol) and Pd/C (0.13 g) in methanol (20 mL) was hydrogenated at one atm. at room temperature for 13 h. The mixture was filtered through Celite pad and concentrated to give a residue which was subjected to chromatography to provide **139** (0.33 g, 94 %) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.51 (9H, s), 1.80-2.30 (4H, m), 3.07 (3H, m), 3.70 (1H, m), 3.77 (3H, s), 3.90 (1H, m), 4.23 (1H, br s), 4.45 (1H, br s), 4.98 (2H, d, *J* = 8.4 Hz), 7.58 (1H, br s). 2 protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M-H]⁺ calcd for C₁₉H₂₇N₆O₆: 435.20. Found: 435.11.

Step 5. *tert*-butyl 1-methyl-4-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridine-6-carboxylate (**140**)




5 To a mixture of *tert*-butyl 4-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]-1-methyl-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridine-6-carboxylate **139** (0.33 g, 0.76 mmol) in pyridine (10.0 mL) was added sulfur trioxide pyridine complex (0.35 g, 2.27 mmol). The mixture was stirred at room temperature for 23 h and concentrated to provide a residue which was subjected to chromatography to give **140** (0.35 g, 90 %) as a
10 light yellow foam.

¹H NMR (400 MHz, CD₃OD): δ 1.50 (9H, s), 1.80-2.00 (4H, m), 3.12 (1H, d, *J* = 11.2 Hz), 3.27 (2H, m), 3.77 (3H, s), 3.96 (1H, m), 4.16 (1H, m), 4.30 (1H, m), 4.50 (1H, m), 5.00 (2H, m), 7.58 (1H, br s). 2 protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M-H]⁺ calcd for C₁₉H₂₇N₆O₉S: 515.16. Found: 515.04.

15 **Step 6.** sodium ([[(2*S*,5*R*)-2-[[[1-methyl-4,5,6,7-tetrahydro-1*H*-pyrazolo[3,4-*c*]pyridin-4-yl]oxy]carbonyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl) oxidanide (Compound **70**, Table 1)



To a mixture of *tert*-butyl 1-methyl-4-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridine-6-carboxylate **140** (0.35 g, 0.68 mmol) in DCM (8.0 mL) was added trifluoroacetic acid (0.40 mL) at 0°C. The mixture was stirred at 0°C for 1 h, concentrated and washed with ether. The white solid was collected by centrifugation. The crude product was purified by ion-exchange resin (Dowex50 Na⁺ form, water) to give **Compound 70** (Table 1) (30 mg) as a
20 white solid as a pair of diastereoisomers.


^1H NMR (400 MHz, D_2O): δ 1.67-1.82 (2H, m), 1.90-2.02 (2H, m), 2.72 (1H, m), 2.86-2.95 (1H, m), 3.13 (1H, m), 3.28 (1H, d, $J = 14.4$ Hz), 3.56 (3H, s), 3.72 (1H, d, $J = 16.0$ Hz), 3.87-4.10 (3H, m), 4.82 (1H, s), 7.46 (1H, s). 3 protons were not observed in D_2O .

HPLC: 94.1 %


5 MS (ES $^-$) m/z : $[\text{M}-\text{Na}]^-$ calcd for $\text{C}_{14}\text{H}_{19}\text{N}_6\text{O}_7\text{S}$: 415.11. Found: 415.03.

Example 34

Sodium [(((2*S*,5*R*)-7-oxo-2-[(pyrazolidin-4-yloxy)carbamoyl]-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide (Compound 104, Table 1)




10 Step 1. di-*tert*-butyl 4-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]pyrazolidine-1,2-dicarboxylate (**142**)



To a mixture of 2-hydroxy-1*H*-isoindole-1,3(2*H*)-dione (1.72 g, 10.541 mmol), di-*tert*-butyl 4-hydroxypyrazolidine-1,2-dicarboxylate **141** (*Journal of Antibiotics*, 1993, Vol 46, (12), 1866-1882, 1.52 g, 5.27 mmol) and triphenylphosphine (2.76 g, 10.54 mmol) in THF (50 mL) was added DIAD (2.24 mL, 11.59 mmol) slowly at room temperature. The resulting mixture was stirred at room temperature overnight and concentrated to provide a residue, which was subjected to chromatography to give **142** (1.8 g, 79 %) as a white foam.

15 ^1H NMR (400 MHz, CDCl_3): δ 1.48 (9H, s), 1.52 (9H, s), 3.30 (1H, dd, $J = 4.0, 13.6$ Hz), 3.71 (1H, d, $J = 14.0$ Hz), 4.11 (1H, m), 4.50 (1H, d, $J = 13.2$ Hz), 5.13 (1H, br s), 7.77 (2H, m), 7.87 (2H, m).


20 MS (ES $^+$) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{28}\text{N}_3\text{O}_7$: 434.19. Found: 434.10.

Step 2. di-tert-butyl 4-(aminooxy)pyrazolidine-1,2-dicarboxylate (143)

To a mixture of di-tert-butyl 4-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)oxy]pyrazolidine-1,2-dicarboxylate **142** (1.81 g, 4.18 mmol) in a solution of DCM (20 mL) and ethanol (4 mL) was added hydrazine hydrate (0.240 mL, 4.18 mmol) at room temperature. The mixture was stirred at room temperature overnight, filtered and concentrated to provide a residue which was subjected to chromatography to give **143** (1.04 g, 83 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.48 (18H, m), 2.99 (1H, m), 3.62 (1H, m), 3.78 (1H, dd, *J* = 5.6 Hz and 12.0 Hz), 4.43 (2H, m), 5.38 (2H, br s).

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₃H₂₅N₃O₅: 304.19. Found: 304.15.


Step 3. di-tert-butyl 4-[[[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]pyrazolidine-1,2-dicarboxylate (144)

To a mixture of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (10.0 mL) were added di-tert-butyl 4-(aminooxy)pyrazolidine-1,2-dicarboxylate **143** (0.411 g, 1.358 mmol), 1-hydroxybenzotriazole (0.183 g, 1.358 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **144** (0.43 g, 85 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.46 (18H, s), 1.62 (1H, m), 2.00 (2H, m), 2.30 (1H, m), 2.68 (1H, m), 3.00 (2H, m), 3.29 (1H, s), 3.51 (1H, m), 3.86 (1H, m), 3.98 (1H, m), 4.42 (1H, m), 4.86 (1H, m), 4.88 (1H, d, *J* = 11.2 Hz), 5.04 (1H, d, *J* = 11.2 Hz), 7.42 (5H, m), 9.14 (1H, m).

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₂₇H₄₀N₅O₈: 562.29. Found: 562.22.

Step 4. di-*tert*-butyl 4-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]pyrazolidine-1,2-dicarboxylate (**145**)




A mixture of di-*tert*-butyl 4-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]pyrazolidine-1,2-dicarboxylate **144** (0.43 g, 0.80 mmol) and Pd/C (0.14 g) in methanol (15 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to give **145** (0.39 g, quant.) as a light brown foam.

¹H NMR (400 MHz, CD₃OD): δ 1.48 (18H, s), 1.80-2.20 (4H, m), 3.02-3.13 (3H, m), 3.55 (1H, m), 3.70 (1H, m), 3.86 (1H, m), 3.93 (1H, m), 4.24 (1H, m), 4.79 (1H, m). 2 protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M-H]⁺ calcd for C₂₀H₃₂N₅O₈: 470.22. Found: 470.14.

Step 5. di-*tert*-butyl 4-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]pyrazolidine-1,2-dicarboxylate (**146**)




To a mixture of di-*tert*-butyl 4-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]pyrazolidine-1,2-dicarboxylate **145** (0.39 g, 0.82 mmol) in pyridine (10.0 mL) was added sulfur trioxide pyridine complex (0.39 g, 2.48 mmol). The mixture was stirred at room temperature for 23 h and concentrated to provide a residue which was subjected to chromatography to give **146** (0.31 g, 68 %) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.48 (18H, s), 1.80-2.20 (4H, m), 3.07 (1H, d, *J* = 12.4 Hz), 3.23 (2H, m), 3.55 (1H, m), 3.93 (2H, m), 4.14 (1H, m), 4.25 (1H, d, *J* = 12.4 Hz), 4.81 (1H, t, *J* = 5.6 Hz). 2 protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M-H]⁺ calcd for C₂₀H₃₂N₅O₁₁S: 550.18. Found: 550.05.

Step 6. sodium [(((2*S*,5*R*)-7-oxo-2-[(pyrazolidin-4-yloxy)carbamoyl]-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide (Compound 104, Table 1)



To a mixture of di-*tert*-butyl 4-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1] oct-2-yl]carbonyl]amino]oxy]pyrazolidine-1,2-dicarboxylate **146** (0.33 g, 0.60 mmol) in DCM (5.0 mL) was added trifluoroacetic acid (0.60 mL) at 0°C. The mixture was stirred at 0°C for 0.5 h and at room temperature for 5.5 h, concentrated and washed with ether. The white solid was collected by centrifugation. The crude product was purified by ion-exchange resin (Dowex50 Na⁺ form, water) to give **Compound 104 (Table 1)** (22.5 mg) as a white solid.

¹H NMR (400 MHz, D₂O): δ 1.60-1.82 (2H, m), 1.87-2.02 (2H, m), 2.92 (1H, d, *J* = 11.6 Hz), 3.08-3.15 (3H, m), 3.25 (2H, d, *J* = 13.6 Hz), 3.90 (1H, d, *J* = 6.4 Hz), 4.01 (1H, m), 4.79 (1H, m). 4 protons were not observed in D₂O.


HPLC: 93.18 %,

MS (ES⁻) *m/z*: [M-Na]⁺ calcd for C₁₀H₁₆N₅O₇SNa: 350.08. Found: 349.99.


15

Example 35

Sodium [(((2*S*,5*R*)-2-[[[1-methyl-4,5,6,7-tetrahydro-1*H*-4,7-methanoindazol-3-yl)methoxy]carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)oxy)sulfonyl]oxidanide (Compound 131, Tabel, 1)



Step 1. 2-[(1-methyl-4,5,6,7-tetrahydro-1*H*-4,7-methanoindazol-3-yl)methoxy]-1*H*-isoindole-1,3(2*H*)-dione (148)




To a mixture of 2-hydroxy-1*H*-isoindole-1,3(2*H*)-dione (4.10 g, 25.2 mmol), (1-methyl-4,5,6,7-tetrahydro-1*H*-4,7-methanoindazol-3-yl)methanol **147** (2.24 g, 12.6 mmol) and triphenylphosphine (6.59 g, 25.2 mmol) in THF (100 mL) was added DIAD (5.35 mL, 27.6 mmol) slowly at room temperature. The resulting mixture was stirred at room temperature overnight and concentrated to provide a residue, which was subjected to chromatography to give **148** (1.80 g, 62 %) as a yellow solid.

¹H NMR (400 MHz, CDCl₃): δ 1.10 (1H, m), 1.24 (1H, m), 1.61 (1H, d, *J* = 10 Hz), 1.87 (3H, m), 3.33 (1H, s), 3.42 (1H, s), 3.71 (3H, s), 5.12 (2H, m), 7.17 (2H, m), 7.81 (2H, m).

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₈H₁₈N₃O₃: 324.13. Found: 324.08.

Step 2. 3-[(aminooxy)methyl]-1-methyl-4,5,6,7-tetrahydro-1*H*-4,7-methanoindazole (149)




To a mixture of 2-[(1-methyl-4,5,6,7-tetrahydro-1*H*-4,7-methanoindazol-3-yl)methoxy]-1*H*-isoindole-1,3(2*H*)-dione **148** (1.80 g, 5.57 mmol) in a solution of DCM (20 mL) and ethanol (4 mL) was added hydrazine hydrate (0.32 mL, 5.57 mmol) at room temperature. The mixture was stirred at room temperature overnight, filtered and concentrated to provide a residue which was subjected to chromatography to give **149** (0.68 g, 64 %) as a colorless oil.

¹H NMR (400 MHz, CDCl₃): δ 1.09 (1H, m), 1.26 (1H, d, *J* = 6.0 Hz), 1.64 (1H, d, *J* = 8.8 Hz), 1.88 (2H, m), 1.99 (1H, m), 3.35 (2H, d, *J* = 8.4 Hz), 3.79 (3H, s), 4.65 (2H, ABq), 5.24 (2H, br s).

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₀H₁₆N₃O: 194.13. Found: 194.08.

Step 3. (2S,5R)-6-(benzyloxy)-N-[(1-methyl-4,5,6,7-tetrahydro-1H-4,7-methanoindazol-3-yl)methoxy]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (150)




- 5 To a mixture of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (10.0 mL) were added 3-[(aminooxy)methyl]-1-methyl-4,5,6,7-tetrahydro-1H-4,7-methanoindazole **149** (0.172 g, 1.358 mmol), 1-hydroxybenzotriazole (0.183 g, 1.358 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **150** (0.34 g, 83 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.08 (2H, m), 1.25 (1H, d, *J* = 6.4 Hz), 1.63 (2H, m), 1.95 (5H, m), 2.38 (1H, m), 2.80 (1H, m), 2.92 (1H, m), 3.30 (1H, s), 3.36 (2H, s), 3.78 (3H, s), 3.94 (1H, d, *J* = 7.6 Hz), 4.85 (3H, m), 5.03 (1H, d, *J* = 11.2 Hz), 7.41 (5H, m), 9.10 (1H, s).

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₂₄H₂₉N₅O₄: 452.23. Found: 452.15.

Step 4. (2S,5R)-6-hydroxy-N-[(1-methyl-4,5,6,7-tetrahydro-1H-4,7-methanoindazol-3-yl)methoxy]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (151)




A mixture of (2S,5R)-6-(benzyloxy)-N-[(1-methyl-4,5,6,7-tetrahydro-1H-4,7-methanoindazol-3-yl)methoxy]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **150** (0.34 g, 0.75 mmol) and Pd/C (0.12 g) in methanol (15 mL) was hydrogenated at 1 atm at room temperature for 3

h. The mixture was filtered through Celite pad and concentrated to give **151** (0.27 g, quantitative yield) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.14 (2H, m), 1.23 (1H, d, *J* = 6.4 Hz), 1.66 (1H, d, *J* = 8.0 Hz), 1.85 (4H, m), 2.03 (1H, m), 2.21 (1H, m), 3.02 (2H, m), 3.42 (1H, s), 3.45 (1H, s), 3.68 (1H, s), 3.76 (3H, s), 3.80 (1H, d, *J* = 7.2 Hz), 4.71 (2H, m). 2 protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₇H₂₄N₅O₄: 262.18. Found: 262.12.

Step 5. sodium ([[(2*S*,5*R*)-2-[[[(1-methyl-4,5,6,7-tetrahydro-1*H*-4,7-methanoindazol-3-yl)methoxy]carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl]oxidanide (Compound 131, Table 1)



To a mixture of (2*S*,5*R*)-6-hydroxy-*N*-[[[(1-methyl-4,5,6,7-tetrahydro-1*H*-4,7-methanoindazol-3-yl)methoxy]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **151** (0.27 g, 0.75 mmol) in pyridine (10.0 mL) was added sulfur trioxide pyridine complex (0.35 g, 2.24 mmol). The mixture was stirred at room temperature for 23 h and concentrated to provide a residue which was subjected to ion-exchange resin column (Dowex50 Na⁺ form, water) to give **Compound 131 (Table 1)** (177 mg, 51 %) as a white solid.


¹H NMR (400 MHz, CD₃OD): δ 1.12 (2H, m), 1.67 (1H, d, *J* = 8.8 Hz), 1.80 (1H, m), 1.91 (4H, m), 2.08 (1H, m), 2.20 (1H, m), 3.05 (1H, t, *J* = 12.4 Hz), 3.17 (1H, m), 3.24 (1H, s), 3.45 (1H, s), 3.77 (3H, s), 3.87 (1H, d, *J* = 5.6 Hz), 4.13 (1H, s), 4.78 (2H, m). One proton was not observed in D₂O.

HPLC: 91.05 %,


MS (ES⁻) *m/z*: [M-Na]⁻ calcd for C₁₇H₂₂N₅O₄SNa: 440.12. Found: 440.00.

Example 36

(2*S*,5*R*)-*N*-[(1-methyl-1*H*-imidazol-5-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 51, Table 1)



- 5 Step 1. Step1: *tert*-butyl 3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate (**153**)




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (15.0 mL) were added *tert*-butyl 3-[[[amino]oxy]methyl]piperidine-1-carboxylate **152** (0.312 g, 1.358 mmol), 1-hydroxybenzotriazole (0.183 g, 1.358 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **153** (0.37 g, 84 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.45 (9H, m), 1.53 (5H, m), 1.90 (3H, m), 2.31 (1H, m), 2.77 (3H, m), 2.97 (1H, m), 3.30 (1H, m), 3.70 (5H, m), 4.88 (1H, d, *J* = 11.6 Hz), 5.06 (1H, d, *J* = 11.6 Hz), 7.42 (5H, m). One proton was not observed in moisture containing CDCl₃.

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₂₆H₃₇N₄O₈: 489.2. Found: 489.2.

Step 2. Step2: *tert*-butyl 3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate (154)



5


A mixture of *tert*-butyl 3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate **153** (0.40 g, 0.82 mmol) and Pd/C (0.13 g) in methanol (20 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to give **154** (0.33 g, quantitative yield) as a white foam.

10

¹H NMR (400 MHz, CD₃OD): δ 1.28 (1H, m), 1.45 (10H, m), 1.68 (1H, m), 1.80 (4H, m), 2.04 (1H, m), 2.20 (1H, m), 2.75 (1H, m), 2.84 (1H, m), 3.10 (2H, m), 3.74 (5H, s), 4.02 (1H, m). Two protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₈H₃₁N₄O₆: 399.2. Found: 399.1.

15 Step 3. Step 3. *tert*-butyl 3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate (155)




20 To a mixture of *tert*-butyl 3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate **154** (0.33 g, 0.83 mmol) in pyridine (4.0 mL) was added sulfur trioxide pyridine complex (0.38 g, 2.48 mmol). The mixture was stirred at room temperature for 23 h and concentrated to provide a residue which was subjected to chromatography to give **155** (0.33 g, 83 %) as a white foam.

25 ¹H NMR (400 MHz, CD₃OD): δ 1.30 (1H, m), 1.42 (10H, m), 1.67 (1H, m), 1.90 (4H, m), 2.08 (1H, m), 2.20 (1H, m), 2.70 (1H, m), 2.85 (1H, m), 3.10 (1H, d, *J* = 12.0 Hz), 3.26 (1H, m), 3.74 (2H, m), 3.88 (2H, m), 4.15 (2H, m). Two protons were not observed in CD₃OD.

MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₈H₂₉N₄O₉S: 477.2. Found: 477.1.


Step 4. **Step 4 (2S,5R)-N-[(1-methyl-1*H*-imidazol-5-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 51, Table 1).**




- 5 To a mixture of *tert*-butyl 3-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate **155** (0.33 g, 0.69 mmol) in DCM (8.0 mL) was added trifluoroacetic acid (0.40 mL) at 0°C. The mixture was stirred at 0°C for 3 h, concentrated and washed with ether, EtOAc and DCM to give TFA salt of **Compound 51** (**Table 1**) (62 mg) as a white solid as a pair of diastereomers.
- 10 ¹H NMR (400 MHz, D₂O): δ 1.21 (1H, m), 1.58-2.06 (8H, m), 2.72 (1H, t, *J* = 12.0 Hz), 2.80 (1H, t, *J* = 12.0 Hz), 2.98 (1H, d, *J* = 11.2 Hz), 3.21 (2H, m), 3.40 (1H, d, *J* = 11.6 Hz), 3.72 (1H, m), 3.79 (1H, m), 3.93 (1H, d, *J* = 7.2 Hz), 4.08 (1H, s). Three protons were not observed in D₂O.
- HPLC: 92.31 %
- 15 MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₃H₂₁N₄O₇S: 377.1. Found: 377.0.

Example 37

Sodium (2*S*,5*R*)-N-(morpholin-2-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 152, Table 1)



Step 1. *tert*-butyl 2-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]morpholine-4-carboxylate (157**)**




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (15.0 mL) were added *tert*-butyl 2-[[[amino]oxy]methyl]morpholine-4-carboxylate **156** (0.317 g, 1.358 mmol), 1-hydroxybenzotriazole (0.183 g, 1.358 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **157** (0.35 g, 79 %) as a colorless oil.

¹H NMR (400 MHz, CDCl₃): δ 1.45 (9H, m), 1.60 (1H, m), 1.90 (2H, m), 2.30 (1H, m), 2.78 (2H, m), 3.00 (2H, m), 3.30 (1H, m), 3.56 (1H, m), 3.70 (1H, m), 3.87 (6H, m), 4.92 (1H, d, *J* = 11.6 Hz), 5.06 (1H, d, *J* = 11.6 Hz), 7.42 (5H, m), 9.36 (1H, s).

MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₂₄H₃₃N₄O₇: 489.2. Found: 489.2.

Step 2. *tert*-butyl 2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]morpholine-4-carboxylate (158**)**




A mixture of *tert*-butyl 2-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]morpholine-4-carboxylate **157** (0.35 g, 0.71 mmol) and Pd/C (0.12 g) in methanol (20 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to give **158** (0.29 g, quantitative yield) as a white foam.

^1H NMR (400 MHz, CD_3OD): δ 1.46 (9H, m), 1.79 (1H, m), 1.92 (1H, m), 2.04 (1H, m), 2.19 (1H, m), 2.80 (1H, m), 2.90 (1H, m), 3.08 (2H, m), 3.49 (1H, m), 3.68 (2H, m), 3.90 (6H, m). 2 protons were not observed in CD_3OD .

MS (ES^+) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{17}\text{H}_{29}\text{N}_4\text{O}_7$: 401.2. Found: 401.2.

5 **Step 3.** *tert*-butyl 2-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]morpholine-4-carboxylate (**159**)




To a mixture of *tert*-butyl 2-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]morpholine-4-carboxylate **158** (0.29 g, 0.72 mmol) in pyridine
10 (5.0 mL) was added sulfur trioxide pyridine complex (0.34 g, 2.17 mmol). The mixture was stirred at room temperature for 23 h and concentrated to provide a residue which was subjected to chromatography to give **159** (0.29 g, 83 %) as a white foam.

^1H NMR (400 MHz, CD_3OD): δ 1.46 (9H, s), 1.82 (1H, m), 1.90 (1H, m), 2.09 (1H, m), 2.22 (1H, m), 2.78 (1H, m), 2.90 (1H, m), 3.10 (1H, d, $J = 11.6$ Hz), 3.22 (1H, m), 3.50 (1H, m),
15 3.68 (1H, m), 3.90 (6H, m), 4.14 (1H, m). Two protons were not observed in CD_3OD .

MS (ES^-) m/z : $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{17}\text{H}_{27}\text{N}_4\text{O}_{10}\text{S}$: 479.2. Found: 479.1.

Step 4. Sodium (2*S*,5*R*)-*N*-(morpholin-2-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound **152**, Table 1)



To a mixture *tert*-butyl 2-[[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]morpholine-4-carboxylate **159** (0.29 g, 0.60 mmol) in DCM (8.0 mL) was added trifluoroacetic acid (0.40 mL) at 0°C. The mixture was stirred at 0°C for 3 h, concentrated and washed with ether to give **Compound 152** (Table 1) as a TFA salt, which
20 was converted to sodium salt by treating with Dowex 50 to give the corresponding sodium
25 salt (74 mg) as a white solid as a pair of diastereomers.

^1H NMR (400 MHz, D_2O): δ 1.60-2.10 (4H, m), 2.98-3.18 (3H, m), 3.20-3.35 (3H, m), 3.80 (1H, t, $J = 12.1\text{ Hz}$), 3.90-4.18 (6H, m). Three protons were not observed in D_2O .


HPLC: 98.23 %

MS (ES^-) m/z : $[\text{M}-\text{Na}]^-$ calcd for $\text{C}_{12}\text{H}_{19}\text{N}_4\text{O}_8\text{SNa}$: 379.1. Found: 379.0.

5


Example 38

(2S,5R)-7-oxo-N-(piperidin-2S-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide



Step 1. *tert*-butyl 2S-[[[[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate (**161**)

10



To a mixture of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (15.0 mL) were added *tert*-butyl 2S-[(aminooxy)methyl]piperidine-1-carboxylate **160** (0.312 g, 1.358 mmol), 1-hydroxybenzotriazole (0.183 g, 1.358 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **161** (0.35 g, 80 %) as a white foam.


15

20

^1H NMR (400 MHz, CDCl_3): δ 1.41 (9H, m), 1.61 (6H, m), 1.97 (2H, m), 2.29 (1H, m), 2.78 (3H, m), 2.97 (1H, m), 3.26 (1H, m), 3.70 (1H, m), 3.99 (2H, m), 4.15 (1H, m), 4.51 (1H, m), 4.88 (1H, d, $J = 11.6\text{ Hz}$), 5.06 (1H, m), 7.42 (5H, m). One proton was not observed in moisture containing CDCl_3 .

MS (ES^-) m/z : $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{25}\text{H}_{35}\text{N}_4\text{O}_8$: 487.2. Found: 487.1.

Step 2. *tert*-butyl 2S-[[[[(2S,5R)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]piperidine-1-carboxylate (**162**).




A mixture of *tert*-butyl 2S-[[[[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]piperidine-1-carboxylate **161** (0.40 g, 0.82 mmol) and Pd/C (0.13 g) in methanol (20 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to give **162** (0.27 g, quantitative yield) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.45 (9H, s), 1.60 (5H, m), 1.80 (2H, m), 1.93 (1H, m), 2.04 (1H, m), 2.21 (1H, m), 2.84 (1H, m), 2.99 (1H, m), 3.31 (1H, m), 3.68 (1H, s), 3.89 (1H, s), 4.02 (3H, m), 4.47 (1H, m). Two protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₈H₃₁N₄O₆: 399.2. Found: 399.1.


Step 3. *tert*-butyl 2S-[[[[(2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]piperidine-1-carboxylate (**163**)



To a mixture of *tert*-butyl 2S-[[[[(2S,5R)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]piperidine-1-carboxylate **162** (0.33 g, 0.83 mmol) in pyridine (4.0 mL) was added sulfur trioxide pyridine complex (0.38 g, 2.48 mmol). The mixture was stirred at room temperature for 23 h and concentrated to provide a residue which was subjected to chromatography to give **163** (0.24 g, 69 %) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.45 (10H, m), 1.63 (4H, m), 1.84 (2H, m), 1.92 (1H, m), 2.06 (1H, m), 2.21 (1H, m), 2.87 (1H, m), 3.09 (1H, m), 3.24 (2H, m), 3.91 (2H, m), 4.03 (1H, m), 4.11 (1H, m), 4.46 (1H, m). Two protons were not observed in CD₃OD.

Step 4. (2S,5R)-7-oxo-N-(piperidin-2S-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (164)



To a mixture of *tert*-butyl 2-[[[[(2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate **163** (0.27 g, 0.58 mmol) in DCM (8.0 mL) was added trifluoroacetic acid (0.40 mL) at 0°C. The mixture was stirred at 0°C for 3 h, concentrated and washed with ether, EtOAc and DCM to give **164** (53 mg) as a white foam.


¹H NMR (400 MHz, D₂O): δ 1.20 (2H, m), 1.36 (1H, m), 1.60 (5H, m), 1.77 (2H, m), 1.90 (1H, m), 2.65 (1H, m), 2.82 (1H, m), 3.00 (1H, m), 3.15 (2H, m), 3.70 (1H, m), 3.80 (2H, m), 3.90 (1H, s). Three protons were not observed in D₂O.

HPLC: 95.22 %


MS (ES⁺) *m/z*: [M-H]⁺ calcd for C₁₃H₂₁N₄O₇S: 377.1. Found: 377.0.

Example 39

(2S,5R)-7-oxo-N-(piperidin-2R-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide



Step 1. *tert*-butyl 2S-[[[[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate (166)




To a mixture of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (15.0 mL) were added *tert*-butyl 2S-[[[[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate **165** (0.312 g, 1.358 mmol), 1-

hydroxybenzotriazole (0.183 g, 1.358 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **169** (0.35 g, 80 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.41 (9H, m), 1.61 (6H, m), 1.97 (2H, m), 2.29 (1H, m), 2.78 (3H, m), 2.97 (1H, m), 3.26 (1H, m), 3.70 (1H, m), 3.99 (2H, m), 4.15 (1H, m), 4.51 (1H, m), 4.88 (1H, d, *J* = 11.6 Hz), 5.06 (1H, m), 7.42 (5H, m). One proton was not observed in moisture containing CDCl₃.

MS (ES⁺) *m/z*: [M-H]⁺ calcd for C₂₅H₃₅N₄O₈: 487.2. Found: 487.1.

Step 2. tert-butyl 2S-[[[[(2S,5R)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]piperidine-1-carboxylate (170)




A mixture of *tert*-butyl 2S-[[[[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]piperidine-1-carboxylate **169** (0.40 g, 0.82 mmol) and Pd/C (0.13 g) in methanol (20 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to give **170** (0.27 g, quantitative yield) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.45 (9H, s), 1.60 (5H, m), 1.80 (2H, m), 1.93 (1H, m), 2.04 (1H, m), 2.21 (1H, m), 2.84 (1H, m), 2.99 (1H, m), 3.31 (1H, m), 3.68 (1H, s), 3.89 (1H, s), 4.02 (3H, m), 4.47 (1H, m). Two protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₈H₃₁N₄O₆: 399.2. Found: 399.1.


Step 3. tert-butyl 2S-[[[[(2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]methyl]piperidine-1-carboxylate (171)



To a mixture of *tert*-butyl 2S-[[[[(2S,5R)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate **170** (0.33 g, 0.83 mmol) in pyridine (4.0 mL) was added sulfur trioxide pyridine complex (0.38 g, 2.48 mmol). The mixture was stirred at room temperature for 23 h and concentrated to provide a residue which was subjected to chromatography to give **171** (0.24 g, 69 %) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.45 (10H, m), 1.63 (4H, m), 1.84 (2H, m), 1.92 (1H, m), 2.06 (1H, m), 2.21 (1H, m), 2.87 (1H, m), 3.09 (1H, m), 3.24 (2H, m), 3.91 (2H, m), 4.03 (1H, m), 4.11 (1H, m), 4.46 (1H, m). Two protons were not observed in CD₃OD.

Step 4. (2S,5R)-7-oxo-N-(piperidin-2R-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (172)



To a mixture of *tert*-butyl 2-[[[[(2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]methyl]piperidine-1-carboxylate **171** (0.27 g, 0.58 mmol) in DCM (8.0 mL) was added trifluoroacetic acid (0.40 mL) at 0°C. The mixture was stirred at 0°C for 3 h, concentrated and washed with ether, EtOAc and DCM to give **172** (53 mg) as a white solid.


¹H NMR (400 MHz, D₂O): δ 1.38 (2H, m), 1.54 (1H, m), 1.75 (5H, m), 2.01 (2H, m), 2.85 (1H, m), 3.00 (1H, m), 3.21 (1H, m), 3.36 (2H, m), 3.91 (3H, m), 4.08 (1H, s). Three protons were not observed in D₂O.

HPLC: 95.22 %


MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₃H₂₁N₄O₇S: 377.1. Found: 377.0.

Example 40

(2S,5R)-N'-acetyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 16, Table 2)



Step 1. (2S,5R)-N'-Acetyl-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (174)




To a mixture of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid
 5 **1** (0.200 g, 0.720 mmol, US2005/20572 A1) in DCM (6.0 mL) were added acetohydrazide
173 (0.090 g, 1.085 mmol), 1-hydroxybenzotriazole (0.147 g, 1.085 mmol), 1-ethyl-(3-
 dimethylamino propyl) carbodiimide hydrochloride (0.208 g, 1.085 mmol) and *N,N*-
 dimethylaminopyridine sequentially at room temperature. The mixture was stirred at room
 temperature overnight, diluted with DCM and concentrated to provide a residue, which was
 10 subjected to chromatography to give **174** (0.14 g, 60 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.60 (1H, m), 1.96 (2H, m), 2.06 (3H, s), 2.34 (1H, m), 3.09 (1H, m), 3.15 (1H, d, *J* = 12 Hz), 3.32 (1H, m), 4.01 (1H, d, *J* = 8.4 Hz), 4.90 (1H, d, *J* = 11.2 Hz), 5.07 (1H, d, *J* = 11.2 Hz), 7.26-7.44 (5H, m), 7.74 (1H, br s), 8.54 (1H, br s).

MS (ES⁺): *m/z* [M+H]⁺ calcd for C₁₆H₂₁N₄O₄: 333.16. Found: 333.21.

Step 2. (2S,5R)-N'-Acetyl-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (175)




A mixture of (2S,5R)-N'-acetyl-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-
 carbohydrazide **174** (0.14 g, 0.43 mmol) and Pd/C (0.070 g) in methanol (10 mL) was
 20 hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite
 pad and concentrated to provide **175** (0.10 g, 95 %) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.71-1.78 (1H, m), 1.88-1.93 (1H, m), 2.04 (3H, s), 2.06-2.09 (1H, m), 2.24-2.29 (1H, m), 3.13 (1H, m), 3.22 (1H, d, *J* = 12 Hz), 3.69 (1H, m), 3.93 (1H, d, *J* = 8.4 Hz). 3 protons were not observed in CD₃OD.

25 MS (ES⁺): *m/z* [M+H]⁺ calcd for C₉H₁₅N₄O₄: 243.11. Found: 243.18.

Step 3. (2S,5R)-N'-Acetyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 16, Table 2)



To a mixture of (2S,5R)-N'-acetyl-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **175** (0.10 g, 0.41 mmol) in pyridine (5.0 mL) was added sulfur trioxide pyridine complex (0.19 g, 1.24 mmol). The mixture was stirred at room temperature for 23 h and concentrated to provide a residue which was subjected to chromatography to give **Compound 16 (Table 2)** (0.040 g, 30 %) as a light yellow solid.

¹H NMR (400 MHz, D₂O): δ 1.64-1.69 (1H, m), 1.76-1.81 (1H, m), 1.88-1.98 (4H, m), 2.03-2.09 (1H, m), 3.03 (1H, d, J = 12.0 Hz), 3.20 (1H, m), 4.00 (1H, m), 4.05 (1H, m). 3 protons were not observed in D₂O.

HPLC: 89.2 %

MS (ES⁺): m/z [M-H]⁺ calcd for C₉H₁₃N₄O₇S: 321.05. Found: 321.05.

The corresponding sodium salt of **compound 16 (Table 2)** was prepared in the following manner:



To a mixture of (2S,5R)-N'-acetyl-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **175** (0.20 g, 0.78 mmol) in pyridine (10.0 mL) was added sulfur trioxide pyridine complex (0.37 g, 2.35 mmol). The mixture was stirred at room temperature for 24 h and concentrated to provide a residue which was subjected to purification by ion-exchange resin (Dowex50 Na⁺ form, water) and reverse phase column to give sodium salt of **Compound 16 (Table 2)** (42 mg) as a white solid.

¹H NMR (400 MHz, D₂O): δ 1.64-1.69 (1H, m), 1.76-1.81 (1H, m), 1.88-1.98 (4H, m), 2.03-2.09 (1H, m), 3.03 (1H, d, J = 12.0 Hz), 3.20 (1H, m), 4.00 (1H, m), 4.05 (1H, m). 3 protons were not observed in D₂O.

HPLC: 96.5 %

MS (ES⁺) m/z: [M-Na]⁺ calcd for C₉H₁₃N₄O₇SNa: 321.05. Found: 321.05.


Example 41

**(2S,5R)-N'-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
(Compound 1, Table 2)****5 Step 1. tert-butyl 2-[[[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]-1-methylhydrazinecarboxylate (177)**

To a solution of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid 1 (0.2 g, 0.72 mmol) in dry DCM (10 mL) were added *tert*-butyl 1-methylhydrazinecarboxylate **176** (0.16 g, 1.08 mmol), 1-hydroxybenzotriazole (0.15 g, 1.08 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.21 g, 1.08 mmol) and 4-dimethylaminopyridine (0.13 g, 1.08 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight, and then concentrated under vacuum. The residue was purified by column chromatography to give *tert*-butyl 2-[[[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]-1-methylhydrazinecarboxylate **177** (0.25 g, 86%) as a clear thick oil.

¹H NMR (400 MHz, CDCl₃): δ 1.46 (9H, s), 1.58 (1H, m), 1.97 (2H, m), 2.37 (1H, m), 3.04-3.16 (5H, m), 3.29 (1H, m), 3.96 (1H, d, J = 6.8 Hz), 4.90 (1H, d, J = 11.2 Hz), 5.05 (1H, d, J = 11.6 Hz), 7.38 (5H, m), 8.32 (1H, br s).


Step 4. *tert*-butyl 2-[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]-1-methylhydrazinecarboxylate (178)



To a solution of *tert*-butyl 2-[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]-1-methylhydrazinecarboxylate **177** (0.29 g, 0.72 mmol) in methanol (15 mL) was added 5% Pd/C (0.3 g). The mixture was hydrogenated under 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give *tert*-butyl 2-[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]-1-methylhydrazinecarboxylate **178** (0.22 g, 98%) as a colorless foam.


¹H NMR (400 MHz, CD₃OD): δ 1.46 (9H, s), 1.74 (1H, m), 1.92 (1H, m), 2.07 (1H, m), 2.26 (1H, m), 3.01-3.22 (5H, m), 3.71 (1H, m), 3.88 (1H, m), 2 protons were not observed in CD₃OD.

Step 5. *tert*-butyl 1-methyl-2-[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinecarboxylate pyridine salt (179)



To a solution of *tert*-butyl 2-[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]-1-methylhydrazinecarboxylate **178** (0.22 g, 0.7 mmol) in dry pyridine (10 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.56 g, 3.5 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated to give *tert*-butyl 1-methyl-2-[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinecarboxylate pyridine salt **179** (0.33 g crude) which was used in the next step without purification.


Step 6. *N,N,N*-tributylbutan-1-aminium ([[(2*S*,5*R*)-2-{[2-(*tert*-butoxycarbonyl)-2-methylhydrazinyl]carbonyl}-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide (**180**)



- 5 *tert*-butyl 1-methyl-2-[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinecarboxylate pyridine salt **179** (0.33 g, 0.7 mmol) was introduced into a concentrated aqueous solution of monosodium dihydrogen phosphate solution (12 mL) so as to obtain a pH of 4. The mixture was washed with ethyl acetate, then added tetrabutyl ammonium hydrogen sulfate (0.136 g, 0.4 mmol) and stirred at room temperature for 10 min.
- 10 The mixture was extracted with ethyl acetate (3 x 20 mL), and the extracts were combined, dried over sodium sulfate and evaporated to give *N,N,N*-tributylbutan-1-aminium ([[(2*S*,5*R*)-2-{[2-(*tert*-butoxycarbonyl)-2-methylhydrazinyl]carbonyl}-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide **180** (0.31 g, 70%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.00 (12H, t, J = 7.2 Hz), 1.18 (3H, m), 1.46 (12H, m), 1.66 (12H, m), 1.94 (2H, m), 2.15 (1H, m), 2.38 (1H, m), 2.84 (1H, d, J = 11.2 Hz), 3.29 (8H, m), 3.87 (1H, m), 3.93 (1H, d, J = 8.0 Hz), 4.35 (1H, s), 8.98 (1H, br s).

Step 7. (2*S*,5*R*)-*N*'-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 1, Table 2)



- 20 To a solution of *N,N,N*-tributylbutan-1-aminium ([[(2*S*,5*R*)-2-{[2-(*tert*-butoxycarbonyl)-2-methylhydrazinyl]carbonyl}-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy)sulfonyl)oxidanide **180** (0.31 g, 0.49 mmol) in DCM (20 mL) was added trifluoroacetic acid (1.2 mL, 15.55 mmol) dropwise at 0 °C. The reaction mixture was stirred for 2 h, then evaporated. Ether was added to the residue and the resulting white precipitate was collected by centrifugation. The solid
- 25 was triturated with acetonitrile (2 x) and the white solid was collected by centrifugation. The white solid was purified by HPLC and freeze-dried to give (2*S*,5*R*)-*N*'-methyl-7-oxo-6-


(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **Compound 1** (Table 2) (0.01 g, 6.9 %) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.77 (2H, m), 1.95 (1H, m), 2.05 (1H, m), 2.97 (5H, m), 3.16 (1H, d, J = 12.0 Hz), 3.26 (4H, m), 3.89 (1H, d, J = 7.6 Hz), 4.06 (1H, m), 3 protons were not observed in CD₃OD.


MS (ES⁺): m/z [M-H]⁺ = 293.04

Example 42

(2*R*,5*S*)-7-oxo-*N'*-(phenylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (**Compound 64**, Table 2)



Step 1. (2*R*,5*R*)-6-(benzyloxy)-7-oxo-*N'*-(phenylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (**182**)




To solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.25 g, 0.90 mmol) in dry DCM (20 mL) were added benzohydrazide **181** (0.118 g, 1.35 mmol), 1-hydroxybenzotriazole (0.19 g, 1.35 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.26 g, 1.35 mmol) and 4-(dimethylamino)pyridine (0.16 g, 1.35 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight, and then concentrated under vacuum. The residue was purified by column chromatography to give (2*R*,5*R*)-6-(benzyloxy)-7-oxo-*N'*-(phenylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **182** (0.35 g, 98%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.58-1.74 (1H, m), 2.02 (2H, m), 2.36 (1H, m), 3.11 (1H, d, J = 12.0 Hz), 3.22 (1H, d, J = 12.0 Hz), 3.32 (1H, s), 4.05 (1H, d, J = 7.2 Hz), 4.90 (1H, d, J =

11.2 Hz), 5.04 (1H, d, $J = 11.6$ Hz), 7.41 (7H, m), 7.51 (1H, m), 7.79 (2H, d, $J = 8.4$ Hz), 8.74 (1H, br s), 8.79 (1H, br s).

Step 2. (2*R*,5*R*)-6-hydroxy-7-oxo-*N'*-(phenylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (183)




5

To a solution of (2*R*,5*R*)-6-(benzyloxy)-7-oxo-*N'*-(phenylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **182** (0.33 g, 0.88 mmol) in methanol (20 mL) was added 5% Pd/C (0.40 g). The mixture was hydrogenated under 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give (2*R*,5*R*)-6-hydroxy-7-oxo-*N'*-(phenylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **183** (0.19 g, 89%) as a colorless foam.

10

¹H NMR (400 MHz, CD₃OD): δ 1.80 (1H, m), 1.98 (1H, m), 2.07 (1H, m), 2.33 (1H, m), 3.20 (1H, d, $J = 11.6$ Hz), 3.35 (1H, m), 3.74 (1H, s), 4.02 (1H, d, $J = 7.6$ Hz), 7.47 (2H, m), 7.57 (1H, m), 7.86 (2H, m), 3 protons were not observed in CD₃OD.

Step 3. (2*R*,5*S*)-7-oxo-*N'*-(phenylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 64, Table 2)



Compound 64, Table 2

To a solution of (2*R*,5*R*)-6-hydroxy-7-oxo-*N'*-(phenylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **183** (0.197 g, 0.69 mmol) in dry pyridine (7 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.44 g, 2.76 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated. The residue was purified by column chromatography followed by HPLC on a prep-X Bridge-30x100 mm column and freeze-dried to give (2*R*,5*S*)-7-oxo-*N'*-(phenylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **Compound 64 (Table 2)** (0.05 g, 16.7%) as a white solid.

20


^1H NMR (400 MHz, CD_3OD): δ 1.83 (1H, m), 1.99 (1H, m), 2.10 (1H, m), 2.33 (1H, m), 3.29–3.39 (2H, m), 4.09 (1H, d, $J = 7.2$ Hz), 4.19 (1H, s), 7.49 (2H, m), 7.56 (1H, m), 7.89 (2H, m), 3 protons were not observed in CD_3OD .

HPLC: 98.2%


5 MS (ES $^-$) m/z : $[M]^- = 383$

Example 43

(2R,5S)-7-oxo-6-(sulfooxy)-N'-(trifluoroacetyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 89, Table 2)




10 Step 1. (2R,5R)-6-(benzyloxy)-7-oxo-N'-(trifluoroacetyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (185)



To solution of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.25 g, 0.90 mmol) in dry DCM (20 mL) were added 2,2,2-trifluoroacetohydrazide **184** (0.17 g, 1.35 mmol, Aldrich), 1-hydroxybenzotriazole (0.19 g, 1.35 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.26 g, 1.35 mmol) and 4-(dimethylamino)pyridine (0.16 g, 1.35 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give (2R,5R)-6-(benzyloxy)-7-oxo-N'-(trifluoroacetyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **185** (0.224 g, 65%) as a white solid.

^1H NMR (400 MHz, CDCl_3): δ 1.62 (1H, m), 2.01 (2H, m), 2.33 (1H, m), 2.99 (1H, d, $J = 12.0$ Hz), 3.07 (1H, d, $J = 12.0$ Hz), 3.34 (1H, s), 4.03 (1H, d, $J = 7.2$ Hz), 4.90 (1H, d, $J = 11.2$ Hz), 5.04 (1H, d, $J = 11.6$ Hz), 7.39 (5H, m), 8.59 (1H, br s), 8.68 (1H, br s).


Step 2. (2*R*,5*R*)-6-hydroxy-7-oxo-*N'*-(trifluoroacetyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (186)



To a solution of (2*R*,5*R*)-6-(benzyloxy)-7-oxo-*N'*-(trifluoroacetyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **185** (0.224 g, 0.58 mmol) in methanol (20 mL) was added 5% Pd/C (0.30 g). The mixture was hydrogenated under 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite and the filtrate was evaporated to give (2*R*,5*R*)-6-hydroxy-7-oxo-*N'*-(trifluoroacetyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **186** (0.15 g, 88%) as a colorless foam.

¹H NMR (400 MHz, CD₃OD): δ 1.77 (1H, m), 1.95 (1H, m), 2.06 (1H, m), 2.30 (1H, m), 3.17 (1H, m), 3.33 (1H, m), 3.73 (1H, s), 3.97 (1H, d, *J* = 7.2 Hz), 3 protons were not observed in CD₃OD.

Step 3. (2*R*,5*S*)-7-oxo-6-(sulfooxy)-*N'*-(trifluoroacetyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 89, Table 2)



To a solution of (2*R*,5*R*)-6-hydroxy-7-oxo-*N'*-(trifluoroacetyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **186** (0.15 g, 0.51 mmol) in dry pyridine (9 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.38 g, 2.37 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated. The residue was purified by column chromatography followed by HPLC on a prep-X Bridge-30x100 mm column and freeze-dried to give (2*R*,5*S*)-7-oxo-6-(sulfooxy)-*N'*-(trifluoroacetyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **Compound 89 (Table 2)** (0.02 g, 10.5%) as a white solid.


¹H NMR (400 MHz, CD₃OD): δ 1.81 (1H, m), 1.96 (1H, m), 2.06 (1H, m), 2.32 (1H, m), 3.05 (1H, d, *J* = 11.6 Hz), 3.31 (1H, m), 4.01 (1H, d, *J* = 8.0 Hz), 4.16 (1H, s), 3 protons were not observed in CD₃OD.

HPLC: 92.6%


MS (ES⁺) m/z: [M]⁺ = 375

Example 44

(2*R*,5*S*)-*N'*-(methylsulfonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 90, Table 2)



Step 1. (2*R*,5*R*)-6-(benzyloxy)-*N'*-(methylsulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (**188**)



- 10 To solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.67 g, 2.42 mmol) in dry DCM (60 mL) were added methanesulfonylhydrazide **187** (0.40 g, 3.63 mmol), 1-hydroxybenzotriazole (0.44 g, 3.63 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.72 g, 3.63 mmol) and 4-(dimethylamino)pyridine (0.44 g, 3.63 mmol) at room temperature. The reaction mixture was
- 15 stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give (2*R*,5*R*)-6-(benzyloxy)-*N'*-(methylsulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **188** (0.37 g, 42%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.67(1H, m), 2.02 (2H, m), 2.26 (1H, m), 2.79 (1H, d, J = 11.6 Hz), 3.02 (3H, s), 3.09 (1H, d, J = 12.8 Hz), 3.32 (1H, s), 4.12 (1H, d, J = 6.8 Hz), 4.89 (1H, d, J = 11.2 Hz), 5.03 (1H, d, J = 11.2 Hz), 7.16 (1H, br s), 7.39 (5H, m), 9.08 (1H, br s).


Step 2. (2R,5R)-6-hydroxy-N'-(methylsulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (189)



To a solution of (2R,5R)-6-(benzyloxy)-N'-(methylsulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **188** (0.37 g, 1.044 mmol) in methanol (35 mL) was added 5 % Pd/C (0.40 g). The mixture was hydrogenated under 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered through Celite and the filtrate was evaporated to give (2R,5R)-6-hydroxy-N'-(methylsulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **189** (0.276 g, 99 %) as a colorless foam.

¹H NMR (400 MHz, CD₃OD): δ 1.78 (1H, m), 1.95 (1H, m), 2.06 (1H, m), 2.24 (1H, m), 3.01 (3H, s), 3.03 (1H, d, J = 12.0 Hz), 3.14 (1H, d, J = 11.6 Hz), 3.69 (1H, s), 3.91 (1H, d, J = 7.6 Hz), 3 protons were not observed in CD₃OD.

Step 3. (2R,5S)-N'-(methylsulfonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 90, Table 2)



To a solution of (2R,5R)-6-hydroxy-N'-(methylsulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **189** (0.276 g, 0.99 mmol) in dry pyridine (18 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.70 g, 4.37 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated. The residue was purified by column chromatography followed by trituration with a mixture of MeOH: DCM: Ether (1:1:1) (4 X) to give (2R,5S)-N'-(methylsulfonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **Compound 90 (Table 2)** (0.12 g, 34 %) as a white solid.


^1H NMR (400 MHz, CD_3OD): δ 1.81 (1H, m), 1.96 (1H, m), 2.06 (1H, m), 2.32 (1H, m), 3.05 (1H, d, J = 11.6 Hz), 3.31 (1H, m), 4.01 (1H, d, J = 8.0 Hz), 4.16 (1H, s), 3 protons were not observed in CD_3OD .

HPLC: 91.8%


5 MS (ES^-) m/z : $[\text{M}]^-$ = 357

Example 45

(2S,5R)-N'-(cyclopentylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 38, Table 2)



10 **Step 1. (2S,5R)-6-(benzyloxy)-N'-(cyclopentylcarbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (191)**



To a solution of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.25 g, 0.90 mmol) in dry DCM (20 mL) were added cyclopentanecarbohydrazide **190** (0.173 g, 1.35 mmol), 1-hydroxybenzotriazole (0.19 g, 1.35 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.26 g, 1.35 mmol) and 4-(dimethylamino)pyridine (0.16 g, 1.35 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight, and then concentrated under vacuum. The residue was purified to give (2S,5R)-6-(benzyloxy)-N'-(cyclopentylcarbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **191** (0.33 g, 94%) as a white solid.

^1H NMR (400 MHz, CDCl_3): δ 1.50-2.00 (11H, m), 2.23-2.38 (1H, m), 2.60-2.70 (1H, m), 3.05 (1H, d, J = 12.0 Hz), 3.20 (1H, d, J = 12.0 Hz), 3.30 (1H, s), 3.98 (1H, m), 4.90 (1H, d, J = 11.2 Hz), 5.04 (1H, d, J = 11.6 Hz), 7.30-7.48 (5H, m), 7.85 (1H, br s), 8.60 (1H, br s).

MS (ES^+) m/z : $[\text{M}]^+$ = 387


Step 2. (2S,5R)-N'-(cyclopentylcarbonyl)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (192)



To a solution of (2S,5R)-6-(benzyloxy)-N'-(cyclopentylcarbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **191** (0.33 g, 0.84 mmol) in methanol (20 mL) was added 10% Pd/C (0.30 g). The mixture was hydrogenated under 15 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered through Celite, and the filtrate was evaporated to give (2S,5R)-N'-(cyclopentylcarbonyl)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **192** (0.24 g, 98%) as a colorless foam.

¹H NMR (400 MHz, CD₃OD): δ 1.50-2.12 (10H, m), 2.21-2.33 (1H, m), 2.63-2.80 (1H, m), 3.10-3.38 (3H, m), 3.70 (1H, s), 3.98 (1H, d, J = 7.6 Hz), 3 protons were not observed in CD₃OD.

Step 3. (2S,5R)-N'-(cyclopentylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 38, Table 2)



To a solution of (2S,5R)-N'-(cyclopentylcarbonyl)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **192** (0.24 g, 0.81 mmol) in dry pyridine (7 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.36 g, 2.25 mmol). The mixture was stirred at room temperature for 72 h, filtered and evaporated. The residue was purified by column chromatography followed by HPLC on a prep-X Bridge-30x100 mm column and freeze-dried to give (2S,5R)-N'-(cyclopentylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **Compound 38** (Table 2) (0.12 g, 40%) as a light brown solid.


¹H NMR (400 MHz, CD₃OD): δ 1.60-1.99 (10H, m), 2.06-2.10 (1H, m), 2.25-2.31 (1H, m), 2.68-2.74 (1H, m), 3.26-3.33 (2H, m), 4.02 (1H, d, J = 7.6 Hz), 4.15 (1H, br s). 3 protons were not observed in CD₃OD.

HPLC: 92.01%


MS (ES⁻) m/z: [M]⁻ = 375

Example 46

(2R,5S)-N'-(2-methylpropanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 18, Table 2)




Step 1. (2R,5S)-6-(benzyloxy)-N'-(2-methylpropanoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (194)



To a solution of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.25 g, 0.90 mmol) in dry DCM (20 mL) were added 2-methylpropanehydrazide **193** (0.14 g, 1.35 mmol), 1-hydroxybenzotriazole (0.19 g, 1.35 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.26 g, 1.35 mmol) and 4-(dimethylamino)pyridine (0.16 g, 1.35 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight, and then concentrated under vacuum. The residue was purified by column chromatography to give (2R,5S)-6-(benzyloxy)-N'-(2-methylpropanoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **194** (0.30 g, 92.6%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.12 (6H, m), 1.60 (1H, m), 1.94 (2H, m), 2.29 (1H, m), 2.47 (1H, q, J = 6.8 Hz), 3.06 (1H, d, J = 12.0 Hz), 3.18 (1H, d, J = 11.6 Hz), 3.30 (1H, s), 3.99 (1H, d, J = 7.2 Hz), 4.90 (1H, d, J = 10.8 Hz), 5.04 (1H, d, J = 11.2 Hz), 7.40 (5H, m), 8.07 (1H, br s), 8.61 (1H, br s).


Step 2. (2R,5S)-6-hydroxy-N'-(2-methylpropanoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (195)



To a solution of (2R,5S)-6-(benzyloxy)-N'-(2-methylpropanoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **194** (0.30 g, 0.83 mmol) in methanol (20 mL) was added 5% Pd/C (0.40 g). The mixture was hydrogenated under 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give (2R,5S)-6-hydroxy-N'-(2-methylpropanoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **195** (0.21 g, 95%) as a colorless foam.

- ¹H NMR (400 MHz, CD₃OD): δ 1.16 (6H, m), 1.74 (1H, m), 1.94 (1H, m), 2.02 (1H, m), 2.29 (1H, m), 2.53 (1H, m), 3.14 (1H, d, J = 12.0 Hz), 3.26 (1H, m), 3.70 (1H, s), 3.94 (1H, d, J = 7.2 Hz), 3 protons were not observed in CD₃OD.

Step 3. (2R,5S)-N'-(2-methylpropanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 18, Table 2)




To a solution of (2R,5S)-6-hydroxy-N'-(2-methylpropanoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **195** (0.21 g, 0.78 mmol) in dry pyridine (7 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.70 g, 4.40 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated. The residue was purified first by column chromatography followed by HPLC on a prep-X Bridge-30x100 mm column and freeze-dried to give (2R,5S)-N'-(2-methylpropanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **Compound 18 (Table 2)** (0.03 g, 11%) as a grey solid.

¹H NMR (400 MHz, CD₃OD): δ 1.64 (6H, m), 1.80 (1H, m), 1.94 (1H, m), 2.07 (1H, m), 2.29 (1H, m), 2.53 (1H, m), 3.30 (2H, m), 4.01 (1H, d, J = 7.6 Hz), 4.15 (1H, s), 3 protons were not observed in CD₃OD.


HPLC: 97.5 %

MS (ES⁺) m/z: [M]⁺ = 349

Example 47

(2*R*,5*S*)-*N'*-(cyclopropylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 32, Table 2)


5

Step 1. (2*R*,5*S*)-6-(benzyloxy)-*N'*-(cyclopropylcarbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (197)

To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.25 g, 0.90 mmol) in dry DCM (30 mL) were added cyclopropanecarbohydrazide **196** (0.135 g, 1.35 mmol), 1-hydroxybenzotriazole (0.19 g, 1.35 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.26 g, 1.35 mmol) and 4-(dimethylamino)pyridine (0.16 g, 1.35 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight, and concentrated under vacuum. The residue was purified by column chromatography to give (2*R*,5*S*)-6-(benzyloxy)-*N'*-(cyclopropylcarbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **197** (0.27 g, 84%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 0.83 (2H, m), 1.04 (2H, m), 1.62 (2H, m), 2.02 (2H, m), 2.34 (1H, m), 3.04 (1H, d, J = 12.0 Hz), 3.15 (1H, d, J = 12.0 Hz), 3.29 (1H, s), 4.00 (1H, d, J = 7.6 Hz), 4.89 (1H, d, J = 11.2 Hz), 5.03 (1H, d, J = 11.2 Hz), 7.38 (5H, m), 8.29 (1H, br s), 8.57 (1H, br s).


Step 2. (2R,5S)-N'-(cyclopropylcarbonyl)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (198)



To a solution of (2R,5S)-6-(benzyloxy)-N'-(cyclopropylcarbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **197** (0.27 g, 0.75 mmol) in methanol (20 mL) was added 5% Pd/C (0.30 g). The mixture was hydrogenated under 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give (2R,5S)-N'-(cyclopropylcarbonyl)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **198** (0.20 g, 98%) as a colorless foam.

¹H NMR (400 MHz, CD₃OD): δ 0.86 (2H, m), 0.91 (2H, m), 1.65 (1H, m), 1.76 (1H, m), 1.94 (1H, m), 2.04 (1H, m), 2.26 (1H, m), 3.13 (1H, d, J = 13.2 Hz), 3.23 (1H, d, J = 12.0 Hz), 3.70 (1H, s), 3.94 (1H, d, J = 7.2 Hz), 3 protons were not observed in CD₃OD.

Step 3. (2R,5S)-N'-(cyclopropylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 32, Table 2)



To a solution of (2R,5S)-N'-(cyclopropylcarbonyl)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **198** (0.20 g, 0.75 mmol) in dry pyridine (7 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.70 g, 4.40 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated. The residue was purified first by column chromatography followed by HPLC on a prep-X Bridge-30x100 mm column and freeze-dried to give (2R,5S)-N'-(cyclopropylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **Compound 32 (Table 2)** (0.035 g) as a grey solid.


¹H NMR (400 MHz, CD₃OD): δ 0.83 (2H, m), 0.90 (2H, m), 1.66 (1H, m), 1.78 (1H, m), 1.94 (1H, m), 2.06 (1H, m), 2.28 (1H, m), 3.30 (2H, m), 4.01 (1H, d, J = 7.6 Hz), 4.14 (1H, s), 3 protons were not observed in CD₃OD.

HPLC: 98.4%

MS (ES⁺) *m/z*: [M]⁺ = 347


Example 48

(2*S*,5*R*)-*N'*-(cyclobutylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 33, Table 2)



5

Step 1. (2*S*,5*R*)-6-(benzyloxy)-*N'*-(cyclobutylcarbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (200)



To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (15.0 mL) were added cyclobutanecarbohydrazide **199** (0.155 g, 1.358 mmol), 1-hydroxybenzotriazole (0.186 g, 1.358 mmol) and 1-ethyl-(3-dimethylamino propyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue, which was subjected to chromatography to give **200** (0.34 g, quant. yield) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.60 (1H, m), 1.90 (4H, m), 2.21 (2H, m), 2.30 (3H, m), 3.10 (3H, m), 3.30 (1H, m), 3.40 (2H, br s), 4.00 (1H, d, *J* = 7.4 Hz), 4.90 (1H, d, *J* = 11.2 Hz), 5.07 (1H, d, *J* = 11.2 Hz), 7.26-7.44 (5H, m).

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₉H₂₅N₄O₄: 373.2. Found: 373.2.

Step 2. (2S,5R)-N'-(cyclobutylcarbonyl)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (201)




A mixture of (2S,5R)-6-(benzyloxy)-N'-(cyclobutylcarbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **200** (0.34 g, 0.91 mmol) and Pd/C (0.12 g) in methanol (20 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite and concentrated to provide **201** (0.30 g, quant. yield) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.86 (1H, m), 1.90 (3H, m), 2.00 (2H, m), 2.09 (2H, m), 2.10 (3H, m), 3.20 (2H, m), 3.71 (1H, s), 3.94 (1H, d, *J* = 7.4 Hz). 3 protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M-H]⁺ calcd for C₁₂H₁₇N₄O₄: 281.1. Found: 281.0.

Step 3. (2S,5R)-N'-(cyclobutylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 33, Table 2)





To a mixture of (2S,5R)-N'-(cyclobutylcarbonyl)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **201** (0.91 mmol) in pyridine (5.0 mL) was added sulfur trioxide pyridine complex (0.52 g, 3.33 mmol). The mixture was stirred at room temperature for 3 days and concentrated to provide a residue which was subjected to chromatography and HPLC purification to give **Compound 33 (Table 2)** (29 mg, 9 % yield) as a white solid.

¹H NMR (400 MHz, D₂O): δ 1.60-2.10 (8H, m), 3.05-3.13 (2H, m), 3.16-3.25 (1H, m), 4.00 (1H, d, *J* = 7.4 Hz), 4.08 (1H, s). 3 protons were not observed in D₂O.

HPLC: 98.31 %

MS (ES⁺) *m/z*: [M-H]⁺ calcd for C₁₂H₁₇N₄O₅S: 361.1. Found: 361.0.

Example 49


(2S,5R)-7-oxo-*N'*-propanoyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 17, Table 2)**5 Step 1. (2S,5R)-6-(benzyloxy)-7-oxo-*N'*-propanoyl-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (203)**

To a mixture of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (15.0 mL) were added propanehydrazide **202** (0.120 g, 1.358 mmol), 1-hydroxybenzotriazole (0.186 g, 1.358 mmol) and 1-ethyl-(3-dimethylamino propyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **203** (0.31 g, 99 %) as a white foam.

15 ^1H NMR (400 MHz, CDCl_3): δ 1.20 (3H, t, $J = 7.4$ Hz), 1.62 (1H, m), 1.98 (2H, m), 2.12 (1H, m), 2.38 (2H, m), 3.10 (1H, d, $J = 12.1$ Hz), 3.19 (1H, d, $J = 12.1$ Hz), 3.30 (1H, s), 3.90 (2H, br s), 4.02 (1H, d, $J = 7.4$ Hz), 4.90 (1H, d, $J = 11.3$ Hz), 5.05 (1H, d, $J = 11.3$ Hz), 7.42 (5H, m).

MS (ES^+) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{11}\text{H}_{23}\text{N}_4\text{O}_4$: 347.2. Found: 347.2.

Step 2. (2S,5R)-6-hydroxy-7-oxo-N'-propanoyl-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (204)




A mixture of (2S,5R)-6-(benzyloxy)-7-oxo-N'-propanoyl-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **203** (0.31 g, 0.89 mmol) and Pd/C (0.12 g) in methanol (20 mL) was hydrogenated at 1 atm at room temperature for 16 h. The mixture was filtered through Celite and concentrated to provide **204** (0.24 g, quant. yield) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.18 (3H, t, *J* = 7.4 Hz), 1.75 (1H, m), 1.85 (1H, m), 1.96 (1H, m), 2.08 (1H, m), 2.30 (2H, m), 3.18 (1H, m), 3.30 (1H, m), 3.70 (1H, br s), 3.95 (1H, d, *J* = 7.4 Hz). 3 protons were not observed in CD₃OD.

MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₀H₁₄N₄O₄: 255.1. Found: 255.0.

Step 3. (2S,5R)-7-oxo-N'-propanoyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 17, Table 2)



To a mixture of (2S,5R)-6-hydroxy-7-oxo-N'-propanoyl-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **204** (0.24 g, 0.93 mmol) in pyridine (5.0 mL) was added sulfur trioxide pyridine complex (0.44 g, 2.81 mmol). The mixture was stirred at room temperature for 23 h and concentrated to provide a residue which was subjected to chromatography and HPLC purification to give **Compound 17 (Table 2)** (0.053 g, 17 %) as a white solid.


¹H NMR (400 MHz, D₂O): δ 0.98 (3H, t, *J* = 7.8 Hz), 1.65 (1H, m), 1.80 (1H, m), 1.95 (1H, m), 2.05 (1H, m), 2.18 (2H, q, *J* = 7.8 Hz), 3.05 (1H, d, *J* = 12.1 Hz), 3.18 (1H, d, *J* = 12.9 Hz), 4.00 (1H, d, *J* = 7.8 Hz), 4.05 (1H, m). 3 protons were not observed in D₂O.

HPLC: 97.12 %


MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₀H₁₅N₄O₇S: 335.1. Found: 335.0.

Example 50

(2*S*,5*R*)-7-oxo-*N*-(piperazin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 100, Table 2)




5 Step 1. *tert*-butyl 4-(((2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)amino)piperazine-1-carboxylate (**206**)



To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.17 g, 0.615 mmol) in dry DCM (10 mL) were added *tert*-butyl 4-aminopiperazine-1-carboxylate **205** (0.19 g, 0.923 mmol), 1-hydroxybenzotriazole (0.125 g, 0.923 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.177 g, 0.923 mmol) and 4-dimethylaminopyridine (0.113 g, 0.923 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight, and then concentrated under vacuum. The residue was purified by column chromatography to give *tert*-butyl 4-(((2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)amino)piperazine-1-carboxylate **206** (0.25 g, 88%) as a clear thick oil.

¹H NMR (400 MHz, CDCl₃): δ 1.46 (9H, s), 1.62 (1H, m), 1.95 (2H, m), 2.38 (1H, m), 2.70 (1H, d, J = 12.0 Hz), 2.76 (4H, m), 2.99 (1H, d, J = 12.0 Hz), 3.30 (1H, m), 3.57 (4H, m), 3.89 (1H, d, J = 8.0 Hz), 4.90 (1H, d, J = 11.6 Hz), 5.04 (1H, d, J = 12.0 Hz), 7.21 (5H, m), 8.90 (1H, br s).


Step 2. *tert*-Butyl 4-(((2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)piperazine-1-carboxylate (207)



To a solution of *tert*-butyl 4-(((2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)piperazine-1-carboxylate **206** (0.25 g, 0.54 mmol) in methanol (15 mL) was added 10% Pd/C (0.3 g). The mixture was hydrogenated under 35 psi hydrogen atmosphere at room temperature for 2 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give *tert*-butyl 4-(((2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)piperazine-1-carboxylate **207** (0.20 g, 99%) as a colorless foam.

¹H NMR (400 MHz, CD₃OD): δ 1.48 (9H, s), 1.78 (1H, m), 1.88 (1H, m), 2.07 (1H, m), 2.20 (1H, m), 2.75 (4H, m), 2.99 (1H, d, J = 12.0 Hz), 3.11 (1H, d, J = 11.6 Hz), 3.53 (4H, m), 3.70 (1H, m), 3.80 (1H, d, J = 7.2 Hz), 2 protons were not observed in CD₃OD.


Step 3. *tert*-Butyl 4-(((2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)piperazine-1-carboxylate (208)



To a solution of *tert*-butyl 4-(((2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)piperazine-1-carboxylate **207** (0.20 g, 0.54 mmol) in dry pyridine (7 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.34 g, 2.16 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated. The residue was purified by column chromatography to give *tert*-butyl 4-(((2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)piperazine-1-carboxylate **208** (0.12g, 49.6%) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.45 (9H, s), 1.86 (2H, m), 2.07 (1H, m), 2.23 (1H, m), 2.75 (4H, m), 3.03 (1H, d, J = 11.2 Hz), 3.21 (1H, m), 3.52 (4H, m), 3.85 (1H, d, J = 11.2 Hz), 4.14 (1H, m), 2 protons were not observed in CD₃OD.

Step 4. (2S,5R)-7-oxo-N-(piperazin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 100, Table 2)



To a solution of *tert*-butyl 4-(((2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)piperazine-1-carboxylate **208** (0.12 g, 0.27 mmol) in DCM (12.5 mL) was added trifluoroacetic acid (1.0 mL, 12.96 mmol) dropwise at 0 °C. The reaction mixture was stirred for 1 h, then evaporated. Ether was added to the residue and the resulting white precipitate was collected by centrifugation. The solid was triturated with acetonitrile (2 x) and the white solid was collected by centrifugation. This white solid was purified by HPLC on a prep-X Bridge-19x250 mm column and freeze-dried to give (2S,5R)-7-oxo-N-(piperazin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **Compound 100 (Table 2)** (0.11 g, 88%) as a white solid.


¹H NMR (400 MHz, CD₃OD): δ 1.77 (2H, m), 1.95 (1H, m), 2.05 (1H, m), 2.97 (5H, m), 3.16 (1H, d, J = 12.0 Hz), 3.26 (4H, m), 3.89 (1H, d, J = 7.6 Hz), 4.06 (1H, m), 3 protons were not observed in CD₃OD.

HPLC: 81.5 %


MS (ES⁻) m/z: [M]⁻ = 348.01

Example 51

(2S,5R)-N-(morpholin-4-yl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 99, Table 2)




Step 1. (2S,5R)-6-(benzyloxy)-N-(morpholin-4-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (210)



To a solution of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.23 g, 0.83 mmol) in dry DCM (15 mL) were added morpholin-4-amine **209** (0.13 g, 1.25 mmol), 1-hydroxybenzotriazole (0.19 g, 1.41 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.24 g, 1.25 mmol) and 4-dimethylaminopyridine (0.15 g, 1.23 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give (2S,5R)-6-(benzyloxy)-N-(morpholin-4-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **210** (0.255 g, 85%) as a clear thick oil.

¹H NMR (400 MHz, CDCl₃): δ 1.62 (1H, m), 1.97 (2H, m), 2.38 (1H, m), 2.71 (1H, d, J = 11.6 Hz), 2.82 (4H, m), 3.00 (1H, d, J = 11.2 Hz), 3.30 (1H, s), 3.8 (4H, m), 3.90 (1H, d, J = 8.0 Hz), 4.90 (1H, d, J = 11.2 Hz), 5.04 (1H, d, J = 12.0 Hz), 7.37 (5H, m), 8.90 (1H, br s).

Step 2. (2S,5R)-6-hydroxy-N-(morpholin-4-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (211)



To a solution of (2S,5R)-6-(benzyloxy)-N-(morpholin-4-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **210** (0.255 g, 0.71 mmol) in methanol (15 mL) was added 10% Pd/C (0.5 g). The mixture was hydrogenated under 35 psi hydrogen atmosphere at room temperature for 2 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give (2S,5R)-6-hydroxy-N-(morpholin-4-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **211** (0.19 g, quantitative yield) as a colorless foam.

¹H NMR (400 MHz, CD₃OD): δ 1.77 (1H, m), 1.95 (1H, m), 2.06 (1H, m), 2.20 (1H, m), 2.81 (4H, m), 3.00 (1H, d, J = 11.2 Hz), 3.11 (1H, d, J = 11.6 Hz), 3.69 (1H, m), 3.76 (4H, m), 3.80 (1H, d, J = 7.2 Hz), 2 protons was not observed in CD₃OD.

Step 3. (2*S*,5*R*)-*N*-(morpholin-4-yl)-7-oxo-6-(sulfooxy)-1,6-

5 diazabicyclo[3.2.1]octane-2-carboxamide (Compound 99, Table 2)




To a solution of (2*S*,5*R*)-6-hydroxy-*N*-(morpholin-4-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **211** (0.19 g, 0.71 mmol) in dry pyridine (7 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.29 g, 1.82 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated. The residue was purified by HPLC on Prep_30x100mm_5μm column and freeze-dried to give (2*S*,5*R*)-*N*-(morpholin-4-yl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **Compound 99 (Table 2)** (0.005g, 2%) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.82 (2H, m), 2.07 (1H, m), 2.21 (1H, m), 2.80 (4H, m), 3.05 (1H, d, J = 11.2 Hz), 3.20 (1H, m), 3.80 (4H, m), 3.89 (1H, d, J = 11.2 Hz), 4.16 (1H, s), 2 protons were not observed in CD₃OD.


MS (ES⁻) *m/z*: [M]⁻ = 348.89

Example 52

(2*R*,5*S*)-*N'*-acetyl-*N'*-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 19, Table 2)




Step 1. (2*R*,5*S*)-*N*'-acetyl-6-(benzyloxy)-*N*'-methyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (213)



To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.25 g, 0.90 mmol) in dry DCM (30 mL) were added *N*-methylacetohydrazide **212** (0.14 g, 1.59 mmol), 1-hydroxybenzotriazole (0.19 g, 1.35 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.26 g, 1.35 mmol) and 4-(dimethylamino)pyridine (0.16 g, 1.35 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give (2*R*,5*S*)-*N*'-acetyl-6-(benzyloxy)-*N*'-methyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **213** (0.20 g, 64%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.65 (1H, m), 1.83-2.12 (5H, m), 2.32 (1H, m), 2.70 (1H, d, *J* = 12.0 Hz), 3.05-3.37 (5H, m), 4.01 (1H, m), 4.88-5.07 (2H, m), 7.41 (5H, m), 8.55 (0.5H, br s), 8.76 (0.5H, br s).


Step 2. (2*R*,5*S*)-*N*'-acetyl-6-hydroxy-*N*'-methyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (214)



To a solution of (2*R*,5*S*)-*N*'-acetyl-6-(benzyloxy)-*N*'-methyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **213** (0.20 g, 0.57 mmol) in methanol (20 mL) was added 5% Pd/C (0.30 g). The mixture was hydrogenated under 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give (2*R*,5*S*)-*N*'-acetyl-6-hydroxy-*N*'-methyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **214** (0.15 g, 99%) as a colorless foam.

¹H NMR (400 MHz, CD₃OD): δ 1.82 (1H, m), 1.89-2.10 (5H, m), 2.25 (1H, m), 2.93 (1H, d, *J* = 12.0 Hz), 3.11-3.26 (4H, m), 3.72 (1H, s), 3.95 (1H, d, *J* = 7.2 Hz), 2 protons were not observed in CD₃OD.

Step 3. (2*R*,5*S*)-*N'*-acetyl-*N'*-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 19, Table 2)



To a solution of (2*R*,5*S*)-*N'*-acetyl-6-hydroxy-*N'*-methyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **214** (0.15 g, 0.58 mmol) in dry pyridine (8 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.70 g, 4.40mmol). The mixture was stirred at room temperature for 40 h, filtered and evaporated. The residue was purified by column chromatography followed by HPLC on a prep-X Bridge-30x100 mm column and freeze-dried to give (2*R*,5*S*)-*N'*-acetyl-*N'*-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **Compound 19 (Table 2)** (0.030 g, 15%) as a grey solid.


¹H NMR (400 MHz, CD₃OD): δ 1.82 (1H, m), 1.96 (1H, m), 2.02 (3H, s), 2.11 (1H, m), 2.26 (1H, m), 2.99 (1H, d, J = 12.4 Hz), 3.11 (3H, s), 3.34 (1H, m), 4.02 (1H, d, J = 8.0 Hz), 4.16 (1H, s), 2 protons were not observed in CD₃OD.

HPLC: 95.4 %


MS (ES⁺) m/z: [M]⁺ = 335

Example 53

(2*S*,5*R*)-7-oxo-*N'*-(pyridin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 72, Table 2)




Step 1. (2S,5R)-6-(benzyloxy)-7-oxo-N'-picolinoyl-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (216)



To a solution of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.276 g, 1.0 mmol) in dry DCM (30 mL) were added **215** (0.206 g, 1.5 mmol), 1-hydroxybenzotriazole (0.211 g, 1.5 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.292 g, 1.5 mmol) and 4-(dimethylamino)pyridine (0.178 g, 1.5 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight, and concentrated under vacuum. The residue was purified by column chromatography to give **216** (0.36 g, 90%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.65 (1H, m), 2.01 (2H, m), 2.42 (1H, m), 3.13 (1H, d, J = 12.0 Hz), 3.19 (1H, d, J = 12 Hz), 3.33 (1H, s), 4.11 (1H, d, J = 7.2 Hz), 4.92 (1H, d, J = 11.6 Hz), 5.063 (1H, d, J = 11.2 Hz), 7.42 (6H, m), 7.85 (1H, t, J = 8.6 Hz), 8.12 (1H, d, J = 9.6 Hz), 8.58 (1H, d, J = 7.2 Hz), 8.67 (1H, br s), 9.75 (1H, br s).

Step 2. (2S,5R)-6-hydroxy-7-oxo-N'-picolinoyl-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (217)




A mixture of (2S,5R)-6-(benzyloxy)-7-oxo-N'-picolinoyl-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **216** (0.30 g, 0.76 mmol) and Pd/C (0.40 g) in methanol (100 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to provide **217** (0.23 g, quant. yield) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.50-2.40 (4H, m), 1.75 (1H, m), 3.20 (1H, m), 3.35 (1H, m), 3.71 (1H, m), 4.05 (1H, m), 7.60 (1H, m), 8.00 (1H, m), 8.18 (1H, m), 8.70 (1H, m). 3 protons were not observed in CD₃OD.

MS (ES⁻) *m/z*: [M+H]⁺ calcd for C₁₉H₁₆N₅O₄: 306.2. Found: 306.1.

Step 3. (2S,5R)-7-oxo-N'-(pyridin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 72, Table 2)



To a mixture of (2S,5R)-6-hydroxy-7-oxo-N'-picolinoyl-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **217** (0.23 g, 0.75 mmol) in pyridine (10 mL) was added sulfur trioxide pyridine complex (0.35 g, 2.26 mmol). The mixture was stirred at room temperature for 24 h. NMR showed no reaction, additional sulfur trioxide pyridine complex (0.70 g, 4.52 mmol) was added, and the mixture was stirred at room temperature for 4 days. The reaction mixture was concentrated and subjected to chromatography to give 140 mg off-white solid; 80 mg of this product was further purified by HPLC to give **Compound 72 (Table 2)** (0.030 g, 20 %) as a white solid.


¹H NMR (400 MHz, D₂O): δ 1.68 (1H, m), 1.82 (1H, m), 1.93 (1H, m), 2.08 (1H, m), 3.13 (1H, d, J = 12.1 Hz), 3.22 (1H, d, J = 12.1 Hz), 4.07 (2H, m), 7.46 (1H, m), 7.86 (2H, m), 8.46 (1H, d, J = 4.69 Hz). 3 protons were not observed in D₂O.

HPLC: 91.81 %.


MS (ES⁺) *m/z*: [M-H]⁺ calcd for C₁₃H₁₄N₅O₇S: 384.3. Found: 384.0.

Example 54

(2S,5R)-N'-(methoxyacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carbohydrazide (Example 29 , Table 2)



Step 1. (2S,5R)-6-(benzyloxy)-N'-(methoxyacetyl)-7-oxo-1,6-diazabicyclo [3.2.1]octane-2-carbohydrazide (219)




To a mixture of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (15.0 mL) were added 2-methoxyacetohydrazide **218** (0.141 g, 1.358 mmol), 1-hydroxybenzotriazole (0.186 g, 1.358 mmol) and 1-ethyl-(3-dimethylamino propyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue, which was subjected to chromatography to give **219** (0.27 g, 82 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.60 (1H, m), 1.99 (2H, m), 2.40 (1H, m), 3.10 (2H, s), 3.32 (1H, s), 3.46 (3H, s), 3.04 (2H, s), 4.06 (1H, m), 4.90 (1H, d, *J* = 11.2 Hz), 5.05 (1H, d, *J* = 11.2 Hz), 7.42 (5H, m).

MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₀H₁₅N₄O₆: 347.2. Found: 361.1.

Step 2. (2S,5R)-6-hydroxy-N'-(methoxyacetyl)-7-oxo-1,6-diazabicyclo [3.2.1]octane-2-carbohydrazide (220)




A mixture of (2S,5R)-6-(benzyloxy)-N'-(methoxyacetyl)-7-oxo-1,6-diazabicyclo [3.2.1]octane-2-carbohydrazide **219** (0.27 g, 0.74 mmol) and Pd/C (0.10 g) in methanol (20 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite and concentrated to provide **220** (0.19 g, 90 %) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.75 (1H, m), 1.90 (1H, m), 1.96 (1H, m), 2.08 (1H, m), 2.28 (1H, m), 3.17 (1H, m), 3.30 (1H, m), 3.44 (3H, s), 3.70 (1H, br s), 3.95 (1H, d, *J* = 7.6 Hz), 4.03 (2H, s). 3 protons were not observed in CD₃OD.

MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₀H₁₅N₄O₅: 271.1. Found: 271.1.

Step 3. (2S,5R)-N'-(methoxyacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carbohydrazide (Compound 29, Table 2)



To a mixture of (2S,5R)-6-hydroxy-N'-(methoxyacetyl)-7-oxo-1,6-diazabicyclo [3.2.1]octane-2-carbohydrazide **220** (0.19 g, 0.70 mmol) in pyridine (5.0 mL) was added sulfur trioxide pyridine complex (0.32 g, 2.10 mmol). The mixture was stirred at room temperature for 2 days and concentrated to provide a residue, which was subjected to chromatography followed by HPLC separation to give **Compound 29 (Table 2)** (9 mg) as a white solid.


¹H NMR (400 MHz, D₂O): δ 1.67 (1H, m), 1.82 (1H, m), 1.92 (1H, m), 3.05 (1H, d, *J* = 12.4 Hz), 3.20 (1H, m), 3.30 (3H, s), 4.00 (2H, s), 4.04 (2H, m). 3 protons were not observed in D₂O.

HPLC: 91.84 %


MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₀H₁₅N₄O₈S: 351.1. Found: 351.0.

Example 55

15 (2S,5R)-7-oxo-N'-(pyrrolidin-3-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide trifluoroacetate (Example 42, Table 2)




Step 1. *tert*-butyl 3-[(2-[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)hydrazinyl]carbonyl]pyrrolidine-1-carboxylate (**222**)




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.304 g, 1.10 mmol) in DCM (20.0 mL) were added *tert*-butyl 3-[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)hydrazinecarboxylate **221** (0.380 g, 1.65 mmol), 1-hydroxybenzotriazole (0.223 g, 1.65 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.315 g, 1.65 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, concentrated to provide a residue which was subjected to chromatography to give **222** (0.48 g, slightly impure) as a white foam.

Step 2. *tert*-butyl 3-[(2-[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)hydrazinyl]carbonyl]pyrrolidine-1-carboxylate (**223**)



A mixture of *tert*-butyl 3-[(2-[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)hydrazinecarboxyl]pyrrolidine-1-carboxylate **222** (0.48 g, 0.984 mmol) and Pd/C (0.60 g) in methanol (100 mL) was hydrogenated at 1 atm at room temperature for 1.5 h. The mixture was filtered through Celite pad and concentrated to give **223** (0.39 g, slightly impure) as an off-white foam.

Step 3. *tert*-butyl 3-[(2-[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)hydrazinyl]carbonyl]pyrrolidine-1-carboxylate (**224**)




To a mixture of *tert*-butyl 2-(2-((2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbonyl)hydrazinecarbonyl)pyrrolidine-1-carboxylate **223** (0.390 g, 0.984 mmol) in pyridine (15 mL) was added sulfur trioxide pyridine complex (0.461 g, 2.952 mmol). The mixture was stirred at room temperature for 23 h. Additional sulfur trioxide pyridine complex (0.461 g, 2.952 mmol) was added. The mixture was stirred at room temperature over the weekend and concentrated to provide a residue which was subjected to chromatography to give **224** (0.245 g, 52 %) as an off-white solid.

¹H NMR (400 MHz, D₂O): δ 1.25 (9H, s), 1.66 (1H, m), 1.84 (1H, m), 1.95 (2H, m), 2.10 (2H, m), 3.04 (2H, m), 3.10-3.60 (5H, m), 4.05 (2H, m). Three protons were not observed in CD₃OD.

MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₇H₂₆N₅O₉S: 476.5. Found: 476.1.

Step 4. (2*S*,5*R*)-7-oxo-*N'*-(pyrrolidin-3-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide trifluoroacetate (Compound 42, Table 2)



To a mixture of *tert*-butyl 2-(2-((2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbonyl)hydrazinecarbonyl)pyrrolidine-1-carboxylate **224** (0.20 g, 0.42 mmol) in DCM (8.0 mL) was added trifluoroacetic acid (0.40 mL) at 0°C. The mixture was stirred at 0°C for 1 h, concentrated and washed with ether and MeOH to give **Compound 42** (Table 2) (90 mg) as a white solid as a pair of diastereomers.

^1H NMR (400 MHz, D_2O): δ 1.63 (1H, m), 1.76 (1H, m), 1.88 (1H, m), 2.01 (2H, m), 2.23 (1H, m), 3.00 (1H, m), 3.19 (4H, m), 3.35 (2H, m), 4.00 (2H, m). Four protons were not observed in D_2O .


^{19}F NMR (376.5 MHz, D_2O): δ - 75.79

5 HPLC: 62.09% and 34.89 %. (Two isomers).


MS (ES $^+$) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{12}\text{H}_{20}\text{N}_5\text{O}_7\text{S}$: 378.4. Found: 378.1.

Example 56

(2*R*,5*S*)-*N'*-methyl-7-oxo-*N'*-propanoyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 20, Table 2)




Step 1. (2*R*,5*S*)-6-(benzyloxy)-*N'*-methyl-7-oxo-*N'*-propanoyl-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (226)



To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid 1 (0.25 g, 0.90 mmol) in dry DCM (30 mL) were added *N*-methylpropanehydrazide 225 (0.14 g, 1.35 mmol), 1-hydroxybenzotriazole (0.19 g, 1.35 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.26 g, 1.35 mmol) and 4-(dimethylamino)pyridine (0.16 g, 1.35 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give (2*R*,5*S*)-6-(benzyloxy)-*N'*-methyl-7-oxo-*N'*-propanoyl-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide 226 (0.19 g, 59%) as a white solid.

^1H NMR (400 MHz, CDCl_3): δ 1.04-1.18 (3H, m), 1.65 (1H, m), 1.98 (2H, m), 2.10-2.20 (3H, m), 2.68-3.32 (6H, m), 3.72-4.02 (1H, m), 4.80-5.05 (2H, m), 7.41 (5H, m), 8.54 (0.5H, br s), 8.63 (0.5H, br s).


Step 2. (2*R*,5*S*)-6-hydroxy-*N'*-methyl-7-oxo-*N'*-propanoyl-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (227)



To a solution of (2*R*,5*S*)-6-(benzyloxy)-*N'*-methyl-7-oxo-*N'*-propanoyl-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **226** (0.19 g, 0.52 mmol) in methanol (20 mL) was added 5% Pd/C (0.20 g). The mixture was hydrogenated under 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered through Celite, and the filtrate was evaporated to give (2*R*,5*S*)-6-hydroxy-*N'*-methyl-7-oxo-*N'*-propanoyl-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **227** (0.11 g, 79%) as a brown foam.

¹H NMR (400 MHz, CD₃OD): δ 1.04-1.14 (3H, m), 1.69-1.80 (2H, m), 1.85-2.14 (2H, m), 2.22-2.40 (2H, m), 2.90-3.34 (5H, m), 3.73 (1H, s), 3.95 (1H, d, *J* = 7.2 Hz), 2 protons were not observed in CD₃OD.

Step 3. (2*R*,5*S*)-*N'*-methyl-7-oxo-*N'*-propanoyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 20, Table 2)



To a solution of (2*R*,5*S*)-6-hydroxy-*N'*-methyl-7-oxo-*N'*-propanoyl-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **227** (0.11 g, 0.41 mmol) in dry pyridine (6 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.60 g, 3.80 mmol). The mixture was stirred at room temperature for 40 h, filtered and evaporated. The residue was purified first by column chromatography followed by washing several times with a mixture of methanol and diethyl ether (1:9) to give (2*R*,5*S*)-*N'*-methyl-7-oxo-*N'*-propanoyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **Compound 20 (Table 2)** (0.015 g, 10.5 %) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.05 (3H, t, *J* = 7.4 Hz), 1.81 (1H, m), 1.94 (1H, m), 2.08 (1H, m), 2.26 (3H, m), 2.99 (1H, d, *J* = 12.0 Hz), 3.11 (3H, s), 3.31 (1H, m), 4.02 (1H, d, *J* = 7.6


Hz), 4.17 (1H, s), 2 protons were not observed in CD₃OD.

HPLC: 91.8%


MS (ES⁻) m/z: [M]⁻ = 349

Example 57

5 (2*R*,5*S*)-7-oxo-6-(sulfooxy)-*N'*-(3,3,3-trifluoropropanoyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 28, Table 2)



Step 1. (2*R*,5*S*)-6-(benzyloxy)-7-oxo-*N'*-(3,3,3-trifluoropropanoyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (229)




10

To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.25 g, 0.90 mmol) in dry DCM (40 mL) were added 3,3,3-trifluoropropanehydrazide **228** (0.19 g, 1.35 mmol), 1-hydroxybenzotriazole (0.19 g, 1.35 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.26 g, 1.35 mmol) and 4-(dimethylamino)pyridine (0.16 g, 1.35 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give (2*R*,5*S*)-6-(benzyloxy)-7-oxo-*N'*-(3,3,3-trifluoropropanoyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **229** (0.26 g, 72%) as a white solid.

20 ¹H NMR (400 MHz, CDCl₃): δ 1.60 (1H, m), 1.99 (2H, m), 2.26 (1H, m), 3.08 (2H, m), 3.23 (2H, m), 3.33 (1H, s), 3.97 (1H, d, J = 7.2 Hz), 4.89 (1H, d, J = 11.2 Hz), 5.02 (1H, d, J = 11.2 Hz), 7.39 (5H, m), 8.82 (2H, br s).


Step 2. (2R,5S)-6-hydroxy-7-oxo-N'-(3,3,3-trifluoropropanoyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (230)



To a solution of (2R,5S)-6-(benzyloxy)-7-oxo-N'-(3,3,3-trifluoropropanoyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **229** (0.26 g, 0.65 mmol) in methanol (20 mL) was added 5% Pd/C (0.30 g). The mixture was hydrogenated under 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give (2R,5S)-6-hydroxy-7-oxo-N'-(3,3,3-trifluoropropanoyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **230** (0.19 g, 93.6%) as a colorless foam.

¹H NMR (400 MHz, CD₃OD): δ 1.76 (1H, m), 1.93 (1H, m), 2.04 (1H, m), 2.28 (1H, m), 3.15-3.34 (4H, m), 3.71 (1H, s), 3.94 (1H, d, J = 7.2 Hz), 3 protons were not observed in CD₃OD.

Step 3. (2R,5S)-7-oxo-6-(sulfooxy)-N'-(3,3,3-trifluoropropanoyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 28, Table 2) :




To a solution of (2R,5S)-6-hydroxy-7-oxo-N'-(3,3,3-trifluoropropanoyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **230** (0.19 g, 0.61 mmol) in dry pyridine (7 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.70 g, 4.40 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated. The residue was purified by column chromatography followed by washing several times with a mixture of methanol and diethyl ether (1:9) to give (2R,5S)-7-oxo-6-(sulfooxy)-N'-(3,3,3-trifluoropropanoyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **Compound 28 (Table 2)** (0.040 g, 16.8%) as a pink solid.

¹H NMR (400 MHz, CD₃OD): δ 1.80 (1H, m), 1.93 (1H, m), 2.06 (1H, m), 2.27 (1H, m), 3.23-3.34 (4H, m), 4.01 (1H, d, J = 7.6 Hz), 4.15 (1H, s), 3 protons were not observed in CD₃OD.


HPLC: 94.2%

MS (ES⁻) m/z: [M]⁻ = 389


Example 58

(2*R*,5*S*)-*N*',*N*'-dimethyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 4, Table 2)

5

Step 1. (2*S*,5*R*)-6-(benzyloxy)-*N*',*N*'-dimethyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (232)


To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.276 g, 1.0 mmol) in dry DCM (20 mL) were added **231** (0.09 g, 1.5 mmol), 1-hydroxybenzotriazole (0.203 g, 1.5 mmol), and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.288 g, 1.5 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give **232** (0.25 g, slightly impure) as a colorless oil.

Step 2. (2*S*,5*R*)-6-hydroxy-*N*',*N*'-dimethyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (233)

A mixture of (2*S*,5*R*)-6-(benzyloxy)-*N*',*N*'-dimethyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **232** (0.25 g, 0.78 mmol) and Pd/C (0.30 g) in methanol (80 mL) was hydrogenated at 1 atm at room temperature for 1 h. The mixture was filtered through Celite

pad and concentrated to provide **233** (0.17 g) as a white foam which was used in the next step without purification.

Step 3. (2R,5S)-N',N'-dimethyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 4, Table 2)



To a mixture of (2S,5R)-6-hydroxy-N',N'-dimethyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **233** (0.17 g, 0.78 mmol) in pyridine (10 mL) was added sulfur trioxide pyridine complex (0.36 g, 2.34 mmol). The mixture was stirred at room temperature for 24 h and concentrated to provide a residue which was subjected to chromatography followed by HPLC separation to give **Compound 4 (Table 2)** (0.0036 g, 1.5 % for three steps) as a white solid.


¹H NMR (400 MHz, D₂O): δ 1.68 (2H, m), 1.94 (2H, m), 2.38 (6H, s), 2.90 (1H, d, *J* = 12.0 Hz), 3.13 (1H, d, *J* = 12.4 Hz), 3.81 (1H, d, *J* = 7.2 Hz), 4.02 (1H, s). 2 protons were not observed in D₂O.

HPLC: 93.82%


MS (ES⁺) *m/z*: [M-H]⁺ calcd for C₉H₁₅N₄O₆S: 307.3. Found: 307.0.

Example 59

(2R,5S)-N'-butanoyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 25, Table 2)




Step 1. (2*R*,5*S*)-6-(benzyloxy)-*N'*-butanoyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (235)



To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.25 g, 0.90 mmol) in dry DCM (40 mL) were added butanehydrazide **234** (0.14 g, 1.35 mmol), 1-hydroxybenzotriazole (0.19 g, 1.35 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.26 g, 1.35 mmol) and 4-(dimethylamino)pyridine (0.16 g, 1.35 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight, and then concentrated under vacuum. The residue was purified by column chromatography to give (2*R*,5*S*)-6-(benzyloxy)-*N'*-butanoyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **235** (0.31 g, 95%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 0.96 (3H, t, J = 7.4 Hz), 1.60-1.72 (3H, m), 1.97 (2H, m), 2.05-2.33 (3H, m), 3.06 (1H, d, J = 12.0 Hz), 3.16 (1H, d, J = 12.0 Hz), 3.31 (1H, s), 4.00 (1H, d, J = 7.2 Hz), 4.90 (1H, d, J = 11.2 Hz), 5.04 (1H, d, J = 11.6 Hz), 7.38 (5H, m), 7.86 (1H, br s), 8.58 (1H, br s).

Step 2. (2*R*,5*S*)-*N'*-butanoyl-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (236)




To a solution of (2*R*,5*S*)-6-(benzyloxy)-*N'*-butanoyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

235 (0.31 g, 0.86 mmol) in methanol (20 mL) was added 5% Pd/C (0.30 g). The mixture was hydrogenated under 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give (2*R*,5*S*)-*N'*-butanoyl-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **236** (0.21 g, 90%) as a brown foam.

¹H NMR (400 MHz, CD₃OD): δ 0.97 (3H, t, J = 7.4 Hz), 1.63-1.79 (3H, m), 1.92 (1H, m), 1.98 (1H, m), 2.08-2.30 (3H, m), 3.14 (1H, d, J = 11.6 Hz), 3.25 (1H, d, J = 12.0 Hz), 3.70 (1H, s), 3.94

(1H, d, J = 7.6 Hz), 2 protons were not observed in CD₃OD.

Step 3. (2R,5S)-N'-butanoyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 25, Table 2)



- 5 To a solution of **236** (0.21 g, 0.77 mmol) in dry pyridine (10 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (1.20 g, 7.60 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated. The residue was purified first by column chromatography followed by HPLC on a prep-X Bridge-30x100 mm column and freeze-dried to give (2R,5S)-N'-butanoyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 **Compound 25 (Table 2)** (0.020 g, 7.5%) as a pink solid.


¹H NMR (400 MHz, CD₃OD): δ 9.7 (3H, t, J = 7.4 Hz), 1.67 (2H, m), 1.77 (1H, m), 1.93 (1H, m), 2.07 (1H, m), 2.22-2.30 (3H, m), 3.30 (2H, m), 4.01 (1H, d, J = 7.6 Hz), 4.15 (1H, s), 3 protons were not observed in CD₃OD.

HPLC: 95.2%


- 15 MS (ES⁺) m/z: [M]⁺ = 349

Example 60

(2S,5R)-7-oxo-N'-(pyridin-3-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 95, Table 2)



Step 1. (2S,5R)-6-(benzyloxy)-7-oxo-*N'*-(pyridin-3-yl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (238)




To a mixture of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid
 5 **1** (0.250 g, 0.905 mmol) in DCM (15.0 mL) were added 3-hydrazinopyridine dihydrochloride
237 (0.120 g, 1.358 mmol), 1-hydroxybenzotriazole (0.186 g, 1.358 mmol) and 1-ethyl-(3-
 dimethylamino propyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at
 room temperature. The mixture was stirred at room temperature overnight, diluted with DCM
 and concentrated to provide a residue which was subjected to chromatography to give **238**
 10 (0.20 g, 60 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.62 (1H, m), 1.97 (2H, m), 2.25 (1H, m), 2.84 (1H, d, *J* = 11.6
 Hz), 3.14 (1H, d, *J* = 11.2 Hz), 3.34 (1H, m), 4.06 (1H, m), 4.91 (1H, d, *J* = 11.2 Hz), 5.05 (1H,
 d, *J* = 11.2 Hz), 7.18 (1H, m), 7.42 (5H, m), 8.14 (1H, m), 8.22 (1H, m), 8.67 (1H, s). 2
 protons were not observed in moisture-containing CDCl₃.

15 MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₁H₂₃N₄O₄: 347.2. Found: 347.2.

Step 2. (2S,5R)-6-hydroxy-7-oxo-*N'*-(pyridin-3-yl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (239)




A mixture of (2S,5R)-6-(benzyloxy)-7-oxo-*N'*-(pyridin-3-yl)-1,6-diazabicyclo[3.2.1]octane-2-
 20 carbohydrazide **238** (0.20 g, 0.54 mmol) and Pd/C (0.08 g) in methanol (20 mL) was
 hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite
 pad and concentrated to provide **239** (0.13 g, 87 %) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.80 (1H, m), 2.00 (1H, m), 2.09 (1H, m), 2.22 (1H, m), 3.07
 (1H, d, *J* = 11.6 Hz), 3.21 (1H, m), 3.72 (1H, br s), 4.03 (1H, d, *J* = 0.8 Hz), 7.25 (2H, m),
 25 7.96 (1H, m), 8.10 (1H, s). 3 protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₂H₁₆N₅O₃: 278.1. Found: 278.1.

Step 3. (2*S*,5*R*)-7-oxo-*N'*-(pyridin-3-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 95, Table 2)



- 5 To a mixture of (2*S*,5*R*)-6-hydroxy-7-oxo-*N'*-(pyridin-3-yl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **239** (0.13 g, 0.47 mmol) in pyridine (6.0 mL) was added sulfur trioxide pyridine complex (0.44 g, 2.80 mmol). The mixture was stirred at room temperature for 2 days and concentrated to provide a residue which was subjected to chromatography followed by HPLC separation to give **Compound 95 (Table 2)** (6.9 mg) as a white solid.

- 10 ¹H NMR (400 MHz, CD₃OD): δ 1.81 (1H, m), 2.00 (1H, m), 2.12 (1H, m), 2.26 (1H, m), 3.09 (1H, d, *J* = 11.6 Hz), 3.36 (1H, m), 4.12 (1H, d, *J* = 2.8 Hz), 4.18 (1H, m), 7.74 (2H, m), 8.19 (2H, m). 3 protons were not observed in CD₃OD.


HPLC: 94.63 %.

MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₂H₁₄N₅O₆S: 356.1. Found: 356.0


15

Example 61

(2*R*,5*S*)-*N'*-[(dimethylamino)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 27, Table 2)




Step 1. (2*R*,5*S*)-6-(benzyloxy)-*N*'-[(dimethylamino)acetyl]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (241)



To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.25 g, 0.90 mmol) in dry DCM (40 mL) were added 2-(dimethylamino)acetohydrazide **240** (0.32 g, 1.68 mmol), 1-hydroxybenzotriazole (0.19 g, 1.35 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.26 g, 1.35 mmol) and 4-(dimethylamino)pyridine (0.40 g, 3.36 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give (2*R*,5*S*)-6-(benzyloxy)-*N*'-[(dimethylamino)acetyl]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **241** (0.15 g, 44.5%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.61 (1H, m), 1.98 (2H, m), 2.33 (7H, m), 3.12 (4H, m), 3.31 (1H, s), 4.03 (1H, d, *J* = 7.2 Hz), 4.90 (1H, d, *J* = 11.2 Hz), 5.05 (1H, d, *J* = 11.6 Hz), 7.38 (5H, m), 8.40 (2H, br s).


Step 2. (2*R*,5*S*)-*N*'-[(dimethylamino)acetyl]-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (242)



To a solution of (2*R*,5*S*)-6-(benzyloxy)-*N*'-[(dimethylamino)acetyl]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **241** (0.15 g, 0.40 mmol) in methanol (20 mL) was added 5% Pd/C (0.20 g). The mixture was hydrogenated under 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite and the filtrate was evaporated to give (2*R*,5*S*)-*N*'-[(dimethylamino)acetyl]-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **242** (0.10 g, 88%) as a white foam.

^1H NMR (400 MHz, CD_3OD): δ 1.75 (1H, m), 1.94 (1H, m), 2.05 (1H, m), 2.28 (1H, m), 2.42 (6H, s), 3.27 (4H, m), 3.70 (1H, s), 3.95 (1H, d, $J = 7.2$ Hz), 3 protons were not observed in CD_3OD .

Step 3. (2*R*,5*S*)-*N'*-[(dimethylamino)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 27, Table 2)



To a solution of (2*R*,5*S*)-*N'*-[(dimethylamino)acetyl]-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **242** (0.10 g, 0.35 mmol) in dry pyridine (6 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.60 g, 3.80 mmol).

The mixture was stirred at room temperature for 20 h, filtered and evaporated. The residue was purified by column chromatography to give (2*R*,5*S*)-*N'*-[(dimethylamino)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide, **Compound 27 (Table 2)** (0.020 g, 12.7%) as a brown solid.


^1H NMR (400 MHz, CD_3OD): δ 1.72 (1H, m), 1.93 (1H, m), 2.09 (1H, m), 2.30 (1H, m), 2.98 (6H, s), 3.27 (4H, m), 4.06 (1H, d, $J = 7.6$ Hz), 4.17 (1H, s), 3 protons were not observed in CD_3OD .

HPLC: 92.3 %


MS (ES $^-$) m/z : $[M]^- = 364$

Example 62

(2*R*,5*S*)-*N'*-[(2,2-dimethylcyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 34, Table 2)




Step 1. (2S,5R)-6-(benzyloxy)-N'-((R)-2,2-dimethylcyclopropanecarbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (244)




To a solution of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.276 g, 1.0 mmol) in dry DCM (20 mL) were added **243** (0.173 g, 1.35 mmol), 1-hydroxybenzotriazole (0.203 g, 1.5 mmol), and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.288 g, 1.5 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give **244** (0.350 g, 91%) as a white foam.

Step 2. (2S,5R)-N'-((S)-2,2-dimethylcyclopropanecarbonyl)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (245)



A mixture of (2S,5R)-6-(benzyloxy)-N'-((R)-2,2-dimethylcyclopropanecarbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **244** (0.35 g, 0.90 mmol) and Pd/C (0.50 g) in methanol (80 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to provide **245** (0.27 g, quant.) as an off-white solid.

Step 3. (2R,5S)-N'-[(2,2-dimethylcyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 34, Table 2)



To a mixture of (2S,5R)-N'-((S)-2,2-dimethylcyclopropanecarbonyl)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **245** (0.27 g, 0.90 mmol) in pyridine (6 mL) was added sulfur trioxide pyridine complex (0.42 g, 2.70 mmol). The mixture was stirred at room temperature for 24 h and concentrated to provide a residue which was subjected to chromatography to give **Compound 34 (Table 2)** (0.166 g) as an off-white solid.


¹H NMR (400 MHz, D₂O): δ 0.80 (1H, m), 0.91 (1H, m), 0.98 (3H, s), 1.04 (3H, s), 1.47 (1H, m), 1.69 (1H, m), 1.84 (1H, m), 1.95 (1H, m), 2.09 (1H, m), 3.10 (1H, t, *J* = 11.0 Hz), 3.22 (1H, d, *J* = 12.0 Hz), 4.03 (1H, d, *J* = 7.2 Hz), 4.09 (1H, s). 3 protons were not observed in D₂O.

HPLC: 97.82 %


MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₃H₁₉N₄O₇S: 375.4. Found: 375.0.

Example 63

(2R,5S)-N'-(2-methylbutanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 26, Table 2)




Step 1. (2S,5R)-6-(benzyloxy)-N'-(2-methylbutanoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (247)




To a solution of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid 1 (0.276 g, 1.0 mmol) in dry DCM (20 mL) were added 246 (0.174 g, 1.5 mmol), 1-hydroxybenzotriazole (0.203 g, 1.5 mmol), and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.288 g, 1.5 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give 247 (0.260 g, 70%) as a colorless sticky mass.

Step 2. (2S,5R)-6-hydroxy-N'-(2-methylbutanoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (248)



A mixture of (2S,5R)-6-(benzyloxy)-N'-(2-methylbutanoyl)-7-oxo-1,6-diazabicyclo [3.2.1]-octane-2-carbohydrazide 247 (0.26 g, 0.69 mmol) and Pd/C (0.30 g) in methanol (80 mL) was hydrogenated at 1 atm at room temperature for 2.5 h. The mixture was filtered through Celite pad and concentrated to provide 248 (0.18 g) as an off-white solid which was used in the next step without purification.

Step 3. (2R,5S)-N'-(2-methylbutanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 26, Table 2)



To a mixture of (2S,5R)-6-hydroxy-N'-(2-methylbutanoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **248** (0.18 g, 0.63 mmol) in pyridine (6 mL) was added sulfur trioxide pyridine complex (0.30 g, 1.89 mmol). The mixture was stirred at room temperature for 24 h and concentrated to provide a residue which was subjected to chromatography followed by HPLC separation to give **Compound 26** (Table 2) (0.0095 g) as a white solid.


¹H NMR (400 MHz, D₂O): δ 0.76 (3H, m), 1.00 (3H, d, *J* = 6.8 Hz), 1.40 (2H, m), 1.70 (1H, m), 1.81 (1H, m), 1.96 (1H, m), 2.09 (1H, m), 2.25 (1H, m), 3.10 (1H, d, *J* = 12.0 Hz), 3.21 (1H, d, *J* = 12.0 Hz), 4.03 (1H, d, *J* = 7.6 Hz), 4.08 (1H, s). 3 protons were not observed in D₂O.

HPLC: 98.38 %


MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₂H₁₉N₄O₇S: 363.4. Found: 363.0.

Example 64

(2S,5R)-N'-[amino(phenyl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide trifluoroacetate (**Compound 31**, Table 2)



Step 1. *tert*-butyl [2-(2-[[[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo [3.2.1]oct-2-yl]carbonyl]hydrazinyl)-2-oxo-1-phenylethyl]carbamate (**250**)




To a mixture of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (15.0 mL) were added *tert*-butyl (2-hydrazinyl-2-oxo-1-phenylethyl)carbamate **249** (0.360 g, 1.358 mmol), 1-hydroxybenzotriazole (0.186 g, 1.358 mmol) and 1-ethyl-(3-dimethylamino propyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **250** (0.40 g, 84 %) as a white foam.

^1H NMR (400 MHz, CDCl_3): δ 1.42 (9H, s), 1.62 (1H, m), 1.97 (2H, m), 2.25 (1H, m), 3.10 (2H, m), 3.27 (1H, m), 3.94 (1H, m), 4.91 (1H, d, $J = 11.6$ Hz), 5.05 (1H, d, $J = 11.6$ Hz), 5.34 (1H, m), 5.60 (1H, m), 7.42 (10H, m), 8.30-8.50 (2H, m).

MS (ES $^-$) m/z : $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{27}\text{H}_{32}\text{N}_5\text{O}_6$: 522.2. Found: 522.1.

5 **Step 2.** *tert*-butyl [2-(2-[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinyl)-2-oxo-1-phenylethyl]carbamate (**251**)




A mixture of *tert*-butyl [2-(2-[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinyl)-2-oxo-1-phenylethyl]carbamate **250** (0.40 g, 0.76 mmol) and Pd/C (0.20 g) in methanol (15 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to provide **251** (0.34 g, quant. yield) as a white foam.

^1H NMR (400 MHz, CD_3OD): δ 1.44 (9H, s), 1.45 (1H, m), 1.88 (1H, m), 2.05 (1H, m), 2.25 (1H, m), 3.11-3.28 (2H, m), 3.71 (1H, br s), 3.94 (1H, d, $J = 7.6$ Hz), 5.30 (1H, m), 7.25 (2H, m), 7.30 (3H, m). 4 protons were not observed in CD_3OD .

MS (ES $^-$) m/z : $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{20}\text{H}_{26}\text{N}_5\text{O}_6$: 432.2. Found: 432.1.

Step 3. *tert*-butyl [2-oxo-2-(2-[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinyl)-1-phenylethyl]carbamate (**252**)




20 To a mixture of *tert*-butyl [2-(2-[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinyl)-2-oxo-1-phenylethyl]carbamate **251** (0.33 g, 0.76 mmol) in pyridine (6.0 mL) was added sulfur trioxide pyridine complex (0.71 g, 4.46 mmol). The mixture was stirred at room temperature for 2 days and concentrated to provide a residue which was subjected to chromatography to give **252** (0.25g, 64 %) as a white solid.

^1H NMR (400 MHz, CD_3OD): δ 1.44 (9H, s), 1.78 (1H, m), 1.90 (1H, m), 2.12 (1H, m), 2.26 (1H, m), 3.30 (2H, m), 4.12 (2H, m), 5.30 (1H, m), 7.38 (3H, m), 7.45 (2H, m). 4 protons were not observed in CD_3OD .

MS (ES $^-$) m/z : $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{20}\text{H}_{26}\text{N}_5\text{O}_9\text{S}$: 512.1. Found: 512.1.

5 **Step 4. (2S,5R)-N'-[amino(phenyl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide trifluoroacetate (Compound 31, Table 2)**



To a mixture of *tert*-butyl [2-oxo-2-((2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl]hydrazinyl-1-phenylethyl]carbamate **252** (0.25 g, 0.48 mmol) in DCM (8.0 mL) was added trifluoroacetic acid (0.40 mL) at 0°C. The mixture was stirred at 0°C for 3 h, concentrated and washed with ether to give **Compound 31 (Table 2)** (0.14 g) as a white solid as a pair of diastereomers in a ratio of 1:2.


^1H NMR (400 MHz, D_2O): δ 1.65 (1H, m), 1.80 (1H, m), 1.95 (1H, m), 2.08 (1H, m), 3.04 (1H, m), 3.22 (1H, d, $J = 11.2$ Hz), 4.02 (1H, d, $J = 6.0$ Hz), 4.08 (1H, m), 5.15 (1H, s), 7.42 (5H, m). Five protons were not observed in D_2O .

HPLC: 92.19 %


MS (ES $^-$) m/z : $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{15}\text{H}_{16}\text{N}_5\text{O}_7\text{S}$: 412.1. Found: 412.0.

Example 65

20 **(2S,5R)-N'-(2,2-dimethylpropanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 24, Table 2)**



Step 1. (2*S*,5*R*)-6-(benzyloxy)-*N'*-(2,2-dimethylpropanoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (254)




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (15.0 mL) were added 2,2-dimethylpropanehydrazide **253** (0.137 g, 1.358 mmol), 1-hydroxybenzotriazole (0.186 g, 1.358 mmol) and 1-ethyl-(3-dimethylamino propyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **254** (0.32 g, 94 %) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.24 (9H, m), 1.62 (1H, m), 1.99 (2H, m), 2.31 (1H, m), 3.10 (2H, m), 3.28 (1H, m), 4.01 (1H, d, *J* = 3.2 Hz), 4.91 (1H, d, *J* = 11.2 Hz), 5.05 (1H, d, *J* = 11.2 Hz), 7.42 (5H, m), 7.64 (1H, s), 8.48 (1H, s).

MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₉H₂₅N₄O₄: 373.2. Found: 373.1.

Step 2. (2*S*,5*R*)-*N'*-(2,2-dimethylpropanoyl)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (255)




A mixture of (2*S*,5*R*)-6-(benzyloxy)-*N'*-(2,2-dimethylpropanoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **254** (0.32 g, 0.86 mmol) and Pd/C (0.15 g) in methanol (20 mL) was hydrogenated at 1 atm at room temperature overnight. The mixture was filtered through Celite pad and concentrated to provide **255** (0.25 g, quant. yield) as a white foam.

^1H NMR (400 MHz, CD_3OD): δ 1.25 (9H, s), 1.75 (1H, m), 1.92 (1H, m), 2.05 (1H, m), 2.28 (1H, m), 3.14 (1H, m), 3.30 (1H, m), 3.70 (1H, br s), 3.94 (1H, d, $J = 7.2$ Hz). 3 protons were not observed in CD_3OD .

MS (ES^+) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{12}\text{H}_{21}\text{N}_4\text{O}_4$: 285.1. Found: 285.1.

5 **Step 3. (2S,5R)-N'-(2,2-dimethylpropanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 24, Table 2)**



To a mixture of (2S,5R)-N'-(2,2-dimethylpropanoyl)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **255** (0.25 g, 0.85 mmol) in pyridine (10.0 mL) was added sulfur trioxide pyridine complex (0.42 g, 2.58 mmol). The mixture was stirred at room temperature overnight and concentrated to provide a residue which was subjected to chromatography followed by HPLC separation to give **Compound 24 (Table 2)** (20 mg) as a white solid.


10 ^1H NMR (400 MHz, D_2O): δ 1.08 (9H, s), 1.65 (1H, m), 1.80 (1H, m), 1.95 (1H, m), 2.10 (1H, m), 3.10 (1H, d, $J = 12.4$ Hz), 3.22 (1H, d, $J = 12.0$ Hz), 4.02 (1H, d, $J = 7.6$ Hz), 4.08 (1H, m). Three protons were not observed in D_2O .

HPLC: 93.08 %.


MS (ES^-) m/z : $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{20}\text{H}_{19}\text{N}_4\text{O}_7\text{S}$: 363.1. Found: 363.0.

Example 66

20 **(2S,5R)-7-oxo-N-(2-oxopiperidin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 103, Table 2)**




Step 1. (2S,5R)-6-(benzyloxy)-7-oxo-N-(2-oxopiperidin-1-yl)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (257)



To a mixture of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid 1 (0.250 g, 0.905 mmol) in DCM (15.0 mL) were added 1-aminopiperidin-2-one **256** (31 mg, 0.27 mmol), HOBt (38 mg, 0.27 mmol), DMAP (32 mg, 0.27 mmol) and EDCI (53 mg, 0.27 mmol). The mixture was stirred at room temperature for 48 h and purified by column to afford **257** as foam (55 mg, 82%).

¹HNMR (CDCl₃): 8.45 (1H, s), 7.40 (5H, m), 4.99 (2H, dd), 4.02 (1H, d), 3.70 (1H, m), 3.43 (1H, m), 3.32 (2H, m), 3.07 (1H, m), 2.40 (3H, m), 1.90 (6H, m), 1.60 (1H, m).


Step 2. (2S,5R)-6-hydroxy-7-oxo-N-(2-oxopiperidin-1-yl)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (258)



To a solution of compound **257** (55 mg, 0.148 mmol) in 10 mL of MeOH was added 100 mg of Pd/C (10%, wet). The mixture was hydrogenated at room temperature for 2 h. The catalyst was removed by filtration through Celite pad. The filtrate was concentrated to afford compound **258** as a colorless gum (37 mg, 88%).

¹HNMR (CD₃OD): 3.98 (1H, d), 3.72 (1H, m), 3.55 (2H, m), 3.30 (1H, m), 3.18 (1H, m), 2.49 (2H, m), 2.30 (1H, m), 1.90 (7H, m).

Step 3. (2S,5R)-7-oxo-N-(2-oxopiperidin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 103, Table 2)



To a solution of compound **258** (35 mg, 0.124 mmol) in 5 mL of pyridine was added sulphur trioxide pyridine complex (190 mg, 1.24 mmol). The mixture was stirred at room temperature under nitrogen atmosphere for 72 h. After silica gel column followed by HPLC purification, pure **compound 103** (Table 2) was obtained as a white solid (20 mg, 45%)


¹HNMR (CD₃OD): 4.18 (1H, s), 4.03 (1H, d), 3.58 (2H, m), 3.30 (2H, m), 2.50 (2H, m), 2.30 (1H, m), 1.90 (7H, m)

HPLC: 93 %.


MS (ES⁻) *m/z*: [M-H]⁻ Found: 361.0.

Example 67

(2R,5S)-N'-(azetidin-3-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 112, Table 2)




Step 1. tert-butyl 3-[(2-[(2R,5S)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinyl)carbonyl]azetidine-1-carboxylate (260)



To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.25 g, 0.90 mmol) in dry DCM (30 mL) were added *tert*-butyl 3-(hydrazinylcarbonyl)azetidine-1-carboxylate **259** (0.29 g, 1.35 mmol), 1-hydroxybenzotriazole (0.19 g, 1.35 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.26 g, 1.35 mmol) and 4-(dimethylamino)pyridine (0.16 g, 1.35 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give *tert*-butyl 3-[(2-[(2*R*,5*S*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}hydrazinyl)carbonyl]azetidine-1-carboxylate **260** (0.35 g, 81%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.38 (9H, s), 1.63 (1H, m), 1.99 (2H, m), 2.31 (1H, m), 3.15 (2H, m), 3.28 (2H, s), 4.00 (1H, d, J = 7.6 Hz), 4.10 (4H, m), 4.90 (1H, d, J = 11.2 Hz), 5.04 (1H, d, J = 11.6 Hz), 7.39 (5H, m), 7.86 (1H, br s), 8.54 (1H, br s).


Step 2. *tert*-butyl 3-[(2-[(2*R*,5*S*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}hydrazinyl)carbonyl]azetidine-1-carboxylate (**261**)



To a solution of *tert*-butyl 3-[(2-[(2*R*,5*S*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}hydrazinyl)carbonyl]azetidine-1-carboxylate **260** (0.35 g, 0.74 mmol) in methanol (25 mL) was added 5% Pd/C (0.40 g). The mixture was hydrogenated under 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give *tert*-butyl 3-[(2-[(2*R*,5*S*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}hydrazinyl)carbonyl]azetidine-1-carboxylate **261** (0.25 g, 88%) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.44 (9H, s), 1.76 (1H, m), 1.91 (1H, m), 2.05 (1H, m), 2.26 (1H, m), 3.15 (1H, m), 3.25 (1H, m), 3.40 (1H, m), 3.71 (1H, s), 3.95 (1H, d, J = 7.2 Hz), 4.08 (4H, m), 3 protons were not observed in CD₃OD.

Step 3. *tert*-butyl 3-[(2-[(*(2R,5S)*-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl]hydrazinyl)carbonyl]azetidine-1-carboxylate (**262**)




To a solution of *tert*-butyl 3-[(2-[(*(2R,5S)*-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl]hydrazinyl)carbonyl]azetidine-1-carboxylate **261** (0.25 g, 0.65 mmol) in dry pyridine (10 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.60 g, 3.80 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated. The residue was purified first by column chromatography to give *tert*-butyl 3-[(2-[(*(2R,5S)*-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-

yl)carbonyl]hydrazinyl)carbonyl]azetidine-1-carboxylate **262** (0.18 g, 60%) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.30 (9H, s), 1.81 (1H, m), 1.94 (1H, m), 2.05 (1H, m), 2.26 (1H, m), 3.30 (2H, m), 3.41 (1H, m), 4.04 (5H, m), 4.16 (1H, s), 3 protons were not observed in CD₃OD.

Step 4. (*(2R,5S)*-*N'*-(azetidin-3-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound **112**, Table 2)



To a solution *tert*-butyl 3-[(2-[(*(2R,5S)*-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl]hydrazinyl)carbonyl]azetidine-1-carboxylate **262** (0.18 g, 0.39 mmol) in DCM (18 mL) was added trifluoroacetic acid (1.45 mL, 18.79 mmol) dropwise at 0 °C. The reaction mixture was stirred for 1 h then evaporated. Ether was added to the residue and the resulting white precipitate was collected by centrifugation. The solid was triturated with a mixture of MeOH:ether (1:5, 6X) and the white solid was collected by centrifugation to give (*(2R,5S)*-*N'*-(azetidin-3-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **Compound 112** (Table 2) (0.04 g, 28%) as a white solid.


^1H NMR (400 MHz, D_2O): δ 1.66 (1H, m), 1.77 (1H, m), 1.90 (1H, m), 2.04 (1H, m), 3.03 (1H, d, $J = 12.4$ Hz), 3.17 (1H, m), 3.65 (1H, m), 4.02 (2H, m), 4.12 (4H, m), 4 protons were not observed in D_2O .

HPLC 92.40%

5 MS (ES^-) m/z : $[\text{M}]^- = 362$


Example 68

(2*S*,5*R*)-7-oxo-*N'*-(pyrrolidin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide trifluoroacetate (Compound 41, Table 2)




10

Step 1. *tert*-butyl 2-(2-((2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbonyl)hydrazinecarbonyl)pyrrolidine-1-carboxylate (264)




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid
 15 **1** (0.304 g, 1.10 mmol) in DCM (20.0 mL) were added *tert*-butyl 3-(hydrazinecarbonyl)pyrrolidine-1-carboxylate **263** (0.380 g, 1.65 mmol), 1-hydroxybenzotriazole (0.223 g, 1.65 mmol) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.315 g, 1.65 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, concentrated to provide a residue, which
 20 was subjected to chromatography to give **264** (0.34 g) as a white solid.

Step 2. *tert*-butyl 2-(2-((2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]-octane-2-carbonyl)hydrazinecarbonyl)pyrrolidine-1-carboxylate (265)



A mixture of *tert*-butyl 2-(2-((2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]-octane-2-carbonyl)hydrazinecarbonyl)pyrrolidine-1-carboxylate **264** (0.34 g, 0.70 mmol) and Pd/C (0.30 g) in methanol (80 mL) was hydrogenated at 1 atm at room temperature for 3 h. The mixture was filtered through Celite pad and concentrated to give **265** (0.28 g, quant.) as an off-white solid.


Step 3. *tert*-butyl 2-(2-((2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]-octane-2-carbonyl)hydrazinecarbonyl)pyrrolidine-1-carboxylate (266).



To a mixture of *tert*-butyl 2-(2-((2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]-octane-2-carbonyl)hydrazinecarbonyl)pyrrolidine-1-carboxylate **265** (0.28 g, 0.70 mmol) in pyridine (6 mL) was added sulfur trioxide pyridine complex (0.33 g, 2.10 mmol). The mixture was stirred at room temperature for 24 h and concentrated to provide a residue, which was subjected to chromatography to give **266** (0.290 g, 87 %) as an off-white solid.

¹H NMR (400 MHz, D₂O): δ 1.24 and 1.27 (9H, 2s), 1.60 – 2.20 (8H, m), 3.02 (1H, m), 3.16 (1H, m), 3.28 (2H, m), 4.01 (2H, m), 4.18 (1H, m). Three protons were not observed in CD₃OD.


Step 4. (2S,5R)-7-oxo-*N'*-(pyrrolidin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide trifluoroacetate (Compound 41, Table 2)




- 5 To a mixture of *tert*-butyl 2-(2-((2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbonyl)hydrazinecarbonyl)pyrrolidine-1-carboxylate **266** (0.29 g, 0.61 mmol) in DCM (12 mL) was added trifluoroacetic acid (0.60 mL) at 0°C. The mixture was stirred at 0°C for 2 h, concentrated and washed with ether and MeOH to give **Compound 41 (Table 2)** (69.8 mg) as a white solid as a pair of diastereomers.
- 10 ¹H NMR (400 MHz, D₂O): δ 1.65 (1H, m), 1.81 (1H, m), 1.90-2.10 (5H, m), 2.34 (1H, m), 3.03 (1H, m), 3.16-3.31 (3H, m), 4.03 (2H, m), 4.33 (1H, m). Four protons were not observed in D₂O.
- ¹⁹F NMR (376.5 MHz, D₂O): δ - 75.75.
- HPLC: 94.84 %, 15 MS (ES⁻) *m/z*: [M+H]⁺ calcd for C₁₂H₂₀N₅O₇S: 378.4. Found: 378.0.

Example 69

(2S,5R)-*N'*-[(2,2-difluorocyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 36, Table 2)



Step 1. (2*S*,5*R*)-6-(benzyloxy)-*N'*-[(2,2-difluorocyclopropyl)carbonyl]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (268)




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid
 5 **1** (0.250 g, 0.905 mmol) in DCM (15.0 mL) were added 2,2-difluorocyclopropanecarbohydrazide **267** (0.184 g, 1.358 mmol), 1-hydroxybenzotriazole (0.186 g, 1.358 mmol) and 1-ethyl-(3-dimethylamino propyl) carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was
 10 subjected to chromatography to give **268** (0.36 g, quant. yield) as a white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.62 (1H, m), 1.80 (1H, m), 2.00 (2H, m), 2.18 (1H, m), 2.36 (1H, m), 2.44 (1H, m), 3.10 (1H, m), 3.30 (1H, m), 4.00 (2H, m), 4.91 (1H, d, *J* = 11.2 Hz), 5.05 (1H, d, *J* = 11.2 Hz), 7.42 (5H, m), 8.40 (1H, br s), 8.60 (1H, br s).

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₁₈H₂₁F₂N₄O₄: 395.1. Found: 395.1.

Step 2. (2*S*,5*R*)-*N'*-[(2,2-difluorocyclopropyl)carbonyl]-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (269)




A mixture of (2*S*,5*R*)-6-(benzyloxy)-*N'*-[(2,2-difluorocyclopropyl)carbonyl]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **268** (0.36 g, 0.90 mmol) and Pd/C (0.15 g) in
 20 methanol (20 mL) was hydrogenated at 1 atm at room temperature overnight. The mixture was filtered through Celite pad and concentrated to provide **269** (0.37 g, quant. yield) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.75-2.10 (4H, m), 2.25 (1H, m), 2.60 (1H, m), 2.70 (1H, m),
 3.20 (2H, m), 3.70 (1H, br s), 3.95 (1H, d, *J* = 7.6 Hz). 3 protons were not observed in
 25 CD₃OD.

MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₁H₁₃F₂N₄O₄: 303.1. Found: 303.0.

Step 3. (2*S*,5*R*)-*N'*-(2,2-dimethylpropanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 36, Table 2)



- 5 To a mixture of (2*S*,5*R*)-*N'*-[(2,2-difluorocyclopropyl)carbonyl]-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **269** (0.37 g, 1.21 mmol) in pyridine (10.0 mL) was added sulfur trioxide pyridine complex (0.57 g, 3.65 mmol). The mixture was stirred at room temperature overnight and concentrated to provide a residue, which was subjected to chromatography and followed by HPLC separation to give **Compound 36, (Table 2)** (60 mg)
- 10 as a white solid as a pair of diastereoisomers.


¹H NMR (400 MHz, D₂O): δ 1.65 (1H, m), 1.72-2.00 (4H, m), 2.05 (1H, m), 2.52 (1H, m), 3.05 (1H, d, *J* = 12.0 Hz), 3.18 (1H, d, *J* = 12.0 Hz), 4.01-4.05 (2H, m). Three protons were not observed in D₂O.

HPLC: 92.75 %.


- 15 MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₁H₁₃F₂N₄O₇S: 383.1. Found: 382.9.

Example 70

(2*S*,5*R*)-7-oxo-*N'*-[(2*S*)-piperidin-2-ylcarbonyl]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 43, Table 2)




Step 1. *tert*-butyl (2*S*)-2-[(2-[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinyl)carbonyl]piperidine-1-carboxylate (271)



- 5 To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.25 g, 0.90 mmol) in dry DCM (30 mL) were added *tert*-butyl (2*S*)-2-[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinyl)carbonyl]piperidine-1-carboxylate **270** (0.33 g, 1.35 mmol), 1-hydroxybenzotriazole (0.19 g, 1.35 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.26 g, 1.35 mmol) and 4-(dimethylamino)pyridine (0.16 g, 1.35 mmol) at
10 room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give *tert*-butyl (2*S*)-2-[(2-[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinyl)carbonyl]piperidine-1-carboxylate **271** (0.37 g, 82%) as a white solid.
- ¹H NMR (400 MHz, CDCl₃): δ 1.37-1.72 (15H, m), 1.95 (2H, m), 2.31 (2H, m), 3.05 (2H, m),
15 3.22 (2H, m), 4.06 (2H, m), 4.86 (1H, m), 4.90 (1H, d, *J* = 11.2 Hz), 5.05 (1H, d, *J* = 11.6 Hz), 7.38 (5H, m), 8.11 (1H, br s), 8.34 (1H, br s).

Step 2. *tert*-butyl (2*S*)-2-[(2-[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinyl)carbonyl]piperidine-1-carboxylate (272)




- 20 To a solution of *tert*-butyl (2*S*)-2-[(2-[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinyl)carbonyl]piperidine-1-carboxylate **271** (0.37 g, 0.74 mmol) in methanol (25 mL) was added 5% Pd/C (0.40 g). The mixture was hydrogenated under 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give *tert*-butyl (2*S*)-2-[(2-[(2*S*,5*R*)-6-hydroxy-7-oxo-

1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}hydrazinyl)carbonyl]piperidine-1-carboxylate **272** (0.29 g, 96%) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.47 (12H, m), 1.65 (2H, m), 1.76 (1H, m), 1.94 (1H, m), 2.04 (1H, m), 2.26 (2H, m), 3.15 (2H, m), 3.26 (1H, m), 3.70 (1H, s), 3.94 (2H, m), 4.79 (1H, m), 3 protons were not observed in CD₃OD.


Step 3. *tert*-butyl (2*S*)-2-[(2-{[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}hydrazinyl)carbonyl]piperidine-1-carboxylate (**273**)



To a solution of *tert*-butyl (2*S*)-2-[(2-{[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}hydrazinyl)carbonyl]piperidine-1-carboxylate **272** (0.29 g, 0.70 mmol) in dry pyridine (10 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.65 g, 4.12 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated. The residue was purified first by column chromatography using DCM: EtAcO: MeOH (20:30:50) as eluent to give *tert*-butyl (2*S*)-2-[(2-{[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}hydrazinyl)carbonyl]piperidine-1-carboxylate **273** (0.30 g, 87%) as a white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.47 (12H, m), 1.64 (2H, m), 1.80 (1H, m), 1.93 (1H, m), 2.01 (1H, m), 2.25 (2H, m), 3.17 (3H, m), 3.99 (2H, m), 4.15 (1H, s), 4.79 (1H, m), 3 protons were not observed in CD₃OD.

Step 4. (2*S*,5*R*)-7-oxo-*N'*-[(2*S*)-piperidin-2-ylcarbonyl]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 43, Table 2)



To a solution *tert*-butyl (2*S*)-2-[(2-[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinyl)carbonyl]piperidine-1-carboxylate **273** (0.30 g, 0.61 mmol) in DCM (30 mL) was added trifluoroacetic acid (2.42 mL, 31.38 mmol) dropwise at 0 °C. The reaction mixture was stirred for 1 h then evaporated. Ether was added to the residue and the resulting white precipitate was collected by centrifugation. The solid was triturated with a mixture of MeOH:ether (1:5, 6X) and the white solid was collected by centrifugation to give (2*S*,5*R*)-7-oxo-*N*-[(2*S*)-piperidin-2-ylcarbonyl]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **Compound 43** (Table 2) (0.09 g, 38%) as a white solid.


¹H NMR (400 MHz, D₂O): δ 1.51 (2H, m), 1.63 (1H, m), 1.75 (2H, m), 1.93 (1H, m), 2.05 (2H, m), 2.91 (1H, m), 3.03 (1H, d, J = 12.4 Hz), 3.18 (2H, m), 3.33 (1H, m), 3.89 (1H, d, J = 11.6 Hz), 4.03 (2H, m), 4.54 (1H, m), 4 protons were not observed in D₂O.

HPLC: 93.40%


MS (ES⁻) m/z: [M-H]⁻ = 390

Example 71

(Compound 30, Table 2)



Step 1. *tert*-butyl [(2*R*)-1-(2-[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinyl)-1-oxopropan-2-yl]carbamate (**275**)




To a solution of **1** (250 mg, 0.9 mmol) in 20 mL of DCM were added *tert*-butyl [(2*R*)-1-(2-[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinyl)-1-oxopropan-2-yl]carbamate **274** (275 mg, 1.35 mmol), HOBT (183 mg, 1.35 mmol), DMAP (162 mg, 1.35 mmol) and EDCI (260 mg, 1.35 mmol). The mixture was stirred at room temperature for 48 h and purified by column to afford compound **275** as foam (400 mg, 95%).

Step 2. *tert*-butyl [(2*R*)-1-(2-[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}hydrazinyl)-1-oxopropan-2-yl]carbamate (276)




10 ¹HNMR (CD₃OD): 4.15 (1H, m); 3.98 (1H, d); 3.70 (1H, m); 3.20 (2H, m); 2.30 (1H, m); 2.10 (1H, m); 1.90 (1H, m); 1.75 (1H, m); 1.45 (9H, s); 1.35 (3H, d).

Step 3. *tert*-butyl [(2*R*)-1-oxo-1-(2-[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)hydrazinyl]propan-2-yl]carbamate (277)



20

Step 4. (2*S*,5*R*)-*N'*-[(2*R*)-2-aminopropanoyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide trifluoroacetate (Compound 30, Table 2)



- 5 To a solution of compound **277** (150 mg, 0.33 mmol) in DCM at 0 °C was added TFA (0.5 mL) slowly. After addition, the mixture was stirred at 0 °C for 2 h then diluted with 50 mL of Et₂O. The solid was collected by filtration and washed with additional amount of Et₂O and dried to afford the crude product **Compound 30** (Table 2) as a white solid (100 mg, HPLC 76%). Re-precipitation of 50 mg of this crude product with MeOH/DCM afforded 20 mg of
- 10 **Compound 30** (Table 2) as a white solid.

¹HNMR (D₂O): 4.00 (3H, m); 3.20 (1H, m); 3.10 (1H, m); 2.10 (1H, m); 1.90 (1H, m); 1.80 (1H, m); 1.65 (1H, m).


HPLC: 84%.

MS (ES⁻) *m/z*: [M-1]⁻ = 350

15


Example 72

(2*S*,5*R*)-*N*-{[(3*S*)-1-carbamimidoylpyrrolidin-3-yl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 92, Table 1)



- Using the similar procedure as described in Example 14, the intermediate **278** was prepared and used for making **compound 92** (Table 1).
- 20

Step 1. di-*tert*-butyl {(3*S*)-3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]pyrrolidin-1-yl)methylidene]biscarbamate (279)




To a mixture of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.250 g, 0.905 mmol) in DCM (20.0 mL) were added di-*tert*-butyl {(*E*)-[[(3*S*)-3-(aminooxy)pyrrolidin-1-yl]methylidene]biscarbamate **278** (0.478 g, 1.358 mmol), 1-hydroxybenzotriazole (0.186 g, 1.358 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.260 g, 1.358 mmol) sequentially at room temperature. The mixture was stirred at room temperature overnight, diluted with DCM and concentrated to provide a residue which was subjected to chromatography to give **279** (0.34 g, 62 %) as white foam.

¹H NMR (400 MHz, CDCl₃): δ 1.45 (18H, s), 1.62 (1H, m), 2.00 (4H, m), 2.30 (2H, m), 2.77 (1H, d, *J* = 12.0 Hz), 2.95 (1H, d, *J* = 10.8 Hz), 3.29 (1H, s), 3.80 (2H, m), 3.92 (2H, m), 4.72 (1H, m), 4.90 (2H, ABq), 7.41 (5H, m). Two protons were not observed in moisture-containing CDCl₃.

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₂₉H₄₃N₆O₈: 603.3. Found: 603.2.

Step 2. di-*tert*-butyl [(3*S*)-3-[[[[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]pyrrolidin-1-yl)methylidene]biscarbamate (280)




A mixture of di-*tert*-butyl [(3*S*)-3-[[[[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]pyrrolidin-1-yl)methylidene]biscarbamate **279** (0.34 g, 0.56 mmol) and Pd/C (0.15 g) in methanol (20 mL) was hydrogenated at 1 atm at room temperature for 3

h. The mixture was filtered through Celite pad and concentrated to provide **280** (0.28 g, 97 %) as white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.48 (19H, m), 1.92 (3H, m), 2.10 (2H, m), 2.25 (1H, m), 3.00 (1H, d, *J* = 11.6 Hz), 3.11 (1H, m), 3.64 (5H, m), 4.62 (1H, m). 3 protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₂₂H₃₇N₆O₆: 513.2. Found: 513.2.

Step 3. di-*tert*-butyl [((3*S*)-3-(((2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]pyrrolidin-1-yl)methylidene] biscarbamate (281**)**




To a mixture of di-*tert*-butyl [((3*S*)-3-(((2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]pyrrolidin-1-yl)methylidene] biscarbamate **280** (0.28 g, 0.54 mmol) in pyridine (6.0 mL) was added sulfur trioxide pyridine complex (0.26 g, 1.63 mmol). The mixture was stirred at room temperature overnight and concentrated to provide a residue which was subjected to chromatography to give **281** (0.30 g, 94 %) as white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.47 (18H, s), 1.80 (1H, m), 1.94 (1H, m), 2.10 (1H, m), 2.20 (3H, m), 2.40 (1H, m), 3.05 (1H, d, *J* = 11.6 Hz), 3.33 (1H, m), 3.90 (4H, m), 4.16 (1H, s), 4.70 (1H, s). 3 protons were not observed in CD₃OD.

MS (ES⁺) *m/z*: [M+H]⁺ calcd for C₂₂H₃₇N₆O₁₁S: 593.2. Found: 593.2.

Step 4. (2*S*,5*R*)-*N*-(((3*S*)-1-carbamimidoylpyrrolidin-3-yl)oxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (Compound 92, Table 1)



To a mixture of di-*tert*-butyl [((3*S*)-3-(((2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl)carbonyl)amino)oxy]pyrrolidin-1-yl)methylidene]biscarbamate **281** (0.30 g, 0.51 mmol) in DCM (6.0 mL) was added trifluoroacetic acid (0.3 mL) at 0°C. The mixture was

stirred at 0°C for 0.5 h followed by at room temperature for 2 h and concentrated to provide a residue which was purified by HPLC to give **Compound 92** (Table 1) (8.8 mg) as white solid.


¹H NMR (400 MHz, D₂O): δ 1.67-1.82 (2H, m), 1.90-2.11 (3H, m), 2.13-2.22 (1H, m), 2.99 (1H, d, *J* = 11.6 Hz), 3.15 (1H, d, *J* = 11.2 Hz), 3.42-3.58 (4H, m), 3.90 (1H, d, *J* = 6.0 Hz), 4.05 (1H, s), 4.60 (1H, m). 5 protons were not observed in D₂O.

HPLC: 96.6 %


MS (ES⁻) *m/z*: [M-H]⁻ calcd for C₁₂H₁₉N₆O₇S: 391.1. Found: 390.9.

Example 73

(2*S*,5*R*)-*N'*-[(3,3-difluorocyclobutyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 116, Table 2)




Step 1. (2*S*,5*R*)-6-(benzyloxy)-*N'*-[(3,3-difluorocyclobutyl)carbonyl]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (283)



To a solution of (2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **1** (0.25 g, 0.90 mmol) in dry dichloromethane (30 mL) were added 3,3-difluorocyclobutanecarbohydrazide **282** (0.20 g, 1.35 mmol), 1-hydroxybenzotriazole (0.19 g, 1.35 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.26 g, 1.35 mmol) and 4-(dimethylamino)pyridine (0.16 g, 1.35 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight and concentrated under vacuum. The residue was purified by column chromatography to give **283** (0.32 g, 87%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.61 (1H, m), 1.98 (2H, m), 2.28 (1H, m), 2.74 (2H, m), 2.88 (3H, m), 3.10 (2H, m), 3.33 (1H, s), 3.97 (1H, d, *J* = 7.2 Hz), 4.90 (1H, d, *J* = 11.2 Hz), 5.03 (1H, d, *J* = 11.6 Hz), 7.39 (5H, m), 8.31 (1H, br s), 8.66 (1H, br s).


Step 2. (2S,5R)-N'-[(3,3-difluorocyclobutyl)carbonyl]-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (284):



To a solution of (2S,5R)-6-(benzyloxy)-N'-[(3,3-difluorocyclobutyl)carbonyl]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **283** (0.32 g, 0.78 mmol) in methanol (25 mL) was added 10% Pd/C (0.40 g). The mixture was hydrogenated under 10 psi hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered out through Celite, and the filtrate was evaporated to give **284** (0.24 g, 96%) as a white foam.

¹H NMR (400 MHz, CD₃OD): δ 1.76 (1H, m), 1.94 (1H, m), 2.05 (1H, m), 2.26 (1H, m), 2.78 (4H, m), 2.98 (1H, m), 3.15 (1H, m), 3.24 (1H, d, J = 12.00 Hz), 3.71 (1H, s), 3.94 (1H, d, J = 8.0 Hz), 3 protons were not observed in CD₃OD.

Step 3. (2S,5R)-N'-[(3,3-difluorocyclobutyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (Compound 116, Table 2)



To a solution of (2S,5R)-N'-[(3,3-difluorocyclobutyl)carbonyl]-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **284** (0.24 g, 0.75 mmol) in dry pyridine (10 mL) under nitrogen atmosphere was added sulfur trioxide pyridine complex (0.60 g, 3.80 mmol). The mixture was stirred at room temperature for 20 h, filtered and evaporated. The residue was purified by column chromatography to give (2S,5R)-N'-[(3,3-difluorocyclobutyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide **Compound 116 (Table 2)** (0.12 g, 40%) as a white solid.


¹H NMR (400 MHz, CD₃OD): δ 1.80 (1H, m), 1.92 (1H, m), 2.06 (1H, m), 2.27 (1H, m), 2.67-2.93 (4H, m), 2.97 (1H, m), 3.30 (2H, m), 4.03 (1H, d, J = 7.2 Hz), 4.15 (1H, s), 3 protons were not observed in CD₃OD.

HPLC: 91.0%


MS (ES⁻) m/z: [M]⁻ = 397

Example 74

5 (2*S*,5*R*)-*N'*-{[(1*R*,2*R*)-2-aminocyclopentyl]carbonyl}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide trifluoroacetate (Compound 40, Table 2)



Step 1. *tert*-butyl {(1*R*,2*R*)-2-[(2-{[(2*S*,5*R*)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}hydrazinyl)carbonyl]cyclopentyl}carbamate (286)



10


15

To a solution of *tert*-butyl [(1*R*,2*R*)-2-(hydrazinylcarbonyl)cyclopentyl]carbamate **285** (0.15 g, 0.54 mmol) in 20 mL of DCM were added compound **1** (0.2 g, 0.82 mmol), HOBT (0.11 g, 0.82 mmol), DMAP (0.2 g, 1.64 mmol) and EDCI (0.16 g, 0.82 mmol). The mixture was stirred at room temperature for 18 h and purified by column chromatography to afford compound **286** as a solid (0.22 g, 82%).

¹HNMR (CDCl₃): 1.44 (9H, s), 1.70 (4H, m), 2.00 (4H, m), 2.20 (1H, m), 2.40 (1H, m), 2.80 (1H, s), 3.08 (1H, m), 3.30 (2H, m), 4.10 (2H, m), 4.90 (1H, s), 5.00 (2H, dd), 7.40 (5H, m), 8.33 (1H, s), 9.92 (1H, s).

MS (ES⁺): 502.

Step 2. *tert*-butyl {(1*R*,2*R*)-2-[(2-[(2*S*,5*R*)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)hydrazinyl]carbonyl]cyclopentyl}carbamate (287)




To a solution of compound 286 (0.22 g, 0.44 mmol) in 10 mL of CH₃OH was added 0.1 g of Pd-C (10%, wet). The mixture was hydrogenated at room temperature for 16 h. The catalyst was removed by filtration through a pad of celite. The filtrate was concentrated to afford compound 287 as a solid (0.15 g, 83%).

¹HNMR (CD₃OD): 1.44 (9H, s), 1.80 (3H, m), 2.10 (6H, m), 2.30 (1H, m), 2.60 (1H, m), 3.20 (2H, m), 3.70 (1H, m), 3.98 (1H, d), 4.10 (1H, m).

MS (ES⁺): 412.

Step 3. *tert*-butyl {(1*R*,2*R*)-2-[(2-[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)hydrazinyl]carbonyl]cyclopentyl}carbamate (288)




To a solution of compound 287 (15 g, 0.36 mmol) in 5 mL of pyridine was added sulphur trioxide pyridine complex (0.58 g, 3.6 mmol). The mixture was stirred at room temperature under nitrogen atmosphere for 16 h. After silica gel column purification, compound 288 was obtained as a solid (0.14 g, 78%).

¹HNMR (CD₃OD): 1.44 (9H, s), 1.70 (4H, m), 2.10 (6H, m), 2.30 (1H, m), 2.60 (1H, m), 4.20 (4H, m).

MS (ES⁻): 490

Step 4. (2S,5R)-N'--{[(1R,2R)-2-aminocyclopentyl]carbonyl}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide trifluoroacetate (Compound 40, Table 2)



5 To a solution of compound **288** (0.1 g, 0.2 mmol) in DCM (10 mL) at 0 °C was added TFA (0.5 mL) dropwise. After addition, the mixture was stirred at 0 °C for 3 h then diluted with 50 mL of ether. The solid was collected by filtration and washed with additional ether and dried to afford the title compound **Compound 40 (Table 2)** as a white solid (0.07 g, 72%)


10 ¹HNMR (CD₃OD): 1.82 (6H, m), 2.23 (4H, m), 2.83 (2H, m), 3.87 (2H, m), 4.04 (1H, d), 4.15 (1H, s).

MS (ES⁻): 390

Antibacterial activity and synergistic activity:


Compounds of the present invention alone, ceftazidime alone, meropenem alone, aztreonam alone and as a combination with these antibiotics were tested for minimum inhibitory concentration (MIC, $\mu\text{g/mL}$) against bacteria listed in Tables 3 - 9. In the Tables 10 - 12, 5 compounds of the present invention were tested in combination with various antibiotics against metallo β -lactamase producing bacteria.

Table 3: Synergy of the inhibitor Ex. 2 (4 µg/mL) in combination with antibiotics




Organism	Enzyme	Ex. 2 Alone	Meropenem	Meropenem + Ex. 2 (4 µg/mL)	Ceftazidime	Ceftazidime + Ex. 2 (4 µg/mL)	Aztreonam	Aztreonam + Ex. 2 (4 mg/mL)
E. coli ATCC 25922	Wt	8	0.06	≤0.031	0.25	≤0.25	0.25	≤0.062
A. baumannii JMI 2659	Ges-14 (Cpase)	>16	64	2	512	>16	512	>4
E. coli JMI 4103	KPC-2, Tem-1, CMY-Type	16	64	≤0.031	>512	8	>512	>4
E. coli JMI 4080	Tem-10	8	≤1	≤0.031	64	1	64	1
E. coli JMI 2692	NDM-1, TEM-1, CTX-M-15	4	256	≤0.031	>512	≤0.25	>512	0.25
E. coli JMI 2671	VIM-19 (Cpase)	4	64	2	64	2	64	≤0.062
E. coli JMI 2665	CMY-2 (Plasmid Cpase)	4	≤1	≤0.031	8	≤0.25	8	≤0.062
K. pneumo JMI 4109	SHV-1, SHV-12	4	≤1	≤0.031	8	≤0.25	8	≤0.062
K. pneumo JMI 2673	CTX-M14 (ESBL)	>16	≤1	≤0.031	32	≤0.25	32	≤0.062
K. pneumo JMI 2674	CTX-M15 (ESBL)	>16	≤1	0.062	512	≤0.25	512	≤0.062
K. pneumo JMI 4088	KPC-3 (Cpase)	4	512	0.062	>512	≤0.25	>512	≤0.062
K. pneumo JMI 4106	KPC-3, TEM-1, SHV-12, SHV-141	16	128	≤0.031	>512	≤0.25	>512	0.25
K. pneumo JMI 2693	NDM-1 (Cpase)	>16	8	0.062	>512	≤0.25	>512	0.125
K. pneumo JMI 2697	IMP-4 (Cpase)	16	64	>2	>512	16	>512	0.25
K. pneumo JMI 2681	Oxa-48 (Cpase)	>16	64	>2	512	4	512	4
K. pneumo JMI 2699	VIM-1, CTX-M3	8	32	2	>512	16	>512	0.5
P. aerug JMI 2686	KPC-2 (Cpase)	>16	512	>2	512	16	512	>4
P. aerug JMI 149	Bla+++D+	>16	4	0.5	256	4	256	>4
E. cloacae JMI 36	P99	>16	≤1	0.062	128	1	128	0.25
E. coli JMI 10767	Wt	8	≤1	≤0.031	≤1	≤0.25	≤1	≤0.062
E. coli JMI 10768	CTX-M15 (Weak ESBL)	8	≤1	≤0.031	8	≤0.25	8	≤0.062
E. coli JMI 10770	CTX-M15 (Hyper ESBL)	8	≤1	≤0.031	64	≤0.25	64	≤0.062
E. coli JMI 11103	CTX-M15 (Intermediate ESBL)	8	≤1	≤0.031	32	≤0.25	32	≤0.062

Table 4: Synergy of the inhibitor Ex. 4 (4 µg/mL) in combination with antibiotics




Organism	Enzyme	Ex. 4 Alone	Meropenem	Meropenem + Ex. 4 (4 µg/mL)	Ceftazidime	Ceftazidime + Ex. 4 (4 µg/mL)	Aztreonam	Aztreonam + Ex. 4 (4 mg/mL)
<i>E. coli</i> ATCC 25922	Wt	1	0.06	≤0.031	0.25	≤0.25	0.25	≤0.062
<i>A. baumannii</i> JMI 2659	Ges-14 (Cpase)	>16	64	>2	512	>16	512	>4
<i>E. coli</i> JMI 4103	KPC-2, Tem-1, CMY-Type	8	64	≤0.031	>512	8	>512	>4
<i>E. coli</i> JMI 4080	Tem-10	4	≤1	≤0.031	64	≤0.25	64	≤0.062
<i>E. coli</i> JMI 2692	NDM-1, TEM-1, CTX-M-15	≤0.5	256	≤0.031	>512	≤0.25	>512	≤0.062
<i>E. coli</i> JMI 2671	VIM-19 (Cpase)	>16	64	0.125	64	0.5	64	≤0.062
<i>E. coli</i> JMI 2665	CMY-2 (Plasmid Cpase)	≤0.5	≤1	≤0.031	8	≤0.25	8	≤0.062
<i>K. pneumo</i> JMI 4109	SHV-1, SHV-12	16	≤1	≤0.031	8	≤0.25	8	≤0.062
<i>K. pneumo</i> JMI 2673	CTX-M14 (ESBL)	>16	≤1	≤0.031	32	≤0.25	32	≤0.062
<i>K. pneumo</i> JMI 2674	CTX-M15 (ESBL)	>16	≤1	0.125	512	≤0.25	512	0.125
<i>K. pneumo</i> JMI 4088	KPC-3 (Cpase)	1	512	0.062	>512	≤0.25	>512	0.5
<i>K. pneumo</i> JMI 4106	KPC-3, TEM-1, SHV-12, SHV-141	>16	128	≤0.031	>512	≤0.25	>512	≤0.062
<i>K. pneumo</i> JMI 2693	NDM-1 (Cpase)	4	8	≤0.031	>512	≤0.25	>512	≤0.062
<i>K. pneumo</i> JMI 2697	IMP-4 (Cpase)	4	64	≤0.031	>512	0.5	>512	≤0.062
<i>K. pneumo</i> JMI 2681	Oxa-48 (Cpase)	>16	64	>2	512	1	512	2
<i>K. pneumo</i> JMI 2699	VIM-1, CTX-M3	4	32	0.062	>512	≤0.25	>512	≤0.062
<i>P. aerug</i> JMI 2686	KPC-2 (Cpase)	>16	512	>2	512	16	512	>4
<i>P. aerug</i> JMI 149	Bla+++D+	>16	4	0.5	256	4	256	>4
<i>E. cloacae</i> JMI 36	P99	>16	≤1	0.125	128	≤0.25	128	0.125
<i>E. coli</i> JMI 10767	Wt	4	≤1	≤0.031	≤1	≤0.25	≤1	≤0.062
<i>E. coli</i> JMI 10768	CTX-M15 (Weak ESBL)	4	≤1	≤0.031	8	≤0.25	8	≤0.062
<i>E. coli</i> JMI 10770	CTX-M15 (Hyper ESBL)	4	≤1	≤0.031	64	≤0.25	64	≤0.062
<i>E. coli</i> JMI 11103	CTX-M15 (Intermediate ESBL)	4	≤1	≤0.031	32	≤0.25	32	≤0.062

Table 5: Synergy of the inhibitor Ex. 9 (4 µg/mL) in combination with antibiotics




Organism	Enzyme	Ex. 9 Alone	Meropenem	Meropenem + Ex. 9 (4 µg/mL)	Ceftazidime	Ceftazidime + Ex. 9 (4 µg/mL)	Aztreonam	Aztreonam + Ex. 9 (4 mg/mL)
E. coli ATCC 25922	Wt	2	0.06	≤0.0312	0.25	≤0.25	0.25	≤0.062
A. baumannii JMI 2659	Ges-14 (Cpase)	>16	64	2	512	>16	512	>4
E. coli JMI 4103	KPC-2, Tem-1, CMY-Type	4	64	≤0.0312	>512	≤0.25	>512	≤0.062
E. coli JMI 4080	Tem-10	2	≤1	≤0.0312	64	≤0.25	64	≤0.062
E. coli JMI 2692	NDM-1, TEM-1, CTX-M-15	2	256	≤0.0312	>512	≤0.25	>512	≤0.062
E. coli JMI 2671	VIM-19 (Cpase)	2	64	≤0.0312	64	≤0.25	64	≤0.062
E. coli JMI 2665	CMY-2 (Plasmid Cpase)	2	≤1	≤0.0312	8	≤0.25	8	≤0.062
K. pneumo JMI 4109	SHV-1, SHV-12	2	≤1	≤0.0312	8	≤0.25	8	≤0.062
K. pneumo JMI 2673	CTX-M14 (ESBL)	>16	≤1	≤0.0312	32	≤0.25	32	0.125
K. pneumo JMI 2674	CTX-M15 (ESBL)	>16	≤1	0.125	512	≤0.25	512	0.5
K. pneumo JMI 4088	KPC-3 (Cpase)	2	512	0.25	>512	≤0.25	>512	1
K. pneumo JMI 4106	KPC-3, TEM-1, SHV-12, SHV-141	2	128	≤0.0312	>512	≤0.25	>512	≤0.062
K. pneumo JMI 2693	NDM-1 (Cpase)	8	8	≤0.0312	>512	≤0.25	>512	0.25
K. pneumo JMI 2697	IMP-4 (Cpase)	8	64	0.25	>512	0.5	>512	0.25
K. pneumo JMI 2681	Oxa-48 (Cpase)	>16	64	0.5	512	≤0.25	512	1
K. pneumo JMI 2699	VIM-1, CTX-M3	4	32	≤0.0312	>512	≤0.25	>512	≤0.062
P. aerug JMI 2686	KPC-2 (Cpase)	>16	512	>2	512	16	512	>4
P. aerug JMI 149	Bla+++D+	>16	4	0.25	256	4	256	>4
E. cloacae JMI 36	P99	>16	≤1	0.062	128	0.5	128	>4
E. coli JMI 10767	Wt	2	≤1	≤0.0312	≤1	≤0.25	≤1	≤0.062
E. coli JMI 10768	CTX-M15 (Weak ESBL)	4	≤1	0.062	8	≤0.25	8	≤0.062
E. coli JMI 10770	CTX-M15 (Hyper ESBL)	>16	≤1	0.062	64	2	64	8
E. coli JMI 11103	CTX-M15 (Intermediate ESBL)	4	≤1	0.062	32	0.5	32	0.5

Table 6: Synergy of the inhibitor Ex. 40 (4 µg/mL) in combination with antibiotics




Organism	Enzyme	Ex. 40 Alone	Meropenem	Meropenem + Ex. 40 (4 µg/mL)	Ceftazidime	Ceftazidime + Ex. 40 (4 µg/mL)	Aztreonam	Aztreonam + Ex. 40 (4 µg/mL)
E. coli ATCC 25922	Wt	2	0.06	≤0.031	0.25	≤0.25	0.125	≤0.062
A. baumannii JMI 2659	Ges-14 (Cpase)	>16	64	>2	512	>16	256	>4
E. coli JMI 4103	KPC-2, Tem-1, CMY-Type	8	64	≤0.031	>512	≤0.25	256	≤0.062
E. coli JMI 4080	Tem-10	2	≤1	≤0.031	64	≤0.25	125	≤0.062
E. coli JMI 2692	NDM-1, TEM-1, CTX-M-15	2	256	≤0.031	>512	≤0.25	256	≤0.062
E. coli JMI 2671	VIM-19 (Cpase)	16	64	0.25	64	2	16	≤0.062
E. coli JMI 2665	CMY-2 (Plasmid Cpase)	2	≤1	≤0.031	8	≤0.25	64	≤0.062
K. pneumo JMI 4109	SHV-1, SHV-12	>16	≤1	≤0.031	8	≤0.25	≤1	≤0.062
K. pneumo JMI 2673	CTX-M14 (ESBL)	>16	≤1	≤0.031	32	≤0.25	8	≤0.062
K. pneumo JMI 2674	CTX-M15 (ESBL)	>16	≤1	0.062	512	≤0.25	32	0.125
K. pneumo JMI 4088	KPC-3 (Cpase)	>16	512	0.125	>512	≤0.25	512	0.25
K. pneumo JMI 4106	KPC-3, TEM-1, SHV-12, SHV-141	>16	128	2	>512	0.5	512	1
K. pneumo JMI 2693	NDM-1 (Cpase)	>16	8	0.125	>512	0.5	256	0.5
K. pneumo JMI 2697	IMP-4 (Cpase)	16	64	0.125	>512	>2	256	≤0.062
K. pneumo JMI 2681	Oxa-48 (Cpase)	16	64	2	512	≤0.25	256	0.5
K. pneumo JMI 2699	VIM-1, CTX-M3	>16	32	≤0.031	>512	2	128	≤0.062
P. aerug JMI 2686	KPC-2 (Cpase)	16	512	>2	512	>16	>512	>4
P. aerug JMI 149	Bla+++D+	>16	4	0.5	256	>16	512	>4
E. cloacae JMI 36	P99	>16	≤1	0.125	128	16	256	>4
E. coli JMI 10767	Wt	8	≤1	≤0.031	≤1	≤0.25	≤1	≤0.062
E. coli JMI 10768	CTX-M15 (Weak ESBL)	8	≤1	≤0.031	8	≤0.25	8	≤0.062
E. coli JMI 10770	CTX-M15 (Hyper ESBL)	8	≤1	≤0.031	64	≤0.25	64	≤0.062
E. coli JMI 11103	CTX-M15 (Intermediate ESBL)	8	≤1	≤0.031	32	≤0.25	16	≤0.062

Table 7: Synergy of the inhibitor Ex. 47 (4 µg/mL) in combination with antibiotics




Organism	Enzyme	Ex. 47 Alone	Meropenem	Meropenem + Ex. 47 (4 µg/mL)	Ceftazidime	Ceftazidime + Ex. 47 (4 µg/mL)	Aztreonam	Aztreonam + Ex. 47 (4 µg/mL)
<i>E. coli</i> ATCC 25922	Wt	>16	0.06	≤0.0312	0.25	≤0.25	0.25	≤0.0625
<i>A. baumannii</i> JMI 2659	Ges-14 (Cpase)	>16	64	>2	512	>16	512	>4
<i>E. coli</i> JMI 4103	KPC-2, Tem-1, CMY-Type	2	64	≤0.0312	>512	≤0.25	>512	≤0.062
<i>E. coli</i> JMI 4080	Tem-10	4	≤1	≤0.0312	64	≤0.25	64	≤0.062
<i>E. coli</i> JMI 2692	NDM-1, TEM-1, CTX-M-15	8	256	0.5	>512	≤0.25	>512	≤0.062
<i>E. coli</i> JMI 2671	VIM-19 (Cpase)	8	64	0.5	64	0.5	64	≤0.062
<i>E. coli</i> JMI 2665	CMY-2 (Plasmid Cpase)	2	≤1	≤0.0312	8	≤0.25	8	≤0.062
<i>K. pneumo</i> JMI 4109	SHV-1, SHV-12	2	≤1	≤0.0312	8	≤0.25	8	0.125
<i>K. pneumo</i> JMI 2673	CTX-M14 (ESBL)	>16	≤1	≤0.0312	32	≤0.25	32	≤0.062
<i>K. pneumo</i> JMI 2674	CTX-M15 (ESBL)	>16	≤1	0.125	512	≤0.25	512	≤0.062
<i>K. pneumo</i> JMI 4088	KPC-3 (Cpase)	>16	512	1	>512	1	>512	0.125
<i>K. pneumo</i> JMI 4106	KPC-3, TEM-1, SHV-12, SHV-141	16	128	≤0.0312	>512	≤0.25	>512	0.125
<i>K. pneumo</i> JMI 2693	NDM-1 (Cpase)	>16	8	0.25	>512	2	>512	1
<i>K. pneumo</i> JMI 2697	IMP-4 (Cpase)	>16	64	2	>512	16	>512	≤0.062
<i>K. pneumo</i> JMI 2681	Oxa-48 (Cpase)	>16	64	0.25	512	0.5	512	0.25
<i>K. pneumo</i> JMI 2699	VIM-1, CTX-M3	16	32	0.5	>512	0.5	>512	≤0.062
<i>P. aerug</i> JMI 2686	KPC-2 (Cpase)	>16	512	>2	512	>16	512	>4
<i>P. aerug</i> JMI 149	Bla+++D+	>16	4	>2	256	>16	256	>4
<i>E. cloacae</i> JMI 36	P99	>16	≤1	0.125	128	0.5	128	0.125
<i>E. coli</i> JMI 10767	Wt	8	≤1	≤0.0312	≤1	≤0.25	≤1	≤0.062
<i>E. coli</i> JMI 10768	CTX-M15 (Weak ESBL)	16	≤1	≤0.0312	8	2	8	≤0.062
<i>E. coli</i> JMI 10770	CTX-M15 (Hyper ESBL)	8	≤1	≤0.0312	64	≤0.25	64	≤0.062
<i>E. coli</i> JMI 11103	CTX-M15 (Intermediate ESBL)	16	≤1	≤0.0312	32	≤0.25	32	≤0.062

Table 8: Synergy of the inhibitor Ex. 49 (4 µg/mL) in combination with antibiotics




Organism	Enzyme	Ex. 49 Alone	Meropenem	Meropenem + Ex. 49 (4 µg/mL)	Ceftazidime	Ceftazidime + Ex. 49 (4 µg/mL)	Aztreonam	Aztreonam + Ex. 49 (4 mg/mL)
<i>E. coli</i> ATCC 25922	Wt	16	0.06	≤0.0312	0.25	≤0.25	0.125	≤0.0625
<i>A. baumannii</i> JMI 2659	Ges-14 (Cpase)	>16	64	>2	512	>16	256	>4
<i>E. coli</i> JMI 4103	KPC-2, Tem-1, CMY-Type	4	64	≤0.0312	>512	≤0.25	256	≤0.062
<i>E. coli</i> JMI 4080	Tem-10	4	≤1	≤0.0312	64	≤0.25	125	≤0.062
<i>E. coli</i> JMI 2692	NDM-1, TEM-1, CTX-M-15	4	256	2	>512	≤0.25	256	≤0.062
<i>E. coli</i> JMI 2671	VIM-19 (Cpase)	>16	64	1	64	0.5	16	≤0.062
<i>E. coli</i> JMI 2685	CMY-2 (Plasmid Cpase)	4	≤1	≤0.0312	8	≤0.25	64	≤0.062
<i>K. pneumo</i> JMI 4109	SHV-1, SHV-12	4	≤1	≤0.0312	8	≤0.25	≤1	≤0.062
<i>K. pneumo</i> JMI 2673	CTX-M14 (ESBL)	>16	≤1	≤0.0312	32	≤0.25	8	≤0.062
<i>K. pneumo</i> JMI 2674	CTX-M15 (ESBL)	>16	≤1	0.062	512	≤0.25	32	≤0.062
<i>K. pneumo</i> JMI 4088	KPC-3 (Cpase)	>16	512	0.5	>512	0.5	512	0.125
<i>K. pneumo</i> JMI 4106	KPC-3, TEM-1, SHV-12, SHV-141	>16	128	≤0.0312	>512	≤0.25	512	≤0.062
<i>K. pneumo</i> JMI 2693	NDM-1 (Cpase)	>16	8	0.125	>512	8	256	2
<i>K. pneumo</i> JMI 2697	IMP-4 (Cpase)	>16	64	2	>512	16	256	≤0.062
<i>K. pneumo</i> JMI 2681	Oxa-48 (Cpase)	>16	64	0.5	512	≤0.25	256	0.125
<i>K. pneumo</i> JMI 2699	VIM-1, CTX-M3	>16	32	0.125	>512	≤0.25	128	≤0.062
<i>P. aerug</i> JMI 2686	KPC-2 (Cpase)	>16	512	>2	512	>16	>512	>4
<i>P. aerug</i> JMI 149	Bla+++D+	>16	4	0.5	256	>16	512	>4
<i>E. cloacae</i> JMI 36	P99	>16	≤1	0.25	128	0.5	256	0.125
<i>E. coli</i> JMI 10767	Wt	>16	≤1	≤0.0312	≤1	≤0.25	≤1	≤0.062
<i>E. coli</i> JMI 10768	CTX-M15 (Weak ESBL)	>16	≤1	≤0.0312	8	≤0.25	8	≤0.062
<i>E. coli</i> JMI 10770	CTX-M15 (Hyper ESBL)	>16	≤1	≤0.0312	64	≤0.25	64	≤0.062
<i>E. coli</i> JMI 11103	CTX-M15 (Intermediate ESBL)	>16	≤1	≤0.0312	32	≤0.25	16	≤0.062

Table 9: Synergy of the inhibitor Ex. 67 (4 µg/mL) in combination with antibiotics




Organism	Enzyme	Ex. 67 Alone	Meropenem	Meropenem + Ex. 67 (4 µg/mL)	Ceftazidime	Ceftazidime + Ex. 67 (4 µg/mL)	Aztreonam	Aztreonam + Ex. 67 (4 mg/mL)
<i>E. coli</i> ATCC 25922	Wt	>16	0.06	≤0.03	0.25	≤0.25	0.25	≤0.06
<i>A. baumannii</i> JMI 2659	Ges-14 (Cpase)	>16	64	2	512	16	512	>4
<i>E. coli</i> JMI 4103	KPC-2, Tem-1, CMY-Type	16	64	0.06	>512	0.5	>512	≤0.06
<i>E. coli</i> JMI 4080	Tem-10	16	≤1	≤0.03	64	0.25	64	≤0.06
<i>E. coli</i> JMI 2692	NDM-1, TEM-1, CTX-M-15	8	256	0.125	>512	>16	>512	1
<i>E. coli</i> JMI 2671	VIM-19 (Cpase)	>16	64	0.125	64	1	64	≤0.06
<i>E. coli</i> JMI 2665	CMY-2 (Plasmid Cpase)	8	≤1	≤0.03	8	≤0.25	8	≤0.06
<i>K. pneumo</i> JMI 4109	SHV-1, SHV-12	4	≤1	≤0.03	8	≤0.25	8	≤0.06
<i>K. pneumo</i> JMI 2673	CTX-M14 (ESBL)	>16	≤1	≤0.03	32	≤0.25	32	≤0.06
<i>K. pneumo</i> JMI 2674	CTX-M15 (ESBL)	>16	≤1	0.06	512	≤0.25	512	0.125
<i>K. pneumo</i> JMI 4088	KPC-3 (Cpase)	16	512	0.06	>512	≤0.25	>512	0.5
<i>K. pneumo</i> JMI 4106	KPC-3, TEM-1, SHV-12, SHV-141	8	128	0.125	>512	≤0.25	>512	0.5
<i>K. pneumo</i> JMI 2693	NDM-1 (Cpase)	>16	8	0.125	>512	≤0.25	>512	0.25
<i>K. pneumo</i> JMI 2697	IMP-4 (Cpase)	16	64	2	>512	8	>512	≤0.06
<i>K. pneumo</i> JMI 2681	Oxa-48 (Cpase)	>16	64	>2	512	≤0.25	512	0.25
<i>K. pneumo</i> JMI 2699	VIM-1, CTX-M3	>16	32	0.5	>512	≤0.25	>512	0.06
<i>P. aerug</i> JMI 2686	KPC-2 (Cpase)	16	512	>2	512	>16	512	>4
<i>P. aerug</i> JMI 149	Bla+++D+	16	4	0.5	256	16	256	>4
<i>E. cloacae</i> JMI 36	P99	>16	≤1	0.06	128	≤0.25	128	0.25
<i>E. coli</i> JMI 10767	Wt	>16	≤1	≤0.03	≤1	≤0.25	≤1	≤0.06
<i>E. coli</i> JMI 10768	CTX-M15 (Weak ESBL)	>16	≤1	≤0.03	8	≤0.25	8	≤0.06
<i>E. coli</i> JMI 10770	CTX-M15 (Hyper ESBL)	>16	≤1	≤0.03	64	≤0.25	64	≤0.06
<i>E. coli</i> JMI 11103	CTX-M15 (Intermediate ESBL)	>16	≤1	≤0.03	32	≤0.25	32	≤0.06

Table 10: Synergy of inhibitor Ex. 2 (4 µg/mL) in combination with antibiotics against metallo-β-lactamase producing bacteria




Organism	Isolate No	Enzyme	Ex. 2 alone	AZT	AZT + Ex. 2	CAZ	CAZ + Ex. 2	MER	MER + Ex. 2
<i>Citrobacter freundii</i>	49469	NDM-1	>64	256	0.5	>256	>64	16	8
<i>Enterobacter aerogenes</i>	47683	VIM-12	>64	4	≤0.03	256	>64	8	2
<i>Enterobacter aerogenes</i>	8397	VIM-1	>64	>256	0.5	>256	>64	64	64
<i>Enterobacter cloacae</i>	1874	IMP-21	4	≤0.12	≤0.03	32	≤0.03	4	≤0.03
<i>Enterobacter cloacae</i>	1280	VIM-5	4	8	≤0.03	64	≤0.03	4	≤0.03
<i>Enterobacter cloacae</i>	3686	IMP-1	4	32	≤0.03	>256	≤0.03	8	0.25
<i>Enterobacter cloacae</i>	25	IMP-4	8	64	0.25	>256	64	16	2
<i>Enterobacter cloacae</i>	1471	VIM-1	4	64	≤0.03	>256	≤0.03	2	≤0.03
<i>Enterobacter cloacae</i>	10	IMP-26	64	128	0.12	>256	≤0.03	16	≤0.03
<i>Enterobacter cloacae</i>	53477	NDM-1	4	128	≤0.03	>256	≤0.03	32	≤0.03
<i>Enterobacter cloacae</i>	1068	VIM-2	8	128	0.06	128	8	2	≤0.03
<i>Enterobacter cloacae</i>	4	VIM-6	64	128	0.12	256	32	2	0.25
<i>Escherichia coli</i>	13	IMP-1	16	16	≤0.03	256	≤0.03	4	≤0.03
<i>Escherichia coli</i>	49	NDM-1	4	128	≤0.03	>256	≤0.03	8	≤0.03
<i>Escherichia coli</i>	17	NDM-1	4	>256	≤0.03	>256	≤0.03	32	≤0.03
<i>Escherichia coli</i>	53749	NDM-1	4	>256	≤0.03	>256	0.06	64	≤0.03
<i>Klebsiella oxytoca</i>	31141	VIM-23	>64	8	≤0.03	128	2	2	0.5
<i>Klebsiella oxytoca</i>	24825	IMP-26	>64	128	0.06	>256	>64	32	4
<i>Klebsiella pneumoniae</i>	38	NDM-1	>64	64	≤0.03	>256	≤0.03	32	≤0.03
<i>Klebsiella pneumoniae</i>	16	VIM-5	>64	256	≤0.03	>256	≤0.03	8	≤0.03
<i>Providencia stuartii</i>	26582	VIM-1	>64	32	0.06	>256	32	1	0.5
<i>Serratia marcescens</i>	35	IMP-4	>64	≤0.12	0.06	64	64	8	4
<i>Serratia marcescens</i>	36098	IMP-19	>64	>256	2	128	64	8	8

Table 11: Synergy of inhibitor Ex. 4 (4 µg/mL) in combination with antibiotics against metallo-β-lactamase producing bacteria



Organism	Isolate No	Enzyme	Ex. 4 alone	AZT	AZT + Ex. 4	CAZ	CAZ + Ex. 4	MER	MER + Ex. 4
<i>Citrobacter freundii</i>	49469	NDM-1	>64	256	0.06	>256	>64	16	4
<i>Enterobacter aerogenes</i>	47683	VIM-12	>64	4	≤0.03	256	32	8	0.5
<i>Enterobacter aerogenes</i>	8397	VIM-1	>64	>256	0.5	>256	>64	64	64
<i>Enterobacter cloacae</i>	1874	IMP-21	2	≤0.12	≤0.03	32	0.06	4	≤0.03
<i>Enterobacter cloacae</i>	1280	VIM-5	4	8	≤0.03	64	≤0.03	4	≤0.03
<i>Enterobacter cloacae</i>	3686	IMP-1	4	32	≤0.03	>256	≤0.03	8	≤0.03
<i>Enterobacter cloacae</i>	25	IMP-4	4	64	≤0.03	>256	32	16	2
<i>Enterobacter cloacae</i>	1471	VIM-1	4	64	0.06	>256	≤0.03	2	≤0.03
<i>Enterobacter cloacae</i>	10	IMP-26	64	128	≤0.03	>256	≤0.03	16	≤0.03
<i>Enterobacter cloacae</i>	53477	NDM-1	8	128	≤0.03	>256	≤0.03	32	≤0.03
<i>Enterobacter cloacae</i>	1068	VIM-2	4	128	≤0.03	128	≤0.03	2	≤0.03
<i>Enterobacter cloacae</i>	4	VIM-6	64	128	≤0.03	256	0.12	2	0.25
<i>Escherichia coli</i>	13	IMP-1	2	16	≤0.03	256	≤0.03	4	≤0.03
<i>Escherichia coli</i>	49	NDM-1	2	128	≤0.03	>256	≤0.03	8	≤0.03
<i>Escherichia coli</i>	17	NDM-1	2	>256	≤0.03	>256	≤0.03	32	≤0.03
<i>Escherichia coli</i>	53749	NDM-1	2	>256	≤0.03	>256	≤0.03	64	≤0.03
<i>Klebsiella oxytoca</i>	31141	VIM-23	>64	8	≤0.03	128	0.5	2	0.25
<i>Klebsiella oxytoca</i>	24825	IMP-26	>64	128	≤0.03	>256	>64	32	8
<i>Klebsiella pneumoniae</i>	38	NDM-1	>64	64	≤0.03	>256	≤0.03	32	≤0.03
<i>Klebsiella pneumoniae</i>	16	VIM-5	>64	256	≤0.03	>256	≤0.03	8	≤0.03
<i>Providencia stuartii</i>	26582	VIM-1	>64	32	≤0.03	>256	16	1	0.5
<i>Serratia marcescens</i>	35	IMP-4	>64	≤0.12	≤0.03	64	32	8	2
<i>Serratia marcescens</i>	36098	IMP-19	>64	>256	2	128	64	8	8

Table 12: Synergy of inhibitor Ex. 40 (4 µg/mL) in combination with antibiotics against metallo-β-lactamase producing bacteria



Organism	Isolate No	Enzyme	Ex. 40 alone	AZT	AZT + Ex. 40	CAZ	CAZ + Ex. 40	MER	MER + Ex. 40
<i>Citrobacter freundii</i>	49469	NDM-1	>64	256	≤0.03	>256	>64	16	2
<i>Enterobacter aerogenes</i>	47683	VIM-12	>64	4	≤0.03	256	64	8	1
<i>Enterobacter aerogenes</i>	8397	VIM-1	>64	>256	0.25	>256	>64	64	64
<i>Enterobacter cloacae</i>	1874	IMP-21	2	≤0.12	≤0.03	32	≤0.03	4	≤0.03
<i>Enterobacter cloacae</i>	1280	VIM-5	4	8	≤0.03	64	≤0.03	4	≤0.03
<i>Enterobacter cloacae</i>	3686	IMP-1	2	32	≤0.03	>256	≤0.03	8	≤0.03
<i>Enterobacter cloacae</i>	25	IMP-4	4	64	≤0.03	>256	32	16	2
<i>Enterobacter cloacae</i>	1471	VIM-1	2	64	≤0.03	>256	≤0.03	2	≤0.03
<i>Enterobacter cloacae</i>	10	IMP-26	64	128	≤0.03	>256	≤0.03	16	≤0.03
<i>Enterobacter cloacae</i>	53477	NDM-1	2	128	≤0.03	>256	≤0.03	32	≤0.03
<i>Enterobacter cloacae</i>	1068	VIM-2	4	128	≤0.03	128	≤0.03	2	≤0.03
<i>Enterobacter cloacae</i>	4	VIM-6	64	128	≤0.03	256	0.25	2	0.25
<i>Escherichia coli</i>	13	IMP-1	1	16	≤0.03	256	≤0.03	4	≤0.03
<i>Escherichia coli</i>	49	NDM-1	2	128	≤0.03	>256	≤0.03	8	≤0.03
<i>Escherichia coli</i>	17	NDM-1	2	>256	≤0.03	>256	≤0.03	32	0.06
<i>Escherichia coli</i>	53749	NDM-1	2	>256	≤0.03	>256	≤0.03	64	≤0.03
<i>Klebsiella oxytoca</i>	31141	VIM-23	>64	8	≤0.03	128	2	2	0.5
<i>Klebsiella oxytoca</i>	24825	IMP-26	>64	128	≤0.03	>256	>64	32	8
<i>Klebsiella pneumoniae</i>	38	NDM-1	>64	64	≤0.03	>256	≤0.03	32	≤0.03
<i>Klebsiella pneumoniae</i>	16	VIM-5	>64	256	≤0.03	>256	≤0.03	8	≤0.03
<i>Providencia stuartii</i>	26582	VIM-1	>64	32	≤0.03	>256	16	1	0.5
<i>Serratia marcescens</i>	35	IMP-4	>64	≤0.12	≤0.03	64	32	8	2
<i>Serratia marcescens</i>	36098	IMP-19	>64	>256	0.5	128	64	8	8

Test for β -lactamase Inhibitory Activity:

The inhibitory activities of present compounds against various enzymes were measured by spectrophotometric assay using 490 nM and using nitrocefin as a substrate [*J. Antimicrob. Chemother.*, 28, pp 775-776 (1991)]. The concentration of inhibitor (IC_{50}) which inhibits by 50% the reaction of hydrolysis of nitrocefin by the enzyme is determined. Table 13 shows the results.

Table 13 Test for β -lactamase Inhibitory Activity

Example No.	IC_{50} (μ M)	IC_{50} (μ M)	IC_{50} (μ M)	IC_{50} (μ M)
	TEM-1	CMY-2	KPC-2	CTX-M-9
Ex. 40	0.052 $\pm$ 0.004	0.008 $\pm$ 0.001	0.091 $\pm$ 0.009	0.327 $\pm$ 0.020


In light of the data described herein, persons of skill in the art would expect that all of the compounds within the scope of formula (I), salts of such compounds, solvates of such compounds and salts thereof, and deuterated compounds of all such compounds, salts and solvates (i.e., compounds of formula (I) modified in that they have been deuterated, salts of compounds of formula (I) modified in that they have been deuterated, and solvates of such compounds and salts, modified in that they have been deuterated) would be effective on their own as antibacterial compounds, and in combination with β -lactam antibiotics.

Efficacy of the β -lactamase inhibitors can be evaluated in combination with ceftazidime (CAZ) aztreonam (AZT), meropenem (MER) and other class of cephalosporins and carbapenems in murine infection models such as septicemia, pneumoniae and thigh infection models (Ref: Andrea Endimiani *et. al. Antimicrob. Agents and Chemother* Jan 2011, pp-82-85). For murine acute lethal septicemia model, mice were infected by the intraperitoneal injection of the clinical strains resulting in death of the untreated controls within 24-48 hrs. In particular, a fresh predetermined bacterial inoculum of approximately 3.3×10^5 to 3.6×10^5 CFU (colony forming units) in 5% hog gastric mucin grown overnight. Thirty minutes post infection, a single subcutaneous dose of CAZ with and without β -lactamase inhibitor was initiated and the survival ratio monitored for 5 days twice daily. For each strain tested, the dosing regimen used are CAZ alone (doses of 512, 1024 & 2048 mg/kg of body weight) and CAZ plus β -lactamase inhibitor at ratio of 2:1, 4:1, 8:1 & 16:1 (CAZ doses were 4, 8, 16, 32 & 64 mg/kg for each ratio). The median effective dose for 50% (ED_{50}) of animals was determined by a computerized program of Probit analysis. Survival rates stratified for different dosing regimen were also obtained. For

experimental pneumoniae model, immunocompromised mice were used and intratracheally infected with *Klebsiella pneumoniae* strains. Mice in this model develop bacteraemia pneumoniae and fatal disease within 2 to 4 days with lung bacterial burden at 16-18 hrs post infection of 10^{11} to 10^{13} cfu/gm lung. Treatment with CAZ and inhibitor at a ratio of 2/1 & 4/1 demonstrate efficacy with significant 3 to 6 log reduction in lung counts compared to CAZ alone and is relevant to the clinical situation. Human testing of the β -lactamase inhibitor can be conducted in combination with partner antibiotic at a set ratio utilizing standard clinical development practice.

Below are a series of numbered passages, each of which defines subject matter within the scope of the present inventive subject matter:

Passage 1. A compound of formula (I):



wherein:

M is hydrogen or a pharmaceutically acceptable salt-forming cation;

Y is OR¹;

R¹ is a radical selected from the group consisting of:


- (1) C₁₋₆ straight or branched chain alkyl which is optionally substituted;
- (2) C₃₋₇ cycloalkyl which is optionally substituted;
- (3) C₄₋₇ saturated heterocycles containing at least one heteroatom selected from O, N and S wherein the said heterocycle is optionally substituted, the ring S is optionally oxidized to S(O) or S(O)₂ and the free ring N atom may optionally take a substituent;
- (4) Heterocyclyl (C₁₋₆) alkyl wherein the said heterocycle has the same definition as defined in (3), and the said heterocycle is optionally substituted;

- 5 (5) C₅₋₇ membered saturated heterocycles optionally fused with a C₃₋₇ membered cycloalkyl group to form a bicyclic ring system where the bicyclic ring system so formed is fused either through two adjacent carbon atoms or through a N atom shared by both the rings and the other end of the cycloalkyl chain is attached to the adjacent carbon atom of the molecule, each ring of the said bicyclic ring system independently optionally substituted;
- 10 (6) C₅₋₇ membered saturated heterocycles optionally fused with another C₅₋₇ saturated heterocycle to form a bicyclic ring system where the bicyclic ring system so formed is fused either through two adjacent carbon atoms or through a N atom shared by both the rings, each ring of the said bi-cyclic ring system independently optionally substituted;
- (7) C₃₋₇ cycloalkyl which is optionally fused with a C₅₋₇ membered saturated heterocycle containing at least one heteroatom selected from O, N and S, the said bicyclic ring optionally substituted;
- 15 (8) Bridged bicyclic ring system having optionally one or two heteroatoms selected from O, N and S, the bicyclic ring system optionally substituted either at the carbon atom or at the free N atom present in the ring;
- 20 (9) C₅₋₇ membered saturated heterocycles optionally fused with C₅₋₇ membered heteroaryl ring where the bicyclic ring system so formed is fused either through two adjacent carbon atoms or through N atom shared by both the rings;
- 25 (10) C₅₋₇ membered saturated heterocycles optionally fused to a C₃₋₆ membered ring system through a common carbon atom to form a spiro system optionally containing one heteroatom selected from O, N and S that is present in the spiro ring where the ring S is optionally oxidized to S(O) or S(O)₂ and the free N atom present in either ring may optionally take a substituent; and

(11) C₅₋₇ membered heteroaryl (C₁₋₆) alkyl which is optionally substituted,

or a deuterated compound of any such compound.

5 Passage 2. A compound of formula (I):



wherein:

M is hydrogen or a pharmaceutically acceptable salt-forming cation;

Y is NR²R³;

10 R² is hydrogen or optionally substituted C₁₋₆ lower alkyl;

R³ is a radical selected from any of following groups consisting of:

(1) C₁₋₆ straight or branched chain alkyl which is optionally substituted;

(2) C₃₋₇ cycloalkyl which is optionally substituted;

(3) C₄₋₇ saturated heterocycles containing at least one heteroatom selected from O, N and
 15 S wherein the said heterocycle is optionally substituted, the ring S is optionally oxidized
 to S(O) or S(O)₂ and the free ring N atom may optionally take a substituent;

(4) C₁₋₆ straight or branched chain alkyl carbonyl which is optionally substituted;

(5) C₃₋₇ cycloalkyl carbonyl which is optionally substituted;

(6) C₄₋₇ membered saturated heterocyclyl carbonyl containing at least one heteroatom
 20 selected from O, N and S wherein the said heterocycle is optionally substituted, the

ring S is optionally oxidized to S(O) or S(O)₂ and the free ring N atom may optionally take a substituent;

(7) C₃₋₇ membered saturated heterocyclyl (C₁₋₆) alkyl carbonyl wherein the said heterocycle has the same definition as defined in (6), and the free ring N atom may optionally take a substituent;

(8) C₆₋₁₀ aryl carbonyl which is optionally substituted;

(9) C₆₋₁₀ aryl (C₁₋₆) alkyl carbonyl which is optionally substituted;

(10) C₅₋₆ membered heteroaryl carbonyl containing at least one heteroatom selected from O, S and N wherein the heteroaryl is optionally substituted;

(11) C₅₋₆ heteroaryl (C₁₋₆) alkyl carbonyl wherein the said heteroaryl has the same definition as defined in (10);

(12) CF₃CO-, CH₃SO₂-, NH₂CO-, and NH₂SO₂- ;

(13) C₆₋₁₀ aryl which is optionally substituted;

(14) C₅₋₆ membered heteroaryl which is optionally substituted;

(15) or R² and R³ together may form an optionally substituted ring system and the said ring may contain another heteroatom selected from O, N, and S,

or a deuterated compound of any such compound.

Passage 3. A compound as recited in passage 1 or passage 2, wherein M is hydrogen.


Passage 4. A compound as recited in passage 1 or passage 2, wherein M is a pharmaceutically acceptable salt-forming cation.


Passage 5. A compound as recited in passage 2, wherein R^2 is hydrogen or C_{1-6} lower alkyl.


Passage 6. A compound as recited in any one of passages 1-5, wherein R^1 , R^2 and R^3 are optionally substituted with one or two substituents independently selected from the following:


Lower alkyl, amino, substituted amino, alkoxy, hydroxyalkyl, halogen, hydroxy, carboxy, alkoxy carbonyl, haloalkyl, trifluoromethyl, trifluoromethoxy, alkylamine, substituted alkylamine, carboxamide, thiocarboxamide, sulfonic acid, sulphate, acylamino, sulfonylamino, substituted or unsubstituted sulfonamide, substituted or unsubstituted urea, substituted or unsubstituted thiourea, oxo, oxyimino, hydroxamic acid, acyl, trifluoromethyl carbonyl, cyano, amidino, guanidino, aryloxy, heterocyclalkyloxy, and heteroaryloxy.


10 Passage 7. A compound as recited in passage 1, which is selected from the following group of compounds:

















5



5




10










and pharmaceutically acceptable salts of such compounds, and deuterated compounds of such compounds and salts.


- 10 Passage 8. A compound as recited in passage 2, which is selected from the following group of compounds:


5

















- 5 and pharmaceutically acceptable salts of such compounds, and deuterated compounds of such compounds and salts.

Passage 9. A compound of formula (I) as defined in passage 1, wherein the compound is selected from the group consisting of:

- 10 (2S,5R)-N-(2-hydroxyethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-N-methoxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-7-oxo-N-propoxy-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-N-(2-aminoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2S,5R)-N-(2-aminopropoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-N-(2-amino-2-oxoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-N-[2-(carbamoylamino)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20

(2*S*,5*R*)-7-oxo-*N*-[2-(sulfamoylamino)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

[{[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}amino]oxy]acetic acid

5 2-methyl-2-[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}amino]oxy]propanoic acid

(2*S*,5*R*)-7-oxo-*N*-[2-(piperidin-4-yloxy)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

10 (2*S*,5*R*)-7-oxo-*N*-(propan-2-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-*tert*-butoxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-(cyclobutyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

15 (2*S*,5*R*)-*N*-(cyclopentyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-(cyclohexyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-(cycloheptyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

20 (2*S*,5*R*)-*N*-[(3-aminocyclopentyl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[(2-aminocyclopentyl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

25 (2*S*,5*R*)-*N*-[3-(methylamino)cyclopentyl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[4-(dimethylamino)cyclohexyl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[(3-aminocyclohexyl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

- (2S,5R)-N-[[3-(methylamino)cyclohexyl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-7-oxo-N-(pyrrolidin-3-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2S,5R)-7-oxo-N-[(5-oxopyrrolidin-3-yl)oxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-N-[(1-acetylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2S,5R)-N-[(1-methylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-7-oxo-N-(piperidin-3-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-7-oxo-N-(piperidin-4-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2S,5R)-N-(azetidin-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-7-oxo-6-(sulfooxy)-N-(tetrahydro-2H-pyran-4-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-7-oxo-6-(sulfooxy)-N-(tetrahydro-2H-thiopyran-4-yloxy)-1,6-
- 20 diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-N-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-N-(azepan-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2S,5R)-N-(1,4-oxazepan-6-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-N-[(1-methylpiperidin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-N-[(1-carbamimidoylpiperidin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-
- 30 diazabicyclo[3.2.1]octane-2-carboxamide

- (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-2-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-(piperidin-2-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-7-oxo-*N*-(piperidin-3-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-(piperidin-4-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-*N*-(morpholin-3-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-(piperazin-2-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(thiomorpholin-3-ylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-*N*-(decahydroquinolin-4-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(hexahydro-1*H*-pyrrolizin-2-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(octahydroindolizin-1-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-*N*-(octahydropyrrolo[1,2-*a*]pyrazin-8-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(octahydropyrrolo[1,2-*a*]pyrazin-7-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2*S*,5*R*)-*N*-(octahydrofuro[2,3-*c*]pyridin-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(3-azabicyclo[3.1.0]hex-6-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 30 (2*S*,5*R*)-*N*-(decahydroquinolin-5-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

- (2*S*,5*R*)-*N*-(hexahydro-4*aH*-cyclopenta[*b*][1,4]dioxin-6-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(octahydrocyclopenta[*c*]pyrrol-5-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-*N*-(hexahydro-1*H*-cyclopenta[*c*]furan-5-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(hexahydro-1*H*-cyclopenta[*c*]thiophen-5-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-*N*-(bicyclo[2.2.1]hept-2-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(7,7-dimethylbicyclo[2.2.1]hept-2-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-*N*-(8-azabicyclo[3.2.1]oct-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(4,5,6,7-tetrahydrothieno[3,2-*c*]pyridin-7-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(6,7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazol-7-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(7-azaspiro[4.5]dec-10-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2*S*,5*R*)-*N*-(7-oxaspiro[4.5]dec-10-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(1*H*-imidazol-2-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 30 (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(4,5,6,7-tetrahydro-1*H*-4,7-methanoindazol-3-ylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

- (2*S*,5*R*)-7-oxo-*N*-(1*H*-pyrazol-3-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-[2-(pyridin-2-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-7-oxo-*N*-[2-(piperidin-4-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-[2-(piperazin-1-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-7-oxo-*N*-[(1-sulfamoylpyrrolidin-3-yl)oxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[1-(methylsulfamoyl)pyrrolidin-3-yl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[1-(carbamoylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-*N*-[(5-carbamoylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-carbamimidoylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-ethanimidoylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-*N*-[1-(iminomethyl)pyrrolidin-3-yl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydrofuran-3-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydro-2*H*-thiopyran-3-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(4-methylpiperidin-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(1,4-oxazepan-2-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 30

- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydrofuran-2-ylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(4,5,6,7-tetrahydrofuro[3,2-*c*]pyridin-7-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-*N*-[(1-methyl-4,5,6,7-tetrahydro-1*H*-pyrazolo[3,4-*c*]pyridin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(4,5,6,7-tetrahydro-1*H*-pyrazolo[3,4-*c*]pyridin-4-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-*N*-[2-(1*H*-imidazol-1-yl)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(4-fluoropyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(1,2-oxazolidin-4-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-7-oxo-*N*-(pyrazolidin-4-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(4-aminopyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-[(4-oxopyrrolidin-3-yl)oxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-*N*-[(4-hydroxypyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[[(4*E*)-4-(hydroxyimino)pyrrolidin-3-yl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2*S*,5*R*)-*N*-[[(4*E*)-4-(methoxyimino)pyrrolidin-3-yl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[[(4*E*)-4-[[1,5-dihydroxy-4-oxo-1,4-dihydropyridin-2-yl)methoxy]imino]pyrrolidin-3-yl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

- (2*S*,5*R*)-*N*-[(4,4-dimethylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(4-fluoropiperidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-*N*-[(3-fluoropiperidin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-[(5-oxopiperidin-3-yl)oxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(5,5-dimethylpiperidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-*N*-(2-methoxyethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[2-(morpholin-4-yl)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-7-oxo-*N*-[2-(pyrrolidin-1-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-[2-(piperidin-1-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[2-(1,1-dioxidothiomorpholin-4-yl)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-*N*-[(1-methylazetidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[[5-(dimethylcarbamoyl)pyrrolidin-3-yl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 methyl 4-[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]prolinate
- (2*S*,5*R*)-*N*-[[6-(dimethylcarbamoyl)piperidin-3-yl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-methylpyrrolidin-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 30

- (2*S*,5*R*)-*N*-[(1-acetylpyrrolidin-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-carbamoylpyrrolidin-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-7-oxo-*N*-[(1-sulfamoylpyrrolidin-2-yl)methoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-carbamimidoylpyrrolidin-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-methyl-1*H*-pyrazol-3-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-*N*-[(1-methyl-1*H*-imidazol-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-methyl-4,5,6,7-tetrahydro-1*H*-4,7-methanoindazol-3-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1,8-dimethyl-4,5,6,7-tetrahydro-1*H*-4,7-epiminoindazol-3-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-*N*-(1*H*-benzimidazol-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(2,3-dihydro-1*H*-indol-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-*N*-[(2-methyl-1*H*-imidazol-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-methyl-1*H*-imidazol-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-methyl-1*H*-imidazol-5-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2*S*,5*R*)-*N*-[(2-amino-1,3-thiazol-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(1,3-oxazol-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 30

(2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(1,3-thiazol-4-ylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[(1-methyl-1*H*-1,2,3-triazol-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

5 (2*S*,5*R*)-*N*-(1*H*-imidazol-4-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[2-(1*H*-imidazol-5-yl)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

10 (2*S*,5*R*)-*N*-[1-(1*H*-imidazol-5-yl)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[(1-methyl-1*H*-pyrrol-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-(1,2-oxazol-3-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

15 (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(1*H*-1,2,4-triazol-3-ylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[(5-methylpyrazin-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

20 (2*S*,5*R*)-*N*-[(2-aminocyclopropyl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-(morpholin-2-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[2-(azetidin-3-yloxy)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

25 (2*S*,5*R*)-7-oxo-*N*-[2-(pyrrolidin-3-yloxy)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-7-oxo-*N*-[2-(piperidin-3-yloxy)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

30 or a deuterated compound of any such compound.

Passage 10. A compound of formula (I) as defined in passage 2, wherein the compound is selected from the group consisting of:

- (2*S*,5*R*)-*N*-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-*N*-ethyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(propan-2-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N,N*-dimethyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-*N,N*-diethyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N,N*-di(propan-2-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-cyclopropyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-*N*-cyclobutyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-cyclopentyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(piperidin-4-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydro-2*H*-pyran-4-yl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydro-2*H*-thiopyran-4-yl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(piperidin-3-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-3-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

- (2*S*,5*R*)-*N*-(1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-acetyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-propanoyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-*N*-(2-methylpropanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-acetyl-*N*'-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-methyl-7-oxo-*N*'-propanoyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-*N*-methyl-*N*'-(2-methylpropanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-acetyl-*N*'-ethyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-*N*'-ethyl-7-oxo-*N*'-propanoyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-(2,2-dimethylpropanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-butanoyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-*N*'-(2-methylbutanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-[(dimethylamino)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*'-(4,4,4-trifluoropropanoyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-*N*'-(methoxyacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*'-[(2*R*)-2-aminopropanoyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

- (2*S*,5*R*)-*N*-[amino(phenyl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(cyclopropylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-*N*-(cyclobutylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(2,2-dimethylcyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-*N*-[(2-methylcyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(2,2-difluorocyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(2-fluorocyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-*N*-(cyclopentylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(cyclohexylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(2*R*)-2-aminocyclopentyl]carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-3-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-7-oxo-*N*-(piperidin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-methyl-7-oxo-*N*-(pyrrolidin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(piperidin-3-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 30

- (2*S*,5*R*)-7-oxo-*N*-(piperidin-4-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydro-2*H*-pyran-4-ylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-*N*-[(1-methylpyrrolidin-2-yl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(1-methylpiperidin-4-yl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydro-2*H*-thiopyran-4-ylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-*N*-[(1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-2-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-3-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(1-methylpyrrolidin-2-yl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(cyclopropylacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-7-oxo-*N*-(piperidin-2-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(1-methylpiperidin-2-yl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-7-oxo-*N*-(piperidin-3-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(piperidin-4-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(1-methylpiperidin-4-yl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 30

- (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-1-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(piperazin-1-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-*N*-(morpholin-4-ylacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(phenylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(naphthalen-2-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-*N*-methyl-7-oxo-*N*-(phenylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-ethyl-7-oxo-*N*-(phenylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-7-oxo-*N*-(phenylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(naphthalen-2-ylacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-methyl-7-oxo-*N*-(phenylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-*N*-ethyl-7-oxo-*N*-(phenylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(pyridin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-7-oxo-*N*-(pyridin-3-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(pyridin-4-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(thiophen-3-ylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 30

- (2*S*,5*R*)-*N*-(furan-3-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(thiophen-2-ylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-*N*-(furan-2-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-methyl-7-oxo-*N*-(pyridin-3-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-7-oxo-*N*-(1*H*-pyrrol-2-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(thiophen-2-ylacetyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(2-amino-1,3-thiazol-4-yl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-*N*-(furan-2-ylacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(pyridin-2-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(pyridin-3-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-7-oxo-*N*-(pyridin-4-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(2-amino-1,3-thiazol-4-yl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-*N*-[(2-amino-1,3-thiazol-4-yl)acetyl]-*N*-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-methyl-7-oxo-*N*-(pyridin-3-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(trifluoroacetyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 30

- (2*S*,5*R*)-*N*-(methylsulfonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 2-([(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)hydrazinecarboxamide
- 5 2-([(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl)hydrazinesulfonamide
- (2*S*,5*R*)-7-oxo-*N*-phenyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-methyl-7-oxo-*N*-phenyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-7-oxo-*N*-(pyridin-3-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-methyl-7-oxo-*N*-(pyridin-3-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(piperidin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-
- 15 carboxamide
- (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(morpholin-4-yl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-7-oxo-*N*-(piperazin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(thiomorpholin-4-yl)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(1,1-dioxidothiomorpholin-4-yl)-7-oxo-6-(sulfooxy)-1,6-
- 25 diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-(2-oxopiperidin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-(3-oxomorpholin-4-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

- (2*S*,5*R*)-7-oxo-*N*-(2-oxopiperazin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydropyrimidin-1(2*H*)-yl)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-7-oxo-*N*-(2-oxotetrahydropyrimidin-1(2*H*)-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(3-aminopiperidin-1-yl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(2-aminocyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-*N*-[(2-aminocyclopropyl)carbonyl]-*N*'-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(azetidin-2-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(azetidin-3-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-*N*-[(2*S*)-2-aminopropanoyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(2*S*)-2-aminopropanoyl]-*N*'-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-*N*-[(2*S*)-2-aminopropanoyl]-*N*'-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[3-(dimethylamino)propanoyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(3,3-difluorocyclobutyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(3-aminocyclobutyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-*N*-[(3-aminocyclobutyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[[3-(methylamino)cyclobutyl]carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[[3-(dimethylamino)cyclobutyl]carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide,
- 30

or a deuterated compound of any such compound.

Passage 11. A method of treating a bacterial infection comprising administering to a mammal in
5 need thereof an antibacterially effective amount of a compound as recited in any one of
passages 1-10.

Passage 12. A pharmaceutical composition containing as an active ingredient, at least one
compound as recited in any one of passages 1-10.

Passage 13. A pharmaceutical composition containing, as an active ingredient, (i) at least one
10 compound as recited in any one of passages 1-10 and (ii) at least one β -lactam antibiotic, at
least one salt of a β -lactam antibiotic, at least one hydrate of a β -lactam antibiotic or at least
one prodrug of a β -lactam antibiotic.

Passage 14. A pharmaceutical composition containing, as an active ingredient, (i) at least one
compound as recited in any one of passages 1-10 and (ii) at least one antibiotic, at least one
15 salt of an antibiotic, at least one hydrate of an antibiotic or at least one prodrug of an antibiotic.

Passage 15. A pharmaceutical composition suitable for the treatment of bacterial infections in
mammals, comprising a pharmaceutical composition as recited in passage 13 or passage 14
and a pharmaceutically acceptable carrier.

Passage 16. A method of treating bacterial infection, comprising administering to a mammal in
20 need thereof a combination of (i) an effective amount of a compound as recited in any one of
passages 1-10 and (ii) an effective amount of at least one β -lactam antibiotic, at least one salt of
a β -lactam antibiotic, at least one hydrate of a β -lactam antibiotic or at least one prodrug of a
 β -lactam antibiotic.

Passage 17. A method of treating bacterial infection, comprising administering to a mammal in need thereof a combination of (i) an effective amount of a compound as recited in any one of passages 1-10 and (ii) an effective amount of at least one antibiotic, at least one salt of an antibiotic, at least one hydrate of an antibiotic or at least one prodrug of an antibiotic.

- 5 Passage 18. A method for the treatment of bacterial infection, by inhibiting bacterial β -lactamases, comprising administering to a mammal in need thereof a pharmaceutical composition as recited in any one of passages 12-15.

Passage 19. A method as recited in passage 18, wherein the pharmaceutical composition is administered separately, simultaneously or spread over time.

- 10 Passage 20. A method or a pharmaceutical composition as recited in passage 13 or passage 16, wherein a ratio of the weight of (i) the compound of formula (I) to the weight of (ii) at least one β -lactam antibiotic, at least one salt of a β -lactam antibiotic, at least one hydrate of a β -lactam antibiotic or at least one prodrug of a β -lactam antibiotic, is in the range of 1:20 to 20:1.


- 15 Passage 21. A method or a pharmaceutical composition as recited in passage 14 or passage 17, wherein a ratio of the weight of (i) the compound of formula (I) to the weight of (ii) at least one antibiotic, at least one salt of an antibiotic, at least one hydrate of an antibiotic or at least one prodrug of an antibiotic, is in the range of 1:20 to 20:1.

Passage 22. A molecular complex comprising a compound as recited in any one of passages 1-10 and at least one solvent.

- 20 Passage 23. A molecular complex as recited in passage 22, wherein the solvent comprises water.


Passage 24. A process for preparing a compound recited in passage 1, wherein $M = H$, and wherein the process comprises:

[A] Reacting substituted hydroxylamine (V) with an acid (VI) in presence of a coupling agent selected from the group consisting of EDCI, HOBT-DCC and PyBop to provide an intermediate of formula (VII);




5

[B] Removing the benzyl protecting group of the intermediate (VII) with a source of hydrogen in presence of Pd catalyst to provide debenzylated product (VIII);




[C] Contacting compound (VIII) with a sulfating agent in the presence of solvent to obtain compound of formula (Ia)

10




Passage 25. A process for preparing a compound recited in passage 2, wherein $M = H$, and wherein the process comprises:


[A] Reacting substituted hydrazine (Va) with an acid (VI) in presence of a coupling agent selected from the group consisting of EDCI or HOBT-DCC and PyBop to provide an intermediate of formula (VIIa),



5 [B] Removing the benzyl protecting group of the intermediate (VIIa) with a source of hydrogen in presence of Pd catalyst to provide the debenzylated product (VIIIa),



[C] Contacting compound (VIIIa) with a sulfating agent in the presence of solvent to obtain compound of formula (Ib)



10 Passage 26. A method or a pharmaceutical composition as recited in any one of passages 13, 16 and 20, wherein the at least one β -lactam antibiotic, pharmaceutically acceptable salt of a β -lactam antibiotic, hydrate of a β -lactam antibiotic or prodrug of a β -lactam antibiotic is


selected from the group consisting of amoxicillin, ampicillin, azlocillin, mezlocillin, hetacillin, bacampicillin, carbenicillin, sulbenicillin, ticarcillin, piperacillin, mecillinam, methicillin, ciclacillin, oxacillin, cloxacillin, dicloxacillin, nafcillin, cephalothin, cephaloridine, cefaclor, cefadroxil, cefamandole, cefazolin, cephalixin, cephradine, ceftizoxime, cefoxitin, cephacetrile, cefotiam, 5 cefotaxime, cefsulodin, cefoperazone, cefmenoxime, cefmetazole, cephaloglycin, cefonicid, cefodizime, cefpirome, ceftazidime, ceftriaxone, cefpiramide, cefozopran, cefepime, cefuzonam, cefpimizole, cefclidin, cefixime, ceftibuten, cefdinir, cefpodoxime axetil, cefpodoxime proxetil, cefteram pivoxil, cefetamet pivoxil, cefcapene pivoxil, cefditoren pivoxil, cefuroxime, cefuroxime axetil, loracarbacef, latamoxef, CXA-101, imipenem, meropenem, biapenem, panipenem, 10 ertapenem, doripenem, aztreonam, carumonam, pharmaceutically acceptable salts of said β -lactam antibiotics, hydrates of said β -lactam antibiotics, and prodrugs of said β -lactam antibiotics.

Passage 27. A method or a pharmaceutical composition as recited in any one of passages 14, 17 and 21, wherein the at least one antibiotic, pharmaceutically acceptable salt of an antibiotic, 15 hydrate of an antibiotic or prodrug of an antibiotic is selected from the group consisting of aminoglycosides, quinolones, tetracyclines, glycylicyclines, glycopeptides, lipopeptides, macrolides, ketolides, lincosamides, streptogramin, oxazolidinones, polymyxins.

Claims

What we claim is:

1. A compound of formula (I):



5

wherein:

M is hydrogen or a pharmaceutically acceptable salt-forming cation;

Y is OR¹;

R¹ is a radical selected from the group consisting of:

- 10 (1) C₁₋₆ straight or branched chain alkyl which is optionally substituted;
- (2) C₃₋₇ cycloalkyl which is optionally substituted;
- (3) C₄₋₇ saturated heterocycles containing at least one heteroatom selected from O, N and S wherein the said heterocycle is optionally substituted, the ring S is optionally oxidized to S(O) or S(O)₂ and the free ring N atom may optionally take a substituent;
- 15 (4) Heterocyclyl (C₁₋₆) alkyl wherein the said heterocycle has the same definition as defined in (3), and the said heterocycle is optionally substituted;
- (5) C₅₋₇ membered saturated heterocycles optionally fused with a C₃₋₇ membered cycloalkyl group to form a bicyclic ring system where the bicyclic ring system so formed is fused either through two adjacent carbon atoms or through a N atom
- 20 shared by both the rings and the other end of the cycloalkyl chain is attached to the

adjacent carbon atom of the molecule, each ring of the said bicyclic ring system independently optionally substituted;

(6) C₅₋₇ membered saturated heterocycles optionally fused with another C₅₋₇ saturated heterocycle to form a bicyclic ring system where the bicyclic ring system so formed is fused either through two adjacent carbon atoms or through a N atom shared by both the rings, each ring of the said bi-cyclic ring system independently optionally substituted;

(7) C₃₋₇ cycloalkyl which is optionally fused with a C₅₋₇ membered saturated heterocycle containing at least one heteroatom selected from O, N and S, the said bicyclic ring optionally substituted;

(8) Bridged bicyclic ring system having optionally one or two heteroatoms selected from O, N and S, the bicyclic ring system optionally substituted either at the carbon atom or at the free N atom present in the ring;

(9) C₅₋₇ membered saturated heterocycles optionally fused with C₅₋₇ membered heteroaryl ring where the bicyclic ring system so formed is fused either through two adjacent carbon atoms or through N atom shared by both the rings;

(10) C₅₋₇ membered saturated heterocycles optionally fused to a C₃₋₆ membered ring system through a common carbon atom to form a spiro system optionally containing one heteroatom selected from O, N and S that is present in the spiro ring where the ring S is optionally oxidized to S(O) or S(O)₂ and the free N atom present in either ring may optionally take a substituent; and


(11) C₅₋₇ membered heteroaryl (C₁₋₆) alkyl which is optionally substituted,


or a deuterated compound of any such compound.

2. A compound as recited in claim 1, wherein the radical R¹ is optionally substituted with one or two substituents independently selected from the following:


Lower alkyl, amino, substituted amino, alkoxy, hydroxyalkyl, halogen, hydroxy, carboxy, alkoxy-carbonyl, haloalkyl, trifluoromethyl, trifluoromethoxy, alkylamine, substituted alkylamine, carboxamide, thiocarboxamide, sulfonic acid, sulphate, acylamino, sulfonylamino, substituted or unsubstituted sulfonamide, substituted or unsubstituted urea, substituted or unsubstituted thiourea, oxo, oximino, hydroxamic acid, acyl, trifluoromethyl carbonyl, cyano, amidino, guanidino, aryloxy, heterocyclalkyloxy, and heteroaryloxy.


3. A compound as recited in claim 1, which is selected from the following group of compounds:








5














and pharmaceutically acceptable salts of such compounds, and deuterated compounds of such compounds and salts.

5

4. A compound of formula (I) as defined in claim 1, wherein the compound is selected from the group consisting of:

(2*S*,5*R*)-*N*-(2-hydroxyethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

10

(2*S*,5*R*)-*N*-methoxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-7-oxo-*N*-propoxy-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-(2-aminoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

15

(2*S*,5*R*)-*N*-(2-aminopropoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-(2-amino-2-oxoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[2-(carbamoylamino)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

20

(2*S*,5*R*)-7-oxo-*N*-[2-(sulfamoylamino)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

[{[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]acetic acid

2-methyl-2-[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]oxy]propanoic acid

25

- (2*S*,5*R*)-7-oxo-*N*-[2-(piperidin-4-yloxy)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-(propan-2-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-*N*-*tert*-butoxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(cyclobutyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(cyclopentyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-*N*-(cyclohexyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(cycloheptyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(3-aminocyclopentyl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-*N*-[(2-aminocyclopentyl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[[3-(methylamino)cyclopentyl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-*N*-[[4-(dimethylamino)cyclohexyl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(3-aminocyclohexyl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[[3-(methylamino)cyclohexyl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-3-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-[(5-oxopyrrolidin-3-yl)oxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[(1-acetylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[(1-methylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

5 (2*S*,5*R*)-7-oxo-*N*-(piperidin-3-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-7-oxo-*N*-(piperidin-4-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

10 (2*S*,5*R*)-*N*-(azetidin-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydro-2*H*-pyran-4-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydro-2*H*-thiopyran-4-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

15 (2*S*,5*R*)-*N*-[(1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-(azepan-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

20 (2*S*,5*R*)-*N*-(1,4-oxazepan-6-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[(1-methylpiperidin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-*N*-[(1-carbamimidoylpiperidin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

25 (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-2-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2*S*,5*R*)-7-oxo-*N*-(piperidin-2-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

30 (2*S*,5*R*)-7-oxo-*N*-(piperidin-3-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

- (2*S*,5*R*)-7-oxo-*N*-(piperidin-4-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(morpholin-3-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-7-oxo-*N*-(piperazin-2-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(thiomorpholin-3-ylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-*N*-(decahydroquinolin-4-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(hexahydro-1*H*-pyrrolizin-2-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(octahydroindolizin-1-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-*N*-(octahydropyrrolo[1,2-*a*]pyrazin-8-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(octahydropyrrolo[1,2-*a*]pyrazin-7-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2*S*,5*R*)-*N*-(octahydrofuro[2,3-*c*]pyridin-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(3-azabicyclo[3.1.0]hex-6-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(decahydroquinolin-5-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2*S*,5*R*)-*N*-(hexahydro-4*aH*-cyclopenta[*b*][1,4]dioxin-6-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(octahydrocyclopenta[*c*]pyrrol-5-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 30 (2*S*,5*R*)-*N*-(hexahydro-1*H*-cyclopenta[*c*]furan-5-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

- (2*S*,5*R*)-*N*-(hexahydro-1*H*-cyclopenta[*c*]thiophen-5-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(bicyclo[2.2.1]hept-2-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-*N*-[(7,7-dimethylbicyclo[2.2.1]hept-2-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(8-azabicyclo[3.2.1]oct-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-
- 10 diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(4,5,6,7-tetrahydrothieno[3,2-*c*]pyridin-7-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-*N*-(6,7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazol-7-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(7-azaspiro[4.5]dec-10-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(7-oxaspiro[4.5]dec-10-yloxy)-7-oxo-6-(sulfooxy)-1,6-
- 20 diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-(1*H*-imidazol-2-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(4,5,6,7-tetrahydro-1*H*-4,7-methanoindazol-3-ylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2*S*,5*R*)-7-oxo-*N*-(1*H*-pyrazol-3-ylmethoxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-[2-(pyridin-2-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-[2-(piperidin-4-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-
- 30 carboxamide

(2S,5R)-7-oxo-N-[2-(piperazin-1-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-7-oxo-N-[(1-sulfamoylpyrrolidin-3-yl)oxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

5 (2S,5R)-N-[(1-(methylsulfamoyl)pyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(1-carbamoylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

10 (2S,5R)-N-[(5-carbamoylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(1-carbamimidoylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(1-ethanimidoylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

15 (2S,5R)-N-[(1-(iminomethyl)pyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-7-oxo-6-(sulfooxy)-N-(tetrahydrofuran-3-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

20 (2S,5R)-7-oxo-6-(sulfooxy)-N-(tetrahydro-2H-thiopyran-3-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(4-methylpiperidin-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-(1,4-oxazepan-2-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

25 (2S,5R)-7-oxo-6-(sulfooxy)-N-(tetrahydrofuran-2-ylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-7-oxo-6-(sulfooxy)-N-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-7-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

30 (2S,5R)-N-[(1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-7-oxo-6-(sulfooxy)-N-(4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-4-yloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[2-(1H-imidazol-1-yl)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

5 (2S,5R)-N-[(4-fluoropyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-(1,2-oxazolidin-4-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

10 (2S,5R)-7-oxo-N-(pyrazolidin-4-yloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(4-aminopyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-7-oxo-N-[(4-oxopyrrolidin-3-yl)oxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

15 (2S,5R)-N-[(4-hydroxypyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(4E)-4-(hydroxyimino)pyrrolidin-3-yl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

20 (2S,5R)-N-[(4E)-4-(methoxyimino)pyrrolidin-3-yl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(4E)-4-[(1,5-dihydroxy-4-oxo-1,4-dihydropyridin-2-yl)methoxy]imino]pyrrolidin-3-yl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

25 (2S,5R)-N-[(4,4-dimethylpyrrolidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(4-fluoropiperidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(3-fluoropiperidin-4-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

- (2*S*,5*R*)-7-oxo-*N*-[(5-oxopiperidin-3-yl)oxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(5,5-dimethylpiperidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2*S*,5*R*)-*N*-(2-methoxyethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[2-(morpholin-4-yl)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-[2-(pyrrolidin-1-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2*S*,5*R*)-7-oxo-*N*-[2-(piperidin-1-yl)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[2-(1,1-dioxidothiomorpholin-4-yl)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2*S*,5*R*)-*N*-[(1-methylazetidin-3-yl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[[5-(dimethylcarbamoyl)pyrrolidin-3-yl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- methyl 4-[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino)oxy]prolinate
- 20 (2*S*,5*R*)-*N*-[[6-(dimethylcarbamoyl)piperidin-3-yl]oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-methylpyrrolidin-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 25 (2*S*,5*R*)-*N*-[(1-acetylpyrrolidin-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-*N*-[(1-carbamoylpyrrolidin-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2*S*,5*R*)-7-oxo-*N*-[(1-sulfamoylpyrrolidin-2-yl)methoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 30

(2S,5R)-N-[(1-carbamimidoylpyrrolidin-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(1-methyl-1H-pyrazol-3-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

5 (2S,5R)-N-[(1-methyl-1H-imidazol-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(1-methyl-4,5,6,7-tetrahydro-1H-4,7-methanoindazol-3-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

10 (2S,5R)-N-[(1,8-dimethyl-4,5,6,7-tetrahydro-1H-4,7-epiminoindazol-3-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-(1H-benzimidazol-2-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-(2,3-dihydro-1H-indol-2-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

15 (2S,5R)-N-[(2-methyl-1H-imidazol-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(1-methyl-1H-imidazol-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

20 (2S,5R)-N-[(1-methyl-1H-imidazol-5-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(2-amino-1,3-thiazol-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-(1,3-oxazol-4-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

25 (2S,5R)-7-oxo-6-(sulfooxy)-N-(1,3-thiazol-4-ylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(1-methyl-1H-1,2,3-triazol-4-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

30 (2S,5R)-N-(1H-imidazol-4-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[2-(1H-imidazol-5-yl)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[1-(1H-imidazol-5-yl)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(1-methyl-1H-pyrrol-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-(1,2-oxazol-3-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-7-oxo-6-(sulfooxy)-N-(1H-1,2,4-triazol-3-ylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(5-methylpyrazin-2-yl)methoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[(2-aminocyclopropyl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-(morpholin-2-ylmethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-N-[2-(azetidin-3-yloxy)ethoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)-7-oxo-N-[2-(pyrrolidin-3-yloxy)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide


(2S,5R)-7-oxo-N-[2-(piperidin-3-yloxy)ethoxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

or a deuterated compound of any such compound.


5. Use of an antibacterially effective amount of a compound as recited in claim 1 in the manufacture of a medicament for treating a bacterial infection in a mammal in need thereof.

6. A pharmaceutical composition containing as an active ingredient, at least one compound as recited in claim 1.
7. Use of an effective amount of a compound as recited in claim 1 in manufacture of a medicament for treating bacterial infection in a mammal in need thereof, wherein said medicament is to be administered into the mammal in combination with an effective amount of at least one β -lactam antibiotic, at least one salt of a β -lactam antibiotic, at least one hydrate of a β -lactam antibiotic or at least one prodrug of a β -lactam antibiotic.
8. Use of an effective amount of a compound as recited in claim 1 in the manufacture of a medicament for treating bacterial infection in a mammal in need thereof, wherein said medicament is to be administered into the mammal in combination with an effective amount of at least one antibiotic, at least one salt of an antibiotic, at least one hydrate of an antibiotic or at least one prodrug of an antibiotic.
9. A molecular complex comprising a compound as recited in claim 1 and at least one solvent.
10. A process for preparing a compound recited in claim 1, wherein $M = H$, and wherein the process comprises:

[A] Reacting substituted hydroxylamine (V) with an acid (VI) in presence of a coupling agent selected from the group consisting of EDCI, HOBT-DCC and PyBop to provide an intermediate of formula (VII);




[B] Removing the benzyl protecting group of the intermediate (VII) with a source of hydrogen in presence of Pd catalyst to provide debenzylated product (VIII);




5

[C] Contacting compound (VIII) with a sulfating agent in the presence of solvent to obtain compound of formula (Ia)



10

11. A compound of formula (I):



wherein:

M is hydrogen or a pharmaceutically acceptable salt-forming cation;

Y is NR^2R^3 ;

R^2 is hydrogen or optionally substituted C_{1-6} lower alkyl;

5 R^3 is a radical selected from any of following groups consisting of:

(1) C_{1-6} straight or branched chain alkyl which is optionally substituted;

(2) C_{3-7} cycloalkyl which is optionally substituted;

(3) C_{4-7} saturated heterocycles containing at least one heteroatom selected from O, N and S wherein the said heterocycle is optionally substituted, the ring S is optionally oxidized to $\text{S}(\text{O})$ or $\text{S}(\text{O})_2$ and the free ring N atom may optionally
10 take a substituent;

(4) C_{1-6} straight or branched chain alkyl carbonyl which is optionally substituted;

(5) C_{3-7} cycloalkyl carbonyl which is optionally substituted;

(6) C_{4-7} membered saturated heterocyclyl carbonyl containing at least one
15 heteroatom selected from O, N and S wherein the said heterocycle is optionally substituted, the ring S is optionally oxidized to $\text{S}(\text{O})$ or $\text{S}(\text{O})_2$ and the free ring N atom may optionally take a substituent;

(7) C_{3-7} membered saturated heterocyclyl (C_{1-6}) alkyl carbonyl wherein the said
20 heterocycle has the same definition as defined in (6), and the free ring N atom may optionally take a substituent;

(8) C_{6-10} aryl carbonyl which is optionally substituted;

(9) C_{6-10} aryl (C_{1-6}) alkyl carbonyl which is optionally substituted;

(10) C₅₋₆ membered heteroaryl carbonyl containing at least one heteroatom selected from O, S and N wherein the heteroaryl is optionally substituted;

(11) C₅₋₆ heteroaryl (C₁₋₆) alkyl carbonyl wherein the said heteroaryl has the same definition as defined in (10);

5 (12) CF₃CO-, CH₃SO₂-, NH₂CO-, and NH₂SO₂- ;

(13) C₆₋₁₀ aryl which is optionally substituted;

(14) C₅₋₆ membered heteroaryl which is optionally substituted;

(15) or R² and R³ together may form an optionally substituted ring system and the said ring may contain another heteroatom selected from O, N, and S,

10

or a deuterated compound of any such compound.







12. A compound as recited in claim 11, wherein R² and R³ are optionally substituted with one or two substituents independently selected from the following:

15













Lower alkyl, amino, substituted amino, alkoxy, hydroxyalkyl, halogen, hydroxy, carboxy, alkoxycarbonyl, haloalkyl, trifluoromethyl, trifluoromethyloxy, alkylamine, substituted alkylamine, carboxamide, thiocarboxamide, sulfonic acid, sulphate, acylamino, sulfonylamino, substituted or unsubstituted sulfonamide, substituted or unsubstituted urea, substituted or unsubstituted thiourea, oxo, oxyimino, hydroxamic acid, acyl, trifluoromethyl carbonyl, cyano, amidino, guanidino, aryloxy, heterocyclalkyloxy, and heteroaryloxy.





20

13. A compound as recited in claim 11, which is selected from the following group of compounds:






5


















5














5 and pharmaceutically acceptable salts of such compounds, and deuterated compounds of such compounds and salts.

14. A compound of formula (I) as defined in claim 11, wherein the compound is selected from the group consisting of:

- 10 (2*S*,5*R*)-*N*-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
 (2*S*,5*R*)-*N*-ethyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
 (2*S*,5*R*)-7-oxo-*N*-(propan-2-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
 (2*S*,5*R*)-*N*,*N*-dimethyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
 15 (2*S*,5*R*)-*N*,*N*-diethyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
 (2*S*,5*R*)-7-oxo-*N*,*N*-di(propan-2-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
 (2*S*,5*R*)-*N*-cyclopropyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
 20

(2*S*,5*R*)-*N*-cyclobutyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-*N*-cyclopentyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

5

(2*S*,5*R*)-7-oxo-*N*-(piperidin-4-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydro-2*H*-pyran-4-yl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydro-2*H*-thiopyran-4-yl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

10

(2*S*,5*R*)-7-oxo-*N*-(piperidin-3-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-3-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

15

(2*S*,5*R*)-*N*-(1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-*N*-acetyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-7-oxo-*N*-propanoyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-*N*-(2-methylpropanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

20

(2*S*,5*R*)-*N*-acetyl-*N*-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-*N*-methyl-7-oxo-*N*-propanoyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

25

(2*S*,5*R*)-*N*-methyl-*N*-(2-methylpropanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-*N*-acetyl-*N*-ethyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2*S*,5*R*)-*N*-ethyl-7-oxo-*N*-propanoyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

- (2*S*,5*R*)-*N*-(2,2-dimethylpropanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-butanoyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(2-methylbutanoyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-*N*-[(dimethylamino)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(4,4,4-trifluoropropanoyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-*N*-(methoxyacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(2*R*)-2-aminopropanoyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[amino(phenyl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-*N*-(cyclopropylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(cyclobutylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-*N*-[(2,2-dimethylcyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(2-methylcyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(2,2-difluorocyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-*N*-[(2-fluorocyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(cyclopentylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

- (2*S*,5*R*)-*N*-(cyclohexylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(2*R*)-2-aminocyclopentyl]carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-3-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-7-oxo-*N*-(piperidin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-methyl-7-oxo-*N*-(pyrrolidin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(piperidin-3-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-7-oxo-*N*-(piperidin-4-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydro-2*H*-pyran-4-ylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(1-methylpyrrolidin-2-yl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-*N*-[(1-methylpiperidin-4-yl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(tetrahydro-2*H*-thiopyran-4-ylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-*N*-[(1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-2-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-3-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 30

- (2*S*,5*R*)-*N*-[(1-methylpyrrolidin-2-yl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(cyclopropylacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-7-oxo-*N*-(piperidin-2-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(1-methylpiperidin-2-yl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(piperidin-3-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-7-oxo-*N*-(piperidin-4-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(1-methylpiperidin-4-yl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(pyrrolidin-1-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-7-oxo-*N*-(piperazin-1-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(morpholin-4-ylacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-7-oxo-*N*-(phenylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(naphthalen-2-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-methyl-7-oxo-*N*-(phenylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-*N*-ethyl-7-oxo-*N*-(phenylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(phenylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 30

- (2*S*,5*R*)-*N*-(naphthalen-2-ylacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-methyl-7-oxo-*N*-(phenylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-*N*-ethyl-7-oxo-*N*-(phenylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(pyridin-2-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-7-oxo-*N*-(pyridin-3-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(pyridin-4-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(thiophen-3-ylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-*N*-(furan-3-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(thiophen-2-ylcarbonyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-(furan-2-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 20 (2*S*,5*R*)-*N*-methyl-7-oxo-*N*-(pyridin-3-ylcarbonyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(1*H*-pyrrol-2-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(thiophen-2-ylacetyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(2-amino-1,3-thiazol-4-yl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 30 (2*S*,5*R*)-*N*-(furan-2-ylacetyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

- (2*S*,5*R*)-7-oxo-*N*-(pyridin-2-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(pyridin-3-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 5 (2*S*,5*R*)-7-oxo-*N*-(pyridin-4-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(2-amino-1,3-thiazol-4-yl)acetyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-[(2-amino-1,3-thiazol-4-yl)acetyl]-*N*-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 10 (2*S*,5*R*)-*N*-methyl-7-oxo-*N*-(pyridin-3-ylacetyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-6-(sulfooxy)-*N*-(trifluoroacetyl)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 15 (2*S*,5*R*)-*N*-(methylsulfonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 2-[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinecarboxamide
- 2-[[[(2*S*,5*R*)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]hydrazinesulfonamide
- 20 (2*S*,5*R*)-7-oxo-*N*-phenyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-*N*-methyl-7-oxo-*N*-phenyl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(pyridin-3-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2*S*,5*R*)-*N*-methyl-7-oxo-*N*-(pyridin-3-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2*S*,5*R*)-7-oxo-*N*-(piperidin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

- (2S,5R)-7-oxo-*N*-(pyrrolidin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-*N*-(morpholin-4-yl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 5 (2S,5R)-7-oxo-*N*-(piperazin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-7-oxo-6-(sulfooxy)-*N*-(thiomorpholin-4-yl)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 10 (2S,5R)-*N*-(1,1-dioxidothiomorpholin-4-yl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-7-oxo-*N*-(2-oxopiperidin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-7-oxo-*N*-(3-oxomorpholin-4-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 15 (2S,5R)-7-oxo-*N*-(2-oxopiperazin-1-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-7-oxo-6-(sulfooxy)-*N*-(tetrahydropyrimidin-1(2H)-yl)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-7-oxo-*N*-(2-oxotetrahydropyrimidin-1(2H)-yl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- 20 (2S,5R)-*N*-(3-aminopiperidin-1-yl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- (2S,5R)-*N*-[(2-aminocyclopropyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 25 (2S,5R)-*N*-[(2-aminocyclopropyl)carbonyl]-*N'*-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2S,5R)-*N*-(azetidin-2-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- (2S,5R)-*N*-(azetidin-3-ylcarbonyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
- 30

(2S,5R)-N'-[(2S)-2-aminopropanoyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2S,5R)-N'-[(2S)-2-aminopropanoyl]-N'-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2S,5R)-N'-[3-(dimethylamino)propanoyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2S,5R)-N'-[(3,3-difluorocyclobutyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2S,5R)-N'-[(3-aminocyclobutyl)carbonyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2S,5R)-N'-{[3-(methylamino)cyclobutyl]carbonyl}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide

(2S,5R)-N'-{[3-(dimethylamino)cyclobutyl]carbonyl}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide,

or a deuterated compound of any such compound.

15. Use of an antibacterially effective amount of a compound as recited in claim 11 in the manufacture of a medicament for treating a bacterial infection in a mammal in need thereof.

16. A pharmaceutical composition containing as an active ingredient, at least one compound as recited in claim 11.

17. Use of an effective amount of a compound as recited in claim 11 in the manufacture of a medicament for treating bacterial infection in a mammal in need thereof, wherein said medicament is to be administered in combination with an effective amount of at least one β -lactam antibiotic, at least one salt of a


β -lactam antibiotic, at least one hydrate of a β -lactam antibiotic or at least one prodrug of a β -lactam antibiotic.

18. Use of an effective amount of a compound as recited in claim 11 in the manufacture of a medicament for treating bacterial infection in a mammal in need thereof, wherein said medicament is to be administered in combination with an effective amount of at least one antibiotic, at least one salt of an antibiotic, at least one hydrate of an antibiotic or at least one prodrug of an antibiotic.


19. A molecular complex comprising a compound as recited in claim 11 and at least one solvent.

20. A process for preparing a compound recited in claim 11, wherein $M = H$, and wherein the process comprises:

[A] Reacting substituted hydrazine (Va) with an acid (VI) in presence of a coupling agent selected from the group consisting of EDCI or HOBT-DCC and PyBop to provide an intermediate of formula (VIIa),




[B] Removing the benzyl protecting group of the intermediate (VIIa) with a source of hydrogen in presence of Pd catalyst to provide the debenzylated product (VIIIa),



VIIIa

[C] Contacting compound (VIIIa) with a sulfating agent in the presence of solvent to obtain compound of formula (Ib)



Ib